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ABSTRACT 
Genetic analysis of the microvascular complications of 
diabetes mellitus 
by 
Deborah Cross 
There is increasing evidence to suggest that genetic factors are involved in the pathogenesis of 
microvascular complications in diabetes mellitus. Recent studies have suggested that genetic 
variations in the aldose reductase (ALR2) gene may contribute to the genetic susceptibility to 
microvascular complications. Aldose reductase is the first and rate-limiting enzyme of the 
polyol pathway and is implicated in the pathogenesis of diabetic microvascular disease 
(nephropathy, retinopathy and neuropathy). It has recently been shown that the three 
polymorphisms of the ALR2 gene are associated with susceptibility to microvascular 
complications in both TIDM and T2DM. The aim of this study was to investigate the CA 
dinucleotide repeat polymorphism (5'ALR2) that is located -2100bp and the C-106T 
substitution in the promoter region of the ALR2 gene, and also the A+ 11842C within intron 8 
of the ALR2 gene itself. DNA from 285 Caucasoid patients with TIDM and well-defined 
microvascular disease and 120 normal healthy controls, as well as 60 Southern Indian patients 
with T2DM and 43 non diabetic controls were typed. The 5'ALR2 Z-2/X genotype was 
significantly increased in patients with nephropathy (n=92), retinopathy (n=160) and 
neuropathy (n=104) compared to those with no microvascular disease after 19 years duration 
of diabetes (uncomplicated, n=66) (46%, 41%, 42% vs. 24%, respectively). In contrast, the 
frequency of the Z+2/Y genotype (where Y is not Z-2) was significantly reduced in the 
patients with nephropathy, retinopathy and neuropathy compared to the uncomplicated (17%, 
23%, 23% vs. 52%, respectively). Similar observations were made in the •Southern Indian 
T2DM patients, however no significant differences were found. In the patients· with TIDM 
the C-106 allele was associated with the Z-2 5'ALR2 allele. The C/Z-2 haplotype was present 
in 32% of the nephropaths, 32% of the retioopaths and 35% of the neuropaths compared to 
11.5% of the uncomplicated. The A+ 11842 allele was also associated with the C-1 06 allele in 
TIDM patients with microvascular disease. The reported mitochondrial pqlymorphism 
(mt5178A/C) was not found in this. TIDM population, possibly due to differences in the 
background frequencies between ethnic groups. Family studies investigating the transmission 
of the 5'ALR2 and C-106T alleles from parents to offspring with diabetic nephropathy found 
preferential transmission of the Z-2 allele although this was not statistically significant. 
Functional studies of the activity of the ORE in TIDM patients with and without 
microvascular disease showed differences in the mean OREBP binding activity. ·oREB and 
OREC were found to have increased activity in resp"onse to hyperglycaemia in the 
complicated patients compared to the uncomplicated and normal controls. In conclusion, these 
results confirm the role of the aldose reductase gene in the genetic susceptibility to diabetic 
microvascular complications, and a possible role of the DI7S934 polymorphism in T2DM. 
These results also provide a novel insight into the role of the ORE of the ALR2 gene in the 
pathogenesis of diabetic microvascular complications. Further studies are now required to 
determine the molecular basis of these observations. Hopefully, in the future it will be 
possible to offer 'high risk' patients therapeutic intervention that will prevent the ravages of 
the long term complications of diabetes mellitus. 
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Preface 
Diabetes and its associated complications, which include retinopathy, nephropathy and 
neuropathy, is one of the leading causes of morbidity and mortality in both the developed 
western world, and also world-wide. The Department of Health's (DOH) 'National Service 
Framework for Diabetes (NSF-D)' was published early this year (2002), and 
implementation in England and Wales is also scheduled to start in 2002. The NSF-D which 
includes diabetic complications, is in the top four priority program's for the National 
Health Service (NHS), preceded only by mental health, coronary heart disease and older 
people (Keen 2001). In April of 1999 Frank Dobson (Secretary for Health) announced a 
new £10 million research and treatment fund for diabetes and related diseases, and 
announced "guaranteed national and local standards of care and treatment" for people with 
diabetes (NSF press release 1999; Saving Lives: Our Healthier Nation 1999). This degree 
of recognition pinpoints the disease as a priority target, indicating a real need for research 
into the molecular biology and genetics involved in the underlying aetiology of diabetes 
mellitus and its associated complications. It is imperative in the interest of future diabetic 
medicine that we aim to fully understand this disease in order to improve healthcare and 
medicine of tomorrow. This perspective is encapsulated by the 61 "1 American Diabetes 
Association (ADA) scientific session mission statement ' to prevent and cure diabetes and 
to improve the lives of all people affected by diabetes' (American Diabetes Association 
2001). 
The medical history of diabetes mellitus 
Diabetes was once a universally fatal disease, which led to a slow consuming death 
involving a gradual wasting away. Diabetic children bad a life expectancy of2-3 years and 
90% died from ketoacidosis. The symptoms of what we currently describe as 'diabetes' 
have been recorded since ancient times, but ideas about its causes have evolved over the 
centuries and still remain uncertain. The story of diabetes is an extensfve one, and 
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importantly an indeterminate one, to which a degree of ambiguity still remains within its 
field. 
Although clinical descriptions of diabetes were well recognised from as early as Egyptian 
times, and had been depicted in the Ebers papyrus, 1550 BC, it wasn't unti11ater that the 
disease was named. Various sources of information attribute the name 'diabetes' to various 
people. The earliest record, however, is ascribed to Demetrios of Apamaia in the second 
century BC who derived the name from the Greek word "diabeinein", meaning to go to 
excess. Later in the second century AD, Arataeus of Cappadocia in Asia Minor, lays claim 
to the term 'diabetes' which is Ionian Greek, likening its symptoms to the passing of water 
through a siphon. Arabic texts from the 9th to 11th centuries detail accurate descriptions of 
the clinical features of diabetes, and in particular mentions two specific com,Plications of 
the disease to be gangrene and the collapse of sexual function. 
More recent advancements began to take place in the 17th century when Thomas Willis 
(1621-1675) an Oxford physician to King Charles II noticed the sweet taste of urine in 
many diabetic patients. Later into the 18th century Matthew Dobson reported that the sweet 
taste of diabetic urine was due to an excess of sugar in the blood, suggesting that diabetes 
may be a systemic disease rather than a problem of the kidneys. John Rollo, the Surgeon 
General to the royal artillery, conducted early attempts at treatment in 1798. He observed 
that careful dietary control with carbohydrate restriction improved glucosuria and greatly 
improved the patients' prognosis. At a similar time Thomas Cawley 1788, observed 
pancreatic tissue damage in diabetic cadavers, in particular he observed diabetes occurring 
alongside 'calcific pancreatitis'. Pioneering work however, really only began to take place 
in the nineteenth century by Claude Bemard's experimental work on dogs which lead to· 
some important discoveries. He surmised that the liver stored glycogen and secreted a 
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sugary substance (glucose) into the blood. He also concluded that the secretory organs in 
particular the pancreas, were controlled by the sympathetic nervous system. Claude 
Bemard also demonstrated links between the central nervous system and diabetes where 
hyperglycaemia was caused by transfixing the medulla of conscious rabbits. 
In 1867 Paul Langerhans used microscopic techniques to identifY clusters of cells within 
sections of pancreas tissue, which were not connected to the ducts carrying digestive juices 
to the gut. These were later to be named the 'islets of Langerhans', and much later in the 
mid 20th century proved to become the anatomical site of insulin production. Joseph V on 
Mering and Oscar Minkowski quite unexpectedly made the link between diabetes and the 
pancreas in 1889 (Von Mering and Minkowski 1889). They succeeded in performing the 
first total pancreatectomy in dogs and in doing so produced severe and fatal diabetes, 
concluding that the anti-diabetic substance was to be found in the pancreas. These fmdings 
sparked 30 years of frantic research right across Europe and North America to isolate a 
pancreatic extract that could reverse the symptoms of diabetes. Georg Zuelzer working in 
Berlin and Nicholas Paulesco in Rumania separately isolated a crude pancreatic extract 
that improved patient's symptoms dramatically, but both showed toxic effects due to 
hypoglycaemia. 
In the summer of 1921 the breakthrough was finally made in Toronto, Canada and led to 
the award of a Nobel Prize. The discovery of insulin or 'iletin' as it was first called, by 
Frederick Banting and Charles Best was a significant milestone in the chronological 
history of the disease. By tying off the pancreatic duct and allowing the glandular part of 
the pancreas to atrophy, they were able to make an extract of the remaining gland (Banting 
and Best 1922 (a)). With assistance from a visiting biochemist named J.B. Collip they 
applied standard biochemical extraction techniques and produced an extract that could be 
tried on patients. The effects of administering this insulin extract to patients were dramatic. 
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In a paper published later that same year they describe a young male patient who had been 
slowly dying of diabetes, who, upon admission showed all signs of severe juvenile diabetes 
with ketosis. His condition became dramatically worse and the pancreatic extract was 
administered by daily injection. This resulted in immediate improvement, a loss of 
consuming thirst and he recovered his strength (Banting and Best 1922 (b)). Insulin 
provided a lifesaving remedy for many diabetic patients and led to a new era for diabetes. 
This once fatal disease could now be controlled, providing patients took their daily insulin 
injections normal life could be restored. 
It was however, soon recognised that not all diabetes sufferers responded to the insulin 
treatment in the same way. In 1936 Himsworth suggested that different forms of diabetes 
mellitus might exist. The first type involving a lack of insulin and an acute onset of 
symptoms, and a second type involving a lack of a sensitising factor where patients show 
. 
little or no clinical symptoms. Their experiments involved injecting insulin intravenously 
followed by an oral glucose drink. It was apparent that the diabetic patients under 
investigation could be divided into two types, those in whom the injected insulin produced 
an immediate suppression of hyperglycaemia and those in whom the insulin had little or no 
effect in suppressing the hyperglycaemia. They named the two forms 'insulin sensitive', 
and 'insulin insensitive' diabetes mellitus (Himsworth 1936). 
The advent of insulin has enabled diabetic patients to control their diabetes through 
stringent insulin administration. However, this has unmasked the devastating consequences 
'of persistent hyperglycaemia, namely the diabetic microvascular and macrovascular 
complications. Dr Elliot Joslin, one of the first clinicians to specialise in the treatment of 
diabetes mellitus, wrote in 1931, 'with the advent of insulin, we moved from the era of 
diabetic coma to the era of diabetic complications' (Lee et a/ 2000). Unfortunately these 
words remain true today as despite significant development in antihypertensive therapy 
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and glycaemic control we still do not understand the underlying causes of diabetic 
complications well enough to allow preventative treatment to be fully effective. The 
history of diabetes was comprehensively reviewed in a paper published by Allan I 972. 
Diabetes today and its clinical implications 
Since the discovery of insulin a great deal of interest has established itself world-wide for 
the clinical management of diabetes. Dr Elliot Joslin founded the first diabetic· clinic in 
Boston, USA in 1910, which has today become one of the worlds leading clinical and 
research establishments for diabetes. Many other research centres have since been 
established within hospitals and universities throughout the world, all striving for the 
improved management and treatment of diabetes. 
In 1938 the British Diabetic Association (BDA) was founded (now called 'Diabetes United 
Kingdom, DUK) primarily for patient education and a medical and scientific section was 
fonned in 1960. The 'American Diabetes Association' (ADA) was founded in 1942 for 
doctors and scientists, publishing the monthly journal 'Diabetes', and similarly the 
'European Association for the Study of Diabetes' (EASD) in 1965, which publishes 
'Diabetologia'. These organisations all hold annual research meetings, which attract both 
scientists and medical doctors from around the world. 
Today diabetes afflicts large numbers of people of all social conditions, ethnic and 
economic groups throughout the world and is one of the most common chronic childhood 
diseases in developed countries. According to demographic and epidemiology studies, the 
prevalence of diabetes is rapidly increasing on a world-wide scale, and in the absence of 
effective intervention will continue to proliferate extensively. A study carried out by the 
World Health Organisation (WHO) in 1985 (WHO 1985) estimated approximately 30 
million diabetics world-wide, and more recently in 1994 estimates for the year 2000 were 
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that more than 100 million people would be affected by diabetes (WHO 1994). In 1997 an 
estimated 124 million people world-wide had diabetes, and it is thought through projection 
analysis that this figure will potentially reach 221 million world-wide by the year 2010 
with 3 million in the UK alone (Amos et a/1997; Zimmet 1999; Dobson; 2000). 
Diabetes clearly imposes a vast public health problem in terms of the clinical implications 
of the disease. The proposals for a 'National Service Framework for Diabetes' (NSF-D) 
published in 200 I, state that diabetes is now one of the UK's governments top health 
priorities. On 12th January 1999 Frank Dobson (Secretary for Health) announced a new 
£10 million research and treatment fund for diabetes and related diseases (NSF press 
release 1999). He also stated that 'The new standards will be set out in a new 'National 
Service Framework' for diabetes, which will ensure that top quality standards of care and 
treatment for diabetes are available in all primary care, local hospitals, and specialist 
centres'. 
It is therefore apparent that it remains important to investigate the underlying 
environmental, molecular and genetic factors influencing the development of diabetes and 
its associated complications. This will pave the way for advancement in medical 
knowledge towards treatment and prevention of disease, improve medical care, and 
improve patient prognosis and quality of life. Considerable advances have been made in 
our understanding of diabetes and diabetic complications yet we do not sufficiently 
understand the underlying pathogenesis of these complications to allow for fully effective 
preventative measures. The fundamental biochemical mechanisms underlying the 
pathogenic processes of diabetic neuropathy, nephropathy and retinopathy remains 
unsolved. A wider approach is therefore now required, as we are still somewhat unable to 
explain satisfactorily the role of obesity, insulin resistance and genetic factors influencing 
diabetes and its complications. 
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A major scientific advancement in the study of diabetes has been the mapping of the 
human genome, enabling research into identifying people who are genetically susceptible 
to developing diabetes and diabetic complications. With further research, it should be 
possible to prevent the onset of complications or to control the damaging processes of the 
disease before they become irreversible. There is still a long way to go in terms of research 
in diabetic medicine and how new information might be used to prevent the disease. 
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Definition and classification of diabetes mellitus 
In any clinical research the first requirement is to have a clear uniform definition of the 
parameters of the disease. This is especially true for the study of diabetes where various 
forms and stages of the disease exist and need to be clearly classified. In the late 1970's the 
International Working Group for the National Diabetes Data Group (N.D.D.G) of the 
National Institute of Health, USA, and the World Health Organisation (W.H.O) Expert 
Committee on Diabetes published their criteria for classification and diagnosis of diabetes 
mellitus (NDDG 1979; WHO 1980). These criteria for a classification system were based 
largely on the pharmacological treatment of the disease, and recognised a distinction 
between insulin dependent (IDDM) and non-insulin dependent (NIDDM) types of diabetes 
mellitus. The World Health Organisation 1980, endorsed the NDDG proposed diagnostic 
criteria for diabetes mellitus, and revised and updated in 1985 (WHO Study Group on 
Diabetes Mellitus 1985). 
There has since been an explosive growth in the scientific and medical knowledge into the 
aetiology and pathogenesis of diabetes mellitus. The earlier classification system based 
largely upon the treatment of the disease, rather than its underlying pathogenic 
mechanisms has therefore led to a requirement for a revised classification criteria. In 1997 
and 1998 the American Diabetic Association (ADA) Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus published updated recommendations on the 
classification of diabetes (The Expert Committee on Diagnosis and Classification of 
Diabetes Mellitus 1997, 1998). The report came as a response to the need for revised 
nomenclature, diagnostic criteria and classification of the disease. The W.H.O. group also 
presented their conclusions for newer recommendations in 1998 in a report by Alberti and 
Zimmet 1998. The most recently updated classification is a review by the ADA 'Clinical 
Practice Recommendations 1999' (The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus 1999; Unwin et a/ 1998). A report by Ravi Shankar 
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presents an up-to-date review on the current diagnostic criteria for diabetes (Ravi-Shankar 
et a/2001). 
The general consensus of the key groups concerned is that diabetes mellitus is a group of 
metabolic diseases characterised by hyperglycaemia resulting from defects in insulin 
secretion, insulin action or both. The reports recognise that there are disturbances of 
carbohydrate, fat and protein metabolism, which can lead to chronic hyperglycaemia as 
well as microvascular, macrovascular, and neurological complications of this disorder. To 
date these main organisations have recognised that the vast majority of cases of diabetes 
mellitus fall into two main aetiopathogenic categories, both of which exist in the UK. The 
first group which is currently termed 'type I' or 'TIDM' is insulin dependent diabetes 
mellitus or juvenile onset diabetes, which includes the immune mediated beta cell 
dysfunction resulting in absolute deficiency of insulin secretion. There is also a subgroup 
ofTIDM where there is no evidence ofautoimmunity and this is termed 'type 1 idiopathic 
diabetes'. Approximately one-quarter of all diabetics suffer from the TlDM form and it 
will be this disorder that will be the main focus of interest during this thesis. Secondly, the 
more prevalent form of diabetes, which accounts for approximately three-quarters of 
patients, is termed 'type 2' or 'T2DM' and is 'non-insulin-dependent diabetes mellitus', 
which is characteristically onset during adulthood. Several subgroups of T2DM are also 
known to exist, an obese form and a non-obese form, as well as rare Maturity Onset 
Diabetes of the Young (MODY). The cause is a combination of resistance to insulin action 
and an inadequate compensatory insulin secretory response. 
Various lines of evidence also exist to classify further sub-groups of diabetes, which are 
numerically small in comparison to the TIDM and T2DM conditions, and are etiologically 
very heterogeneous. These include diabetes secondary to some other disorder such as 
pancreatic or endocrine diseases, gestational diabetes where the onset occurs in women 
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during pregnancy where glucose tolerance often returns to normal postpartum, and thirdly, 
all other types of diabetes mellitus associated with fibrocalcific pancreatitis and 
malnutrition related diabetes mellitus (MRDM). The up-to-date classification of diabetes 
subgroups proposed by the A.D.A. and adopted by the W.H.O is summarised in table l 
(Alberti and Zimmet 1998). 
During the development of this thesis a collection ofBritish Caucasoid TlDM subjects and 
Southern Indian T2DM subjects were studied. Therefore, both subgroups require a brief 
summation here. The classification criteria used throughout this thesis are based upon the 
recommendations of the 'aforementioned 'American Diabetes Association' clinical 
pmctice recommendations 1998/1999, along with World Health Organisation criteria 1998. 
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TlDM 
(Type 1) 
T2DM 
(Type 2) 
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Sub-groups 
(beta cell destruction, usually leading to absolute insulin 
deficiency) 
• Autoimmune . 
• Idiopathic 
• Predominantly insulin resistance with relative insulin 
deficiency. 
• Predominantly secretory defect with insulin resistance. 
Other specific • Genetic defects of ~-cell function. 
types • Genetic defects in insulin action. 
• Diseases of the exocrine pancreas 
• Endocrinopathies 
• Drug or chemical induced 
• Infections 
• Uncommon forms of immune-mediated diabetes 
• Other genetic syndromes associated with diabetes 
Gestational • Gestational impaired glucose tolerance 
diabetes (GDM) • Gestational diabetes 
Table 1. Classification of diabetes mellitus as outlined by WHO 1998. Adapted 
with slight modification from 'World Health Organisation' recommendations 1998 
(Aiberti and Zimmet 1998). 
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Diabetes mellitus 
In investigating any disease it is important to understand the fundamental underlying 
factors leading to the patients disease symptoms. This is particularly important in the case 
of diabetes, especially as two different forms of the disease are being studied within this 
thesis. This section will aim to define the two forms of diabetes under investigation 
'TlDM' and 'T2DM', which differ in their aetiological, pathogenic and epidemiological 
characteristics. 
Type 1 diabetes mellitus (TlDM) 
During the development of this thesis a collection of TlDM subjects of British Caucasoid 
origin were investigated as well as a family trio collection where the proband had TlDM. 
The TlDM subclass of diabetes is generally characterised by abrupt onset of severe 
symptoms, which indicate the presence of hyperglycaemia. Evidence suggests that there is 
a long pre-diabetic period where the initiation of pathogenesis may begin up to several 
years prior to the onset of diabetes (Gorsuch 1981). In some patients diabetes is brought to 
light by the onset of distinct physical symptoms which include polyuria, polydipsia, 
unexplained weight loss in spite of polyphagia and glucosuria. In extreme cases patients 
may also present with ketosis, acidosis and even coma. Other symptoms can include 
genital itching, impairment of visual acuity, repeated skin sepsis and unaccountable pain 
and paraesthesiae in the limbs. All patients are dependent upon exogenous insulin in order 
to sustain life and its omission results in life-threatening diabetic ketoacidosis caused by 
absolute insulin deficiency (insulinopenia). 
There are widespread biochemical abnormalities, but the fundamental defects to which 
most of the abnormalities can be traced are (I)-reduced entry of glucose into various 
peripheral tissues, and (2) increased liberation of glucose into the circulation from the 
liver. Only the TlDM form has an autoimmune aetiology with a genetic predisposition 
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linked to certain class 2 major histocompatibility (MHC) genes. There is also an idiopathic 
form of TlDM where the aetiology is unknown, there is no evidence of autoimmunity 
however patients are prone to insulinopenia and ketoacidosis. 
Diagnostic criteria for autoimmune TlDM 
The detection of glucose in the urine (glucosuria) is usually the first diagnostic indication 
of the diabetic state, and can be easily performed using the non-invasive 'Diastix' method. 
Although glucosuria is not a definitive marker of diabetes, it indicates a requirement for a 
blood-screening test. TlDM subjects also have an extra-cellular glucose excess and, in 
many cells, an intracellular glucose deficiency, a situation that has been described as 
starvation in the_ midst of plenty. The definitive clinical diagnosis of TIDM is therefore 
relatively straightforward and involves testing the patient's fasting blood glucose levels. In 
non-diabetic people under normal conditions of life, blood glucose concentration is 
regulated at values between about 3 mmolll (54 mg/dl) and 6 mmolll {108 mg/dl). In 
people with diabetes, both glycaemic setting levels and homeostatic corrective mechanisms 
are deranged in varying sometimes gross, degrees. Blood glucose values in untreated 
diabetes are often found to be in the range of 15-25 mmolll (270-450 mg/dl). 
In accordance to the new and updated 'ADA-expert committee' criteria guidelines for 
diagnosis, diabetes can be confirmed by one of three methods. These diagnostic figures 
vary slightly from earlier definitions reflecting the increase in knowledge with regard to 
the development of complications. The first indication of diabetes is the presentation of 
classic symptoms of diabetes such as polydipsia, polyuria and unexplained weight loss 
with a casuaVrandom plasma glucose concentration greater than or equal to 11.1 mmolll 
(200mgldl) (where casual is defined as anytime of the day irrespective of time since last 
meal). Secondly, diagnosis can be achieved by taking plasma glucose tests following 8 
hours of fasting (no calorific intake). This test requires repeat testing on a different day as 
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confirmation, and is set at 7.0 mmol/L (126 mg/dl) using the fasting plasma glucose (FPG) 
test. The third technique, which is not recommended for routine clinical use, involves 
using a glucose load containing 75-g anhydrous glucose dissolved in water and testing 
glucose levels 2 hours post load, where positive levels are greater than or equal to 
ll.lmmol/1 (200mg/dl). The ADA diagnostic criteria as proposed by 'The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus' in 1997 are shown in 
table 2. 
Interest has also been shown in the use of glycated haemoglobin A1c (HbA1c) in 
conjunction with the FPG value as a tool for screening and identification of impaired 
glucose tolerance and diabetes (Peters et a/ 1996; Rohlfing et a/ 2000). The mean blood 
glucose level as a means of estimating glucose control can be measured by the HbA1c 
value, which is a component ofHbA1. It is known that glucose can attach to many proteins 
via a nonenzymatic, post-translational process through the formation of a Schiff base 
followed by an Amadori rearrangement to form an irreversible ketoarnine. Haemoglobin 
within newly formed red blood cells enters the circulation free from any glucose 
attachment. Red blood cells are freely permeable to glucose, and glucose becomes attached 
to haemoglobin at a rate that is dependent upon blood glucose concentration. Importantly, 
the turn over of red blood cells is relatively rapid and as a consequence of this, the average 
amount of glycated haemoglobin change reflects the mean blood glucose blood 
concentration over a 6-8 week period (Nathan et a/ 1984; Goldstein et al 1984). 
Suggestions have been made that diabetes should not be diagnosed in subjects with a FPG 
less than 7.8 mmol/1 (140mg/dl) unless accompanied with a high HbA1c value (Davidson et 
al 1999). However, due to problems in the standardisation of HbA1c assays this is not a 
technique routinely used in the diagnosis of diabetes mellitus. 
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Diabetes Mellitus 
Fasting 
or 
2-h post glucose load 
or both 
Impaired Glucose 
Tolerance (IGT}: 
Fasting concentration 
and 
2-h post glucose load 
Impaired Fasting 
Glycaemia (IFG): 
Fasting 
2-h 
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Glucose concentration (mmol 1-1 (mg dl-1} 
Whole blood a Plasma 
Venous 
;:.: 6.1 (;:.: 110) 
;:.: 10.0 ( ;:.: 180) 
<6.1 (<110) 
;:.: 6.7 (;:>: 120) 
and 
< 10.0 (<180) 
;:.: 5.6 (;:>: 100) 
and 
< 6.1 (< 110) 
< 6.7 (< 120) 
Ca~illa~ 
;:.: 6.1 ( ;:.: 110) 
;:.: 11.1 ( ;:.: 200) 
<6.1 (<110) 
;:.: 7.8 (;:>: 140) 
and 
< 11.1 ( <200) 
;:.: 5.6 (;:>: 100) 
and 
< 6.1 (< 110) 
< 7.8 (< 140) 
Venous 
;:.: 7.0 (?; 126) 
;:.: 11.1 ( ;:.: 200) 
<7.0 (<126) 
;:.: 7.8 (;:>: 140) 
and 
< 11.1 (<200) 
;:.: 6.1 (;:>: 100) 
and 
< 7.0 (< 126) 
< 7.8 (< 140) 
Ca~illa~ 
;:.: 7.0 ( ;:.: 126) 
;:.: 12.2 ( ;:.: 220) 
<7.0 (<126) 
;:.: 8.9 (;:>: 160) 
and 
< 12.2 (<220) 
;:.: 6.1 (;:.: 110) 
and 
< 7.0 (< 126) 
< 8.9 (< 160) 
Table 2. Values for diagnosis of TlDM as recommended by WHO 1998 criteria 
for diagnosis of diabetes mellitus (adapted from Alberti and Zimmet 1998). 
a Corresponding values for capillary plasma are: for Diabetes Mellitus, fasting ;:>:7.0 
(;:.:126), 2-h ;:.:12.2 (;:>:220); for Impaired Glucose Tolerance, fasting< 7.0 (< 126) and 2-
h ;:>:8.9 (;:.:160) and <12.2 (<220); and for Impaired Fasting Glycaemia ;:.:6.1 (;:>:110) and 
<7.0 (<126) and if measured, 2-h <8.9 (<160). 
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Glycaemic control in TlDM 
As a consequence of the immune mediated genetically programmed destruction of the islet 
~-cells, TlDM patients have much reduced or complete loss in the production of insulin. 
In some rare patients where there are still some remaining 13-cells adequate glycaemic 
control can be achieved by weight reduction, exercise and/or the use of oral agents to 
stimulate insulin production. These patients do not require insulin providing they follow a 
strict dietary control of carbohydrate and fat intake. Other diabetic subjects require insulin 
in order to maintain adequate glycaemic control, but its absence is not life threatening. 
Most TIDM cases however, fit into the category where survival of the patient is only made 
possible by the administration of insulin. 
Insulin therapy 
Administration of insulin has become the primary treatment for TIDM. Firstly in the form 
of animal insulin's such as bovine or porcine, and later with genetically engineered semi-
synthetic human insulin (Fletcher 1990). Almost all insulin now used in the United States 
is synthetic recombinant human insulin. Today insulin still requires injecting 
subcutaneously and there is no form of administering orally, however pulmonary and rectal 
routes are currently under investigation (Laube et al 1998), as well as a surgically 
implanted programmable insulin pump (Dunn et at 1997). The primary aim of insulin 
injection therapy is to restore the plasma concentration of insulin to a normal level that 
would have been maintained by the islet ~-cells, and consequently achieve long-term 
glycaemic normalisation. Several different insulin regimens can effectively control 
hyperglycaemia in subjects through multiple daily injection of regular, intermediate-acting 
and long acting insulin's or continuous subcutaneous insulin infusion with a pump. 
Therapeutic problems do however exist such that ~-cell secretion of insulin is stringently 
controlled to a more accurate degree than can be achieved by injection regimes, and also 
- 17-
Chapter 1: Diabetes mellitus and its complications 
that there is a physiological difference in the ratio of portal to peripheral insulin 
concentration to normal. 
Pancreas and islet transplantation 
Pancreatic transplantation and immunosuppressive regimes using cyclosporin and anti-T-
cell antibodies have been successful in the treatment of diabetic patients with renal failure 
where success results in independence from exogenous insulin therapy and a normalisation 
of blood glucose concentrations and HbA1c values. Recently a great deal of research has 
been employed to establish techniques for a far less invasive procedure of islet cell 
transplantation. This involves 500,000 or more islets from cadaveric pancreases injected 
into the portal vein of the recipient. Current success in diabetic patients is however very 
low and improvement in immunosuppressive drugs and islet harvesting techniques are 
required. This has begun to be seen in one study carried out in Edmonton, Canada, where 
seven TlDM subjects were transplanted with -800,000 islet cells and maintained on 
sirolirnus, tacrolimus and daclizumab. All subjects showed normal HbAlc values without 
exogenous insulin one year after transplantation (Shapiro et a/ 2000; Shapiro et a/ 2001 ). 
Improvements in experimental harvesting techniques have also been seen in studies that 
have so far only been carried out in animals to generate islet cells from islet-producing 
stem cells (Ramiya et a/ 2000; Halban et a/ 2001). 
Epidemiology of TlDM 
The onset of TlDM is rare in the first few months of life but rises gradually throughout 
early childhood and peaks during the pubertal years in both males and females. Following 
this, there is a sharp fall in incidence with approximately 30% of cases being diagnosed 
after the age of 20 (Lounamaa 1996). Although the incidence is highest in schoolchildren 
and adolescents it is also now clear that TlDM may develop at any age and there are 
indications that the age-at-onset pattern of the disease is changing (Tuomilehto 1992; 
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Melbak and Marner 1994). The presentation of diabetes is similar in both children and 
adults, and the same diagnostic criterion applies to both (Pinkey 1994). There is little 
difference in the incidence of TIDM between males and females, but the EURODIAB 
ACE study showed a slightly higher incidence in males compared to females but without 
statistical significance (Green 1992). A family history of diabetes has been shown to be a 
contributing factor to the onset of diabetes where approximately 5% of frrst degree 
relatives of a diabetic proband also have the disease. Twin studies have also shown a 50% 
concordance rate for the disease (Barnett 1981 [b ]). The majority of diabetic patients 
however do not have a first degree relative with the disease. Other influences affecting the 
incidence of T1DM also appear to exist and are thought to include temporal trends where 
most North European countries show a steady increase in incidence, and also seasonal 
variations where a decline in incidence is often seen during the summer months (Karvonen 
1993; Karvonen 1996; Karvonen 1998). 
Incidence in UK population and worldwide 
TIDM has an annual incidence of 15.6 cases per 100,000 of the population under 21 years 
in the U.K. There is a weak North-South gradient in incidence with Scotland and Northern 
Ireland having overall higher rates in incidence than England (Amos et al 1997; Zimmet 
1999; Dobson. 2000). The incidence of TIDM is currently being monitored by the WHO 
Diabetes Mondiale (DiaMond) study project, consisting of diabetes monitoring registries 
throughout the world (WHO 1991). On a world-wide scale diabetes currently affects 135 
million people of which 13 million have the TIDM subgroup. The incidence of TlDM 
accounts for 10-15% of all diabetic cases in European populations. The incidence is 
highest in Finland/Scandinavia, affecting more than 45 cases/year/100,000 inhabitants 
(Tuomilehto et al 1999), and Sardinia affecting 30/100,000 per year (Muntoni and Songini 
1992). It is of medium incidence in Europe and the USA (approximately 10-15 
cases/year/1 00,000). The incidence decreases dramatically towards the Mediterranean area 
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affecting 8/100,000 inhabitants per year, and is lowest in oriental groups (0.5 
cases/year/100,000) and populations living in the tropics (Green et al 1992; Yang et al 
1998). 
Karvonen et al 1993 reported a steady temporal increase in the incidence of diabetes in 
North America, Northern Europe, Japan and New Zealand between 1960 and 1989. The 
same group also published a later report, which further substantiated this, as well as 
highlighting a significant global variation in the incidence of T1DM (Karvonen et al 
2000). Gardner reported data from Finland and the UK showing that the main increase in 
the incidence of diabetes is occurring in children under 5 years (Gardner et a/1991). The 
world-wide prevalence of diabetes was predicted to more than double between 1994 and 
2010, to 239 million people (McCarty and Zimrnet 1994). 
Pathogenesis of TlDM 
The exact processes initiating the onset of Tl DM are not yet completely understood, 
although several environmental and genetic influences have been found to be strongly 
associated to the disease. The pathogenesis of TIDM is known to be associated with an 
organ specific autoimmune reaction against the pancreatic islet ~-cells for which the 
pathognomic sign is a nearly complete loss of the pancreatic ~-cells at the time of clinical 
diagnosis. 
Anatomy and physiology of the non-diabetic and TlDM pancreata 
The pancreas is a composite and lobulated gland, which lies immediately behind the 
peritoneum of the posterior abdominal wall. It consists of a head, neck, body and tail and 
normally weighs between 60g and 160g with a length of about 15cm. The pancreas is 
composed of two types of secretory cells. Approximately 98% of the pancreatic cells are 
exocrine 'serous acini', which are under the influence of secretin and cholecystokinin 
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(CCK) produced by enteroendocrine cells of the small intestine. These cells discharge 
various digestive enzymatic secretions such as trypsin, lipase and bicarbonate into the 
duodenum to assist in digestion. The remaining 2-3% are pale staining metabolic endocrine 
cells, which cluster together in a cellular aggregate known as the islets of Langerhans, and 
are involved in hormone secretion into the portal vein. The normal adult human 'islets' are 
ovoid, with an average diameter of 76 x 175J.Lm, and consist of a compact mass of 
epithelial cells permeated by a dense network of capillaries. These collections of cells are 
scattered throughout the pancreas, although they are more plentiful in the tail than in the 
body and head (Lazarus and Yolk 1962). There is a wide variation in the number of' islets' 
in the human pancreas, however there are approximately 1 05 - 106 scattered throughout the 
exocrine parenchyma of the pancreas. Each aggregate contains approximately 1000 
endocrine cells, of which four cell types can be distinguished on the basis of their staining 
properties, and morphology using electron microscopy. Approximately 80% are the insulin 
producing 'beta' (fl) cells, and about 15% are glucagon secreting 'alpha' (a.) cells. The 
remaining 5% are composed of 'delta' (o) cells that produce somatostatin, and 'pancreatic 
polypeptide'-containing (PP) cells. The beta cells are generally located in the centre of 
each islet, and tend to be surrounded by the alpha cells (Goldstein et a/1968; Deconinck et 
a/1971). 
Insulin is synthesised in the beta cells firstly as preproinsulin in the ribosomes of the rough 
endoplasmic reticulum (ER) which is then cleaved to form proinsulin and transported to 
the golgi apparatus where it is packed into secretory granules located close to the cell 
membrane. Insulin secretion is regulated primarily by extracellular glucose concentration 
whereby glucose is taken up into the beta cells via glucose transporters (GLUT2 and 
GLUTl) and is consequently metabolised to glucose-6-phosphate. This results in an 
intracellular increase in ATP concentration closing potassium dependent ATP (KA TP) 
channels in the beta-cell membrane causing membrane depolarisation and an influx of 
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calciwn. This increase in intracellular free calcium promotes margination of the secretory 
granules, their fusion with the cell membrane and the release of their contents into the 
extracellular space. The secretion of insulin in normal subjects is pulsatile with a 
periodicity of9-14 minutes, and loss ofthis is an early sign ofp-cell dysfunction. 
Pancreata from patients with recent onset TIDM are normal in appearance, size and 
weight, however, patients with chronic TIDM display a considerable reduction in weight 
and volwne of the pancreas. This volwne reduction, results from severe, pathognomonic 
changes which mainly involves the reduction of P-cells by pancreatic endocrine cell 
atrophy (Gepts 1965; Gepts and Lecompte 1981). Quantitative evaluation using 
immunohistochemistry and inununoflourescence techniques on islet tissue from newly 
diagnosed diabetic pancreatic biopsy specimens has revealed a marked decrease in the total 
P-cell insulin containing cells to about one-third to one-seventh of that of non-diabetics. 
These studies have also shown that the diabetic pancreas exhibits preservation of glucagon 
containing cells, as well as evidence of some immunological changes (Stefan et a/ 1982; 
' Rahier et al 1983; Hanafusa et al 1990). The P-cells do not always disappear completely, 
but are still present in most patients with diabetes of less than 10 years duration, and in 
40% of patients with disease duration between 11 and 40 years. Severe acinar cell atrophy 
is seen in the surrounding cells of insulin deficient islets, and the peri-lobular spaces are 
enlarged and contain loosely arranged connective tissue, but acinar tissue around insulin-
containing islets is normal (Foulis and Stewart 1984). The large arteries are often affected 
by arteriosclerosis, while the small arterial vessels show diabetic microangiopathy. The 
islet cell organisation is also distorted with many endocrine cells scattered as single cells in 
the exocrine tissue (Gepts and Lecompte 1981; Cossel et a/ 1983; Kawanishi et a! 1966; 
Kloppel 1985). 
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Aetiology of J3-cell destruction in TlDM 
The precise aetiology of autoimmune ~-cell destruction of TlDM is still not completely 
clear and strong evidence indicates a multifactoral basis, determined by both genetic and 
non-genetic (environmental) factors (Tisch and McDevitt 1996; Haverkos 1997). Several 
groups have written comprehensive reviews with respect to the pathogenesis of TlDM 
(Atkinson and MacLaren 1994; Mandrup-Poulsen 1998; Chowdhury et a/ 1999 [c]). 
Evidence suggests that TlDM results from a cellular-mediated autoimmune destruction of 
the P-cells of the pancreas, determined by defects in immune regulatory genes, which is 
often initiated several years prior to the onset of diabetes. However, twin studies have 
shown that there is also considerable evidence for the involvement of environmental 
factors in the pathogenesis of ~-cell destruction. It has been hypothesised that telomeres 
might play a role in the pathophysiology of TlDM, where altered cell turnover and 
different rates of attrition in the length of the telomeres leads to premature replicative 
senescence of the cell (Jeanclos et a/ 1998). It has also, recently been suggested (Pipeleers 
et a/ 2001) that the ~-cell itself may actively participate in its own destruction, rather than 
being a passive victim of a cytotoxic process. They suggested that the surrounding non-P-
cells also influence the process of P-cell death by making the islets internal milieu more 
protective or toxic. Evidence for the immunologically mediated destruction of insulin 
secreting P-cells comes from several lines which will be discussed here: 
Autoimmune markers 
One indication of diabetes is the presence of insulitis, where the 'islets of Langerhans' of 
recently diagnosed diabetic patients are infiltrated by mononuclear cells. This islet· 
infiltrate consists primarily ofT lymphocytes, from both of the two major subtypes 'cluster 
of differentiation'- 4 and 8 (CD4 and CD8) with a predominance of CD8+ cells together 
with macrophages (Foulis et a/ 1986). The presence of markers of the autoimmune 
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processes, which lead to the destruction of the P-cells of the pancreas, is also a factor. 'Islet 
cell auto-antibodies' {ICA's) are a feature of newly diagnosed diabetes and comprise 
autoantibodies to a number of antigens (Wilkin 1990; Bonifacio et al 1990; Genovese et at 
1992). Such antibodies include autoantibodies to insulin (IAA's), autoantibodies to 
glutamic acid decarboxylase (anti-GAD6s), and autoantibodies to protein tyrosine 
phosphatases (I-A2) which can be detectedin up to 90% of patients (Atkinson et a/1986; 
Christie et a/1992; Baekkeskov et a/1990; Leslie et a/1999 [a]; Lernmark 1987; Hawa et 
a/1997). Approximately 10% of new cases of TlDM occur in first degree relatives of a 
diabetic proband. Amongst these, positivity for ICA's and at least one other autoantibody 
gives an 88% risk of developing TlDM, and identifies 75% of those who are actually 
progressing to disease. It is important to note that none of the autoantigens described to 
date have been found to be the defmitive diabetes autoantigen. 
Metabolic markers also provide a prediction tool for the onset of TlDM where the acute 
insulin response to several secretagogues such as glucose, arginine, glucagon and 
isoproterenol decrease progressively during the preclinical period. The most widely 
performed test is the acute insulin response to glucose (AIR-g) test where the serum insulin 
increase after an intravenous glucose challenge is measured, the result of which correlates 
with functioning beta cell mass (McCulloch et a/1993). 
Animal studies 
Animal studies into immune-related P-cell destruction using BioBreeding (BB) rats and 
Non Obese Diabetic (NOD) mice have served as models for human TlDM. Studies carried 
out by Like et a/1982, using 'BB' rats have shown evidence for cell mediated autoimmune 
pathogenesis of diabetes by administering antiserum to rat lymphocytes which prevented 
the onset of diabetes. Further studies using the BioBreeding/Worcester (BB/Wor) rat, 
showed that pancreatic islet insulitis occurs in the presence of enhanced class I antigen 
- ?.d. -
Chapter 1: Diabetes mellitus and its complications 
expression (Weringer and Like 1988). Studies using transplantation methods on the NOD 
mouse were carried out by Stein et al 1992, which showed that destructive insulitis can be 
transferred to non-diabetes prone mice. 
Genetic susceptibility to TlDM 
The genetics of TlDM have been comprehensively reviewed by Cavan et a/ 1992; Julier et 
a/1996; and Todd 1997. These articles have discussed the various lines of evidence for the 
involvement of several key genetic components in the aetiology of TlDM, and it is these 
points that will also be discussed here. The involvement of a genetic component in the 
underlying aetiology of TlDM has been confirmed, based upon findings from twin studies 
and also from family studies, suggesting that susceptibility to developing TlDM may be in 
part due to a genetic component. Monozygotic and dizygotic twin studies have argued a 
strong case for a genetic involvement in the genesis of TlDM. Twin study's where the 
'index' twin has developed TlDM has been carried out on large patient collections from 
several populations. These include studies carried out by O!mos et a/ 1988; Barnett et a/ 
1981 (b); Kaprio et a/ 1992 on a population of Finnish twins, by Kumar et a/ 1993 on 
North-American twins, Kyvik et a/1995 on young Danish twins, and recently by Redondo 
et a/1999 and 2001 on monozygotic twins in Great Britain and the United States. These 
studies have collectively shown a higher disease concordance rates for TlDM in identical 
monozygotic twin pairs (45% to 96%), compared to non-identical twins (3% to 37%). 
These C<?ncordance rates are however below unity, implying that there is also an 
environmental component involved in the aetiology. These studies have also concluded 
that the twins that progressed to heterogeneity of diabetes (25%), did so if the patients 
were diagnosed at a younger age, and also that the rates of developing diabetes in the eo-
twins declines sharply in the years after diagnosis of the index twin. 
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A positive family history is also a risk determinant, with familial clustering occurring 
among first-degree relatives. In siblings of diabetic probands the risk of developing the 
disease is about 5% (WHO 1994), and there is evidence of preferential transmission where 
the risk is higher if the child's father (5-6%) rather than the mother (2-3%) has TlDM. 
Between 80-90% of all newly diagnosed diabetics have no family history of the disease, 
however the remaining 20% of patients show familial aggregation (Warram 1984; The 
EURODIAB ACE Study Group 1998). Genome wide searches of families with two or 
more affected sib pairs have been carried out using fluorescence based technology and 
linkage analysis. These searches have identified more than 30 genomic susceptibility 
intervals and potential candidate genes for TIDM situated on different chromosomes, with 
varying degrees of evidence for linkage (Easton 1989; Davies et a/ 1994; Todd 1997; 
Friday et a/ 1999). In addition to the argument for a genetic involvement, epidemiological 
data suggests that disease incidence rate is increasing at a rate which is faster than can be 
explained by changes in the gene pool alone (Karvonen et a/ 1993). 
Susceptibility genes for TlDM 
Two main chromosomal influences have been found to be associated with TIDM. Firstly, 
and the most influential is the IDDMI in the Major Histocompatibility Complex (MHC) on 
chromosome 6p21, and the second is the IDDM2 in the insulin gene region (INS) on 
chromosome 11 p 15 and these will be briefly discussed below. 
Major Histocompatibility Complex (MHC) (IDDMl) 
The Major Histocompatability Complex (MHC) is situated in the region associated with 
the genes for the immune system recognition molecules known as the Human Leucocyte 
Antigen (HLA). The MHC is situated on chromosome 6p21, consists of around 3500 Kb of 
DNA which code for more than 200 genes and has been shown to be a principle region 
associated with the genetic predisposition to TIDM. Most of these genes are known to be 
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involved in the antigen presentation and processing events of the immune response. The 
MHC is composed of three major regions, namely class I, class II and class Ill, which are 
described by Campbell and Trowsdale 1993 and Trowsdale and Camp bell 1997. The class 
I region (covering HLA-A, -B, -C, -E, -F, -G and -H) encodes the single polypeptide beta-
chain peptide which forms part of the trans-membrane molecules expressed on the surface 
of nucleated cells to activate CD8+ cytotoxic T -lymphocytes. The class II region contains 
genes, which code for the alpha and beta chains of the HLA-DR, DQ and DP molecules, 
which are involved in activating CD4+ T-helper (Th) cells. The class Ill region encodes a 
·large number of genes related and unrelated to the immune response. Such genes include 
complement factors, tumour necrosis factors (TNF) ex. and J3, heat shock proteins and many 
others. 
The pathological processes that take place during J3-cell death are thought to begin with the 
expression of interferon-alpha by the beta cell. Secretion of this cytokine is associated with 
hyperexpression of class I MHC by all endocrine cells within the islet and the presence of 
aberrant class II MHC molecule expression by B-cells (Foulis 1996). Early studies for 
genetic markers of TlDM in the MHC 'class I' region showed a positive association 
between HLA-BlS, B8 and B18. The strongest associations came from B8 where positive 
associations were found in both Caucasoid and Negroid populations with a neutral 
association in Asians (Cudworth and Woodrow 1975, 1976.; Nerup et al1974; Singal and 
Blajchman 1973). A number of other studies have also shown evidence that the 'class I' 
region contains genes that play an important role in the susceptibility to TlDM (Demaine 
et all995; Fujisawa et all995). Also, studies carried out by Hodgkinson et all999 have 
found an association between the HLA-E locus and age at onset and susceptibility to 
TlDM in British Caucasoids. It is within the 'class II' and 'class ill' regions of the MHC 
however, that several stronger associations have since been made for candidate genes for 
TIDM. The pathology involving autoimmune destruction of pancreatic islets in TIDM has 
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been found to have a strong association with possession of Human Leukocyte Antigen 
(HLA) -DR3 and/or -DR4 antigens (Platz et a/ 1981; Ratter et a/ 1983; Wolf et a/1983). 
In the British Caucasoid population, approximately 90-95% of patients with TIDM has the 
DR3 and/or DR4 HLA antigens, compared with 45-54% of the general population (Jenkins 
et a/1990; Cavan et a/1997). Approximately 50% ofTIDM patients are heterozygous for 
HLA-DR3/DR4 whereas this is only seen in 5% of the normal population (Gottlieb and 
Eisenbarth 1996). It has been suggested that the HLA association with diabetes relates to 
the affinity of the MHC molecules for different diabetogenic peptides (Nepom and 
Robinson 1990). 
In conclusion, the combination of these regions within 'class I, I1 and ill' of the MHC 
represents the genetic susceptibility associated to the MHC (Lie et a/1999). However it is 
important to note that this does not completely confer susceptibility and that other genes 
within and outside of the MHC are also important in the susceptibility or protection from 
the onset ofTlDM. 
Insulin gene (INS) (IDDMl) 
The insulin gene region located on chromosome 11p15 has also been found to show 
association with, and linkage to TlDM. This 20-kb chromosome region is known to 
contain genes encoding tyrosine hydroxylase (TH), insulin (INS) and insulin like growth 
factor II (IGF-II). The human insulin gene and its flanking regions are known to exhibit 
conserved and highly variable sequences, which have previously been sequenced, 
originally by Bell et a/1982, and showed DNA sequence polymorphisms. It is known that 
there is a highly polymorphic region flanking the 5' end of the insulin gene (Ullrich et a/ 
1982; Owerbach and Aagaard 1984). A TlDM susceptibility region has been found to be 
present in the 5' region of chromosome llp15.5, in a case control study (Bell et a/1984). 
Owerbach and Gabbay 1993 reported finding that suggest the localisation of the TIDM 
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susceptibility locus on chromosome llp15.5 is in the 5' variable number tandem repeat 
(VNTR) region of the insulin gene. Also Lucassen et al 1993 reported susceptibility to 
T lDM to be mapped to a 4.1-kb region including the insulin gene and VNTR, but 
excluding TH and IGF2. By cross-match haplotype analysis and linkage disequilibrium 
mapping, Bennett et at 1995 and 1997 mapped the mutation to within the VNTR itself. 
They have shown that IDDM2 expression is influenced by parent-of-origin effects, and 
that allelic variation of the VNTR may correlate with the level of INS- ribonucleic acid 
{RNA). 
A transracial study carried out by Undlien and colleagues looked at TlDM patients from 
three different ethnic groups, namely Tanzanian blacks, Norwegian Caucasoids and 
Japanese Orientals. They concluded that polymorphisrns in the insulin gene only conferred 
significant susceptibility to TlDM in Caucasoids (Undlien et a/1994). Mijovic et a/1997 
reported further studies on INS region genotypes in Japanese, Hong Kong Chinese, North 
Indian Asians and Afro-Caribbean's finding no INS polymorphism across all races. 
It would therefore appear that the additional risk ofTlDM conferred by the insulin gene is 
small in comparison to the contribution of particular HLA-DQ alleles. However, it is clear 
that it plays an important role as an additional marker and the contribution from other INS 
gene region polymorphisms cannot be excluded and warrants further investigation. 
Other genes contributing to TlDM 
Theoretical calculations suggest that the combined effects of IDDMl and IDDM2 do not 
count entirely for the genetic component of susceptibility to the disease. The respective 
contributions of the genes to the susceptibility to TlDM is approximately 42% for IDDM1 
and 10% for IDDM 2, indicating that other genes must also be involved (Davies et at 
1994). Several other genes have been proposed to be associated with susceptibility to 
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TIDM. Such genes include a locus on chromosome 15q26 (IDDM3) (Field et a/ 1994), 
11q13 (IDDM4) (Hashimoto et a/1994; Nakagawa et a/1998), 6q (IDDM5) (Davies et al 
1996), and 2q (IDDM7) (Copeman et a/ 1995). Also several investigators have found an 
association between the T -cell receptor (TCR) constant beta chain polymorphism located 
on chromosome 7q35 and TIDM (Hibberd et a/ 1992; Robinson et a/ 1993; Zhao et a/ 
1994). Analysis of a large collection of 356 United Kingdom affected sib pair (ASP) 
families (Warren 1) also found the IDDM1/MHC to be the major locus associated to 
T1 DM, and only four other regions outside of the MHC were not excluded. Two of these 
regions on chromosome 10pl3-p11chromosome 16q22-16q24 showed evidence oflinkage, 
along with two possible susceptibility genes located at chromosome 14p12-q21 and 
chromosome 19p13-ql3 (Bain et al 1990; Mein et a/1998). It is therefore likely that the 
genetic aspect of the autoimmune pathogenesis of TIDM outside of the established MHC 
region, is an amalgamation of several different contributory genes (Friday et a/ 1999). 
Non genetic risk factors of TlDM 
There are strong arguments for the involvement of an environmental influence in the 
pathogenesis of TIDM (Cooper et at 1999). These primarily include a low rate of 
concordance in monozygotic twins, where more than 70% of monozygotic twin pairs have 
been found to be discordant for the disease (Bamett et at 1981 [a and b). The incidence of 
diabetes also varies significantly according to geographical location. Large differences in 
frequency between different countries has been shown (Diabetes Epidemiology Research 
International Group 1988), and also migrants from areas of low risk to areas of high risk 
have been seen to acquire an increased risk of disease (Bodansky et at 1992). The clinical 
manifestation of the disease also shows a seasonal pattern with fewer cases diagnosed in 
the summer months and a peak in the autumn months (LaPorte and Cruickshanks 1984). 
Karvonen et at 1993 reported that in some countries of the world the rise in incidence of 
TIDM is occurring at a rate that cannot be explained by changes in the gene pool. Whilst it 
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has been proven to be difficult to elucidate a direct putative environmental agent involved 
in the onset of TlDM, research has shown several candidate factors to have a modulating 
or disease-triggering effect, and these are briefly outlined below; 
Viral Infection 
A role for an infectious agent has been indicated by the occurrence of epidemics, non-
familial clustering and seasonality in the incidence of disease (Leslie and Elliot 1994). A 
viral infection can initiate the autoimmune destruction of the islet cells of the pancreas 
through autoreactive lymphocytes by molecular mimicry mechanisms. This process occurs 
through an immune response against a viral protein that shares an amino acid sequence 
with a beta-cell protein resulting in the appearance of antiviral cytotoxic CD8 lymphocytes 
that react with self protein on the beta cells. Among the most strongly suspected 
environmental agents are certain viruses, enteroviruses and Coxsackie B viruses in 
particular and exposure early in life, possibly in utero may contribute to the aetiology of 
TlDM (Lounamaa 1996). Diabetes has been seen to occur in subjects with congenital 
rubella (Forrest et al 1971), Coxsackie B, cytomegalovirus, hepatitis C and other viruses 
which have been implicated in inducing the disease (King et al 1983; Karjalainen et a/ 
1988; Pak et al 1988). Several studies in animals have demonstrated that seveml viruses 
trigger the onset of diabetes and these include encephalomyocarditis (EMC) virus, 
Coxsackie B4 virus, Kilhams rat virus (KRV) and rubella virus. These viruses trigger 
diabetes either by directly infecting and destroying the insulin producing pancreatic beta 
cells, or by initiating an autoimmune response against the beta cells. 
Environmental Insult 
A second process could be an environmental insult which may generate cytokines and 
other inflammatory mediators that induce the expression of adhesion molecules in the 
vascular endothelium of the pancreatic islets, resulting in extravasation of circulating 
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leukocytes and the presentation of beta cell antigens (Atkinson et a/1994). Environmental 
insult may be in the form of exposure to certain food proteins or certain toxins and drugs. 
Early studies into the effects of poor nutrition during infanthood and the incidence of 
TlDM came from research carried out on a Scandinavian population (Borch-Johnson et a/ 
1984; Borch-Johnson et a/1984). The studies show some evidence to suggest that reduced 
breast-feeding during infancy is associated with the development of islet cell 
autoirnmunity. The association is suggested to be due to early exposure to cows milk 
protein (CMP) triggering an immune destruction of the ~-cells (Martin et a/1991; Virtanen 
et a/ 1994; Akerblom and Knip 1998). Amino acid homologies between the cows milk 
protein bovine serum albumin (BSA) and .the islet cell autoantigen ICA69 may explain the 
onset in some patients, in particular the CMP variants ~-casein A I variant and ~-casein 
(AI +B). Many drugs are also known to impair insulin secretion or insulin action, such as 
nicotinic acid and g1ucocorticoids (Pandit et a/ 1993; O'Byrne et a/ 1990), and toxins such 
as Vacor (rat poison) and pentamidine can permanently destroy pancreatic beta cells 
(Gallanosa et a/1981; Assan et a/1995). 
Prevention of TlDM 
Effort has been made to find effective preventative therapy for subjects at high risk for 
TlDM that can be identified using a combination of immune, genetic and metabolic 
markers. Recent data from prospective studies in humans suggests that it will soon be 
possible· to predict with reasonable certainty from genetic and autoantibody screening 
people who are likely to develop TlDM. Immunotherapy using a combination of drugs 
including azathioprine, cyclosporine, nicotinamide and insulin to reduce the immune 
mediated destruction of beta-cells has been investigated in pilot studies (Skyler and Marks 
1993). Success in these uncontrolled pilot trials has led to larger controlled trials such as 
the European Nicotinamide Diabetes Intervention Trial (ENDIT) and the Diabetes 
Prevention Trial for type I diabetes (DPT-1), the outcome of which are still to be 
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determined. Other approaches are looking at the expression of intercellular adhesion 
molecules (ICAM) such as ICAM-1 that is involved in accelerating beta cell destruction by 
cytotoxic T cells (Yagi et al 1995). Animal studies have also indicated that vaccination 
with insulin or its peptides looks very promising as a prevention method. Results from 
pilot trials in humans are also encouraging for the prospect of using insulin for primary 
prevention (Graves and Eisenbarth 1999). 
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Type 2 diabetes mellitus (T2DM) 
· During the development of this thesis a collection of Dravidian T2DM subjects from the 
Southern Indian region of Madras were also investigated. It is therefore necessary to 
differentiate between the T2DM subjects and TlDM subjects that are also included in the 
study. T2DM is often asymptomatic for many years and frequently remains undiagnosed 
because the level of hyperglycaemia is often not severe enough to provoke noticeable 
symptoms of diabetes. Patients may present either as a result of complications of diabetes 
as such patients are at increased risk of developing macrovascular and microvascular 
complications, or incidentally with an abnormal blood or urine test (Harris et al 1992). 
Subjects have relative insulin deficiency and do not normally require insulin treatment to 
survive. T2DM is characterised by hyperglycaemia caused by impaired insulin secretion, 
impaired insulin resistance in muscle, and elevated hepatic glucose production. Due to its 
clinical heterogeneity T2DM can be divided into obese and non-obese forms and also into 
early and late onset forms. The early onset form includes the formerly named 'maturity 
onset diabetes of the young' (MODY), which is a genetically heterogeneous monogenic 
form of T2DM characterised by an early onset <25 years of age, and autosomal dominant 
inheritance. The majority of T2DM subjects are obese or have characteristically increased 
percentage of body fat distributed predominantly in the abdominal region (Kissebah 1982). 
It occurs more frequently in women with prior gestational diabetes, and individuals with 
hypertension or dyslipidaemia. Ketoacidosis is seen rarely in T2DM and when it does it is 
usually in association with illness or infection. 
Diagnostic criteria for T2DM 
The diagnostic criteria for T2DM are the same as for TlDM where the fasting plasma 
glucose test is used. Insulin resistance may improve with weight reduction and/or 
pharmacological treatment of hyperglycaemia. Patients with T2DM are not dependent on 
insulin for prevention of ketonuria and are not prone to ketosis. However they may require 
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insulin for correction of symptomatic or persistent fasting hyperglycaemia if unable to 
correct using diet controls or oral hypoglycaemic agents (sulphonylureas/biguanidines). 
T2DM is often also accompanied by hypertension, high serum low-density-lipoprotein 
(LDL) cholesterol concentrations and low serum high-density-lipoprotein (HDL) 
cholesterol concentrations that can increase ~ardiovascular risk. 
Treatment of T2DM 
As with TIDM it is necessary to control the blood glucose levels in T2DM subjects, which 
can be achieved through both non-pharmacological treatment and pharmacological 
therapy. The United Kingdom Prospective Diabetes Study (UKPDS) suggested that as with 
TIDM maintaining as near normal blood glucose concentration in T2DM subjects by oral 
hypoglycaemic drugs or insulin markedly reduces the risk of microvascular complications 
(UKPDS 33). Non-pharmacological intervention in T2DM can improve many aspects of 
the disease including hypertension, obesity and insulin releaSe and effect. Weight reduction 
and calorific control are known to greatly improve glycaemic control and insulin 
sensitivity in T2DM subjects (Henry et a/1985). However, although diet, weight reduction 
and exercise are known to improve glucose metabolism compliance with these 
interventions is not sustained in many patients (Uusitupa et a/ 1993). As a consequence, 
drug or insulin therapeutic intervention is usually required for which there are currently 
four options, which can be applied independently or through polypharmacy. An increase in 
insulin release can be achieved with sulfonylureas (glipizide or glyburide) or meglitinides 
(Repaglinide). Increased insulin responsiveness can be achieved with a biguanide 
(metformin) or a thiazolidinedione (rosiglitazone- Avandia or pioglitazone- Actos). The 
intestinal absorption of carbohydrate can be modified with an alpha-glucosidase inhibitor 
(acarbose and miglitol), and a lipase inhibitor (Orlistat- Xenical) can be used to modify the 
absorption of fat. The administration of exogenous insulin can also be applied in subjects 
who have persistent hyperglycaemia despite other intervention. 
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Epidemiology of T2DM 
T2DM is the most common form of diabetes, accounting for 80-90% of all cases in 
developed countries, and the majority of cases in developing countries. The prevalence of 
T2DM varies enormously from population to population and between countries throughout 
the world. The highest prevalence has been recorded in Pima Indians and the Micronesian 
population in the Central Pacific where up to 25% of each population is affected (Trevisan 
1998). In most industrially advanced societies, the incidence of T2DM rises throughout 
adult life and is usually highest in old age. It has been noted that while the incidence of 
new cases of T2DM seems fairly stable, the prevalence in the general population may be 
rising. A study carried out in Canada showed that the prevalence of T2DM rose from 4.5 to 
7 percent between 1986 and 1991 (Blanchard 1996). Several reviews have highlighted 
differences in the clinical profiles of diabetes between the developed countries of the 
temperate region and tropical countries (Mohan 1986).. The T2DM subjects included in this 
study were collected from the Southern Indian region of Madras, a mainly Dravidian sub-
population region where T2DM is the most common form of diabetes seen. Previous 
studies carried out in the Southern Indian toWn of Kudremukh have shown that the overall 
prevalence of diabetes was as high as 5%, and in those older than 40 years it rose to 21% 
(Ramachandran 1988 [a and b)). In the region of Madras studies have shown a higher 
prevalence of diabetes in the urban population (8.2%) compared to the rural areas (2.4%) 
(Ramachandran et a/1992). Ramachandran et a/1988 [a] also demonstrated that there is a 
very high risk of diabetes in Southern Indian families with one diabetic parent. 
Pathogenesis of T2DM 
In the pathogenesis of T2DM there are at least two pathological defects either of which 
may be the predominant feature and it is uncertain whether one causes the other or whether 
both are necessary to cause T2DM (Beck-Nielsen and Groop 1994; Kahn 1994). One is 
insulin resistance where there is a decreased ability of insulin to act on peripheral tissue 
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(muscle and liver) to stimulate glucose metabolism or inhibit hepatic glucose output. A 
second defect is due to insulin deficiency where the endocrine pancreas is unable to 
compensate for insulin resistance due to a defect in the glucose stimulated insulin secretion 
and glucose desensitisation of the pancreatic f3-cell. This impairment has been associated 
to a beta cell dysfunction in the processing of proinsulin to insulin, where the proportion of 
immunoreactive proinsulin is greater in T2DM subjects (40%) compared to normal 
subjects (10%) (Kahn 1997). 
Following the stimulation of insulin secretion, insulin action can be divided into three 
stages. The first stage involves the binding of the hormone insulin to the insulin receptor 
(tyrosine kinase enzyme) on the plasma membrane of the cell. This binding leads to a 
conformational change in the receptor and stimulation of kinase activity. The second stage 
is the cascade of serine ·phosphorylation and dephosphorylation by mitogen-activated 
protein kinase (MAP), and thirdly the biological effectors of the insulin cascade involving 
translocation of the glucose transport molecules to the plasma membrane (Kahn 1994). 
Several cell mechanism defects are thought to be associated with increased insulin 
resistance including decreased activation of enzymes (glucokinase, glycogen synthase), 
reduced levels of cell-membrane glucose transporters and increased levels of circulating 
fatty acids. The cause of B-cell failure is still undetermined, however f3-cell mass is only 
modestly reduced by 20-40%. It is likely that the defect in insulin secretion is due to 
glucose toxicity in beta cells by which chronic sustained hyperglycaemia leads to impaired 
insulin secretion possibly by decreasing insulin gene expression (DeFronzo 1992; Moran 
1997). 
Aetiology of T2DM 
It is recognised that defects of insulin secretion and insulin sensitivity in the pathogenesis 
ofT2DM are multifactoral in nature influenced by both genetic and environmental factors. 
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Animal and human studies have indicated that insulin resistance alone is insufficient to 
cause diabetes in humans and that multiple abnormalities are required in the expression 
and interaction of genes controlling insulin secretion and action. Primary diabetogenes are 
involved in the initiation of diabetes, and secondary changes involve altered gene 
expression. In certain populations where there is evidence of a major genetic component, a 
'thrifty genotype' has been implicated where a metabolic efficiency is advantageous when 
food is scarce, but becomes disadvantageous when food is plentiful (Dowse 1993; 
McCance 1994; Hales et al 1992). Also, environmental factors such as diet, activity and 
environmental toxins such as use of steroids and antihypertensive agents may act as 
initiating or progression factors. 
Genetic susceptibility to T2DM 
It is becoming more and more apparent that the aetiology of T2DM is genetically and 
clinically very heterogeneous in nature and that several genes may be involved in its 
aetiology (Rotter et al 1981). Studies in unaffected eo-twins of T2DM parents, different 
prevalence between ethnic groups, familial clustering and the high concordance rate for 
T2DM monozygotic twins all suggest a predominantly inherited aetiology for T2DM 
(Newman et a/1987; Turner et a/1995; Carter 1996). Thirty nine percent of patients with 
T2DM have at least one parent with the disease (Klein et a/ 1996), and among 
monozygotic twin pairs with one affected twin, 60 to 90 percent of unaffected twins 
eventually develop the disease (Barnett et a/ 1981 [b ]). The importance of genetic factors 
in T2DM is also highlighted by the observations that lean, normoglycaemic offspring of 
parents with T2DM have reduced non-oxidative glucose metabolism associated with 
reduced muscle glycogen synthesis (Eriksson et a/1989; Rothman 1995). Several attempts 
have been carried out to identify T2DM genes by linkage studies which has led to 
conflicting results, indicating that distinct genes are probably involved in different 
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populations. It is likely that different genes may be involved in different families within the 
same ethnic group. 
Candidate genes for T2DM 
The search for possible candidate genes has focused on genes coding for proteins that 
might be involved in insulin secretion or action. For early onset T2DM (MODY) linkage 
studies have identified genes that are mutated in different MODY pedigrees. The MODYl 
locus is found on chromosome 20 (hepatocyte nuclear factor-4a gene), MODY2 locus is 
on chromosome 7 (glucokinase gene), the MODY3 locus is on chromosome 12 
(hepatocyte nuclear factor-la). A fourth form formerly referred to as MODY4 associated 
to T2DM and as a rare cause ofMODY has also been described which appears to be linked 
to insulin promoter factor-1 (IPF-1). Mutations in the IPF-1 gene result in reduced binding 
of the protein to the insulin gene promoter and decreased insulin gene transcription in 
response to hyperglycaemia (Staffers et al 1997; Macfarlane et a/ 1999). All of these 
mutations present as specific descriptions of genetic defects of beta cell function which are 
associated with abnormal patterns of glucose stimulated insulin secretion (Froguel et a/ 
1992; Hattersley et a/1992; Horikawa et a/1997). 
A genome wide search in affected sibling pairs has identified a locus encoding the cysteine 
protease calpain-10 on chromosome 2 (NIDDM1) that appeared to confer major 
susceptibility to T2DM in Mexican-Americans (Hanis et a/1996). Two genes associated to 
late onset T2DM have been reported both of which have been mapped to the long arm of 
chromosome 12. Firstly, NIDDM2, and secondly a locus between markers D12S1693 and 
D12S326. The identity of this NIDDM2 gene located on the long arm of chromosome 12 is 
unknown. However, the region on chromosome 12q has been linked to T2DM subjects 
from the Botnia region of western Finland, and also in a single pedigree from Australia 
(Mahtani et al 1996; Shaw et al 1998). Genome scans in other populations, including 
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Finland and an autosomal dominant T2DM U.S. population failed to detect linkage (Bektas 
et a/1999). A possible T2DM locus has also been reported to exist 50cM centromeric to 
NIDDM2 on chromosome 12ql5 between markers D12Sl693 and D12S326 (Bektas et a/ 
1999; Bektas et a/ 2001 ). 
The association of T2DM with deafness in families where inheritance occurred through the 
mother identified a point mutation in position 3243 of the mitochondrial gene encoding 
tRNA Leu, but this has been found to be <1% prevalence in diabetics (van den Ouweland 
1994; Kobayashi et a/1991; Tawata et a/ 1998). Polymorphisrns have. been identified in 
the insulin receptor substrate 1 (IRS-1) gene and these are a common substrate for insulin 
receptor tyrosine kinases, but suggestions are that they are not pathogenic mutations 
(Almind et a/ 1993; Withers et a/ 1998). Initial observations in humans has suggested that 
a mutation in the gene for the f33-adrenergic receptor which is involved in regulating 
lipolysis in visceral fat may be associated with obesity and the onset ofT2DM (Walston et 
a[ 1995; Widen et al 1995). These findings support the hypothesis that multiple 
abnormalities in genes controlling insulin action or secretion explain the non-mendelian 
inheritance and the variable penetrance ofT2DM. 
Non genetic risk factors of T2DM 
The development of T2DM is also known to be influenced by exposure to different 
environmental factors, evidence of which has come from studies where the frequency of 
the disease in migrants is compared with the frequency in individuals remaining in the 
original environment (Kawate et a/ 1979). Observations have been made that the 
prevalence of impaired glucose tolerance and T2DM has increased dramatically in several 
ethnic groups whose lifestyle has become 'westernised' in the last few decades (Collins et 
a/1994). A study carried out by Ramachandran et a/1988 [b) looked at a population living 
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in Southern India and found that 5% tested positively for diabetes, when compared to the 
prevalence in Indians living in London and Fiji, this rose to 10%. 
Reduced physical activity and central obesity has been found to be a major detenninant of 
T2DM, prospective studies have shown that physical activity is associated with a reduced 
risk ofT2DM. Obesity is known to decrease the sensitivity of the ~-cells to glucose (Henry 
et al 1985) which is largely reversible by weight loss. The mechanisms by which obesity 
induces insulin resistance is poorly understood however several factors are thought to be 
important and these include; free fatty acids (FF A), tumour necrosis factor (TNF)-alpha, 
the pattern of fat distribution and the genetic abnormality in the ~3-adrenergic receptor. An 
inverse relationship has· also been detennined between low birth weight and diabetes 
mellitus (Phillips et a/1994) where the relative risk of T2DM decreases with greater birth 
weight (Rich-Edwards et a/1999). 
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Complications of diabetes mellitus 
The introduction of insulin in 1922 was of paramount importance in modem 20th century 
diabetic medicine. It provid~d a lifesaving treatment for many patients, but in doing so .also 
unmasked the second consequence of diabetes which is the onset of late diabetic 
complications. Historically the complications of diabetes have been recorded for a long 
time, in as early as 1798 Rollo described pain and parasthesia in the legs of diabetic 
patients and was .also the first to note eye changes which associated diabetes to the 
development of cataracts (Grenfell 1989; Mandrup-Poulsen 1998). Although most of the 
recognised features of diabetic complications had been described well before the 
introduction of insulin, it was not until patients survived for longer periods that the full 
extent and often-fatal nature of the complications were revealed. Diabetic patients live 
today controlled by insulin but still suffering the unremitting pain, amputation, blindness, 
dialysis and death from the long-term microvascular and macrovascular complications of 
their diabetes. Although TlDM and T2DM have different underlying pathogenic 
mechanisms, the chronic long-term microvascular and macrovascular complications affect 
both groups and are the major cause of morbidity and mortality in diabetes mellitus. 
Presentation of diabetic complications 
Although a great deal of research into diabetes has centred on susceptibility to diabetes, the 
major cause of morbidity and mortality result from the long-term microvascular, 
neurologic and macrovascular complications associated with the disease. In fact it is well 
recognised that a high proportion of patients with diabetes will develop one or more 
rnicroangiopathic complications during the course of their disease. The complications of 
diabetes mellitus affect many types of tissue including nerves, skin, retina, kidney, heart 
and brain. In all of these tissues, the major cause of tissue damage is vascular disease 
affecting both the microvasculature and macrovasculature. 
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Microangiopathy of diabetes mellltus 
The common microvascular complications of diabetes occur in the diabetic retina, the 
kidney, and the nerves, and lead to retinopathy, nephropathy and neuropathy respectively, 
each of which will be discussed here; 
Diabetic nephropathy 
The kidneys are one of the key organs to be affected by diabetes and diabetic nephropathy, 
which was first described by K.immelstiel and Wilson in 1936, remains to be the most 
serious, life threatening, long-term complication of TlDM. The internal structure of the 
kidney consists of a cortex and a medulla which are enclosed within a capsule. The 
medulla contains pyramids, which drain into the pelvis collecting system. The histological 
and functional unit of the kidney is the nephron, and there are about 1 million in each 
kidney. Each nephron consists of a glomerulus and a tubule system. The glomerulus is a 
tuft of capillaries surrounded by very thin epithelial cells forming a rounded Bowmans 
Capsule. The thin walled tubule region of the nephron, namely the Loop of Henle consists 
of a proximal and a distal convoluting tubule, a collecting tubule and a collecting duct. 
Urine is the glomerular filtrate, which passes into the space of the Bowmans Capsule and 
so into the tubule system where it is modified by selective absorption and secretion. It is 
this precise mechanism which is greatly affected by diabetes and can lead to a range of 
complications categorised under the title of nephropathy. 
The incidence of renal complications in TlDM patients has been reported to be 25-40% 
after 25 years duration of diabetes, a further 15-28% of patients are reported to have 
microalbuminuria (Andersen 1983). Borch-Johnsen and colleagues reported that 
proteinuria is strongly associated with death from uraemia and cardiovascular disease 
(Borch-Johnsen 1985). In Caucasoid subjects with T2DM the prevalence of progressive 
renal disease has generally been thought to be lower than in TlDM subjects (Cowie et al 
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1989). Recent evidence however, has suggested that the renal risk is equivalent in the two 
types of diabetes where the time to proteinuria from the onset of diabetes, and the time to 
end-stage renal disease from the onset of proteinuria were similar (Ritz and Orth 1999; 
Ritz and Stefanski 1996). Large epidemiological studies carried out to follow the 
progression of diabetic nephropathy in TIDM have shown that typically there is a lag 
phase from the time of diagnosis of diabetes to the incidence of development of 
nephropathy. Following this there is a rapid rise in incidence, which peaks after 15-20 
years duration, and declines to I% per year thereafter. Therefore the likelihood of 
developing nephropathy after 20 years duration of diabetes is very small (Krolewski 1985; 
Christensen 1985). The clinical progression and manifestation of nephropathy in T2DM 
subjects is less well defmed, as subjects usually have a long duration of diabetes before 
clinical manifestation of the disease. However, it would appear to follow a similar course 
to that in TIDM subjects as described below (Nelson 1993; 1996). It has been suggested 
that T2DM subjects with normoalbuminuria or microalbuminuria may have impaired renal 
function and that cardiovascular risk factors are closely related to renal damage. As a result 
diabetic nephropathy is probably the most common indication for haemodialysis treatment 
and renal transplantation in the USA and the western world, and consequently it imposes a 
very high social and economic burden on the individual and society. 
The clinical course of diabetic nephropathy can be divided into 5 key stages, which are 
comprehensively reported and reviewed by Mogensen 1984, 1985, 1996 [a], 1997; and 
Tuttle 1990. There are considerable patient-to-patient differences in the rate of progression 
of diabetic nephropathy, however certain stages such as the progression of renal failure are 
predictable (Jones 1979). Stage 1 of nephropathy occurs shortly after the onset of diabetes 
and is first manifested as an increase in glomerular filtration where the kidney shows 
hyperfiltration and kidney hypertrophy. Early structural glomerular changes in morphology 
include thickening of the glomerular basement membrane and accumulation of 
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extracellular matrix components (Ziyadeh 1993). Stage 11, which may last for between 7 
and 15 years is a 'silent stage', where albumin is maintained in the circulatory system and 
is not excreted. However, it is during this stage that the early structural glomerular changes 
such as the expansion of the mesangial matrix and renal tubular damage take place 
(Fletcher et a/1986; Yaqoob et a/1994). Stage ill begins when microalbuminuria becomes 
evident, when urinary albumin excretion rate is greater than 20J.Lg/min and less or equal to 
200J.Lg/min (table 3). Incipient diabetic nephropathy is suspected when microalbuminuria is 
found in 2 out of 3 urine samples collected consecutively. This is the point of established 
renal injury. Once constant microalbuminuria is established, and unless there is clinical 
intervention, progression to nephropathy is inevitable. Studies have shown that 
approximately 80% of patients with microalbuminuria progress to overt nephropathy in I 0 
years. Stage IV is established when overt diabetic nephropathy is suspected, when the 
urinary albumin excretion mte is greater than 200J.Lg/min for at least 2 out of 3 urine 
samples collected within maximal 6 months. Almost all diabetic patients at this stage of 
nephropathy will also exhibit diabetic retinopathy. Once overt nephropathy is established, 
a relentless decline in renal function is seen, associated with an elevation· in arterial 
pressure. At this stage anti-hypertensive treatment, particularly with angiotensin converting 
enzyme (ACE) inhibitors may be beneficial in reducing the rate of progression to renal 
failure (Raskin 1996; Bilous 1996; Mogensen 1996 [b]). Finally, stage V, otherwise known 
as end-stage renal disease is defined clinically by an increase in the excretion of larger 
plasma protein, ~-2-microglobulin, with an albumin excretion rate of approximately 1000 
J.Lg/min, with a generalised glomerular closure leading to uraemia requiring dialysis or 
kidney transplantation. 
It has been postulated that diabetic nephropathy occurs as a result of the interplay of 
metabolic and haemodynamic factors in the renal microcirculation. Pivotal studies, 
including the DCCT (DCCT 1993 [a], 1995 [a], 1998) have demonstrated the effects of 
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intensive blood glucose control and antihypertensive therapy on the progression of urinary 
albumin excretion. This implicates poor glycaemic control and hypertension in the 
progression from normoalbwninuria to microalbwninuria. It has been suggested that once 
urinary albumin concentration exceeds the normal range ( 4 ± I mg/1) the risk of developing 
diabetic nephropathy is increased. A large prospective clinic-based study of 1200 TlDM 
subjects which were followed for 4 years suggested that a urinary albumin concentration of 
7.4 mg/1 implicates a significantly increased risk for the development of nephropathy 
(Royal College of Physicians of Edinburgh Diabetes Register Group 2000; Walker et a/ 
1999). Significant improvements have been made in the treatment of diabetic subjects and 
population based studies have shown a delay in the onset of renal disease probably due to 
improved glycaemic control and clinical intervention (Bojestig et a/ 1994; Krolewski 
1996; Walker 2001; Hovind et a/2001 [b]). Studies have also suggested that unlike TIDM, 
where strict glycaemic control is the main preventative factor of diabetic nephropathy, in 
T2DM the control of hypertension, hyperlipidernia, obesity and hyperuricemia may have 
priority (Molnar et a/ 2000). The accumulation of advanced glycation end products 
(AGEs), the activation of isoforms of protein kinase C (PKC) and the acceleration of the 
polyol pathway may provide explanations of the effects of hyperglycaemia and 
nephropathy in TlDM and T2DM. Management strategies designed to modify progression 
from normoalbuminuria to microalbwninuria and early identification of patients at such 
risk should therefore be targeted. 
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Clinical nephropathy 
Urinary albumin concentration (UAC). > 300mg/l (30mg/dl) 
Urinary albumin excretion rate > 300mg/24h 
(UAER). 
Urinary protein excretion. 
Microalbuminuria 
UAC 
UAER 
Albumin:Creatinine (ACR) 
> 500mg/24h 
20-30 mg/1 
20-200J.Lg/min (timed overnight 
collection) 
30-300mg/24h (24 hour 
collection) 
2.5-25mg/mmol- male 
30-300mg/ g- male 
3.5-25mg/mmol- female 
40-300mg/ g- female 
Table 3. Definitions of nephropathy (adapted from recommendations by Bilous 
1996). 
• The diagnosis of clinical nephropathy is generally carried out using dipstick urinalysis for 
proteinuria. These tests detect albumin at a concentration of >300 mg/1, and a positive 
result on three or more consecutive occasions spread out over several months is the 
conventionally accepted definition of clinical nephropathy. 
• The accuracy of the detection of microalbuminuria is improved by relating albumin and 
creatinine concentrations in an albumin:creatinine ratio (ACR). 
• False positive results with concentrated urine, biological variation, posture/diurnal 
variation, exercise, urinary infection, other renal disease, and cardiac failure. False 
negative results with dilute urine or diuresis. 
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Diabetic retinopathy 
Another key system to be affected by diabetes is the retina and there are several causes of 
blindness in diabetic patients including retinopathy, cataract and glaucoma, this study 
however focuses specifically on retinopathy. Retinopathy is a highly specific vascular 
complication that is debilitating in that it can lead to diminished visual acuity and blindness 
in both TIDM and T2DM patients. Early studies such as the 'Bedford Survey' indicated 
that impaired glucose tolerance carries minimal risk of eye disease, however, the risk 
increased dramatically upon diagnosis of diabetes (McCartney 1983 ). Retinopathy shows a 
clear pattern of progression, with incidence rising continually with increasing duration of 
diabetes. The incidence of retinopathy is relatively low in subjects with impaired glucose 
tolerance or newly diagnosed diabetes (Klein 1991). However, after a lag period of several 
years from the diagnosis of diabetes, the presence of diabetic retinopathy increases 
unremittingly, affecting approximately 90% of TIDM patients and >60% T2DM patients 
after 15-20 years duration of diabetes (Klein 1992). The 'Wisconsin Epidemiologic Study 
of Diabetic Retinopathy' (WESDR) evaluated the prevalence and incidence of retinopathy 
in a defined population in an 11 county region of Southern Wisconsin, USA (Klein et at 
1984 [a and b]). Results from this study showed that one third to 86% of blindness in 
diabetic subjects was attributable to diabetic retinopathy (K.lein 1998). Progression of 
retinopathy to the proliferative stage occurs in about 30% ofTIDM subjects after 10 years 
of the disease, and in 60% after 40 years. 
Retinopathy is primarily a vascular disorder, probably beginning with capillary dilation in 
the retinal capillary bed and promoted by chronic hyperglycaemia. Retinopathy involves 
both morphological and functional changes in the retinal capillaries, including basement 
membrane thickening, loss of pericytes, increased permeability and vascular dysfunction. 
Diabetic patients are routinely screened for retinopathy in the absence of any visual 
symptoms by pupilary dilation performed by an ophthalmologist. The progression of 
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retinopathy is orderly, advancing from mild non-proliferative abnormalities, characterised 
by increased vascular permeability and the formation of rnicroaneurysms, to moderate and 
severe non-proliferative diabetic retinopathy, characterised by vascular closure. From this, 
pre-proliferative stage, retinopathy advances through to proliferative diabetic retinopathy 
which is characterised by the growth of new blood vessels on the retina and posterior 
surface of the vitreous (American Diabetes Association 1998; Aiello 1998). Vision loss 
due to diabetic retinopathy results from macular oedema or capillary nonperfusion, 
distortion or detachment of the retina, or through bleeding of new blood vessels. 
Factors that have been associated with the development and progression of diabetic 
retinopathy include gender, HLA type, age at onset, duration of disease, degree of 
metabolic control, presence of pubertal development, growth hormone secretion and 
presence of proteinuria (D'Angio et a/2001). A follow up study carried out by Annunzio 
1997, on patients with retinopathy who were treated with conventional therapy, suggested 
that poor metabolic control, age, and degree of pubertal development at diagnosis were the 
most important risk factors. Similarly, Kalter-Leibovici 1997 supported this view, 
reporting that poor glycaemic control was significantly and independently associated with 
an· early progression to proliferative retinopathy. Cohen 1999 found that the levels of 
hyperglycaemia and diastolic blood pressure predicted progression of retinopathy in 
TlDM. The development of proliferative retinopathy has also been shown to be closely 
related to the development of proteinuria. This has been shown in a study by Pirart 1984, 
where 80% of patients with persistent proteinuria developed proliferative retinopathy. 
Intensive treatment of diabetes aimed at maintaining as near normoglycaernia as possible 
has been shown to significantly reduce the risk for the development and progression of 
diabetic retinopathy. Laser photocoagulation surgery has proved to be beneficial in 
reducing the risk of further visual loss, but not seen to be able to reverse already 
diminished acuity (Chantelau 2001). In the Diabetic Retinopathy Study (DRS) and the 
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Early Treatment of Diabetic Retinopathy Study (ETDRS) photocoagulation by argon laser 
or xeno~ arc light prevented new visual loss in patients with proliferative retinopathy and 
macular oedema and improved vision in some patients (ETRDS 1985; DRS 1978). 
Vitrectomy is beneficial in patients where visual loss is caused by proliferative retinopathy 
with vitreous haemorrhage, scarring, and retinal detachment. In the Diabetic Retinopathy 
Vitrectomy Study (DRVS), early vitrectomy improved the chance of good vision (DRVS 
1985). Therefore, there are clear benefits in screening patients for the often-asymptomatic 
early stages of retinopathy such as clinically detectable capillary dilation and retinal 
capillary basement membrane thickening (RCBMT) (Glover et a/ 2000; Janghorbani et a/ 
2001; Keen et al 2001 [a and b). It is recommended that dilated eye examination and 
retinal photography should be included in the routine management of TlDM during the 
first 5 years to identify subjects at risk of developing vision-threatening problems (Malone 
et a/2001). 
Diabetic Neuropathy 
Peripheral and autonomic nerves are also significantly affected by the altered metabolism 
of diabetes mellitus, resulting in pathological change, functional disturbance and clinical 
morbidity. Approximately half of patients who have had diabetes for 20 years will have 
some evidence of neuropathic involvement. In diabetic subjects with end stage renal 
disease, the incidence of neuropathy varies from 60-90% (Parving 1988). The cumulative 
prevalence of neuropathy increases with duration of diabetes and neuropathy represents a 
concomitant or consequence of the diabetic state. 
Diabetic neuropathy is a clinical state of nerve damage in which a patient complains of 
symptoms (pain, paraesthesiae) or is shown to have neurological deficit likely to lead to 
problems. Diabetic neuropathy is notably heterogeneous in its clinical presentation, 
encompassing several distinct syndromes that differ with respect to anatomical distribution 
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of neurological deficit and clinical course. Multiple aspects of neural function are currently 
being studied to enable accurate diagnosis of diabetic neuropathies, as early and accurate 
identification of this complication is essential for effective clinical intervention (Arezzo 
1999; Hirai 2000). Sub-clinical neuropathy refers to the presence of evidence of impaired 
nerve function in the absence of clinical signs or symptoms of diabetic neuropathy. The 
most common form of clinical neuropathy associated with diabetes is distal symmetrical 
polyneuropathy with predominant sensory and autonomic involvement, and slow 
progressive loss of distal sensory, autonomic and motor fibres. Polyneuropathy is 
characterised by a loss of peripheral nerve function, which can cause sensory disturbances, 
motor weakness and autonomic dysfunction. Other forms of neuropathy are the 
asymmetric neuropathies involving one or more discrete cranial or peripheral nerves, 
which constitute roughly 15% of all diabetic neuropathies and are generally, restricted to 
older diabetic patients. The onset is usually acute and painful and the median, ulnar, deep 
peroneal radial, femoral and sciatic nerves are the most frequently affected. 
Mononeuropathy may involve single or multiple cranial nerves especially those 
innervating the extraocular muscles and the facial nerve. Diabetic neuropathy also 
underlies the development of diabetic foot ulcers, which can lead to lower limb 
amputations. Erectile impotence in male diabetic patients is also largely attributable to this 
disorder. 
It is thought that diabetic neuropathy is conditioned by insulin deficiency and/or 
hyperglycaemia, although the specific pathogenic mechanisms that underlie this 
conditioning effect are not fully understood. It has been suggested that TlDM patients with 
autonomic neuropathy may have a degree of protection against the development of diabetic 
ketoacidosis as plasma fatty acids and ketone body concentration rises less rapidly in these 
patients following withdrawal of insulin (Krentz et al 1994). There is evidence based on 
animal work that there is a link with hyperglycaemia, through sorbitol accumulation, myo-
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inositol depletion and Na+-K+-ATPase activity, with nerve dysfunction and damage 
(Greene 1984). Observations reported from experiments in rats and also in patients, 
looking at nerve blood flow suggest that hyperglycaemia induced blood flow reductions in 
sural nerve and resultant endoneuria! hypoxia are important factors underlying nerve 
conduction deficits early in the development of diabetic neuropathy (Dyck 1989; Cameron 
1991; 1994; Tesfaye 1994). An increase in platelet aggregation has also been observed in 
otherwise uncomplicated patients with neuropathy, which may have pathogenic 
implications (Jennings et a/ 1986). The EURODIAB IDDM complications study 1996 
identified further associations with neuropathy which included elevated diastolic blood 
pressure, the presence of severe ketoacidosis, an increase in the levels of fasting 
triglyceride, and the presence of microalbuminuria. Further trials have also associated 
• significant roles for height, cigarette smoking and female gender as risk factors for 
progression of distal symmetric polyneuropathy (Christen 1999). 
Vasodilatory treatment aimed at improving blood flow, adrenoceptor blockade, aldose 
reductase inhibition and calcium channel antagonist treatment have all shown positive 
results, however as several metabolic abnormalities combine to produce deleterious 
changes in nerve perfusion multi-action therapy is important (Cameron 1997; Fedele 1997; 
Parry 1999). The mainstay treatment of the symptoms of painful neuropathies currently 
incorporates the use of tricyclic antidepressants (desipramine), or serotonin reuptake 
inhibitors (SSRis), although the later has not proven to be as successful as the former. 
Gabapentin (neurontin) can also reduce the pain associated with polyneuropathy. However 
the only strategy shown to be consistently beneficial to the treatment of diabetic 
neuropathy is meticulous control of blood glucose by multiple injections or continuous 
subcutaneous infusion of insulin. It is imperative therefore that therapy is directed at early 
diagnosis, exclusion of other neuropathic disorders, prudent glucose control, and avoidance 
of secondary complications of neuropathy such as foot ulceration by aggressive foot care, 
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hygiene and patient education (Greene 1990; DCCT Research Group 1998). Physical 
therapy evaluation is important in patients followed with use of ankle-foot orthoses, 
splints, and walking assistance devices. 
Macroangiopathy of diabetes mellitus 
Macrovascular diseases occur in the large peripheral arteries of the lower limbs, in cerebral 
vessels and in coronary arteries, and are due to atherosclerosis of blood vessels, which 
result in reduced blood flow to tissues. Macrovascular complications of diabetes include 
coronary, cerebral and peripheral vascular disease such as angina, heart attacks, strokes, 
and amputations (Foley et al 1997). Diabetes and abnormal glucose tolerance is a major 
risk factor and is known to enhance the development of atherosclerosis and coronary heart 
disease (CHD) (Stamler et a/1993). Evidence has shown a significant relationship between 
long-term hyperglycaemia and diabetic macrovascular disease in T2DM (Kuusisto 1994). 
Results published in the DCCT 1993 [a and b] indicate that the risk of a cardiovascular 
event occurring in diabetic subjects was reduced by 41% by strict glycaemic control, albeit 
not a significant correlation. Atherosclerotic macrovascular disease accounts for more than 
80% of all mortality in the diabetic population, with increased risk if diagnosed over 40 
years of age or over 30 years duration of diabetes (Foley and Parfrey 1998; Morrish et al 
2001). The risk for fatal and nonfatal CHD events in subjects with T2DM has been 
reported to be two to four times higher than in non-diabetic subjects. It is thought that 
dyslipidemia, hyperglycaemia, hypertension and obesity may account for the risk of 
developing atherosclerosis 
Inter-linkage of diabetic complications 
It can be seen that the common chronic complications of diabetes encompass multiple 
organ systems, and includes macrovascular diseases such as cardiovascular disease and 
atherosclerosis, and microvascular diseases such as retinopathy, neuropathy and 
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nephropathy (Rich 1997). Borch-Johnsen et a/ 1985 reported evidence for an association 
between microvascular and macrovascular diabetic complications where a large number of 
patient deaths due to macrovascular disease also presented with proteinuria. It has been 
suggested that microvascular complications are also interrelated with each other, for 
example, 90% of patients with nephropathy also have retinopathy. Studies by Florkowski 
1988 and Parving 1988 and more recently by Aroca et al 2000 found that 
microalburninuria was significantly associated with retinopathy, an association was also 
suggested between microalbuminuria and neuropathy in the absence of retinopathy. 
Jennings 1990 [a and b] reported an association between retinopathy and severity of 
neuropathy. However, non-concordance for the onset of the microvascular complications 
was reported in a follow up study carried out by Pirart 1977, which is illustrated in figure 
l. A study carried out by Fong 1995 to determine prospectively whether cardiovascular 
autonomic neuropathy is a risk factor for proliferative diabetic retinopathy, showed 
evidence that there was an association. Some insight into the correlation between 
nephropathy and retinopathy came from a study carried out by Schwartz et a/ 1998 using 
T2DM subjects who underwent renal biopsy. This study indicated that severe retinopathy 
was more closely associated with K.immelstiel-Wilson nodules than with mesangial 
sclerosis (p=0.0043), the reasons for which are not yet known. The relationship between 
diabetic nephropathy and retinopathy is less predictable in T2DM. For example studies of 
T2DM subjects found that subjects with marked proteinuria and retinopathy most likely 
have diabetic nephropathy, while those without retinopathy have a high incidence of non-
diabetic glomerular disease (Parving et al 1992; Christensen et al 2000). It has been 
speculated that there is a common underlying cellular mechanism behind the diabetic 
complications, which leads to widespread microvascular disease and causes organ damage. 
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Retinopathy 
89% 
Neuropathy Nephropathy 
26% 
Figure 1. Concordance between diabetic microvascular complications in the follow up 
study carried out by Pirart 1984. For each new case of one given complication, the 
probability to display another complication is indicated by the percentage attached to the 
arrow directed to this complication (adapted with minor alterations from Pirart eta/1984). 
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Aetiology of diabetic complications 
The development of diabetic complications in subjects with TlDM and T2DM is not by 
any means straightforward, and cannot as yet be confidently predicted. Some patients with 
diabetes are fortunate in that they can live through the duration of their diabetes without 
developing any sign of microvascular or macrovascular disease. Other patients on the other 
hand develop a whole handful of complications, which are both debilitating and 
significantly reduce the quality of life of the patient. A significant amount of research is 
currently underway to try to elucidate the mechanisms by which these complications take 
effec::t and to attempt to predict their onset in order to design appropriate preventative and 
treatment regimes to improve prognosis of the patient. To date several key components in 
the underlying aetiology of diabetic complications have been identified. These include 
various risk factors such as duration of diabetes, hyperglycaemia, hypertension and 
hyperlipidemia, as well as certain pathological features such as capillary basement 
membrane thickening and haemostatic abnormalities. Alterations in certain biochemical 
pathways as a result of the diabetic state have also been identified such as the increase in 
the synthesis of diacyglycerol (DAG), non-enzymatic glycation of proteins and an increase 
in the flux through the polyoVsorbitol pathway. An increase in the formation of reactive 
oxygen species (ROS), and Nitric Oxide (NO) has also been extensively examined. 
Alterations in the cell signal transduction pathways have also I?een investigated and 
implicate protein kinase C and mitogen activated protein kinases (MAPKs). Also gene 
expression promoters such as Transforming Growth Factors {TGF), Vascular Endothelial 
Growth Factors (VEGF) and Nucleotide Factor KB (NFKB) have attracted a great deal of 
interest. Numerous inter-related genetic and environmental factors have also been 
examined. These components (illustrated in figure 2) are reviewed here. 
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Diabetes Mellitus 
Diabetic 
Complications 
Risk factors; 
Hyperglycaemia 
Hypertension 
Hyperlipidemia 
Biochemical pathway disturbances; 
Polyol pathway 
Formation of AGEs 
Superoxide production 
Nitric oxide production 
Cell signalling pathway disturbances; 
PKC 
Growth factors; 
NFKB 
TGF-B 
PDGF 
VEGF 
Genetic predisposition; 
Enzymes affecting glucose 
metabolism 
Enzymes affecting vascular risk 
Environmental influences; 
Cigarette smoking 
In utero stress 
Figure 2. Factors affecting the onset and progression of diabetic 
microvascular and/or macrovascular complications (importantly, this is not a 
conclusive list). 
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Risk factors for diabetic microangiopathy 
Various risk factors are thought to be involved in diabetic microvascular and 
macrovascular disease, and appear to include the duration of the disease, hypertension, 
hyperlipidemia and the quality of glycaemic control. Better metabolic control through anti-
hypertensive therapy, and improved glycaemic control has been shown to be effective in 
decreasing the incidence of diabetic complications (K.ofoed-Enevoldsen 1987; Hostetter 
1994; Rossing 1998). Hyperlipidemia has also been associated with the development of 
microvascular complications although conclusive evidence from clinical trials is yet to be 
attained. 
Hyperglycaemia and microangiopathy 
Epidemiological, animal, and biochemical studies have strongly suggested that there is a 
relationship between hyperglycaemia and development and progression of diabetic 
microvascular complications involving the retina, glomeruli, and neuronal tissues. Early 
studies carried out by Jarret 1976, and also by Jean Pirart 1978 showed that poor control of 
glycaemia in TIDM subjects predisposes to chronic complications. Retrospective 
epidemiological studies have shown that nephropathy and retinopathy are more likely to 
occur in those patients with poorer glycaemic control (K.rolewski 1988; Rosenstock and 
Raskin 1988; Molitch 1993; Dahl-Jorgensen; Barzilay 1992). Other studies, including the 
Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) and the Oslo Study 
of Diabetic Retinopathy have also demonstrated a strong consistent relationship between 
hyperglycaemia and the incidence and progression of microvascular and macrovascular 
complications in TIDM and T2DM populations (Brinchmann-Hansen et a/ 1992; Klein 
1995; Leslie 1999 [b]). The United Kingdom Prospective Diabetes Study (UKPDS [b]) 
carried out a study of over 4000 patients with prolonged follow up, and suggested that 
strict glycaemic control results in a reduced risk of microvascular disease in patients with 
T2DM (UKPDS 1998 [b]). The DCCT research group provided conclusive evidence that 
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strict glycaemic control can both delay the onset of microvascular complications and slow 
the rate of progression of already established complications. They demonstrated in a multi-
centre, randomised, prospective controlled clinical study that there was a 76% reduction in 
the development of retinopathy, a 54% lower incidence of nephropathy and 60% reduction 
of neuropathy with intensive therapy aimed at achieving glycaemic control as close to the 
non-diabetic range as possible. In the DCCT report intensive insulin therapy consisted of 
multiple daily injections or by continuous insulin administration through the use of an 
insulin pump. The DCCT also suggested that the total lifetime exposure to glycaemia was 
the principle determinant to the risk of developing retinopathy and other complications of 
diabetes, and that there was a continuous non-linear relationship between this risk and the 
mean level of HbAlc (DCCT Research Group 1993 [a], 1993 [b], 1995 [b]). A separate 
report by the DCCT looked at the development of diabetic nephropathy under intensive 
insulin therapy and found that there was a beneficial effect, where the onset of nephropathy 
was possibly prevented or at least delayed in its progression (DCCT Research Group 1995 
[a]). The DCCT also found that there was no glycaemic threshold below which the risk of 
developing retinopathy was reduced (DCCT Research Group 1996). However, other 
authors have suggested a glycaemic threshold for microalbuminuria and for retinopathy 
exists, below which the risk of patients progression from microalburninuria to overt 
proteinuria is reduced. The DCCT did show that the risk of development of 
microalburninuria increases substantially when HbAlc increases beyond 8.8%. This is 
similar to findings from the Joslin Clinic (Krolewski 1995 [a]) and the Stockholm Study 
(Reichard 1995), both of which indicated that albumin excretion increases substantially 
when long term HbAlc is more than 8.8-9.0%. No cases of serious retinopathy were 
observed in patients over the period of observation when long-term HbAlc was less than 
7.0%. To be reasonably sure that a patient will not develop any microvascular 
complications, the treatment goal should therefore be glycated haemoglobin within the 
normal range. Improved glycaemic control and maintaining an HbA1c level of below 8.5% 
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has therefore been shown to improve the prognosis of serious microangiopathy (Krolewski 
1995 [a]; Hanssen 1995; Warram 2000). 
A relationship between levels of chronic hyperglycaemia and diabetic microvascular and 
macrovascular disease in patients with T2DM has also been found in several studies 
(Ohkubo et a/ 1995; Kuusisto et a/ 1994; Colwell et a/ 1994; Kaiser et a/ 1993). As with 
TlDM patients, retrospective studies show a strong association between indexes of 
hyperglycaemia and the prevalence of diabetic retinopathy, nephropathy and neuropathy in 
T2DM (Klein 1995). A 6-year Japanese trial carried out to compare intensified and 
standard insulin treatment in T2DM and the progression of diabetic microangiopathy found 
a considerable risk reduction with intensive therapy, which was comparable to the DCCT 
study (Ohkubo et a/ 1995). In the DCCT, cardiovascular events were also reduced albeit 
not significantly by 41% in the intensively treated group. Several other studies have also 
shown a correlation between glycated haemoglobin and the development of cardiovascular 
disease (Andersson et a/1995; Abraira et a/1995). 
Extracellular hyperglycaemia has therefore been conclusively related to the development 
of diabetic complications. Studies have looked at the cells that are damaged by 
hyperglycaemia, namely the vascular endothelial cells, and found that there is a reduction 
in the ability to down regulate glucose transport into the intracellular environment 
(Giardino et a/ 1996). Therefore it would appear that intracellular hyperglycaemia is the 
major determinant of diabetic tissue damage. Intracellular hyperglycaemia is thought to 
cause tissue damage by repeated acute changes in cellular metabolism and through 
cumulative changes in long lived macromolecules. 
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Hypertension and microangiopathy 
A second risk factor, which has been implicated in the progression of diabetic 
complications in particular nephropathy, retinopathy and CHD, is hypertension (Baba 
1997; Williams 1997; Mogensen 1999). Hypertension is a very common abnormality in 
diabetics, and in approximately 90% of patients with elevated blood pressure the cause is 
unknown. Among those with TlDM the incidence of hypertension rises from 5% at 10 
years, to 33% at 20 years, and 70% at 40 years duration of diabetes (Epstein 1992). In the 
'World Health Organisation Multinational Study of Vascular Disease in Diabetes' (WHO 
MSVDD), among TlDM subjects, hypertension (BP ~ 140/90 mmHg or use of 
antihypertensive drugs) was associated with a relative risk for cardiovascular mortality of 
1.7 in men and 2.7 in women at 12 years of follow up (Fuller et al 1996; Lee et al 2001 
[b ]). Hypertension has also been highly associated and inter-linked with microvascular 
complications, for example hypertension is thought to be a risk factor for development of 
retinopathy, and an aggravating factor of retinopathy in TlDM subjects with nephropathy 
(Klein et al 1989; Jnaka et al 1989; Norgaard 1991). An association has also been made 
between raised arterial pressure and the development and progression of diabetic 
nephropathy, which has indicated that local intrarenal alteration in haemodynamics or high 
glomerular capillary pressure may influence diabetic glomerular structural damage (Selby 
et al 1990; Burbury 1998; Agardh and Torffvit 1999). The association of blood pressure 
levels with progression of renal disease has been investigated in several observational 
studies. The Multiple Risk Factor Intervention Trial 1982 followed 332,544 men for 16 
years and found a strong and independent association between both systolic and diastolic 
blood pressure and erid stage renal disease, with an increased risk with higher blood 
pressure (Klag et a/ 1996). This was further supported by studies carried out by Perry et a/ 
1995 through the Veterans Affairs Hypertension Screening and Treatment Program, and 
also Shulman et al 1989 through the Hypertension Detection and Follow-up Program. 
Raised blood pressure in patients with diabetic nephropathy was initially considered to be a 
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consequence of renal failure, however Viberti et a/1987 described elevated arterial blood 
pressure in parents of TlDM patients with proteinuria, which led to the hypothesis that 
susceptibility to diabetic nephropathy is linked to genetic predisposition to hypertension. 
Therefore high blood pressure in non-diabetic parents may also be a marker of 
susceptibility to clinical nephropathy in their TlDM offspring. Fagerudd et al 1998 also 
reported findings that familial predisposition to essential hypertension increases the risk of 
diabetic nephropathy and may also contribute to the development of systemic hypertension 
in patients with TlDM and diabetic nephropathy. Fogarty et al 2000 carried out a study to 
estimate heritibility of urinary albumin excretion (UAE) and blood pressure using a large 
family T2DM collection. The study showed a significant correlation between UAE and 
blood pressure in the presence of diabetes. These findings cumulatively indicate that high 
blood pressure and diabetic complications share a common genetic determinant. 
Early identification and treatment of hypertension is therefore imperative in diabetic 
patients to prevent cardiovascular disease and to minimise progression of renal disease and 
diabetic retinopathy. There is clinical trial evidence in non-diabetic subjects that treating 
blood pressure decreases the risk of cerebral infarction (Collins 1990) and CHD events in 
older people (Thijs et al 1992; Beard et al 1992). Early treatment of hypertensive diabetic 
subjects should include nonpharmacologic methods, such as weight reduction, exercise, 
sodium restriction, and avoidance of smoking and excess alcohol ingestion. Several expert 
groups have made specific recommendations on the management of hypertension in 
diabetic patients. In accordance to recommendations published in the St Vincent 
Declaration (Krans et al 1995) the threshold for defining hypertension and the point at 
which clinical intervention using antihypertensive therapy should start is with a blood 
pressure at or above 140/90 mmHg. Other groups which include the 'American Diabetes 
Association Consensus Panel' 1993, 'The Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure-IV', and 'The National High 
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Blood Pressure Education Working Group' 1994 have also published similar 
recommendations. Intensive drug therapy has been shown to be unequivocally protective in 
all diabetics (Gall et a/ 1997; Gaede et a/ 1999; UKPDS Group 1998 [a]; Hansson et al 
1998; Parving 1999; Collado-Mesa et a/ 1999). Parving 1996 [a]; 1999 reported results 
from a randomised, double blind parallel study, which revealed that the major 
cardiovascular disease rate was lowered by 34% for antihypertensive treatment compared 
with placebo. The study also showed that effective blood pressure reduction with ACE 
inhibitors and/or non-ACE inhibitors reduced albuminuria, delays the progression of 
nephropathy, postpones end-stage renal failure, and improves survival in diabetic 
nephropathy. Similar evidence has· also recently been shown in the Heart Outcomes 
Preventative Evaluation (HOPE) study, where the incidence of cardiovascular events in 
diabetic subjects was reduced when treated with ramipril (Jones et al 2001; Pate! et al 
2001). Angiotensin converting enzyme inhibitors (ACE-I) such as ramipril (Pate! et a/ 
2001) and possibly angiotensin 11-receptor blockers (ARBs) (losartan) can be used to lower 
blood pressure and lower the plasma glucose concentration by increasing responsiveness to 
insulin. ACE-I protect against the development of progressive diabetic nephropathy by 
lowering intraglomerular pressure, and appear to lower the incidence of adverse 
cardiovascular disease. Dietary salt restriction and diuretics are also likely to be effective 
in hypertensive diabetic patients for prevention of complications. Nondihydropyridine and 
dihydropyridine calcium channel blocker's such as diltiazem and verapamil, alpha-
adrenergic antagonists and beta-blocker's are also commonly used therapeutic treatments 
for hypertension in diabetics, but the thiazide diuretics and beta-blockers have metabolic 
side effects which make them less appropriate as first line agents (Bamett 1994). Hovind 
et al 2001 [a] examined whether remission and regression of diabetic nephropathy are 
possible in TIDM subjects from a prospective observational cohort study, and found that 
aggressive anti-hypertensive treatment can induce remission and regression in a sizeable 
fraction of patients with diabetic nephropathy. 
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Hyperlipidemia and microvasculopathy 
It has been suggested that an average or a below average cholesterol level may have an 
impact on coronary heart disease, and patients with diabetes mellitus are reported to be at 
an increased risk for cardiovascular disease (Haffner et a/1998; Colhoun et a/200 1 ). Lipid 
abnormalities are common in patients with diabetes, and are thought to contribute to the 
increased risk of cardiovascular disease. In TlDM subjects the DCCT found that poor 
glycaemic control was associated with hypertriglyceridemia, high serum low-density-
lipoprotein (LDL) cholesterol and low high-density-lipoprotein (HDL) cholesterol 
concentrations (DCCT Research Group 1992; Perez et a/2000). In T2DM subjects, insulin 
resistance, relative insulin deficiency, and obesity are associated with 
hypertriglyceridemia, low serum HDL cholesterol concentrations, and occasionally high 
serum LDL cholesterol and lipoprotein values (O'Brien et al 1998). The UK Prospective 
Diabetes Study (UKPDS [a]) showed that high LDL cholesterol and low HDL cholesterol 
levels were two of several potentially modifiable risk factors of diabetic cardiovascular risk 
in subjects with T2DM (Davis et a/200 I). 
Cholesterol-lowering intervention through the use of lovastatin which was first introduced 
in 1987, and other lipid lowering drugs such as simvastatin and atorvastatin which have 
since become available have been used primarily in the US and Europe in the treatment of 
hypercholesterolaemia (Pedersen and Tobert 1996; Stein et a/ 1997). Attention has since 
turned to the advantages of lipid lowering drugs in the treatment of some diabetic patients 
at risk of diabetic complications (Gall et al 1997). Studies have shown that lipid-lowering 
intervention in non-diabetic subjects decreased the risk of a cardiovascular event in both 
primary and secondary prevention studies. One such study was 'The Scandinavian 
Simvastatin Study' ( 4S) which consisted of 4444 patients with coronary disease and 
hyperlipidemia. In a subset group consisting of 202 patients with diabetes (mostly T2DM) 
those who were treated with simvastatin had a lower incidence of major cardiovascular 
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events (PyorSIS et at 1997). Evidence therefore suggests that lipid-lowering therapy is 
worthwhile for secondary prevention in diabetics although no trials have yet been 
successfully completed specifically in these patients. One such study which is currently in 
process is 'The Lipids in Diabetes Study' (LDS), which is a five year, randomised, multi-
centre, prospective primary intervention trial. Four thousand T2DM subjects were recruited 
nation-wide, randornised, and allocated to double-blind therapy with a fixed dose of 3-
hydroxy-3-methylglutarly-CoA (HMG-CoA) reductase inhibitor (cerivastatin), and/or 
. fibrate (fenofibrate). The aim of the study is to determine whether statin and fibrate lipid-
lowering therapies are effective in preventing cardiovascular disease in people with 
diabetes. Following the rapid withdraw I of cerivastatin from the market by Baycol (Beyer) 
as a result of the serious adverse effect (SAE) involving an unacceptably high rate of 
rhabdomyolysis this has now been replaced with fluvastatin as pravastatin and fluvastatin 
are least likely to provoke muscle cell damage (Sica and Gehr 2002). The outcome of this 
study is yet to be determined. However, a recent study carried out over 2 years, as a 
randornised, double blinded placebo controlled pilot trial of simvastatin/diet vs. diet alone 
in TIDM subjects with overt diabetic nephropathy suggested that treatment with 
simvastatin may have beneficial effects on early nephropathy and diabetic neuropathy 
(Fried et a/2001). 
Pathophysiological features of cell damage 
It has been postulated that diabetic complications occur as a result of the interplay of 
metabolic and hemodynarnic factors in the renal microcirculation (Cooper et a/ 1998; 
Cooper 200 l ). Several pathophysiological cellular and extracellular features of diabetic 
complications exist. This includes capillary basement membrane thickening and associated 
hemostatic abnormalities. The structural hallmark of diabetic microangiopathy is 
thickening of the capillary basement membrane in all tissues, including the glomerular 
basement membrane, resulting in increased capillary permeability, blood flow and 
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viscosity and disturbed platelet function (Mogensen 1979). The increase in basement 
membrane is found in the protein components (type IV collagen, fibronectin) and the 
carbohydrate content. High glucose has been found to up-regulate in a co-ordinated fashion 
the transcription of genes coding for basement membrane components through effects 
exerted intra-cellularly or at the cell matrix boundary (Cagliero 1991). Basement 
membrane thickening could cause vascular dysfunction by several mechanisms. First a 
decrease of negative charges could change the filtration properties of renal glomerular 
capillaries. Second, alterations in basement membrane components could affect vascular 
cell metabolism. Thirdly, non-enzymatic glycation of extracellular protein and its by-
products have been reported to affect vascular cell metabolism. Vasodilation and increased 
blood flow are early characteristic vascular responses to acute hyperglycaemia and tissue 
hypoxia. In hyperglycaemic tissues these vascular changes are also linked to increased 
ratio of NADH/NAD+, and mediated by a branching cascade of imbalances in lipid 
metabolism, increased production of superoxide anion and possibly increased nitric oxide 
formation (Williarnson et a/1993). 
Brief overview of cellular pathways implicated in diabetes induced complications 
Although we now know that the degree of hyperglycaemia is directly correlated to the 
extent of diabetic complications, we are still trying to elucidate the exact underlying 
mechanisms by which glucose disrupts cellular metabolism causing hyperpermeability and 
hemodynarnic changes leading to vascular and neural dysfunction. However, it is likely 
that multiple pathways are involved because the metabolites of glucose can affect many 
metabolic pathways. It is also indicated from the vast array of literature, that metabolic 
anomalies contributing to the development of diabetic complications must in some way 
overlap with each other (Tomlinson 1999). Hyperglycaemia is causally related to a number 
of ultrastructural, biochemical and ·haemostatic processes, which culminate in tissue 
ischemia (reviewed by Barnett 1991, 1993; Ruderman 1992; King 1994; King 1996). The 
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mechanism by which a lack of glycaemic control predisposes to vascular disease is 
incompletely understood, however several contributing factors have been proposed 
(Larkins et al 1992). Considerable advancements have been made in our understanding of 
diabetic complications yet we still do not sufficiently understand the underlying 
pathogenesis of these complications to allow for effective preventive measures. The reason 
why only some patients with diabetes develop microvascular complications and not others 
is unclear, however they are generally thought to result from the interaction of multiple 
metabolic factors, which are briefly discussed here: 
Increase of glucose transporters 
High extracellular glucose concentration is known to lead to increased glucose uptake into 
the mesangial cell. The process by which glucose enters the cell involves facilitative 
integral membrane glycoprotein glucose transporters, of which several family members 
have been identified in renal mesangial cells (RMC). Glucose transporters have a low-Km, 
and a high affinity for glucose, and at physiological glucose concentration would be at or 
near saturation. It has been shown that increased glucose concentration (20mM) increases 
the glucose transporter 1 (GLUT1) expression [Heilig et a/ 1997(a); Heilig et a/1997(b)]. 
Experiments carried out by Henry et a/ 1999 reported that increased GLUT1 expression 
leads to a positive feedback of greater GLUTI expression, increased AR expression and 
active PKCa protein levels, which leads to detrimental stimulation of matrix protein 
synthesis by diabetic mesangial cells. 
Non-enzymatic glycation of proteins 
Work carried out by Michael Brownlee and eo-workers at the Joslin Diabetes Centre as 
well as other groups, have suggested that accelerated nonenzyme modification of serum 
and tissue protein macromolecules by glucose and other sugars plays a central role in the 
pathogenesis of diabetic complications (Brownlee 1991; Brownlee 1994; Vlassara 1996; 
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Hamada 1996; Hammes et a/1998). Initially, under hyperglycaemic conditions, reversible 
early glycosylation products are formed by non-enzymatic attachment of glucose to amino 
groups, a well-recognised example of which is the glycated haemoglobin, HbAlc. This 
attachment result in the formation of covalently bound Amadori products known as early 
glycation products, which are reversible, if normal glucose levels are restored. However, if 
hyperglycaemia persists these Amadori products are converted to irreversible advanced 
glycosylation end products (AGE's) via an Amadori rearrangement. The formation of 
irreversible AGE's originate from the glycohaemoglobin modification, the l-arnino-1-
deoxyketose product, forming at a rate directly proportional to the glucose concentration. 
The glycohaemoglobin products go on to generate a variety of fragmentation products, 
particularly highly reactive carbonyl compounds such as 3-deoxyglucosone. It has been 
shown that the 3-deoxyglucosone reacts either oxidatively or non-oxidatively with 
different free amino groups to form a heterogeneous group of AGEs, for example the N-
(carboxymethyl) lysine (CML) is formed oxidatively, and the imidazolone-type AGE (AG-
1) is non-oxidatively formed. It is not yet known how many types of AGE's there are, 
however AGE localisation in complications varies according to AGE structure (Horie 
1997). For example Hammes 1999 [a] reported that there appeared to be differential 
accumulation of AGE's in the course of diabetic retinopathy, indicating that oxidatively 
formed N-(carboxymethyl) lysine (CML) increases in diabetic neuroglial and vascular 
components and imidazolone-type AGE are restricted to microvessels and spread over the 
entire retina during the later stages of retinopathy. 
Evidence for the accumulation of AGE's comes from enzyme linked immunosorbent assay 
(ELISA) techniques using AGE-specific antibodies which have shown that diabetic renal 
cortex samples have 10 to 45 times more AGE's than non-diabetic samples after 5 to 20 
weeks of diabetes (Mitsuhashi 1993). Publications by Brownlee et a/1984, 1992 and 1994 
comprehensively reported that three principle mechanisms are involved in accelerated 
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AGE production and diabetic complications. Firstly, AGE's alter signal transduction 
pathways by changing the structure and function of the extracellular matrix components 
such as collagen, vitronectin and laminin. AGE formation on intact matrix also effects 
biological functions important to normal vascular tissue integrity. Secondly, AGEs alter 
the levels of soluble signals such as cytok:ines, hormones and free radicals through 
interaction with AGE-specific cellular receptors i.e. the receptor for advanced glycation 
end products (RAGE). It is suggested that interaction of AGE's with their cellular 
receptors induces procoagulatory changes such as preventing the activation of protein 
k:inase-C pathway, and also induces the increased production of the vasoconstrictor peptide 
endothelin-1, which together result in focal thrombosis and excessive vasoconstriction. 
Signal transduction by the AGE receptor also appears to involve generation of oxygen free 
radicals and leads to oxidant stress that results in potentially damaging changes in gene 
expression. For example, Galectin-3 (Gal-3) is a multifunctional AGE-binding protein that 
is associated with other AGE-binding receptor components and it is thought that up-
regulation of Gal-3 is associated with diabetic nephropathy. Thirdly, intracellular glycation 
by glucose, fructose, and metabolic pathway intermediates occurs at a much faster rate 
than glucose derived extracellular AGE formation, and can directly alter protein function 
in target tissues, or have deleterious effects on gene expression. Basic fibroblast growth 
factor (bFGF) is the major AGE modified protein in endothelial cells, and its mitogenic 
activity is reduced 70% by AGE formation. 
Enzymes such as glyozalase I detoxifY AGE precursors and prevent AGE formation in 
endothelial cells and the ability to enzymatically detoxifY AGE-intermediates may be 
genetically determined. Pharmacologic agents that specifically inhibit AGE formation such 
as aminoguanidine have been used in diabetic animal models, and studies found a 
considerable reduction of diabetic acellular capillaries (Hammes 1991 [b ]; Brownlee 1991, 
1986, 1995), and AGE accumulation in the renal glomerulus was also prevented (Soulis-
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Liparota 1995). The decrease in peripheral nerve conduction velocities in diabetic rats was 
also prevented by treatment with aminoguanidine (Cameron 1992 [b ]). Over the past 
decade, a great deal of research has gone into studying the efficacy of aminoguanidine in 
blocking or slowing the progression of diabetes related organ damage. It has been proposed 
that aminoguanidine acts as a glucose competitor for the same protein bond that becomes 
the link for formation of AGE's, and also in improving action of nitric oxide (Corbett et al 
1992). Primary prevention with aminoguanidine has been successfully employed to 
prevent diabetic retinopathy in the rat (Hammes et al 1995). A number of multi-centre 
clinical trials into the effects of using aminoguanidine in TlDM and T2DM diabetic 
subjects are in progress (Friedman 1999). Other studies have also looked at the effects of a 
novel inhibitor of AGE formation; NNC39-0028 (2,3-diaminophenazine), and a breaker of 
already formed AGE cross links, N-phenacylthiazolium bromide {PTB) in STZ-diabetic 
female Wistar rats. This study demonstrated that a pharmacological inhibition of collagen 
solubility alterations in diabetic rats without affecting diabetes-induced pathophysiology 
such as the increase in UAE or albumin clearance, and also that treatment with PTB had no 
effect (Oturai et al 2000). The prevention of diabetic retinopathy, nephropathy and 
neuropathy by pharmacological inhibition of AGE formation in animal models suggests 
that aminoguanidine and other AGE inhibitors have a potential therapeutic role in the 
treatment of diabetic complication in patients. 
Increased flux through the polyol/sorbitol pathway 
One of the theories of the proposed effect of hyperglycaemia and microvascular 
complications involves an increased flux of glucose through the polyol pathway. This 
pathway is an accessory pathway in glucose metabolism, and was first recognised over 30 
years ago (Gabbay et al 1966). At elevated glucose levels, glucose metabolism via the 
polyol pathway accounts for 33% of glucose consumption by the lens and 10% by human 
erythrocytes (Cheng and Gonzalez 1986; Travis et al 1971). This increased flux through 
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the polyol pathway has been reported to be associated with a decrease in myoinositol 
uptake, decreased sodium/potassium adenosine triphosphatase activity (NaK.-ATP), and 
increased production of vasodilatory prostaglandins in some target tissues. It is also 
associated with an alteration of the NADHINAD+ ratio. It is this pathway that is the main 
focus of this thesis, therefore its mechanisms have been comprehensively reviewed in 
chapter 2. 
Depletion of myoinositol!Na+/myo-inositol cotransporter (SMIT) 
Myo-inositol has been identified as one of the major osmolytes in various tissues and types 
of cells (Nakanishi et a/ 1988). Animal studies have previously shown that myo-inositol is 
the only osmolyte found in substantial amounts in the cortex and the outer medulla of the 
kidney (Wirthensohn et a/ 1989). Under hypertonic stress Madin-Darby canine kidney 
(MDCK) cells have been shown to accumulate myo-inositol through Na+/myo-inositol 
cotransporter (SMIT), the transcription of which is also increased in response to 
hypertonicity (Yamauchi et a/ 1993). A study by Kitamura et a/ 1998 reported that an 
inhibitor of myo-inositol, 2-0,C-methylene-myo-inositol (MMI) led to extensive injury of 
the tubular cells of the outer medulla and also in the renal cortex. Further to this 
administration of myo-inositol was seen to prevent acute renal failure in the rat suggesting 
that myo-inositol plays a crucial role in osmoregulation of the cell under hyperglycaemic 
conditions. A depletion of not only myo-inositol but also taurine and other amino acids 
was observed in the sciatic nerve of a galactosemic rat. Treatment of the galactosemic rats 
with sorbinil, an AR inhibitor was also found to protect against the loss of myo-inositol, 
taurine and other amino acids (Nishimura et a/ 1987). 
Increased formation of reactive oxygen species (ROS) 
Hyperglycaemia increases intracellular reactive oxygen species (ROS), lipid peroxidation 
and attenuates anti-oxidative mechanisms. Oxidative stress is defined as a tissue injury 
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induced by increase in ROS such as hydrogen peroxide (H202), superoxide anion (02··), 
and hydroxyl radical (·OH) (Baynes and Thorpe 1999). ROS causes strand breaks in DNA, 
which has been shown to be increased in diabetic subjects and might contribute to the 
pathogenesis of diabetic complications (Ha et a/ 1994, 1995; Dandona et a/ 1996). Hinokio 
et a/ 1999 reported increased oxidative DNA damage in diabetic subjects compared to 
control subjects. The major source of oxidative species in the diabetic state is thought to be 
from the increase in glucose autoxidation and non-enzymatic glycation (Wolff and Dean 
1987; Sakarai and Tsuchiya 1988; Hunt et a/1990; Williamson et a/1993). It has however, 
also been demonstrated by Lee and Chung 1999 that the flux of glucose through the polyol 
pathway is also a major source of diabetes associated oxidative stress in the ocular lens. It 
has been shown that in cells affected by diabetic complications such as aortic endothelial 
cells, 30 rnrnol!L glucose increases ROS formation by 250% within 24 hours, and resultant 
lipid peroxidation by 330% by 168 hours (Nishikawa et al2000 [a]). This increase in ROS 
has been shown to be prevented by an inhibitor of the electron transport chain complex II 
by an uncoupler of oxidative phosphorylation, by uncoupling protein-! and by manganese 
superoxide dismutase. A consequent reduction of glucose-induced activation of protein 
kinase C, formation of advanced glycation end-products, sorbitol accumulation and NF 
kappa B and AP-1 transcription factor activation were all seen with each of the above 
agents (Nishikawa et a/ 2000 [b]). Data has shown that exposure to high glucose 
concentrations induces an antioxidant defence in skin fibroblasts from nonnal subjects, in 
TlDM subjects with nephropathy however, this defensive mechanism is defective. On the 
other hand it has been shown that TIDM subjects without complications or non-diabetic 
nephropathic patients have an intact antioxidant response to glucose-induced oxidative 
stress (Ceriello et a/2000). A pathogenic role ofROS in diabetes is also strongly supported 
by the observations that antioxidants suppress high glucose-induced extracellular matrix 
protein synthesis in mesangial cells (Trachtrnan et at 1993; Trachtrnan et at 1994; Ha et at 
1997). Mitochondria is also a target of oxidative stress consuming approximately 90% of 
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oxygen, where superoxide anions are produced from electron transport system and are 
scavenged by an intramitochondrial enzyme manganese superoxide dismutase (MnSOD). 
The major biochemical pathways of hyperglycaemic vascular damage and hyperglycaemia 
induced activation of NFkB have recently been shown to result from a single common 
mechanism; hyperglycaemia-induced overproduction of superoxide by mitochondria 
(Nishikawa et al2000 [a]; Du et a/2000). The formation of reactive oxygen species (ROS) 
has been proposed to be the single unifying mechanism for the development of diabetic 
complications. In fact it has been demonstrated that the increased production of ROS 
serves as a causal link between elevated glucose levels and each of the three major 
pathways responsible for diabetic tissue damage; activated polyol pathway, PKC and AGE 
formation (Nishikawa et a/ 2000 [b]). It is suggested that ROS may be an integral 
component of membrane receptor signalling in mammalian cells. The production of ROS 
has been detected in various cells stimulated by cytokines, growth factors and 
transmembrane receptor agonists (Ha and Lee 2000). It has been reported by Hammes et al 
1999 [a] that monitoring of intracellular concentrations of ROS causes increased oxidative 
stress in long-lived CD45RA + lymphocytes by markers such as Nepsilon-
( carboxymethyl)lysine possibly identifies a subgroup of patients of high risk for 
microvascular complications. 
Decreased nitric oxide synthase (NOS) activity 
Nitric oxide (NO) is a signalling molecule in blood vessels which maintains vasodilation 
and blood flow and acts as a potent inhibitor of platelet aggregation and adhesion to the 
vascular wall. Endothelial nitric oxide controls the expression of proteins involved in 
atherogenesis, decreasing expression of chemoattractant protein (MCP-1) and of surface 
adhesion molecules such as CD11/CD18, p-selectin, VCAM-1 and ICAM-1. It is also 
known to have a role in immune defence where activated macrophages synthesise large 
amounts of NO to destroy microorganisms and cancerous cells. NO is formed by the 
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oxidation of arginine by nitric oxide synthase (NOS) in endothelial cells ( ecNOS), 
macrophage/inducible (iNOS) or neuronal cells (ncNOS). eNOS is activated by the 
phosphorylation of serine 1177 by the protein kinase Akt/PKB (Fulton et a/ 1999; 
Dimmeler et a/ 1999). NO is a highly reactive molecule that can interact with a variety of 
cellular components. It has been demonstrated that NO can cause damage to the nuclear 
DNA of beta-cells (Fehsel et a/1993). Wilson et a/1997 also demonstrated that mtDNA is 
vulnerable in NO-induced damage. Endothelium dependent vasodilation is impaired in 
both microcirculation and macrocirculation during acute hyperglycaemia in normal and 
diabetic subjects (Luscher et a! 1993; Makimalti et a/ 1996), suggesting that NOS activity 
may be impaired in diabetic subjects. Decreased Nitric Oxide (NO) production has been 
associated with the development and progression of diabetic nephropathy in diabetic 
spontaneously hypertensive rats (Wessels et a/ 1997). It is a distinct possibility that 
diabetic microangiopathy in humans may be, in part, due to defective endothelial NO 
production (Anggard et a/1994; Snyder and Bredt 1992; Kolb and Kolb-Bachofen 1992). 
Du et at 2001 reported that hyperglycaemia inhibits eN OS activity in cultured bovine 
aortic endothelial cells (BAECs) by activating the hexosamine pathway via mitochondrial 
over-production of superoxide, which increases eNOS modification by GlcNAc and 
decreases eN OS serine phosphorylation. Earle et a! 2001 investigated T2DM patients of 
African-Asian and White origin with microalbuminuria under euglycaemic conditions. The 
study measured glomerular filtration, renal plasma flow and clearance of the stable 
metabolites of nitric oxide, and found significant differences whereby the percentage 
clearance of nitrate was higher in the white compared with the African-Asian groups. The 
differences in the incidence of end~stage renal failure would therefore appear to involve 
defective nitric oxide production or indeed its bioavailability. Another similar study by 
Hiragushi et a/ 2001 looked at the relationship between diabetic glomerular hyperfiltration 
and the NO system in Japanese T2DM patients. Creatinine clearance and urinary NO 
excretion was measured in T2DM subjects and non-diabetic controls, and found 
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significantly higher levels of urinary NO in the T2DM subjects. These results suggested 
that NO might contribute to the pathogenesis of glomerular hyperfiltration in Japanese 
T2DM patients. Studies using pharmacologic modulators of nitric oxide in proteinuric rats 
have also yielded interesting findings. Rangan et a! 200 I investigated in rats, the effect of 
continuous oral administration of an NO donor (molsidomine),.NO precursor (L-arginine), 
or selective inhibitors of inducible NO synthase (iNOS; aminoguanidine, L-NIL) on the 
progression of tubulointerstitial inflammation. The study found endogenous NO to have a 
protective role against tubulointerstitial injury. Ido et al 2001 designed experiments using 
skin chambers mounted on the backs of Sprague-Dawley rats, and exposed an inhibitor of 
NOS to the granulation tissue. Albumin permeation and blood flow were significantly 
attenuated implicating nitric oxide in mediating permeability and blood flow changes in the· 
diabetic milieu. Reduced levels of NO may therefore play a key role in the development 
and progression of microvascular disease in diabetic subjects. 
Increase in ceU adhesion molecules (CAM) 
Increasing evidence indicates that hyperglycaemia increases the formation of free radicals 
by glucose auto-oxidation, which stimulate cytokine release and consequently induce 
expression of adhesion molecules (AM) on the endothelial cell surface (Pigott et a/ 1992). 
AM's are thought to be involved in chemotaxis of circulating monocytes and binding of 
leukocytes and platelets to endothelium. Raised concentrations of circulating AM's have 
been shown to exist in a variety of disorders including TIDM. They reflect endothelial 
activation and stimulation of leukocytes in diabetes and have a potential involvement in 
diabetes associated micro- and macrovascular disease. A study by Fasching et a! 1996 
showed that higher concentrations of vascular cell adhesion molecule-1 (cVCAM-1) was 
observed in TlDM subjects with retinopathy (+18%, P<0.05), and micro- and 
macroalbuminuria (+26%, P<0.05) than in those without. Similar fmdings were seen in 
TIDM patients with nephropathy (Schrnidt et a/1996 [b]), and also neuropathy (Jude et a! 
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1998). Other studies have indicated an increase in expression ofVCAM-1 and intracellular 
adhesion molecule-1 (clCAM-1) on retinal and choroidal tissue of diabetic patients with 
retinopathy (Tang et a/ 1994; McLeod et al 1995). It is therefore possible that elevated 
concentrations of c VCAM -1 as an indicator of widespread endothelial damage may serve 
as a risk marker for the presence and progression of diabetic microangiopathy in TlDM. A 
study by Park et al 2000 measured the effect of high glucose on the expression of 
intercellular adhesion molecule-1 and vascular adhesion molecule -1 in mesangial cells 
and found that high glucose can up-regulate ICAM-1 but not VCAM-1 through osmotic 
effect. Hyperglycaemia increased activation of cell adhesion molecules may therefore be 
an important factor in the development of diabetic microvascular disease. 
Alterations of intraceUular signalling pathways 
It is likely that glucose and its metabolites mediate their adverse effects by altering the 
various signal transduction pathways, which are used by vascular cells. Several mitogen-
activated protein (MAP) kinase signal transduction pathways have so far been 
characterised. These pathways are activated by multi-step phosphorylation cascades after 
ligand-cell surface receptor binding, and transmit signals to cytosolic and nuclear targets. 
The MAP kinases are activated through Ras-dependent signal transduction pathway by 
hormones and growth factors, leading to cellular proliferation and differentiation by 
stimulating transcription factors that induce the expression of growth responsive genes 
(lgarashi et al 1999). Intracellular signalling pathways are therefore an important target for 
studying the diabetic cellular milieu leading to damage. Intracellular signalling pathways 
are discussed in more detail in chapter 2. 
Increased de novo synthesis of diacylglycerol (DAG) and protein kinase C (PKC) 
Hyperglycaemia increases the synthesis of diacylglycerol (DAG) by enhancing the 
metabolism of glucose to DAG precursors through glycolysis. DAG is an important 
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cellular metabolic regulator in vascular cells, involved in the activation of the protein 
kinase C (PKC) signal transduction pathway. This elevation of DAG is the presumed 
mechanism for the elevated protein kinase C activity observed in several tissues obtained 
from diabetic animals, or exposed in vitro to high glucose concentrations (Lee et a/ 1989; 
Koya and King 1998). Hyperglycaemic activation of the PKC pathway has been shown to 
alter several parameters in vascular metabolism and function. Such fmdings include a 
decrease in the sodium potassium A TPase activity in peripheral nerves and vasculature 
through increased phospholipase A2 (cPLA) activity, altered regulation of gene expression 
of many proteins including those involved in vascular contractility and those found in the 
basement membrane (Craven et a/1990). 
Protein kinase C (PKC) is a family of serine-threonine kinases that influence a range of 
functions including cellular proliferation, blood flow and vascular permeability. A novel 
pathway for glucose transport has also been suggested involving PKC-:V~ 
(Bandyopadhyay et a/ 2001 ). Early suggestions of a role for PKC in the pathogenesis of . 
diabetic complications have been made from the results of animal studies in diabetic rats. 
Studies have found that PKC is activated in glomeruli isolated from diabetic rats (Craven 
et a/ 1989), and activation of PKC by exposure to a PKC agonist is seen to reproduce the 
vascular abnormalities induced by diabetes and high glucose levels (Shiba et a/1993; Wolf 
et a/1991). Mesangial cells cultured in high concentrations of glucose (27.8 mmol/L) for 
five days have increased PKC and mitogen activated protein kinase activity (Haneda et a/ 
1995), and it is thought that activation of the PKC system is an important pathway 
involved in diabetic glomerulopathy (DeRubertis and Craven 1994). PKC also increases 
levels of mRNA encoding matrix components in glomeruli isolated from streptozotocin-
induced (STZ) diabetic rats (Ziyadeh et a/ 1995). Activation ofPKC has also been found to 
further activate intracellular signal transduction systems such as extracellular regulated 
kinase (ERK) forming a DAG-PKC-ERK chain. It is thought that therapies aimed at 
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lowering the PKC levels may be beneficial and· diabetic rats treated with d-alpha-
tocopherol, which inhibits PKC activation has been seen to prevent glomerular 
hyperfiltration and minimise the development of proteinuria (Koya et a/ 1997; Way et a/ 
2001). Haneda et a/ 2001 examined the DAG-PKC-ERK pathway and found that 
thiazolidinedione compounds could inhibit PKC activation by activating DAG kinase. 
Glucose altered content, cellular distribution and activity of diacylglycerol-sensitive PKC-
alpha, -beta, -delta, and -epsilon isoforms has also shown to be dependent on polyol 
pathway (Kapor-Drezgic et a/ 1999), and could be prevented using aldose reductase 
inhibitors tolrestat and ARI-509. Insulin treatment also normalises membrane PKC 
isoforms content (Babazono et a/ 1998). Such findings highlight the importance of the 
DAG-PKC-ERK. pathway in the development of glomerular dysfunction in diabetes. Early 
trials of PKC inhibition indicate the potential benefits of treatment against end-stage renal 
disease with PKC inhibitors. 
Transcription factor nuclear factor kappa B (NFKB) 
Nuclear factor kappa B (NFKB) is a member of the Rei family proteins and is a eukaryotic 
transcription factor that is involved in mediating the immune response (LeBeauet et a/ 
1992; Baeuerle 1998; Brand et a/ 1996). Studies using glomerular mesangial cells have 
shown that NFKB activation occurs as a response to hypoxia, cytokines, angiotensin IT and 
AGE proteins (Khachigan et a/1995). Animal studies have shown higher renal expression 
of the NFKB system in diabetic animals compared with healthy control animals (Bierhaus 
et a/ 1997 [a and b). It has also been shown that increased activity of NFKB is present in 
the peripheral mononuclear cells isolated from TlDM and T2DM patients with diabetic 
nephropathy (Mohamed et a/ 1999; Hoffman et a/ 1999). Romeo et al 1999 found that 
increased activation of NFKB is the first molecular abnormality detected in situ in retinal 
pericytes of diabetic donors. Characterisation of the biosynthetic program driven by NFKB 
in vivo, and its inhibition, will clarify the role of the transcription factor in diabetic 
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complications. Studies carried out using porcine vascular smooth muscle cells have shown 
that hyperglycaemia activates NFKB (Yemeni et a/!999). This has been shown to be true 
in ex-vivo isolated peripheral blood mononuclear cells (PBMC's) ofTIDM patients, where 
poor. glycaemic control induces the activation of NFKB (Hoffman et a/ I 998). Kumar et a/ 
1999 demonstrated that hyperglycaemia-induced activation of NFKB in vascular smooth 
muscle cells was inhibited by a protein kinase C inhibitor, calphostin. Studies by Hoffman 
et a/ 1999; Du et a/ 1999 and Bierhaus et a/ I 997 [a] demonstrated that NFKB activation is 
in part dependent on oxidative stress as a-Lipoic acid was seen to reduce NFKB binding 
activity (Muller et a/ 1997). It has therefore been suggested that hyperglycaemia induced 
activation of NFKB may be involved in the susceptibility to diabetic microvascular 
complications and be a key mechanism for accelerated vascular disease observed in 
diabetics. 
Transcription factor activating protein-I (APl) 
Activating protein-! (APl) is a sequence specific transcription factor involved in 
regulating the expression of several genes including those involved in mediating growth, 
inflammation and differentiation. API is reported to be regulated in response to 
hyperglycaemic conditions and resultant intracellular redox imbalances (Sen and Packer 
1996; Nishio et a/1998; Natarajan et a/1999). Wilmer et a/ 1998 demonstrated increased 
binding of APl to in human mesangial cells (HMC) cultured in high glucose environment 
(30mM d-glucose). APl may therefore be activated in the diabetic state and involved in the 
development of microvascular disease. Weigert et al 2000 have reported evidence that 
APl proteins mediate hyperglycaemia induced activation of the human TGF-BI promoter 
in mesangial cells. 
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Role of growth factors/cytokines in microvasculopathy 
High glucose and its various metabolites such as nonenzymatic glycation products and 
hemodynamic changes can all stimulate the synthesis and release of a host of factors which 
stimulate proliferation of hypertrophy of cells and the production of extracellular proteins 
(Wolf and Ziyadeh 1999), some of which are discussed here; 
Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a heparin-binding homodimeric protein of 
46-kDa, and at least five different molecular species with varying amino acid number have 
been shown to exist (Tisher et a/ 1991). So far four VEGF family members have been 
identified, VEGF-A, VEGF-B (Olofsson et a/1996), VEGF-C (Joukov et a/1996) and an 
endocrine derived ED-VEGF (LeCoute et a/ 2001). VEGF has been shown to be an 
angiogenesis and vasopermeability-inducing molecule and its expression has been shown 
to be increased in many hyperproliferative disorders. VEGF is a principle mediator in 
diabetic retinopathy and also appears to play a central role in diabetic vasculopathy in 
many other organs, although its precise involvement is not understood. VEGF expression 
is increased in mesangial cells cultured in high glucose media, and glomerular VEGF 
levels and urinary VEGF are increased in patients with diabetes (Aiello and Wong 2000). 
VEGF mediates its action through transmembrane autophosphorylating tyrosine kinase 
proteins of high VEGF binding affinity. These receptors are expressed predominantly in 
endothelial cells although they have been identified in renal mesangial cells, monocytes, 
hematopoietic cells and the retina. Evidence suggests that nitric oxide mediates some of 
VEGF's mitogenic effects on coronary endothelial cells and that VEGF mRNA expression 
is dramatically regulated by oxygen tension, with markedly increased VEGF gene 
expression under hypoxic conditions (Shweiki et a/ 1992). It is suggested that VEGF might 
regulate neovascularisation in hypoxia induced diabetic retinopathy leading to increased 
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retinal vascular permeability and new retinal vessel growth. In animal models specific 
inhibition of VEGF by soluble VEGF receptor chimeric proteins, reduced 
neovascularisation in 95% to 100% of animals tested (Aiello et a/ 1995). Clinical studies 
have also confmned that there is elevated VEGF concentrations in vitreous and aqueous 
samples of eyes in patients with proliferative retinopathy (Aiello et a/ 1994). Tilton et al 
1999 showed that intravenous infusion of VEGF can acutely impair endothelial cell barrier 
functional integrity and relax resistance arterioles in ocular tissues and brain. Inhibition of . 
VEGF action might therefore provide novel therapeutic approaches to diabetic 
vasculopathy. 
Transforming Growth Factor Beta (TGF-f3) 
Cellular signalling pathways involved in Transforming Growth Factor Beta (TGF-13) 
induced renal injury are being extensively investigated. TGF-13 is activated by the 
extracellular signal-regulated kinase (ERK) pathway and also p38 mitogen activated 
protein kinase (MAPK) system. TGF-13 has been shown to have antiapoptotic effects in 
macrophages, and is implicated in type 1 collagen synthesis in mesangial cells, and induces 
fibronectin and plasminogen activator inhibitor (PAl-l) expression in mesangial cells. 
TGF-13 also down regulates inositol 1,4,5-triphosphate (IP3) receptors which may also · 
mediate vascular dysfunction in diabetes. Down regulation of ECM degradation is thought 
to be through a TGF-13 dependent mechanism through glucose induced down regulation of 
matrix metalloproteinases (MMP) which may contribute to the pathogenesis of diabetic 
glomerulosclerosis. Lovastatin, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor has been shown to suppress glomerular TGF-13 expression and 
ameliorate diabetic nephropathy in STZ induced diabetes in rats (Del Prete et a/ 1998; Lee 
et a/2000). 
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Other growth factors and chemokines 
A whole variety of growth factors, cytokines, chemokines and vasoactive agents which 
have not already been mentioned have also been investigated and implicated in the 
pathogenesis of diabetic microvasculopathy. Such agents inClude; the cytokines- platelet 
derived growth factor-B (PDGF-B) (Kasuya et al 1999 [a]), insulin-like growth factor-! 
(IGF-1), hepatocyte growth factor (HGF); the chemokines- interleukin-8 (TI-8) and 
monocyte chemotactic peptide-! (MCP-1); and the vasoactive substances, angiotensin II 
(Angll), andothelin-1 (ET-1) and the prostanoides such as thromboxane (Flyvberg et al 
1998; Abboud 1997). These factors will however not be discussed in detail as they are 
beyond the scope of this thesis. 
Interactions between hyperglycaemia altered pathways 
Many lines of evidence indicate that there is a multifactoral pathogenesis of diabetic 
complications, and that several pathways are affected by diabetes, which lead to the onset 
and progression of microvascular disease. These pathways are thought to be interconnected 
and overlap with each other as illustrated in figure 3. It has been shown that increased 
sorbitol pathway metabolism and non-enzymatic glycation products are involved in the 
pathogenesis of vascular and neural dysfunction associated with diabetes. A study carried 
out by Ido 1996 using animal models looked at the vascular dysfunction induced by 
elevated glucose levels, and found that increased blood flow and increased albumin 
permeation was reduced by inhibitors of the sorbitol pathway, nitric oxide synthesis and of 
prostaglandin synthesis respectively. These fmdings suggest that the vascular dysfunction 
induced by increased sorbitol pathway metabolism and by products of non-enzymatic 
glycation are mediated by a common final pathway. Increased superoxide production is 
important in mediating vascular dysfunction and it is likely that increased flux of glucose 
via the sorbitol pathway increases superoxide production as a consequence of hypoxia like 
reductive stress resulting from reduction of NAD+ to NADH coupled to oxidation of 
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sorbitol to fructose. The final common pathway between the various biochemical 
abnormalities would therefore appear to involve the increase in oxidative stress (Cappiello 
2000). 
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as a result of hyperglycaemia. 
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Genetic susceptibility to diabetic complications 
There is substantial evidence to support the involvement of genetic factors in the 
development and progression of certain diabetic microvascular complications. This 
evidence comes from genetic epidemiological studies of diabetic complications (Rich et a/ 
1997). Molecular characterisation of genetic susceptibility is imperatively important and 
would not only increase our understanding of the pathogenesis of diabetic complications 
but would also provide diagnostic tools for identifying susceptible patients so that they 
could be targeted for intensive control of hyperglycaemia. Such information would also 
assist in the development of new preventative and therapeutic programs. Possible genetic 
models for the interaction between the diabetic milieu and susceptibility to complications 
have been proposed where genes may have a major or minor effect. These include, an 
additive genetic model where the genetic influence serves to regulate the progression of the 
disease, an interactive model where genes in conjunction with poor glycaemic control lead 
to the development of disease, and a mixed model where some genes influence 
development whereas other genes influence progression of disease (Krolewski et at I 992; 
Krolewski 1999). The suggestion that there is an interaction between genes could also help 
towards explaining why some patients with well-controlled diabetes still develop 
complications, whereas there are others with poorly controlled diabetes who 'escape' any 
complications. This may also suggest that it will be possible to predict the beneficial effect 
of different targeted therapeutic intervention (Cooper 1998). However despite promising 
fmdings that suggest a role for various genetic factors in the pathogenesis of complications, 
genetic screening cannot yet be considered appropriate as part of routine clinical practice 
in diabetic patients. 
Genetic epidemiology of nephropathy 
Transracial studies (Cowie et al 1989; Burden et at 1992), family studies (Seaquist 1989; 
Pettitt et a/1990; Borch-Johnsen 1992; Quinn et a/1996; DCCT 1997; Fioretto et a/1999) 
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and large epidemiological studies (Anderson et a/ 1983) have all shown marked 
differences in the incidence of diabetic nephropathy. These studies collectively indicate 
that only a subgroup of diabetic subjects (33%) are susceptible to diabetic nephropathy, 
that there is familial aggregation for renal disease, and that there are marked inter-racial 
differences in the disease prevalence, all indicating a genetic basis for nephropathy. 
A large epidemiological study consisting of 1475 TIDM subjects diagnosed before 1953 
and before the age of 31 years was conducted, all patients were diagnosed with diabetes at 
the Steno Memorial Hospital, Denmark (Anderson et a/ 1983). Patients were followed 
until 25 years duration of diabetes or until death. The study found that 41% of patients 
developed nephropathy, 3% had proteinuria due to other causes and 57% did not develop 
persistent proteinuria. Variation has been shown to exist in the prevalence of diabetic 
nephropathy in different racial groups. Asian, Hispanic, Native American or Afro 
Caribbean ethnic origin have iricreased rates of diabetic renal disease as compared to 
matched groups ofCaucasoid patients (Pugh 1988; Cowie 1989; Collins 1989; Pettitt 1990; 
Reddan et a/2000; Bennett et a/ 2001). A trans-racial study that looked at the incidence of 
end-stage renal disease in diabetic subjects found an increased incidence in African-
Americans compared to Caucasoids (Brancati et a/ 1992). The family study carried out by 
Seaquist et a/ 1989 demonstrated an increase in the incidence of diabetic nephropathy in 
siblings of TIDM probands with nephropathy compared to siblings of normoalbuminuric 
TIDM subjects, concluding that nephropathy occurs in familial clusters. Similar findings 
were also reported from a study carried out by Borcb-Johnsen 1992 who found a 
significant increase in renal complications in TlDM siblings ofprobands with nephropathy 
than in TlDM diabetic siblings of probands without nephropathy. Studies in Pima Indians 
with T2DM showed that there was familial aggregation for proteinuria among diabetic 
siblings and that nephropathy was observed in 46% of diabetic offspring if both patients 
were proteinuric, 23% if one parent had proteinuria and 14% if neither parents bad 
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proteinuria (Pettit et a/ 1990). Further evidence for familial aggregation of nephropathy 
was found in a study of siblings with TlDM. This study found that for probands and 
siblings combined the cumulative incidence of advanced diabetic nephropathy after 30 
years duration of diabetes was 35%, however if the proband had persistent proteinuria the 
risk to the sibling rose to 71.5% (Quinn et a/ 1996). In 1997 the DCCT research group 
published the results of a large study investigating familial clustering of diabetic 
microvascular complications. The study aimed to determine familial associations and 
clustering of the severity of complications. The data with respect to nephropathy suggested 
that there was an increased risk of nephropathy in relatives of nephropathy positive versus 
nephropathy negative subjects and suggested that possible genetic factors influenced the 
development of diabetic nephropathy (DCCT 1997). A study by Fioretto et a/ 1999 
examined the lesions of diabetic nephropathy among TlDM siblings and determined that 
there was strong concordance for the severity and patterns of glomerular lesions among the 
sibling pairs, suggesting familial concordance in the risk for nephropathy. Complex 
segregation analysis has been performed in diabetic members of Pima Indian families to 
determine whether familial aggregation of nephropathy reflects the action of a single major 
gene. Analysis of prevalent cases in this study supported evidence for the existence of a 
gene with a major role in the susceptibility to diabetic nephropathy in Pima Indians. This 
was shown where-by the hypotheses of no major effect and of no transmission of a major 
gene effect were rejected (P=O.OOOOI; P= 0.003) (lmperatore et a/ 2000). These 
observations suggest that one or more hereditary causes may be involved in the 
pathogenesis of this complication, and that the proposed difference in risk suggests a major 
gene effect. 
Genetic epidemiology of retinopathy 
The DCCT 1997 report investigating familial clustering of diabetic microvascular 
complications indicated that the risk of severe retinopathy in the relatives of retinopathy 
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positive versus negative subjects was statistically significant. Correlation's for the severity 
of retinopathy which were computed from log-adjusted retinopathy scores were 0.187 (all 
family members), 0.327 (parent-offspring), 0.249 (father-child), 0.391 (mother-child), and 
0.060 (sib-sib) and all were statistically significant (P<0.05). The WHO Multinational 
Study of Vascular Disease in Diabetes (WHO MSVDD) designed a study to compare the 
vascular complications of diabetes in different ethnic groups which included an estimate of 
visual function (Diabetes Drafting Group 1985; Miki et a/ 2001). This provided the 
opportunity to ascertain incidences and progression of visual impairment and its risk 
factors, which were found to include baseline systolic pressure and cholesterol levels. In 
the United States and the UK approximately 12% of all new blindness was attributable to 
diabetic retinopathy (Kiein 1995). The prevalence rate in the WHO MSVDD study showed 
significant variation of visual impairment prevalence rates among centres with high total 
rates, American Indian Oklahoma (33.4%) and Pima (26.3), contrasting with lower 
European rates. These data provide evidence that the severity of diabetic retinopathy is 
influenced by familial (possibly genetic) factors (DCCT 1997), and to some degree 
ethnicity. 
Genetic epidemiology of neuropathy 
Diabetic neuropathy is the most common form of peripheral neuropathy in the western 
world and is a common complication in both TIDM and T2DM subjects. Much of the data 
on prevalence and incidence of neuropathy comes from the Rochester Diabetic Neuropathy 
study which was a population based longitudinal study of participants from Rochester, 
Minnesota (Dyck et a/1991). This study revealed that the prevalence of neuropathy did not 
differ greatly between TIDM (66%) and T2DM (59%) subjects or by clinical subtype. 
Another study, the San Louis Valley Study found a much lower prevalence of neuropathy 
(28%) in T2DM subjects of Anglo and Mexican/American heritage, although there were 
no indications of ethnic difference in incidence (Franklin et a/1990). The failure of studies 
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such as the San Louis Valley study to observe ethnic differences indicated that genetic 
effects do not play a major role in the aetiology of neuropathy as ethnic differences in 
disease are often a hallmark of genetic effects. Therefore, the observed factors such as 
duration of diabetes, hyperglycaemia and hypertension are suggested to may play a major 
role in neuropathy risk (DCCT 1993 [a and b ]). 
Genetic epidemiology of macrovascular disease 
Epidemiological data indicate that diabetes and a familial predisposition are independent 
risk factors for cardiovascular disease. Research has identified evidence of familial 
aggregatiol} of early coronary heart disease (Hopkins et a/ 1988), and a familial correlation 
for CHD risk factors (Glueck et a/ 1974). Excess mortality from stroke among diabetic 
patients is at least two~fold compared with the non-diabetic population (Garcia 1974). In 
the Honolulu Heart Program, the rate of thromboembolic stroke for diabetic men was 
62.3/1,000 vs. 32.711,000 for non-diabetic men (Abbott et a/ 1987). In the Framingham 
Study the risk of stroke for T2DM subjects was 2.6 fold greater for men and 3.8 fold 
greater for women than for non-diabetic individuals (Stokes et a/1987). Tarnow et a/2000 
has shown that cardiovascular morbidity and early mortality clusters in parents of TIDM 
subjects with nephropathy. 
Tbe searcb for susceptibility genes 
The positional cloning of multifactoral disease genes is a major challenge in human 
genetics. Several forms of genetic mutations are known to exist and are identifiable using 
various molecular genetic techniques. Genetic variations include single nucleotide 
polyrnorphisms (SNPs), dinucleotide repeats and microsatellites. · Several of the 
polymorphisms are located in the promoter region of the gene and affect transcription or 
translation, and not infrequently determine the level of expression of the protein product. 
Single nucleotide polyrnorphisms involve the substitution of one nucleo~de for another, 
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and some can be identified using restriction endonuclease digestion. As a consequence of 
the Human Genome Project effort is underway to develop a dense set of biallelic markers 
(SNP's) throughout the human genome (Collins et a/1998). Technology to detect SNP's 
includes the use of a gene chip, a glass wafer, to which is bound high-density arrays of pre-
pooled primers for multiplex PCR assays. It is anticipated that up to 100,000 SNP's 
scattered throughout the genome will become available (Wang 1998). The finishing of 
human genome sequence determination, improvements in inforrnatics and large-scale 
identification of SNP's will undoubtedly increase the feasibility of identifying 
polymorphisms that predispose to diabetic complications (Johnson and Todd 2000). 
Dinucleotide repeats consist of continuous repeating units of a dinucleotide sequence, for 
example (CA)n, and similarly Variable Number Tandem Repeats (VNTR) consist of 
repeating units of more than two base pairs. Microsatellites are tandernly repeated arrays of 
one to six nucleotides and these sequences are both ubiquitous and highly polymorphic. 
Microsatellites are repeated 10-60 times and they are dispersed throughout the genome on 
average every 105 bp (Weber and May 1989; Love 1990). When they are mutated they are 
also an important cause of human disorders. Microsatellite markers possess high levels of 
allelic variation so that parental chromosomes often bear different alleles enabling 
chromosomes to be tracked from parents to affected offspring. Studies in a wide variety of 
systems have shown that replication slippage is the predominant means by which the 
number of repeats in a rnicrosatellite array changes, and that alterations most commonly 
consist of insertion or deletion of one or two repeat units (Schlotterer and Tautz 1992). 
Microsatellite mutation rates are increased in cells deficient for mismatch repair (Strand et 
a! 1993). It is suggested that alteration in repeat number occurs in distinct classes (rare, 
large changes and common, single or two step ones) (Freimer and Slatkin 1996). It is also 
possible that there is a constraint on the mutation process that would cause allele size to 
remain within a certain limit. Valdes et a! 1993 showed that there was no obvious 
relationship between the variance in repeat number, which should be proportional to the 
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mutation rate, and the average allele size. Microsatellites are flanked by unique sequences 
to which PCR primers can be designed to allow amplification of the microsatellite region. 
Variations in the length of flanking sequences could affect the overall size of the PCR 
product lengths and obscure a relationship between the mean and the variance in allele 
size. A number of lines of evidence indicate that the total length of the microsatellite may 
have less of an effect on the mutation rate than the length of uninterrupted or perfect 
repeats. Direct sequencing data through semi-automated mapping has now become a 
widely used technique in analysing microsatellite polymorphisms (Reed et a/1994 ). 
Whole genome scanning for susceptibility loci 
A whole genome scan is the analysis of about I 00 evenly spaced markers in mouse 
pedigrees, or about 300 markers in human families in which there are affected and non-
affected progeny. The aim is to identifY chromosome regions that are inherited by affected 
progeny more often than expected from Mendelian random segregation. Using large data 
sets, a map with dense markers, and multipoint programs, which make the map even more 
informative, can reduce false positive linkage results. One approach to detect linkage of 
genes has been based on the squared sib pair trait difference that is regressed on the 
estimated proportion of marker alleles shared by descent. The test for linkage is then based 
on the significance of a negative slope. For all pairs of affected concordant, unaffected 
concordant and discordant sib-pairs, the mean proportion of marker alleles shared can be 
estimated. The power of the sib-pair method depends on the proportion of the phenotypic 
variance due to segregation at the major locus and the sample ascertainment (Risch et al 
1995). This strategy of whole genome scanning has been applied to screening for 
determinants of microvascular disease related to diabetes. For example Imperatore et al 
1998 [a and b] used sib-pair linkage analyses to identifY loci influencing susceptibility to 
microvascular complications in Pirna Iitdians with T2DM. The study suggested that a 
genetic element on chromosomes 7 and 20 may influence susceptibility to nephropathy and 
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a genetic element on chromosomes 3 and 9 may determine susceptibility to both 
nephropathy and retinopathy. In this study chromosome 7 showed the strongest evidence 
for linkage, and contains the candidate gene aldose reductase (ALR2). A further study 
using TIDM sib-pairs discordant for diabetic nephropathy found a susceptibility locus on 
chromosome 3q which contains the candidate genes involved in angiotensin II sub-type I 
receptor (A TlR) (Moczulski et a/ 1998). 
Fine mapping of susceptibility loci 
A disease mutation will be flanked by microsatellite markers with certain alleles which can 
be typed and provide a recognisable signature to the chromosome region containing the 
disease mutation. If a marker is very close, within 1 centimorgan (cM) (Jorde 1995) to a 
disease mutation, then despite opportunities for recombination during meiosis between the 
marker and the disease mutation, there will still be a strong chance that the marker and the 
mutation will be in linkage disequilibrium. In regions of the genome that show some 
evidence of linkage to disease detected in the genome scan testing markers every 
centimorgan should yield a marker that shows linkage disequilibrium with disease. A study 
carried out by Herr et al 2000 empirically tested the utility of the available polymorphic 
microsatellite map to locate the already identified TIDM locus IDDMI. Allelic association 
of each of 13 evenly spaced polymorphic rnicrosatellites markers was carried out using 385 
affected sib-pair families. The study demonstrated that fine mapping of a multifactoral 
disease gene is possible with high accuracy even in a region with high linkage 
disequilibrium. By characterising new markers in the lcM region flanking the disease 
associated marker, the disease mutation can be located to regions smaller than I cM (Vyse 
and Todd 1996). The candidate gene approach in detecting disease mutation has to some 
extent dominated the genetic analysis of diabetic complications. However, candidate genes 
are numerous and have in many cases been reported but not confirmed. 
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Candidate genes investigated in diabetic compUcations 
The candidate gene approach in detecting susceptibility genes for diabetic complications 
has also proved to be fiuitful. This strategy has so far focused on target tissues that are 
susceptible to diabetic complications and biochemical pathways affected by altered glucose 
metabolism. The search for candidate genes has so far involved searching gene 
polymorphisms of the enzymes that drive glucose metabolism and also gene 
polymorphisms affecting background vascular risk (Marre 1999). Studies have looked at 
polyrnorphisms within candidate genes involved in the pathogenesis of complications and 
have found certain genotypes to have a progression promoter effect (table 4). Such studies 
include human leukocyte antigen (HLA) loci, genes of the renin-angiotensin system, 
polyoVsorbitol pathway, lipid metabolism and glucose transporter genes (Chowdhury et al 
1995; Doria et a/ 1995; Doria et a/ 1998; Krolewski and Warram 1995 [b]; Chowdhury et 
a/1999 [a and b]; Marre et a/2000). It is thought to be worthwhile testing polyrnorphisms 
within each component of these various regulatory systems to determine their possible role 
in the development of diabetic complications in the event that gene polymorphisms are 
associated with variable levels of expression of the concerned protein. 
Human Leukocyte Antigen (HLA) gene polymorphisms 
Several groups, with somewhat conflicting results have extensively examined the human 
leukocyte antigen (HLA) locus and the insulin gene locus. Both positive and negative 
associations have been made for HLA A2, B8, DR4 and DR3/4 and diabetic nephropathy 
and retinopathy (Barbosa and Saner 1984; Stewart et a/ 1993). Previous examination of 
HLA identical non-diabetic siblings of T IDM pro bands showed basement membrane 
expansion, which was not observed in HLA non-identical siblings, which suggested that 
even in the absence of diabetes microangiopathy may occur due to HLA-related factors 
(Barbosa et a/1980). However, other association studies of HLA and insulin gene loci in 
large cohorts ofTIDM subjects with and without nephropathy found no such associations. 
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It has therefore been suggested that the HLA and insulin gene loci are unlikely to have a 
major role in the susceptibility to nephropathy in Caucasoid TlDM subjects (Chowdhury 
et a/1998; Chowdhury et a! 1999 [b ]). 
Receptor for advanced glycation end products (RAGE) gene polymorphisms 
AGE's can bind to several binding sites including receptor of advanced glycation end-
products (RAGE). Kankova et a! 2001 investigated polymorphisms in the RAGE gene 
(G82S, 1704G/T, 2184A/G and 2245G/A) in T2DM subjects and found statistically 
significant differences in allelic frequencies between T2DM subjects and non-diabetic 
controls. Hudson et a! 2001 [a] carried out a study of the -429 t/c and -374 t/a RAGE 
promoter polymorphisms in diabetic and non-diabetic subjects with macrovascular disease. 
The study evaluated the effects on transcriptional activity of functional polymorphisms and 
suggested that polymorphisms involved in differences in RAGE gene regulation may 
influence the pathogenesis of diabetic vascular complications. 
Renin-angiotensin system (RAS) gene polymorphisms 
Studies have demonstrated that a family history of hypertension or cardiovascular disease 
in association with poor glycaemic control greatly increases the risk of nephropathy in both 
TlDM and T2DM patients (Earle et a! 1992; Barzilay et a! 1992; Takeda et a/ 1992). 
Genes of the renin-angiotensin system (RAS) have therefore also been targeted as potential 
candidate genes for nephropathy. Prorenin, renin, angiotensin converting enzyme (ACE) 
and angiotensin II levels have all been reported to be elevated in diabetic nephropathy, and 
are thought to be genetic determinants for hypertension and cardiovascular disease 
(Parving et a/1996 [b ]; ~allab et a/1992). The angiotensinogen gene (AGT) has also been 
reported to contribute to susceptibility to complications in some affected sib-pair studies 
(Jeunemaitre et a/ 1992; Caulfield et a/1994), and family based studies (Rogus et a! 1998). 
Studies of the Insertion/Deletion polymorphism within intron 16 of the angiotensin 1-
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converting enzyme gene (ACE/ID) have found conflicting results. One positive study 
carried out by Doi et al 1996 found a significant correlation between the ACE gene 
polymorphism and nephropathy, but not retinopathy in Japanese patients with T2DM. On 
the other hand Utsugi et al 1999 found that the ACE polymorphism could be a risk factor 
for both nephropathy and retinopathy in Japanese patients with T2DM. This study 
suggested that patients with the D allele were at a higher risk of severe retinopathy than 
subjects without. Tarnow et al 2000 carried out a study using TIDM subjects from 
Denmark and found evidence for a protective effect of the homozygous 11 genotype and 
myocardial infarction. However studies have cumulatively shown the association of the 
ACE/ID polymorphism with nephropathy to be small, and consequently it is not thought to 
be a useful marker of nephropathy (Doria et a/1994; Marre et a/2000). The EURODIAB 
study has however shown that the ACE gene polymorphism can predict the beneficial 
effect of ACE inhibition (Penno et a/1998), where renoprotective therapy has been seen to 
be differentially effective according to ACE genotype (van Essen et al 1996). A further 
polymorphism of the angiotensin gene (M235T) has also initiated interest and has been 
shown to be in linkage with essential hypertension (Caulfield et al 1994). However, 
conflicting results have been seen in association with diabetic nephropathy (Fogarty et al 
1996; Chowdhury et a[ 1996; Schmidt et a/ 1996 [a]; lttersurn et al 2000) and it was 
reported by Doria et al 1996 that the angiotensinogen polymorphism M235T might 
influence susceptibility to nephropathy in TlDM subjects, but its effect, if any, is small 
and independent of hypertension. A polymorphism of the angiotensin 11 type 1 receptor 
gene (Al166C) has also been linked to essential hypertension (Bonnardeaux et al 1994), 
and microalbuminuria (Doria et a/ 1997), although two large studies into diabetic 
nephropathy have suggested no association (Chowdhury et a/1997; Tarnow et a/1996). 
Genetic studies of hereditary hypertension in the rat, and genome-wide scans have 
identified several loci involved in blood pressure regulation (Hilbert et a/1991; Jacob et a/ 
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1991; Dubay et a/ 1993; Pravenec et a/1995; Schork et a/1995; Brown et a/1996). Brown 
et a/ 1996 studied crosses involving the fawn-hooded rat, an animal model of hypertension 
that develops chronic renal failure to determine if there are susceptibility genes involved. 
They reported the localization of two genes, Rf-1 and Rf-2 responsible for about half the 
genetic variation of renal impairment. They found that Rf-1 strongly affects the risk of 
renal impairment, but has no significant effect on blood pressure. Their results suggested 
that susceptibility to a complication of hypertension is under at least partially, independent 
genetic control from susceptibility to hypertension itself. One of the principle loci 
identified in spontaneously hypertensive stroke-prone (SHR/SP) and Dahl salt-sensitive 
hypertensive rats has been localised near the angiotensin 1 converting enzyme (ACE) on 
rat chromosome 10 (Nara et a/ 1991; Deng and Rapp 1992). Based on comparative 
mapping data, the human homologues of the corresponding gene should reside within 
human chromosome 17, which contains the ACE gene. Julier et al 1997 carried out a study 
using affected sib-pair human hypertensive families to explore the whole homology region 
for a putative susceptibility locus for hypertension. Using microsatellite markers the study 
found nominal evidence of linkage to hypertension, from which the strongest markers were 
D 17S 183 and D 17S934, that map l8cM proximal to the ACE locus. Baima et a! 1999 used 
stroke-prone spontaneously hypertensive rat models to investigate linkage to blood 
pressure regulatory genes, and found evidence for an association with rat chromosomes 2, 
lO and X, whereby rat chromosome lO is syntenic to human chromosome 17. The study 
investigated five microsatellite markers spanning the chromosome 17 blood pressure 
quantitative trait loci (QTL), spanning a 12cM region and found significant evidence for 
linkage in a 5-cM interval between D 17S946 and Dl7S932. Levy et a! 2000 used a 
genome wide scan approach and found strong evidence for a blood pressure (BP) 
quantitative trait locus on chromosome 17. These results indicated that chromosome l7q 
could contain a susceptibility locus for human hypertension (Dominiczak et a/ 2000). 
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Aldose Reductase (ALR2) gene polymorpbisms 
The enzyme aldose reductase has been implicated in a number of microangiopathic 
complications of diabetes. Using the strategy to search for gene polymorphisms of the 
enzymes that drive glucose metabolism, a dinucleotide repeat polymorphism was found at 
the 5' end of the aldose reductase gene. Certain studies have found the polymorphism to be 
associated with early onset of retinopathy and also nephropathy (Heesom et a/ 1997; 
Demaine et a/ 2000) in diabetics. Other polymorphisms have also been identified and 
include a C to T polymorphism -1 06bp upstream of the aldose reductase start site, and an 
A to C polymorphism within intron 8 of the ALR2 gene itself. It is possible that aldose 
reductase, an enzyme able to affect glucose metabolism within target tissues of diabetic 
microangiopathy may effect microvascular prognosis for TIDM patients as a result of 
effects on variable, genetically determined levels of its activity. Polymorphisms and altered 
genetic expression of the aldose reductase gene form the main thread of this thesis and are 
therefore discussed in more detail in chapter 2. 
Glucose Transporter (GLUT) gene polymorphisms 
A recent study carried out by Hodgkinson et a/ 200l[a] reported that a polymorphism 
within the glucose transporter I (GLUT!) gene was significantly associated with 
susceptibility to diabetic nephropathy in Caucasoid TIDM subjects, this was also found to 
be in association with the 5 'ALR2 polymorphism. The glucose transporters mediate the 
facilitative uptake of glucose into cells and within the glomeruli of the kidney the GLUT I 
is known to be the most important (Heilig et a/ 1995; Heilig et at 1997 [b ]). The results of 
this study suggest that those individuals with the 1.1 kb GLUT! allele and the Z-2 5' ALR2 
allele would be at a much higher risk of developing nephropathy than those without. 
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Apollpoprotein E (APOE) gene polymorpbisms 
Studies into the genes affecting lipid metabolism have shown a positive association of the 
E2 allele of the apolipoprotein E gene polymorphism, this is a particularly significant 
finding as physiological studies have implicated lipid abnormalities in the pathogenesis of 
diabetic nephropathy (Arald et al 1998; Chowdhury et al 1998). It has been suggested that 
TlDM subjects with the E2 allele have a reduced creatinine clearance and elevated 
albumin excretion rate compared to subjects without the E2 allele (Werle et a/1998). 
Endothelial nitric oxide synthase (eNOS) gene polymorpbisms 
Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may be implicated in 
the development of nephropathy in patients with TIDM. A study by Zanchi et a/ 2000 
looked at four eNOS polymorphisms and found that two were associated with diabetic 
nephropathy in a case-control comparison . and also a family based transmission 
disequilibrium test (TDD. These were a T to C substitution in the promoter at position -
786 and the a-deletionlb-insertion in intron 4. Their findings demonstrate that sequence 
differences in eNOS influence the risk of advanced nephropathy in TIDM. Asakimori et a/ 
2001 also investigated the intron 4 polymorphism of the ecNOS gene and found a higher 
frequency of the a-allele of intron 4 in both non-diabetic and diabetic hemodialysis 
patients, although this was not supported in a study using T2DM subjects (Taniwaki et a/ 
2001). 
Plasminogen Activator Inhibitor-I (PAI-l) gene polymorphisms 
Plasminogen activator inhibitor type I (PAI-l), is an inhibitor of fibrolysis and an 
important and independent cardiovascular risk factor which has been shown to be elevated 
in obesity and T2DM (Mertens et al 2001). The 40/50 polymorphism in the promoter 
region of the PAI-l gene has been related to plasma levels of PAI-l, the main inhibitor of 
fibrinolysis. P AI -1 is higher in TlDM subjects with microalbuminuria. Pucci et a/ 1999 
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investigated this polymorphism in 375 Caucasoid TlDM subjects and found that the 
presence of the 4G/4G genotype to be associated with a higher risk of proliferative 
retinopathy, but not with a higher risk of raised AER. 
Paraoxonase gene (PON) polymorphisms 
There is increasing evidence to suggest that paraoxonase (PON) protects tissues from 
oxidative stress. PON is an enzyme, which is exclusively bound to high-density lipoprotein 
(HDL), and it has been shown by in vitro studies that it protects low-density lipoprotein 
from oxidative stress. It has been shown that the serum activity and concentration of PON 
is lower in subjects with cardiovascular disease than those without (Heinecke et al 1998; 
Sanghera et a/1998). Two separate studies by Araki et a/2000 in TlDM subjects and by 
lkedo et al 1998 in T2DM subjects looked at three common polymorphisms of PON-gene-
1. These polymorphisms, namely T(-107)C in the promoter, Leu 54Met and Gln192Arg 
have previously been associated to cardiovascular disease (Ruiz et a/ 1995; Garin et a/ 
1997). The studies did not find any significant relationship between any of these three 
polymorphisms and the development of nephropathy in either Tl or T2DM patients. 
Another study however, did find an association between diabetic nephropathy and the 
Glnl91Arg polymorphism (Jenkins et a/ 2000). The human genome contains two other 
similar genes to PONJ (PON2 and PON3), located on chromosome 7 and it is 
hypothesised that these should also be considered as candidate genes for the susceptibility 
to diabetic nephropathy. Pinizzotto et a/ 2001 has reported an association between diabetic 
nephropathy in T2DM subjects and two polymorphisms in PON2 that cause amino-acid 
substitutions (Alal48Gly and Ser311Cys). This correlation was however, not supported in 
a further study carried out by Canani et al 2001 using TlDM subjects. Thus concluding 
that the PON2 polymorphisms are associated with diabetic nephropathy exclusively in 
subjects with T2DM, or that the results are spurious and require further studies in different 
populations. 
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Nuclear transcription factor B (NFkB) polymorphisms 
The gene coding for NFkB located on. chromosome 4q24 has been shown to be up 
regulated under hyperglycaemic conditions in porcine vascular smooth muscle cells and 
PBMC's from diabetic subjects with nephropathy. A polymorphic dinucleotide (CA) 
repeat has been identified close to the human NFkB gene (Ota et a/ 1999). A recent study 
by Hegazy et a/ 2001 reported that the AlO allele may contribute to susceptibility to 
TIDM, however no association was found with the NFkB allele or genotypes with either 
presence or absence of diabetic microvascular complications in TIDM subjects. It is still 
possible that there may be a minor gene effect with NFkB and diabetic complications, and 
further studies in different populations are required. 
Vascular endotbeUal growth factor (VEGF) polymorphisms 
It has been suggested that the cytokine vascular endothelial growth factor (VEGF) may 
play a role in the pathogenesis of diabetic complications. Studies have identified 
polymorphisms in the promoter region of the VEGF gene. A study carried out by Yang et 
a/ 2001 looked at an insertion polymorphism at position -2578 in the promoter region of 
the VEGF gene in TIDM subjects with and without diabetic complications. The study 
found that there was a significant increase in the frequency of the CC genotype in patients 
with microvascular disease compared to those without. This increase was particularly 
pertinent in the nephropathy subjects compared to the diabetic controls. The C allele was 
also significantly increased in the nephropathy subjects compared to the controls. The 
results of this study suggest that polymorphisrns in the promoter region of the VEGF gene 
may be associated with the pathogenesis of microvascular disease. 
Mitochondrial gene polymorphisms 
Mitochondria are cytoplasmic organelles found in all Eukaryotic cells. They contain the 
enzymes of the Krebs cycle, carry out oxidative phosphorylation, and participate in fatty 
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acid biosynthesis. Mitochondria posses their own genome and ribosomes, both of which 
are distinctive from their counterparts in the nucleus and cytoplasm of the cell. Cells 
depending on their energy demand posses hundreds to thousands of mitochondria, each 
containing 2-10 mitochondrial DNA molecules. Mutations of mitochondrial DNA 
(mtDNA) are a well-described genetic cause of diabetes mellitus, and have also been found 
to be involved in the pathogenesis of diabetic microvascular diseases. Both mtDNA point 
mutations and rearrangements have been identified in families with diabetes (Van Den 
Ouweland 1994). Mitochondrial DNA has a number of interesting properties including 
exclusive maternal transmission, the ability to replicate in post mitotic cells, a high 
mutation rate and an extremely compact molecular architecture with no introns and no 
large non-coding sequences. Unlike the nuclear DNA, which is linear, the human 
mitochondrial genome consists of a closed double stranded, circular DNA molecule, and 
consists of 16569 bp of DNA, which have been fully sequenced (Anderson et a/1981). 
Although the mtDNA encodes highly conserved proteins it exhibits a very high mutation 
rate which is 10-20 times more susceptible than the nuclear genome. Reasons for this are 
that the mt genome evolves 5-l 0 times faster than single copy nuclear DNA genes. Its half-
life is between 6-10 days compared to nuclear DNA, which has a half-life of about 100 
days. The mutability may reflect the relatively high insertion error-rate of the 
mitochondrial DNA polymerase-y of about 1/7000 bases, resulting in 2-3 mismatched 
nucleotides per round of replication of the 16.6 kilobases (kb) mt genome. A change in 
phenotype however, only becomes apparent when the proportion of mutant DNA exceeds a 
threshold level, which varies for each organ. A critical threshold level of mutant mtDNA 
must be exceeded before the genetic defect is expressed. This threshold effect is a direct 
consequence of the maintenance of wild-type copy numbers by relaxed replication of 
mtDNA (Wallace 2001). The high mutation rate also derives from the fact that mtDNA is 
more exposed to chemical attack than the nuclear DNA. The mt genome is vulnerable 
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because. it is not protected by histones, absence of DNA repair mechanisms, its highly 
compact structure, and the production of highly energetic oxygen radicals· from the 
electron transport chain. Continuous hyperglycemia induces to generate several oxygen 
radical species and consequently result in developing diabetic microvascular 
complications. Oxidative damage is of particular relevance to mtDNA, since a large 
fraction of reactive oxygen species (ROS) in cells is thought to originate by leakage of 
electrons from the electron transport system. The proximity of mtDNA to the ROS 
generator suggests that there may be a high rate of endogenous oxidative damage to 
mtDNA. 
Early observations of mtDNA were that pyrimidine dimers introduced into mtDNA were 
not repaired (Clayton et a/1974), suggesting that mammalian mitochondria were incapable 
of repairing their DNA. Despite the importance of each mitochondrial gene, mitochondria 
are relatively deficient in DNA repair mechanisms (Lightowlers et a/ 1997). However we 
know that mtDNA mutations occur too frequently for them to go completely un-repaired. 
The emerging pattern is that mitochondria in higher organisms are reasonably well 
equipped to conduct base excision repair (BER) but appear to be deficient in nucleotide-
excision repair (NER) and mismatch repair (MMR) (Bogenhagen 1999). In a healthy cell, 
the number of mtDNA moleculas is tightly regulated (Lightowlers 1997). By contrast, 
mtDNA proliferation is one of the hallmarks ofheteroplasmic mtDNA mutations involving 
tRNA genes, There are increasing numbers of publications showing that certain deletions, 
insertions or point mutations of the mtDNA may occur and are associated with distinct 
diseases (Gerbitz et a/ 1996). Individuals with pathogenic mtDNA defects (deletions and 
point mutations usually harbor a mixture of mutant and wild type mtDNA within each cell 
(Clayton). The percentage level of heteroplasmy varies between different organs and also 
between adjacent cells in the same organ. There is increasing evidence that the level of 
mutant mtDNA in non-dividing tissues may change during a human lifetime (Chinnery et 
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at 1999). A number of age related neuromuscular degenerative diseases have been 
associated with mutations in mitochondrial DNA (mtDNA), and progressive accumulation 
of oxidative damage in mtDNA from neuronal tissues over time has been shown. Recently 
distinct point mutations of the mitochondrial DNA mutations have been implicated in a 
wider range of clinical disorders including alzheimers, diabetes and nerve deafness (Lien et 
a/2001). 
Recently it was reported in a Japanese population by Gong et a/1998 that a polymorphism 
(mt5l78A at nucleotide 5178 within the NADH dehydrogenase subunit 2 gene is 
associated with longevity. The study identified mitochondrial genotypes associated with 
longevity, being an C- to- A transversion at nucleotide position (np) 5178 within the ND2 
gene causing a Leu to Met replacement; aC-to -T transition at np 8414 within the ATP8 
gene, causing a Leu to Phe replacement; and a G- to A transition at np 3010 within the 16S 
rRNA gene. These, being more frequently observed in the centenarians than in the 
controls. They focused their study on mt5178 A/C transversion and found the frequency of 
Mt5178A to be significantly higher in the centenarians (62%) than in the blood donors 
(45%). Further to this they evaluated the effect ofMtDNA variations on the occurrence of 
disease by analyzing the frequency of Mt5178A and Mt5178C in 33 8 randomly selected 
patients. They found the ratio of Mt5178 A/C to be significantly lower in old patients than 
in both the centenarians and the healthy controls. This suggests that to carry a MtDNA 
genotype predisposing resistance to adult onset disease is one of the genetic factors for 
longevity. Therefore the longevity genotype Mt5178A would appear to be more resistant 
than Mt5178C genotype against oxygen radicals, and those individuals with Mt5178C 
genotype are more susceptible to adult onset chronic disease than those with Mt5178A. 
Miura et al 1999 furthered this line of research and examined whether or not this 
polymorphism influences development of diabetic complications, in particular diabetic 
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nephropathy. They selected a random population oflong standing Japanese TIDM patients 
with diabetic duration of more than 20 years and carried out PCR-RFLP after Alul 
digestion to distinguish Mt5I78A and Mt5178C. Their findings suggested that TIDM 
patients with Mt5178C are more predisposed to diabetic nephropathy than those with 
Mt5178A. Uchigata et al carried out further studies on Japanese patients, to examine 
whether or not this polymorphism influences development of TIDM or T2DM and its 
complications. They analyzed the frequencies of Mt5I78NC by PCR-RFLP with Alu I in 
TIDM and T2DM patients. They found the frequency of Mt5I78C to be significantly 
higher in the TIDM patients than in the healthy controls. They also found that in the 
Tl DM patients with diabetic duration of more than 20 years, the Mt5178C frequency in 
nephropathy group was statistically higher than in the no nephropathy group. There was 
however no significant difference in the Mt5178NC between T2DM patients and healthy 
controls. These results suggest that Mt5I78C genotype predisposes to T I DM and diabetic 
nephropathy significantly more than those with Mt5178A genotype. 
Other gene polymorphisms 
Other studies have looked at inherited differences in the ability to enzymatically detoxify 
AGE intermediates such as 3-deoxyglucosone which may be one important genetic factor 
responsible for determining the impact of a given level of hyperglycaemia on diabetic 
complications. Other studies suggest that differences in the response of glomerular 
filtration rate in response to hyperglycaemia may be involved. This is thought to implicate 
enhanced nitric oxide synthesis by nitric oxide synthase (ecNOS) in afferent arterioles and 
glomerular endothelial cells and increased expression of insulin-like growth factor (IGF-1) 
receptor and cause glomerular hyperfiltration (Rudberg 1992; Makino 1999). These 
findings, along with observations that nephropathy susceptibility groups having large 
glomeruli, which may be a marker of nephropathy (Striker 1993) suggest multiple genetic 
components to be involved in the aetiology of diabetic complications. After hypertonic 
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stress transcriptional activation of heat shock proteins as well as several other genes 
occurs. This facilitates the accumulation of non-toxic intracellular osmoles. The induction 
of these genes by hypertonicity involves the activation of members of the MAP kinase 
family, including c-Jun NH2-terminal kinase (JUNK) and p38 MAP kinase (Wojtaszec et 
al 1998: Sprague 1998). Prostaglandin forming cycloxygenases (COXs) may represent an 
additional class of genes that promote medullary interstitial cell viability. A search for 
polymorphisms of COX-I and COX2 genes may be important in the search for 
susceptibility genes to microvascular disease (Hao et a/ 2000). 
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Candidate Gene Locus Site Pol~mor~hism Reference 
Human Leukocyte Antigen-A HLA-1 6p21 DQA1 and DQB1 Chowdhury eta/1998. 
Chowdhury et a/ 1999 [b] 
Aldose Reductase ALDR1 7q35 (CA)n Heesom et a/ 1997 
Moczulski et a/ 1999 
Demaine et a/ 2000 
Receptor for Advanced Glycation RAGE 6p21.3 G82S, 1704A/G, Kankova et a/2001 
End products 2184A/G, Hudson et a/ 2001 [b] 
2245G/A 
Tumor Necrosis Factor (a. and p) TNF 6p21.3 G(-308)A Hawrami eta/1996 
Angiotensin AGT lq42-q43 M235T Caulfield et a/ 1994 
Doria eta/1996 
Angiotensin II Type 1 Receptor AGTRl 3q2l-q25 A1166C Bonnardeaux et a/ 1994 
Doria eta/1997 
Tarnow eta/1996 
Angiotensin Converting Enzyme ACE l7q23 I/D Marre eta/1994 
Chowdhury et a/ 1996 
Doi eta/1996 
Tarnow eta/2000 
AGT-M235T Ittersum et a/ 2000 
Apolipoprotein E ApoE 19q13.2 Exon4 Araki et a/ 2000 
Chowdhury et a/ 1998 
Werle eta/1998 
Endothelial Nitric Oxide eNOS 7q36 T(786)C Zanchi et a/ 2000 
Synthase a(Intron 4 )b Asakimori et a/ 2001 
Plasminogen Activator Inhibitor PAI-l 1p31-p22 4G/5G Pucci eta/1999 
Paraoxonase PONl 7q21.3 T(-107)C Araki eta/2000 
Leu54Met Sanghera et a/ 1998 
Gln192Arg Jenkins eta/2000 
PON2 7q21.3 Alu148Giy Pinizzotto et a/ 2001 
Ser311Cys Canani eta/2001 
Glucose Transporter-! GLUTl 1p31.3- G/T Hodgkinson et a/ 2001 [a] 
p35 
Nuclear Factor Kappa Beta NFkB 4q24 (CA)n Hegazy et a/ 2001 
Ota eta/1999 
Vascular Endothelial Growth VEGF 6p12 (-2578)C Yang eta/2001 
Factor 
Hypertension-linked HYT-11 17q (CA)n Julier et a/ 1997 
D175934 
Table 4. Candidate genes so far investigated and implicated in the onset and progression 
of diabetic vascular complications. 
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Environmental influences 
Cigarette smoking has been identified as an important factor in the development and 
progression of diabetic renal complications in both TlDM and T2DM subjects 
(Biesenbach et al 1997; Reddy et a/ 1996; Orth et al 1997). Also compared to normal 
subjects the prevalence of smoking in diabetics has been seen to be significantly higher (27 
vs.· 33%, p<O.OOOl) (Dierkx et al 1996). The overall incidence of microvascular 
complications in particular retinopathy and increased urine albumin excretion, have been 
shown to be more common and more severe in TlDM subjects who smoked and more so 
in heavy smokers (Sinha et a/ 1997). Smoking has been shown to increase the risk of 
microalbuminuria and progression of proteinuria in both TlDM and T2DM subjects where 
the prevalence of increased albumin excretion rates was 2.8 times higher in smokers than 
non-smokers. Albuminuria has been seen to improve significantly when diabetic subjects 
ceased smoking indicating that it is an independent risk factor of early diabetic renal 
damage (Chase et a/1991). The link between smoking and diabetic renal microangiopathy 
is thought to be through mechanisms such as increased platelet aggregation, accentuated 
tissue hypoxia and haemodynamic or metabolic effects of repeated noradrenaline release 
(Norden and Nyberg 1984). 
Low birth weight is a reflection of adverse effects on development in utero and it therefore 
thought to be partly environmentally influenced. Many studies have also shown that low 
birth weight (LBW) is strongly associated with hypertension, stroke and myocardial 
infarction. It has been shown that retarded intrauterine growth is associated with a 
significant reduction in nephron number, and that there are strong correlations between 
glomerular number and size with LBW. It has hence been postulated that decreased 
nephron numbers may be a risk factor for hypertension and the progression of renal disease 
as it is more vulnerable to damage from a range of pathological processes (Manalich et al 
2000; Lackland et a/ 2000). Correlation's have also been made between low maternal 
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education and smoking during pregnancy and the risk of developing incipient nephropathy 
in offspring with TIDM (Rudberg 2000). Recently studies have also shown a significant 
association between end-stage renal disease and low birth weight in both African 
Americans and Caucasoids (Lackland et a/2001). Similar studies have been carried out to 
examine the relationship between LBW and early onset of diabetic retinopathy, however 
no significant correlation has been found. These results indicate that foetal growth is not a 
factor of major importance for the development of diabetic retinopathy (Agardh et a/ 
2000). 
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Chapter 2: Aldose reductase and the polyol pathway 
Hyperglysolia and the polyol pathway 
It has been observed that tissues susceptible to developing diabetes-linked abnormalities 
are in general not dependent upon circulating insulin for the uptake of glucose (Nathan 
1996). Therefore, under extracellular hyperglycaemic conditions these tissues also exhibit 
hyperglysolia (elevated intracellular glucose levels) (van den Enden 1995). This 
observation suggests that in selected tissues an increase in glucose concentration of the 
cellular cytosol may perturbate intracellular metabolic patterns. One of the principle 
intracellular biochemical mechanisms that has been implicated in the pathogenesis of 
diabetic microvascular complications is the increased flux of glucose through the polyol 
pathway under diabetic hyperglycaemic conditions. Under euglycaemic conditions glucose 
is metabolised by three key pathways, primarily by a hexokinase dependent 
phosphorylating pathway to form glucose 6-phosphate, which then enters the glycolytic 
pathway to form lactate, or the hexose monophosphate shunt to form pentose-phosphate. 
Secondly, glucose may be oxidised to gluconic acid via an NAD+-dependent glucose 
dehydrogenase. Thirdly, non-phosphorylated glucose may enter an accessory pathway of 
glucose metabolism known as the polyol pathway, which is comprised of a series of 
enzyme dependent reactions, namely aldose reductase (ALR2 or AKRJBJ) (alditol: 
NADP+ oxidoreductase [EC 1.1.1.21]) and sorbitol dehydrogenase (SORD) (L-iditol: 
NAD+2-oxidoreductase [EC 1.1.1.14]), metabolising glucose to sorbitol and fructose 
respectively. Throughout this thesis aldose reductase will be referred to as ALR2, however 
the most recent abbreviation is AKRJBJ. The polyol pathway is an alternative route of 
glucose metabolism, which is illustrated in figure 4. Under physiological conditions, this 
polyol pathway plays a minor role in glucose metabolism, except in the kidney where 
ALR2 may regulate osmolytes (Bagnasco et a/1988). 
The polyol pathway was first identified in the seminal vesicle of the sheep by Hers 1956 in 
a report demonstrating the conversion of blood glucose into fructose, an energy source of 
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sperm cells. As already mentioned, the metabolism of glucose by the polyol pathway 
involves two reactions resulting in the conversion of D-glucose into sorbitol and D-
fructose, catalysed by two rate-limiting enzymes, namely aldose reductase (ALR2) and 
sorbitol dehydrogenase (SORD). In the first rate-limiting reaction of the polyol pathway 
ALR2 sequentially catalyses the NADPH-mediated reduction of glucose to the organic 
osmolyte sorbitol. This NADPH dependent enzyme reduces a carbonyl oxygen to a 
hydroxyl ion in an ordered 'bi-bi' mechanism, in which NADPH is bound frrst and NADP+ 
released last after the catalytic conversion of the aldehyde to the alcohol (Kubieski et a/ 
1992; Grimshaw et a/ 1990). This reduction is stereospecific with respect to the coenzyme 
(Boghosian et al 1981; Grirnshaw et a/ 1995). In the second step of the polyol pathway 
SORD oxidises sorbitol to fructose using NAD+ as the co-factor. 
The catalytic efficiency of aldose reductase for D-glucose is relatively low with a 
Michaelis-Menton Constant (Km) of~ l 00 mM, a '20-fold higher concentration to normal 
glycaemic levels of ~s mM (Bohren 1989). Under normoglycemic conditions the majority 
of the glucose is therefore phosphorylated to glucose 6-phosphate by hexokinase and the 
flux through the polyol pathway is minimal (Boel et a! 1995). Under hyperglycaemic 
conditions however, the hexokinase pathway becomes saturated with ambient glucose and 
the increased glucose level in the tissues activates the polyol pathway. In hyperglycaemic 
states, metabolism of glucose by the polyol pathway has been reported to account for up to 
33% of total glucose utilisation in the rabbit lens and 11% in human red blood cells 
(Kinoshita et a/1988; Morrison et a/1970). 
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D-Sorbitol 
Xylose Isomerase 
L-Iditol 
Dehydrogenase 
(Sorbitol 
NAD•) Dehydrogenase) 
NADH+H·~ 
Figure 4 . The sorbitol (polyol) pathway (adapted from; Tomlinson 1994), converts 
glucose into fructose using the enzyme aldose reductase and sorbitol dehydrogenase. 
Aldose reductase catalyses the conversion of D-Giucose into sorbitol in an NADPH 
dependent reaction and sorbitol dehydrogenase oxidises sorbitol to D-Fructose using 
NAD+ as a cofactor. There is also an interdependence of ALR2 and the hexose 
monophosphate shunt (HMPS). 
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Aldose Reductase (ALR2) 
Aldose reductase is a member of the aldo-keto reductases, which constitute a superfamily 
of monomeric oxidoreductases. There are three main enzymes within this group namely, 
aldehyde reductase (ALRI), aldose reductase (ALIU) and carbonyl reductase (ALR3). 
ALRI is involved in the detoxification of a variety of different aldehydes, and reduces 
isocorticosteroids during steroid catabolism. The primary physiological role of ALRI is the 
reduction of D-glucoronate to L-gluconate. ALR3 is also an oxidoreductase mainly for 
ketones but has broad substrate specificity. ALR2 is the rate-limiting enzyme of the polyol 
pathway and is believed to be of primary importance in the development of severe 
degenerative complications of diabetes mellitus, through its ability to reduce excess D-
glucose to D-sorbitol in non-insulin dependent tissues. Importantly, ALR2 has also been 
shown to efficiently reduce by-products of glucose and cellular metabolism such as 
methyglyoxal, 4-hydroxynonenal and 3-deoxyglucosone suggesting that it may be 
responsible for detoxification of these harmful metabolites (Vander Jagt et all992; 1995). 
Another postulated function of ALR2 is osmoprotection in the kidney as sorbitol is an inert 
compound and reaches levels in certain tissues great enough to affect osmotic pressure 
(Bagnasco et all987). 
ALR2 is a small monomeric NADPH-dependent oxidoreductase composed of 315 amino 
acid residues (Mr 35,900) (Petrash et al 1994). The sequence is well conserved from one 
tissue to another and also between species, for examples the ALR2 gene sequence from the 
rabbit kidney has 84% homology with ALR2 gene sequence from bovine lens and 89% 
homology with rat lens (Garcia-Perez et al 1989). Several biochemically-modified forms 
of ALR2 have been identified, however tissue specific isozymes have not yet been 
confirmed in humans (Yabe-Nishimura 1988; Grimshaw and Lai 1996), however Yang et 
al 2000 identified a renal-specific oxido-reductase (RSOR) in newborn diabetic mice. 
Structural studies by crystallographic analysis have been performed on ALR2 which have 
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revealed that AR folds as a (~-a.)8 barrel and that its catalytic sites lie at the bottom of a 
deep hydrophobic cleft (figure 5). ALR2 catalyses the reduction of a wide variety of 
carbonyl compounds to the corresponding alcohol's. Interestingly, glucose is not the 
preferred substrate for ALR2, in fact it is more efficient in reducing various aromatic and 
aliphatic aldehydes such as glyceraldehyde (Inazu et a/1994). 
The catalytic cycle and kinetics of ALR2 
The catalytic cycle of ALR2 follows an ordered reaction mechanism whereby binding of 
NADPH induces a first conformational change in the enzyme that occurs before substrate 
binding {figure 6). NADPH binds at the carboxy-terminus of the enzyme in an extended 
conformation. Then ALR2 stereospecifically transfers the 4-pro-R hydrogen from the C4 
of the nicotinamide ring to the re face of the carbonyl carbon of the substrate. The 
substrate active site contains Tyr 48 as the proton donor during aldehyde reduction. After 
aldehyde reduction, the enzyme undergoes a second conformational change, which is 
associated with the dissociation of the enzyme-oxidised NADP+ complex (Constantino et 
a/1999; Varnai et a/1999). It has been suggested that the enzyme conformational change 
is the limiting factor of the overall reaction. Findings have shown that ALR2 from diabetic 
tissue displays linear kinetics with a V max two or three times higher than normoglycemic 
tissue (Srivastava et a/ 1985). Grimshaw et al 1995 reported transient kinetic data to 
estimate the rate constants for the ALR2 catalysed reaction: E•NADPH +-+ E•NADPH +-+ 
*E•NADPH•RCHO +-+ *E•NADP+ •RCH20H +-+ *E•NADP+ +-+ E•NADP+ +-+ E .. The 
proposed kinetic mechanism for ALR2 suggests that the isomerisation of E•NADPH 
complexes may be the rate-limiting step of the reaction. It has hence been proposed that 
under certain conditions, such as ionic stress or non-enzymatic glycosylation of the 
enzyme, ALR2 is able to assume an active conformation. 
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Aldose R eductase (EC 1.1.1.2 1 ) 
Figure 5. Schematic of the 3-dimensional x-ray crystal structure of AR in complex with 
its cofactor NADPH (Purple). It consists of >2,500 atoms and folds in the beta/alpha 
barrel formation. htto:/ /www.biochem.szote.u-szeaed.hu/astro ian/oroteinl.htm 
ALR2 
Figure 6. The catalytic cycle of ALR2 adapted from Constantino et a/1999. The free 
enzyme binds to NADPH first and undergoes a conformational change. Next the 
aldehyde substrate binds which reacts to form the alcohol product and NADP+. The 
alcohol product is released and the enzyme undergoes another conformational change 
releasing NADP+. 
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Sorbitol dehydrogenase (SORD) 
Sorbitol dehydrogenase (SORD) is a zinc-containing enzyme and is the second enzyme of 
the polyol pathway. SORD is involved in the conversion of sorbitol to fructose by 
oxidation using NAD+ as a cofactor. Little is known about the physiological function of 
the enzyme SORD, however, its activity has been found in a number of tissues, for 
example, kidney, liver, lens, testis, prostate, placenta, erythrocytes, brain, spinal cord and 
peripheral nerves (Gabbay and O'Sullivan 1968; King et al 1996). SORD displays 
moderately broad substrate specificity, catalysing the conversion of xylitol to D-xylulose, 
ribitol to D-ribulose, and iditol to L-sorbose, as well as sorbitol to D-fructose. The Km for 
sorbitol of SORD is -6 mM. Elevated levels of A TP, lactate, and high NADHINAD+ 
ratios that accompany hyperglycaemia are known to inhibit the action of SORD. The 
human SORD protein was reported to be 355 amino acids long and to have a Mw of 
38,067 daltons (Karlsson et al 1989). SORD is a member of the long chain alcohol 
dehydrogenase gene superfamily which interconvert alcohol's to the corresponding ketone 
or aldehyde. Lee et al 1994 first cloned the human SORD gene and used fluorescence in 
situ hybridisation to determine its chromosomal location. Carr et al 1995 and Iwata et al 
1995 also reported the position, structure and expression of the human SORD gene, and 
described a range of polymorphic variants. By in situ hybridisation the SORD gene was 
found to be located on chromosome 15q21.1, with two transcription sites. A SORD-related 
pseudogene was also found to exist which shows a high degree of similarity with the 
SORD1 gene (Carr et a/1991). A deficiency in SORD activity has been previously linked 
to cataract formation in non-diabetics (Vaca et al 1982; Shin et al 1984). Studies to 
investigate the role of SORD have been carried out using SORD inhibitors (SDHI) 
(Geissen et a/1994; Tilton et a/ 1995; Cameron et a/ 1997; Oates et a/1998). However, 
there have been contradictory fmdings, whereby some studies have shown that SDHis 
reduce nerve conduction deficit induced by diabetes in rats (Tilton et al 1995). Other 
studies using diabetic rats treated with SliD I or SORD deficient diabetic mice, however 
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have not found this to be the case (Cameron et a/ 1997; Ng et a/ 1998). Obrosova et a/ 
1999 investigated the use ofSORDI upon diabetic neuropathy using STZ-diabetic rats, the 
findings of which were that inhibition of SORD resulted in adverse neural dysfunction 
effects. The activity of SORD by mRNA expression has been shown to be modestly 
increased in diabetic subjects with diabetic complications (Hodgkinson et a/2001 [b]). 
The polyol pathway and diabetic complications 
When hyperglysolia occurs the hexokinase pathway for glucose metabolism becomes 
saturated due to undefined regulatory mechanisms and the relatively high affinity of 
hexokinase for glucose. Hyperglycaemia has hence been shown to activate the polyol 
pathway in tissues that are insulin independent and freely permeable to glucose such as the 
peripheral nerves, renal cortex and lens tissue (Dvornik 1987; Greene 1988 [a and b]; 
Pugliese 1991; Larkins 1992). An excessive flux through the polyol pathway has long been 
thought to be involved in the pathogenesis of diabetic microangiopathy (Ido 1996). There 
have been no findings so far of a metabolite feedback mechanism for lowering the activity 
of aldose reductase in reducing glucose to sorbitol although citrate and nitric oxide have 
been shown to inhibit ALR2 in vitro (Harrison et a/ 1994; Chandra et a/ 1997). Gabbay 
1966 recognised that there was a potential link between the formation of sorbitol from 
glucose via the polyol pathway involving aldose reductase, and the onset of diabetic 
complications (Gabbay 1966; 1972 [a and b]; 1973). Under hyperglycaemic conditions 
there is an intracellular increase in sorbitol production and as sorbitol is not rapidly 
removed from the cell and the conversion to fructose is slow there is a significant 
intracellular accumulation of sorbitol (Sharma 1997). This is particularly true in tissues 
such as the renal cortex, peripheral nerve, lens and retina that exhibit polyol pathway 
activity and do not require insulin to facilitate the uptake of glucose and are therefore 
freely permeable to glucose. It is these insulin independent tissues that are greatly affected 
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by the microvascular complications of diabetes, indicating that the polyol pathway is an 
important mediating factor (Sato 1992; Dorin 1995). 
Ruth V on Heyningen 1959 made early descriptions of an excess of sorbitol in the lens of 
diabetic rats. Similar cataracts have been found to develop even more rapidly. in animals 
fed a diet containing a high percentage of galactose (30-50% by weight). The explanation 
for this being galactitol, the sugar alcohol galactose, cannot be reduced by sorbitol 
dehydrogenase, the second enzyme in the pathway, and therefore accumulates to much 
higher levels in susceptible tissues than sorbitol (Kinoshita 1965). Sorbitol has also been 
found to accumulate in the peripheral nerves of diabetic animals (Gabbay 1966) as does 
galactitol in the nerves of rats fed excess of galactose. The motor nerve conduction 
velocity in these animals is substantially slowed (Gabbay 1972 [b]) and studies have 
shown similar results in humans (Gregersen 1968). Aldose reductase has been shown to be 
present in the inner medulla, the loop of Henle, collecting tubules and glomerular 
podocytes of the rat kidney and also in the human glomeruli. The enzymatic activities of 
the human diabetic glomeruli have shown diminished hexokinase, elevated ALR2 activity 
and decreased SORD activity. Lee et a/ 1995 demonstrated that sorbitol accumulation was 
implicated in the development of diabetic cataract using transgenic mice expressing the 
ALR2 gene in the lens. In this study, when the SORD deficient mutation was also present 
there was a further increase in sorbitol accumulation and further acceleration of the 
diabetic cataract. The second half of the polyol pathway is therefore also thought to be 
important in facilitating the development of microvascular disease. Schmidt et al 1998 
reported that the use of a sorbitol dehydrogenase inhibitor (SDI) CP-166,572, which 
interrupts the conyersion of sorbitol to fructose resulted in markedly increased levels of 
sorbitol in the peripheral nerve in the diabetic rat model. Ho et al 2000 developed mice 
deficient in ALR2 gene and found that they exhibited a phenotype similar to that of 
nephrogenic diabetes insipidus. These factors cumulatively suggest that the polyol pathway 
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may be a contributing factor in the pathogenesis of human diabetic retinopathy, 
glomerulosclerosis and neuroaxonal dystrophy via the accumulation of intracellular 
sorbitol. 
Hyperglysolia induced increase in expression and action of ALR2 
An increase in glucose levels has been associated with high ALR2 containing cells. In the 
case of diabetic patients with and without microvascular complications many studies have 
been carried out to determine differences in the ALR2 levels between these groups. 
Increased amounts of ALR2 mRNA were found in rabbit inner renal medullary cells under 
hyperosmotic stress (Garcia-Perez et a/1989; Uchida et a/1989). The increased expression 
of aldose reductase under hyperosmotic stress has also been reported in a variety of cells of 
non-renal origin such as Chinese hamster ovary cells (Kaneko et a/ 1990). Other studies 
also showed similar findings in glomerular endothelial cells and cultured rat mesangial 
cells (Hohrnan et a/ 1991; .Kikkawa et a/ 1992). A 132% increase in white cell ALR2 
mRNA levels was reported in both TlDM and T2DM subjects compared to normal healthy 
controls (Kicic and Palmer 1996). Ratliff et a/ 1996 found that levels of ALR2 protein in 
mononuclear blood cells were twice as high in T1DM subjects with neuropathy than in 
T1 DM patients without. Ito et a/ 1997; Ohnishi et a/ 1996; Nishimura et a/1994, 1997 and 
Takahashi et a/ 1998 also reported similar patterns in T2DM subjects with respect to 
neuropathy and also retinopathy, where the higher levels of erythrocyte ALR2 protein was 
significantly associated with microvascular disease. A significant report, which was 
published by Shah et a/1997, showed that the expression of the ALR2 gene is significantly 
increased in the lymphocytes of patients with diabetic nephropathy. The study measured 
ALR2 mRNA from peripheral blood monocytes and found a significant increase in TlDM 
patients with renal disease compared to TlDM subjects without or normal controls. 
Hamada et al 1998 used the two-site ELISA technique to determine the enzyme protein 
content of human ALR2 in erythrocytes from patients with T2DM and normal controls. 
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The study found a strong correlation between enzyme activity and an increase in enzyme 
content and also an increase in sorbitol and fructose as well as an elevated lactate-to-
pyruvate ratio. They suggested that inter-individual variability of ALR2 content might 
contribute to the polyol pathway flux in diabetic patients. Recently, Hasegawa et al 1999 
also measured ALR2 protein in peripheral mononuclear cells (PMCs) from patients with 
T2DM using two site ELISA using anti-human AR monoclonal antibody. The study found 
no differences between ALR2 levels and the presence or absence of diabetes. However a 
significant increase in ALR2 levels was found in diabetic subjects with microvascular 
disease than in those without. 
Srivastava et al 1986 suggested that the properties of ALR2 were changed by 
hyperglycaemia. They showed that the activation of the enzyme in human erythrocytes 
incubated with glucose was also accompanied by changes in enzyme kinetics. They 
suggested that the ALR2 enzyme is activated by non-enzymatic g1ycosylation (Srivastava 
et a/ 1986; Srivastava et a/ 1985; Das and Srivastava 1985; Srivastava 1989). Ghahary et a/ 
1989 reported the STZ-diabetic rats showed increased renal ALR2 activity. It has since 
also been shown that ALR2 protein and the activity of the enzyme is significantly 
increased in the erythrocytes and neutrophils of patients with both TlDM and T2DM and 
microvascular disease compared to those with no complications (Hamada et a/1991[a and 
b]; Nishimura et a/1994, 1997). Dent et a/ 1991 reported an increase in neutrophil ALR2 
activity in T2DM subjects with complications compared to those without. Importantly, 
there were no significant difference found between patients without complications and 
normal controls. Hamada et al 1993 reported that there was an association between 
erythrocyte ALR2 activity and diabetic complications in TlDM subjects. In the TIDM 
population investigated the study found that patients with greater ALR2 activity were four 
times more likely to develop diabetic complications than those patients whose enzyme 
activity was close to that of non-diabetic individuals. These observations suggest that the 
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variability of ALR2 activity may be the cause of differences in susceptibility to diabetic 
complications. It has also been proposed that ALR2 is induced in human microvascular 
endothelial cells by advanced glycation end products. This is supported by a recent study 
carried out by Nakamura et at 2000 who investigated the effects of advanced glycation end 
products on the levels on ALR2 mRNA, protein and activity in human microvascular 
endothelial cells. Their results suggested that accelerated formation of AGEs in vivo might 
elicit activation of the polyol pathway, possibly via oxidative stress, to enhance endothelial 
cell damage leading to microvascular dysfunction. In conclusion there is strong evidence 
for an increase in ALR2 activity, protein levels and mRNA in diabetics with complications 
suggesting that its regulation through gene expression and altered conformation may be 
important factors in modulating the risk of developing microvascular disease. 
Metabolic perturbations induced by increased flux through polyol pathway 
The accelemtion of the polyol pathway elicits various metabolic · imbalances in those 
tissues that undergo insulin independent uptake of glucose for which there are several 
metabolic consequences. These include alterations of the intmcellular redox state by 
decreased availability ofNADPH and increased NAD+/NADH ratio (pseudohypoxia). Also 
implicated is osmotic stress resulting from lowered myo-inositol concentrations and 
sorbitol accumulation, protein kinase C activation, impaired phosphatidylinositol 
metabolism, glutathione and antioxidant depletion, reduced NO production and increased 
glycosylation (Williamson 1993; King and Brownlee 1996; Oates 1997). Additionally 
Morrisey et al 1999 reported that polyol pathway activation was also associated with 
fibronectin generation in the proximal tubule cells of the kidney, enhancing thickening of 
the tubular basement membrane. An increased flux through the polyol pathway would also 
implicate an increase in the production of fructose, which has been reported to be a 1 0-fold 
better substrate than glucose for glycosylation and formation of AGEs (Brownlee 1992). 
Such metabolic perturbations provoke the early tissue damage in the target organs of 
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diabetic complications, such as ocular lens, retina, peripheral nerves and renal glomerulus 
(Kinoshita 1988; Pugliese 1991) (figure 7). 
The overflow of the products of the polyol pathway is associated with depletion in reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and the oxidised form of 
nicotinamide adenine dinucleotide (NADl the cofactors used in the pathway (Williamson 
1993). This metabolic imbalance is thought to be related to abnormalities such as altered 
vascular permeability and increased synthesis of diacylglycerol (DAG) precursors through 
glycolysis and consequent PKC activity (Ishii and Isogai 1998). DAG is a rate-limiting co-
factor for Ca2+-dependent protein kinase C that is involved in the signal transduction 
pathway. This subsequently effects the gene expression of many proteins involved in cell 
growth and proliferation, vascular contractility and the synthesis of basement membrane 
proteins. The increased use of NADPH by the over-activity or ALR2 could also alter the 
pentose phosphate pathway by depleting the inhibiting factor (NADPH) and enabling 
constant passage of glucose to pentose phosphate pathway intermediates. 
Intracellular sorbitol accumulation has also been associated with a decrease in the levels of 
myo-inositol in tissues including lens, nerve, retinal pericytes and the kidney glomeruli by 
competitively inhibiting its uptake into the cell (Greene 1987; 1988 [b ]). This fall in myo-
inositol may result from an osmoregulatory compensation for elevated sorbitol, by acting 
as a compatible osmolyte where abnormal accumulation of one osmolyte results in 
reciprocal depletion of others (Finegold et a/1983; Stevens 1993). Tissue myo-inositol is a 
precursor of phosphatidylinositol (PI) which activates sodium/potassium adenosine 
triphosphatase (Na+/K + A TPase ), a component of the sodium pump. This perturbation 
undermines the cells osmotic regulation by effecting cell permeability. Protein kinase C 
stimulation also becomes impaired by diacylglycerol and a reduction of Na+-K +-A TPase 
activity. 
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Figure 7. Diagrammatic representation of hyperglycaemia induced metabolic 
perturbations resulting from increased flux through the polyol pathway (adapted 
with alterations from King and Brownlee 1996 ). 
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Aldose reductase inhibitors (ARI's) 
Reports from experimental studies carried out in the US and Europe on diabetic study 
populations, have associated ALR2 to elevated diabetic microvascular disease risk. Based 
upon these described observations, it is thought that inhibiting aldose reductase activity 
should reduce diabetic microvascular complications by minimising tissue injury without 
requiring the often difficult to attain euglycaemia (Dvomik 1996; Oates 1997; Oates et al 
1999). The potential value of blocking ALR2 came from a Brazilian natural medicine for 
diabetes which is made from Myricia multi flora which contained myrciaitrin 1 and 
myrciaphenone B which are potent inhibitors of aldose reductase (Y oshikawa et al 1998). 
As previously mentioned structural studies carried out on ALR2 have determined the 
catalytic sites of the enzyme are at the bottom of a deep hydrophobic cleft. Various 
structurally diverse compounds have been observed to inhibit this enzyme site. Aldose 
reductase inhibitors such as sorbinil, ponalrestat, epalrestat, tolrestat, zopolrestat as well as 
other synthetic inhibitors have since been developed based upon these observations, as 
possible therapeutic agents for diabetic complications. However, the clinical efficacy of 
these inhibitors in diabetic patients has not been fully proved. These compounds have been 
grouped into four main classes according to their structure, firstly flavonoids (quercetin), 
secondly carboxylic acids (epalrestat, FK-366, AD-5467, tolrestat, TAT,- NZ-314, 
zopolrestat), thirdly hydantoins (SNK-860), and fourthly other compounds (Dvornik et al 
1987; Hotta 1997). Studies into specificity pockets and binding of inhibitors have shown 
that the ALR2 active site adapts itself to bind tightly to different inhibitors, indicating 
flexibility and explains the large variety of substrates (Urzhumtsev et al 1997; Lee et a/ 
1998; Rogniaux et al 1999; Calderone et al 2000). El-Kabbani et al 1999 also found that 
certain structural features are responsible for differences in coenzyme and inhibitor 
specificity's of ALR2, whereby differences in structural changes required for the binding 
of ARis are responsible for differences in the potency of ALR2 inhibition. 
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Many animal studies of aldose reductase inhibition have been carried out using 
streptozotocin (STZ) or alloxan-induced diabetic rats (Robinson et a/1990; Ido et a/1996). 
From the results obtained from animal studies of diabetic complications, ARis have been 
shown to have a beneficial inhibitory effect on the development of neuropathy, 
retinopathy, nephropathy, keratopathy, cataract formation, infection and atherosclerosis. 
Additionally, Keegan et a/2000, have shown a protective effect of the ARI WAYI21509 
in the corpus cavernosum and mesenteric vessels in diabetic rats. 
Kinoshita et al 1979 studied the effect of an ALR2 inhibitor CP-45,634 on the corneal 
epithelium of a diabetic rat, and found that the ARI treated epithelium showed faster 
regeneration than the untreated eye. Animal studies of ARis have shown that they are 
capable of normalising some of the polyol-pathway linked biochemical imbalances in the 
renal cortex in rats. For example, Robinson et at 1990 showed that the aldose reductase 
inhibitor, sorbinil, minimises albuminuria and glomerular basement membrane thickening 
in STZ diabetic rats treated for 5 months. Ido et a/ 1996 using animal models of diabetes 
observed reduced vascular dysfunction by inhibition of the sorbitol pathway. It has also 
' 
been reported that daily administration of epalrestat to STZ diabetic rats prevented gastric 
erosion and ulceration and normalised mucosal blood flow, suggesting that aldose 
reductase inhibitors act in part by blocking the action of induced nitric oxide (Suzuki et a/ 
1999). Many animal studies have focused on the effects of ARI's on neuropathy, for 
example, Cameron and Cotter 1992 [a] conducted a study to examine the effects of two 
different doses of the ARI, ponalrestat on the peripheral nerve in diabetic rats. The study 
found that the administration of 8 mg/kg-1 day-1 and 1 OOmg/kg-1/day-1 both resulted in a 
reduction in sciatic nerve sorbitol content, however the flux through the polyol pathway 
still remained substantially elevated in the lower dose rats. Only the higher dose treated 
rats showed complete restoration in sciatic motor branches and sensory saphenous nerve. 
During the course of a 5-year study, nerve conduction velocity progressively decreased in 
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untreated diabetic dogs, and this decrease was prevented by treatment with an aldose 
reductase inhibitor (sorbinil) (Engerman et a/1994). The same study however showed no 
beneficial effects on renal structure or albuminuria (Kern and Engerman 1999). Several 
studies of ALR2 inhibition and vasodilator treatment have shown to improve nerve 
conduction velocities in STZ rats, and prevent the formation of diabetic cataracts 
(Nishimura et al 1994; Stevens et a/ 1994; Kador et al 1985). A comparative study by 
Mizuno et al 1999 investigated the effects of three ARis, fidarestat, epalrestat and 
zenarestat on the slowing of sensory (SNCV) and motor (MNCV) nerve conduction 
velocities in STZ induced diabetic rats. The study found that fidarestat showed significant 
effects in lowering sorbitol content continuously up to 24 hours after administration, and 
improved slowing of SNCV, indicating that continuous inhibition of polyol pathway flux 
can improve diabetic neuropathy. Positive results have also been attained in the use of 
epalrestat in reducing morphological and biochemical deficits in galactose fed dogs where 
galactose is known to stimulate the polyol pathway and result in diabetic like 
microangiopathic defects (K.asuya et al 1999 [b ]). Experimental studies in diabetic rats 
have also indicated a cardioprotective effect of ARI's (zopolrestat), where it has been 
shown that attenuation in the rise in Na and Ca during ischemia provides protection 
(Ramasamy et a/ 1999). It is important to add that there have been negative results 
obtained in certain animal studies, where aldose reductase inhibitors have not been seen to 
prevent or improve retinopathy, or reduce capillary basement membrane thickening in the 
retina, renal glomerulus or leg muscle in alloxan-induced diabetic dogs (Kern et a/ I 991; 
Engerman et a/1993). 
Clinical trials carried out over the last decade have attempted to assess the efficacy of 
aldose reductase inhibitors in humans in the treatment of diabetic microvascular 
complications. Although clinical, experimental and pharmacological data indicate. that 
there is an involvement of ARI's in slowing the progression of diabetic complications past 
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clinical trials have been disappointing. Importantly, sorbinil has been withdrawn from 
further use because of its severe and frequent toxicity, and tolrestat has shown elevated 
hepatic enzymes which return to normal when administration is discontinued (Foppiano 
and Lombardo 1997). Positive and negative findings have been made in the use of ARI's in 
the treatment of retinopathy. The use of epalrestat treatment of retinopathy over a three-
year period has been shown to generate improvements in retinal structure and 
electroretinogram (Hotta et a/ 1990; Hotta et a/ 1990). Cunha-Vaz et a/ 1986 also showed 
positive findings for the use of sorbinil over a six-month period, finding a reduction in 
blood-retinal barrier alterations and a reduced incidence of microaneurysms of the retina. 
Negative findings have however also been made in the case of retinopathy. For example 
the Sorbinil Retinopathy Trial Research Group 1990 showed no significant differences 
between sorbinil treatment and placebo groups, and the same conclusions appeared to be 
true in similar studies using ponalrestat (Sorbinil Retinopathy Trial 1990; Tromp et a/ 
1991 ). Although these studies appear to have conflicting findings there is still some degree 
of evidence for a positive role for ARI's in the treatment of diabetic retinopathy, indicating 
a strong requirement for further studies into the role of ARI's and retinopathy. 
Aldose reductase inhibitors may improve diabetic nephropathy, which has been shown by 
its lowering of the glomerular filtration rate and an alteration in the course of 
microalbuminuria (Passariello 1993; Oates 1994). Studies have shown that ARis have only 
a partial effect in ameliorating renal microvascular complications. For example, a six-
month trial of ARI administration had an effect on hyperfiltration in the presence of 
normoalbuminuria (Pedersen et a/ 1991). However, many other studies of ARis and 
nephropathy have also proven negative findings (Ranganathan et a/1993; McAuliffe et a/ 
1998). 
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Many clinical trials of ARis have also focused on diabetic neuropathy (Pfeifer et a/ 1997; 
Oates 1997). Sima et a/ 1988 carried out a double blind study in patients with diabetic 
neuropathy, and found exciting evidence for the efficacy of sorbinil against degeneration in 
surial nerve biopsies, which was also accompanied by a decrease in the nerve sorbitol-level 
and an increase in the nerve conduction velocity. A study by Nicolucci et a/ I 996 found 
that treatment of diabetic neuropathy with tolrestat showed a reduced risk for developing 
nerve function loss compared with placebo treated patients. Robust inhibition of aldose 
reductase in human nerve has been shown to have a dose dependent effect on nerve 
structure and function and continuous inhibition of increased polyol pathway flux can 
improve diabetic neuropathy. However, several groups have suggested that in the case of 
neuropathy the use of ARI's such as tolrestat and epalrestat in it management act mainly to 
slow the progression of neuropathy rather than to reverse it (Gerven 1993; Goto et a/ 1993; 
Pfeifer et a/ 1997). Greene et al 1999 carried out a study to determine whether the ARI 
zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic 
peripheral polyneuropathy. This randomised, placebo-controlled, double-blinded, multiple-
dose clinical trial found an improvement in NCV slowing and a reduction in small 
myelinated nerve fiber loss, but indicated the >80% suppression of nerve sorbitol content is 
required. In controversy to these previous studies Airey et a/ 2000 investigated the 
efficacy of ARI's in the prevention, reversal or delay in the progression of diabetic 
peripheral neuropathy. They used nerve conduction velocities as the trial end points to 
evaluate treatment with 4 different ARI's. They found a small reduction in the decline of 
median and peroneal motor nerve conduction velocities, but no clear benefit was seen in 
terms of median and sural sensory nerves. 
In summary, enzyme inhibition as a direct pharmacokinetic approach to the prevention of 
diabetic complications resulting from the hyPerglycaemia of diabetes has not been fully 
effective because of non-specificity of the inhibitors and some appreciable side effects. 
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Such negative findings may be partly due to the multiple cell types involved in diabetic 
complications, potential differences in ALR2 expression, the long time course for the 
development of complications and the relatively short length of human trials, and the 
variability in potency and penetration of ARI's (Dunlop 2000). Improvement has however 
been seen in human diabetic subjects who receive ARI's as compared to those on a placebo 
mainly in terms of motor, sensory and autonomic neuropathy. It has been suggested that 
promising therapy may come from the administration of two or more synergistic metabolic 
blockers, for example using aldose reductase inhibitors in combination with 
aminoguanidines (Boel et a/ 1995). Interestingly vitamin E and other antioxidants have 
been reported to delay or prevent cataract in diabetic animals (Creighton and Trevithick 
1979). Furthermore, in vitro studies have indicated that ascorbic acid (vitamin C) is able to 
reduce sorbitol levels in humans by inhibiting ALR2 activity (Cunningham et a/ 1994; 
Lindsay et a/ 1998). It has also been suggested that the synthesis of new phthalazinyl 
derivatives may provide compounds to inhibit both ALR2 and SORD (Fourmaintraux et a/ 
1999). 
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ALR2 as a candidate gene for diabetic microvascular complications 
There is strong evidence for an involvement of a major genetic susceptibility component in 
the aetiology of diabetic complications. It is possible that variation within the genes coding 
for the enzymes of the polyol pathway explain why only some patients with diabetes are 
affected by diabetic complications. Variations in the gene encoding the enzymes of the 
polyol pathway may result in either the increased expression or increased action of the 
respective enzymes. Conversely variation may result in the under expression of the sorbitol 
dehydrogenase gene however both result in an accumulation of sorbitol in cells (Lee et a! 
1995) (figure 8). 
tAR activity .J..soRD activity 
t t 
tGiucose _ __...,. tsorbitol --•..,. Fructose 
Figure 8. Illustration of the effect of polyol pathway enzyme expression and the 
accumulation of sorbitol. 
The presumption that the involvement of the polyol pathway in diabetic complications, 
along with the presumption that genetic factors play an important role in the pathogenesis 
of diabetic microvascular disease has stimulated the search for candidate genes. The 
cloning of genes coding for aldose reductase (Graham 1991 [a]) and sorbitol 
dehydrogenase (Lee 1994) now enables the role of the polyol pathway to be studied at a 
molecular level. The sib-pair linkage analysis carried· out in T2DM Pima Indians showed 
evidence that the strongest linkage with diabetic nephropathy was on chromosome 7 
(Imperatore et al 1998 [a]). This has also been confirmed in a Caucasoid T2DM study 
population (Fogarty et al 1999). Interestingly this chromosomal location is in the region 
corresponding to the ALR2 region 7q35. Patients with TIDM and microvascular 
complications have been shown to have raised enzymatic activity of ALR2 and also 
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increased amounts of the ALR2 protein itself. It is a possibility that high ALR2 levels are 
genetically provided reflecting either heterogeneity of gene expression or the presence of a 
significant polymorphism of the structural ALR2 gene. These genetic alterations may 
modulate the risk of rnicroangiopathy in association with various other metabolic, genetic 
and environmental factors. 
The ALR2 gene and its promoter region (AR; EC 1.1.1.21) 
The gene for ALR2 has been isolated, cloned and sequenced from a number of tissues in 
man (Petrash and Favello 1989; Bohren et a/ 1989; Chung et a/ 1989; Nishimura et a/ 
1990). Graham and colleagues 1991[a and c], mapped the putative functional human ALR2 
gene to chromosome 7 in the q35 region adjacent to the TCRJ3 loci, using somatic cell 
hybrids and in situ hybridisation. It has previously been shown that the ALR2 and adjacent 
TCRI3 loci on chromosome 7q35 are strongly associated with diabetic nephropathy 
{Hibberd et a/1992; Pate! et a/1993, 1996). The ALR2 gene has hence been proposed as a 
candidate gene for the development of late diabetic complications. Bateman et a/ 1993 
used a complementary DNA clone encoding human ALR2 to further map the gene 
sequence to human chromosomes 1,3,7,9,11,13,14 and 18. They also used in situ 
hybridisation analysis to localise sequences to human chromosomes lq35-q42, 3p 12, 7q31-
q35, 9q22, 11 p 14-p 15, and 13q 14-q21 which may represent other active genes, non-aldose 
reductase homologous sequences or pseudogenes. Cao et a/ 1998 identified a novel human 
protein that is highly homologous to ALR2 namely ARL-1, which shows 71% sequence 
homology to human ALR2, and 81% and 83% homology with mouse vas deferens protein 
and fibroblast growth factor-regulated protein. This protein was found to have similar 
enzymatic activities and to act on a similar spectrum of substrates, although there was a 
difference in the site of expression of the genes. Importantly, this study determined by 
Northern blot analysis that ARL-1 is not expressed in tissues prone to diabetic lesions. A 
study carried out by Ho et a/ 1999 investigated the genomic structures and chromosomal 
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locations of the mouse ALR2 gene and ALR2-Iike genes. Using a comparative approach 
they determined that the area of the mouse chromosome in which ALR2 (Aldorl) is 
mapped, corresponds to the q33-34 region of chromosome 7 of the human genome. The 
study also found that the mouse Aldorl gene is highly homologous to the fibroblast growth 
factor regulated protein gene (Fgfrp) and the androgen regulated vas deferens protein gene 
(Avdp). The importance of which is that there is a possibility that these closely related 
genes may have similar physiological function and may be implicated in the aetiology of 
diabetic complications. 
The human ALR2 gene located on chromosome 7q35 extends over approximately 18 
kilobases and consists of 10 exons which give rise to a 1,384 nucleotide mRNA (excluding 
the poly A tail). The ATG codon at nucleotide 37 encodes the first amino acid methionine, 
and the codon 985 signifies translation termination (Chung and LaMendola 1989). The 
human aldose reductase gene codes for a 316 amino-acid protein with a molecular mass of 
35,858 Dalton's (Graham 1991 [a and b]). The size range of the exon's is 82 to 168 base 
pairs, whilst the size range for intron's is 325 to approximately 7,160 base pairs. Four Alu 
elements have also been found in the aldose reductase gene: two were found in intron I 
and one each in in ton 4 and intron 9. An Sp I sequence has also been shown to lie in the 5' 
untranslated region of exon 1. A major site for transcription initiation in hl.Jman liver has 
been mapped to an A residue 31 nucleotides upstream from the A of the ATG initiation 
codon. The promoter region of the ALR2 gene has also been well characterised, firstly in 
the rat by Graham et a/1991 [a] and also in the human by Wang et a/1993. The promoter 
region of the ALR2 gene has been found to contain a regulatory TAT A (TA TT A) box and 
a CCAAT box which are located 37 and 104 nucleotides upstream, respectively, from the 
transcription initiation site (Graham et al 1991 [a]; Wang et a/ 1993). Wang et al 1993 
characterised the human ALR2 gene promoter region and demonstrated that the basal 
promoter activity of the human aldose reductase gene is located between -192 and + 31 
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upstream of the mRNA cap site. Several common cis-elements were isolated and point 
mutations in certain sequences such as the TATTTA sequence reduced promoter activity to 
35% of the wild type DNA. This finding suggests that the TATA box is very important to 
the promoter activity of the ALR2 gene. The basal promoter region has also been found to 
contain a consensus sequence of an androgen response element (Wang et a/ 1993), three 
osmotic response element (ORE) sequences, a sequence homologous to a consensus Ap-1 
site, and a microsatellite dinucleotide repeat sequence. A report by Ferraris et al 1994 
investigated the rabbit ALR2 gene and found that a 235bp fragment within the promoter 
region of the ALR2 gene was able to drive the downstream reporter gene in transfected 
PAP-HT25 cells under isoosmotic conditions. Hyperosmotic stress induced a 40-fold 
increase in luciferase expression indicating an important role for osmotic response 
elements in diabetic complications. A number of genes have been localised to the 5 'ALR2 
region, these include endothelial nitric oxide synthase ( eNOS), XRCC2 DNA repair, long 
QT2 interval {LQT2), skeletal muscle chloride channel and thromboxane synthase genes. 
Polymorphisms of the ALR2 gene and its promoter region 
Pate! et a/ 1993 and K.icic et a/ 1993 investigated restriction fragment length 
polymorphisms at the human ALR2 gene locus. Pate! et a/1993 used amplified regions of 
the ALR2 gene as probes to screen for restriction fragment length polymorphisrns (RFLPs) 
in subjects with TIDM. Using 7 different restriction endonucleases (Bamlll, Sstl, Hindlll, 
Taql, Mspl, EcoRI, and Pstl) the study identified two polymorphisms. Firstly, a 
3 'ALR2/BamHI polymorphism within the ALR2 gene was found, however there was a 
complex hybridisation pattern as the probe detected both the functional and pseudo- ALR2 
genes. Secondly, a Pstl polymorphic site was found at the 5' end of the ALR2 gene in the 
non-coding region. No significant differences were found between any of the genotypes or 
alleles for 5'ALR2/Pstl with either TIDM or microvascular complications. However, the 
3'ALR2/BamHI polymorphism showed a statistically significant increase in frequency in 
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TlDM subjects with retinopathy compared to uncomplicated subjects (66.7% vs. 32.0% 
p<0.007), and nephropathy groups (66.7% vs. 34:9% p<0.006). This was also shown to be 
true when analysed in association with the previously identified TCRB polymorphism 
(Pate! et a/ 1996). 
To date there have been three reported biologically significant polymorphisms within the 
ALR2 gene and its promoter region. Firstly, a polymorphism which has provoked a great 
deal of interest has been the discovery of the (AC)n microsatellite dinucleotide repeat 
sequence polymorphism in the 5' region of the ALR2 gene. This CA dinucleotide repeat 
polymorphism designated 5'ALR2 is located approximately 2.lkb upstream of the 
initiation site of ALR2 close to the ORE sequences. Secondly, a C-l 06T polymorphism 
situated in the basal promoter region of the ALR2 gene has also been well investigated. 
Thirdly, and less well investigated, an A(+ll842)C polymorphism within intron 8 of the 
ALR2 gene itself (figure 9). A fourth polymorphism has also been recently reported, this 
being a C(-l2)G polymorphism reported in a Chinese population (Li et a/2002), although 
this has not been well investigated to date. 
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Figure 9. A schematic organisation of the promoter elements in the 5' ALR2 promoter 
region as described by Wang et a/ 1993 
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5' ALR2 (CA)n microsatellite 
Ko et a! 1995 studied the ALR2 gene promoter region and identified a highly polymorphic 
dinucleotide repeat marker (microsatellite) located 2.1 kilobases upstream of the 
transcriptional initiation site of the ALR2 gene as illustrated in figure 10. 
GAATCTTAACATGCTCTGAACCAGTAATCTCCCACTATGG 
5' GAATTTTTCCTAAGGAAATAATTTAAAAGGAAAACACACAC 
ACACACACACACACACACACACACACACACACACACACAC 
TAGGTATAGGGCTGGGC 
Figure 10. Chromosome 7q35 illustrating the location of the 5' ALR2 (CA)n 
microsatellite dinucleotide repeat polymorphism (Graham et a/ 1991 [c); Ko et a/ 
1995). 
Many studies in various countries using population groups of varying ethnicity have 
investigated the 5' ALR2 polymorphism (table 5). From the published investigations 
between 7 and 12 alleles have been detected at the polymorphic site. The most common 
allele is the (AC)24 repeat (138bp), designated as 'Z' allele. In some studies the (AC)23 
repeat (13xbp)has been associated with a high risk for diabetic complication, designated 
'Z-2', and (AC)2s repeat (13xbp) has been associated with a protective role, designated 
'Z + 2'. Discrepancies have however been reported to exist between studies, in particular 
between different ethnic groups and the different types of diabetes mellitus. The following 
section attempts to review the work that has been carried out to investigate this exciting 
polymorphism. 
5' ALR2 (CA)n microsatellite and microvascular disease in TlDM 
Investigations have been carried out to determine the relationship between the (CA)n 
polymorphism and microvascular disease in TlDM subjects. Diabetic retinopathy, 
nephropathy and neuropathy have been extensively investigated. Kao et a/ 1999 reported 
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that in a cohort of TIDM subjects of Caucasoid (Australian) origin which included 97 
retinopathy subjects and 67 non retinopathy subjects the frequency of the Z-2 allele was 
significantly higher in those patients with retinopathy than those without retinopathy 
(P<0.0005). Negative findings have however also been made with regard to the onset of 
retinopathy in TlDM subjects. Chistyakov et a/1997 reported no associations of the ALR2 
(CA)n polymorphism in TIDM subjects of Caucasoid (Moscow, Russia) origin and 
diabetic retinopathy. Yamamoto et a/ 1999 reported no association with retinopathy in 
TIDM subjects of Japanese (Oaska, Japan) origin. Iserman et al 2000 also looked at the 
(CA)n polymorphism in TIDM Caucasoid (Heidelberg, Germany) subjects with and 
without diabetic retinopathy. No significant differences were found in this study, however 
the Z+2 allele tended to be less frequent (11.5%) in subjects with retinopathy compared 
with TIDM subjects with no complications (17.8%), although this did not reach statistical 
significance. 
Several studies have also investigated the (CA)n polymorphism in association with diabetic 
nephropathy in TIDM subjects and have found a statistically significant relationship. 
Importantly, a study carried out in our own laboratory using a collection of Caucasoid 
(Plymouth, UK) subjects with TIDM demonstrated a highly significant decrease in the 
frequency of the Z+2 allele in TIDM patients with nephropathy (Heesom et a/ 1997). The 
Z+2 5'ALR2 allele was significantly increased in subjects with no complications after 20 
years duration of diabetes (uncomplicated) compared to those with nephropathy. This was 
accompanied by a significant increase in the Z-2 allele in the nephropathy group compared 
to those without. At least one copy of the Z+2 allele was found in 65% of the 
uncomplicated group to only 21.3% of the patients with nephropathy (odds ratio 7.1). 
These results indicate that the dinucleotide repeat polymorphism at 5' flanking region of 
the ALR2 gene might play a role in the regulation of the constitutive expression of ALR2 
in TIDM and thus provide a useful genetic marker for diabetic microangiopathy. Another 
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groundbreaking study by Shah et a/ 1998 also found significant associations with this 
polymorphism in two different study cohorts. Firstly, in a Caucasoid (USA) cohort the 
prevalence of the Z-2 allele among TlDM subjects was increased in those with diabetic 
nephropathy where 60% of subjects with nephropathy v. 22% TIDM subjects without 
nephropathy were homozygous for Z-2. The second cohort of subjects with TIDM of 
Caucasoid!Hispanic origin (Milan, Italy) origin also showed the same trend. In this cohort 
the prevalence of the Z-2 allele was higher in the subjects with diabetic nephropathy than 
in the diabetics without nephropathy, where 81% of subjects with diabetic nephropathy had 
one or more copies of the Z-2 allele. This study did not find any association with the Z+2 
allele and subjects without nephropathy. Moczulski et a/ 2000 also furthered this line of 
evidence by investigating the (CA)n polymorphism in Caucasoid (Boston, USA) Tl DM 
subjects with and without diabetic nephropathy. The study showed that the Z-2 allele was 
significantly more frequent in cases than controls (38% vs. 28.8%, P = 0.005), and carriers 
of the Z-2 allele had a higher risk of diabetic nephropathy than non-carriers. Yamamoto et 
a/ 1999 also looked at this polymorphism in TIDM subjects of Japanese (Osaka, Japan) 
origin. Conversely this study found that there was a higher increase in the frequency of 
nephropathy in subjects with the Z+2 allele, and also that homozygosity for the Z+2 allele 
was significantly associated. This therefore leads to some discrepancy between positive 
association results. 
Several other studies however, do not agree with the (CA)n results seen in the previously 
mentioned studies into diabetic nephropathy. Chistyakov et a/ 1997 also investigated the 
(CA)n polymorphism in a smaller cohort of Caucasoid (Moscow, Russia) TlDM subjects 
(29 no nephropathy vs. 20 diabetic nephropathy), and found no significant associations 
with diabetic nephropathy. Dyer et a/ 1999 also investigated whether the 5'ALR2 (CA)n 
microsatellite marker could be used as a genetic marker for susceptibility to diabetic 
nephropathy by analysing 442 British Caucasoids with TIDM. PCR was used to amplify 
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the DNA followed by size fractionation with a sequencer and genotyped. They detected 
nine alleles, and found no significant difference in allele frequencies between patient 
groups. Specifically they also found no significant difference in the frequency of the 
reported associated allele Z-2, and the protective allele Z+2. Isserman et at 2000 also 
looked at TLDM subjects of Caucasoid (Germany) origin with and without diabetic 
nephropathy and also found no significant increase in incidence of Z-2 (CA)23 allele 
between groups. The study did show a tendency that the Z and Z+2 alleles were slightly 
lower in the group with nephropathy compared to the group with no complications but no 
statistical significance was achieved. Furthermore, the Caucasoid cohorts (North of 
England and Belfast) TIDM subjects included in the study carried out by Neamat-Allah et 
a! 200 l also showed no evidence of an association between the microsatellite marker 
(CA)n alleles and diabetic nephropathy. Additionally, stratification of the Belfast cohort in 
this study according to HbA1c also revealed no evidence of altered risk of diabetic 
nephropathy in Z-2 carriers vs. non Z-2 carriers. Ng et a! 2001 carried out the same studies 
using Caucasoid (Australia) TLDM subjects and found no associations with diabetic 
nephropathy. Reporting that despite the study being relatively small with regard to the size 
of the cohort, the 5'ALR2 (CA)n polymorphism is not useful as a genetic marker for 
susceptibility to nephropathy in Caucasoid TIDM subjects. 
A positive association has also been shown in Caucasoid (Plymouth, UK) TlDM subjects 
with diabetic neuropathy (Heesom et a! 1998). The study again carried out by our 
laboratory found that there was a highly significant decrease in the frequency of the Z+2 
allele in those patients with overt neuropathy compared to those with no neuropathy after 
20 years duration of diabetes. The neuropathy group also had a significant decrease in the 
frequency of the Z/Z+2 genotype compared to subjects without diabetic neuropathy. This 
finding was not supported in the Caucasoid (Australia) neuropathy TLDM subjects 
investigated by Ng et a/ 2001. 
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5' ALR2 (CA)0 microsatellite and microvascular disease in T2DM 
There have been several studies reported which have found positive associations between 
the (CA)n polymorphic region and certain diabetic microvascular complications in T2DM 
subjects of varying ethnicity. Studies into the (CA)n polymorphism in T2DM and diabetic 
retinopathy have however lead to conflicting reports being published. Firstly, the 
pioneering study carried out by Ko et a/ 1995 suggest that the gene encoding aldose 
reductase (ALR2) may be involved in the early onset of diabetic retinopathy in T2DM 
patients. The study. showed that the (AC)0 dinucleotide repeat polymorphism 2.1kb 
upstream of the promoter region of the ALR2 gene is associated with early onset diabetic 
retinopathy in 44 unrelated Chinese (Hong Kong) patients with T2DM and nearly identical 
HbA I c values. They found seven alleles at this locus and observed a strong association 
between the (AC)23 (also called 'Z-2') allele and early onset diabetic retinopathy in 
patients with T2DM (59%), compared with the group with no complications (9%). The 
results strongly suggest that the (AC)23 allele was related to early appearance of retinal 
microangiopathy. This report therefore suggests that aldose reductase or a gene in the close 
vicinity might be involved in the pathogenesis of this diabetic complication in T2DM 
subjects of Chinese origin. Secondly, Fulisawa et a/ 1999 carried out a study of the 
5 'ALR2 microsatellite in T2DM subjects of Japanese origin. Eleven different alleles were 
observed in this study and it was reported that the length of the alleles was significantly 
different between the two groups. It was suggested that the frequency of the shorter alleles 
(equal to or shorter than Z-4) were more associated with retinopathy than the longer alleles 
(greater than Z-4). The molecular mechanism associating the length polymorphism is ill 
understood, although it has been suggested that the dinucleotide repeat length may directly 
effect ALR2 gene expression through enhancer/promoter interaction. Alternatively, the 
allelic variation may be in linkage disequilibrium with an unknown aetiological mutation, 
which may affect the expression or function of aldose reductase. The line of thought which 
is suggested is that the shorter form of the dinucleotide repeat is associated with disease 
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phenotype. Thirdly, a small study of27 Spanish T2DM subjects was carried out by Olmos 
et a/1999 reporting that the absence of the (AC)24 allele of the (AC)0 polymorphic marker 
was associated to a five fold reduction of retinopathy appearance rate. A later report by the 
same group (Olmos et al 2000) also tested the hypothesis that the (ACb allele of the 
ALR2 gene is related to an enhanced rate of progression of retinopathy in Chilean 
Caucasoid T2DM subjects. The longitudinal-retrospective study showed that the subjects 
with the (AC)23 allele had a retinopathy progression rate that was 8.9 times higher than that 
of the diabetics having other alleles. A fourth study carried out by Ikegishi et a! 1999 also 
investigated the (CA)n polymorphism in 27 T2DM subjects with retinopathy and 34 T2DM 
subjects without retinopathy and 96 controls of Japanese origin. The study identified 10 
alleles and found a significant difference in the frequency of the Z-4 and Z-2 alleles. The 
frequency of the Z-4 allele was seen to be significantly greater in subjects with 
proliferative retinopathy, whereas the Z+2 allele was significantly greater in subjects 
without retinopathy. The study also found, using transfection experiments, that the Z-4 
allele showed significantly higher transcription of the reporter gene. A fifth study by 
Ichikawa et a/ 1999 carried out an investigation using microsatellite PCR and direct 
sequencing methods, to assess the association of the 5'ALR2 (CA)n locus and diabetic 
microvascular complications in Japanese patients with T2DM. They were able to identify 
six alleles, and found no significant difference in allele distribution between diabetic 
patients and controls. The Z-2 allele frequency was however, significantly higher in 
subjects with diabetic retinopathy than those without retinopathy, suggesting that aldose 
reductase is involved in the development of diabetic retinopathy. In contrast however the 
microsatellite marker was not associated with diabetic nephropathy, peripheral or 
autonomic neuropathy. But they concluded that the discrepancy might be partly 
attributable to the low frequency of Z+2 allele in the Japanese subjects. 
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Contradictory to these findings however, several groups investigating the (AC)n 
polymorphic region in T2DM subjects with retinopathy have found no significant 
associations. Maeda et a/1999 studied a population of Japanese T2DM subjects and found 
no association between any of the alleles and diabetic retinopathy. Groves et a/ 1999 
investigated 250 British Caucasoid T2DM subjects with retinopathy which were carefully 
matched with controls, and found no association with the (CA)n polymorphism. Lee et a/ 
2001 [a] investigated 384 late onset T2DM subjects of Hong Kong Chinese origin and 
identified 10 alleles at the (CA)n polymorphic region. The study found no significant 
differences in allelic distributions of the Z+2/ Z/ Z-2 allelic variants between subjects with 
and without diabetic retinopathy. However, the study did report an increased presentation 
of the Z-4 allele in T2DM subjects with retinopathy compared to those without (9% vs. 
4%, p < 0.05). 
Studies into T2DM and diabetic nephropathy have so far also produced positive and 
negative correlation's. Maeda et a/ 1999 studied a population of Japanese T2DM subjects 
and found no association between any of the alleles and nephropathy, although ALR2 
protein content was increased in subjects with nephropathy. The T2DM subjects of British 
Caucasoid or Pima Indian origin investigated by Neamat-Ailah et a/ 2001 showed no 
significant associations of either the Z-2 or Z+2 alleles with diabetic nephropathy. The 
study also carried out a meta-analysis of all the published data for the (CA)n 
polymorphism and revealed no evidence for an effect of the rnicrosatellite marker in 
T2DM subjects with nephropathy. The Olmos et a/ 2000 study investigated the 
nephropathy progression rate in T2DM Caucasoid subjects with and without the (AC)23 
allele. Although the mean nephropathy progression rate was higher in the (AC)23 group no 
statistically significant differences were found. Moculski et a/ 1999 examined the 
association between the 5 'ALR2 (CA)n polymorphism and diabetic nephropathy in a large 
group of Caucasoid patients with T2DM which consisted of 179 normoalburninuria 
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subjects, 225 microalbuminuria subjects and 70 proteinuria subjects. They also found no 
association between the Z-2 allele and nephropathy in Caucasoid T2DM subjects. Park et 
al 2002 investigated the relationship between the aldose reductase gene polymorphisms 
and microvascular complications in Korean patients with T2DM, and found no 
associations with the frequencies of the Z-2 and Z+2 alleles between subjects with and 
without diabetic nephropathy and retinopathy. A recent study however, carried out by Liu 
et al 2002 has found an association between the 5 'ALR2 (CA)n polymorphism in the 
development of diabetic nephropathy in Southern Chinese with T2DM. In this study the 
normoalbuminuric subjects had the lowest Z-2!X genotype frequency 18.8% vs. 36.5% in 
rnicroalbuminuric (p<O.OOl), and 38.5% in albuminuric patients (p=<0.02). 
S' ALR2 C(-106)T polymorphism 
A bi-alleleic polymorphism situated close to the osmoregulatory element (ORE) has also 
been identified and located to position - 106. It has been found to be aCto T substitution 
(C-106T) at this position in the 5' flanking region ofthe ALR2 gene (figure l I). 
cctttctgcc acgcggggc gcgggcgagc gttgggggcg 
5' gaaagaatcc gctgccacta ggaccaggcg gaagaag.cat ccccgccgac ccttggggaa ggccgccgcg gcacccc£ag 
cgcaaccaat cagaaggctc cttcgcgcag cggcgcgcca 
accgcaggcg ccctttctgc cgacctcacg ggctatttaa 
aggtacgcgc cgcggccaag gccgcaccgt actgggcggg 
ggtctgggga gcgcagcagc c 
Figure 11. Chromosome 7q35 illustrating the location of the 5' ALR2 C(-106)T 
polymorphism (Graham et a/ 1991 [a and c]). 
In a study by Kao et a/ 1999, young adolescent Caucasoid (Australia) TlDM subjects with 
and without diabetic retinopathy were investigated. This study suggested that the C(-106) 
allele was associated with the Z-2 allele in subjects with retinopathy, and conversely that 
both the C and the T alleles were associated with the Z+2 allele in the uncomplicated 
group. However, Moczulski et al 2000 showed, in a Caucasoid (North American) 
population of T1DM subjects with diabetic nephropathy, that the T(-106) allele was 
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associated with the Z-2 allele. The Z-2ff haplotype was also shown to have a higher 
incidence in the TlDM subjects with nephropathy than in TlDM subjects without 
nephropathy. A more recent study by Neamat-Ailah et a/ 2001 reported a significant 
association between the T allele of the ALR2 -106 marker and diabetic nephropathy in 
both TlDM and T2DM subjects of Caucasoid (UK) origin. The Pima Indian cohort also 
investigated did not however show any statistical correlations. They also found that the Z-2 
allele was positively associated with the T allele, and the Z allele was positively associated 
with the C allele in TlDM and T2DM subjects. Also the carriage of the combination of 
both Z-2 and -1 06T was increased in subjects with diabetic nephropathy compared to 
subjects without diabetic nephropathy, although not to statistical significance. Li et a/ 2002 
have also carried out a study into the C( -1 06)T polymorphism using a population of 
Chinese subjects and controls. This study found that there was an association with the C(-
106)T polymorphism and diabetic retinopathy in the Chinese population. 
ALR2 A(+ll842)C intragenic polymorphism 
A single base substitution A(+ 11842)C has been previously described within intron 8 of 
the ALR2 gene (Kicic et a/ 1993; Pate) et a/ 1996; Pate) et a/ 1993). The A(+ll842)C 
polymorphism is a silent substitution that creates a new Barn Hl restriction endonuclease 
site (figure 12). Kicic et a/ 1993 found an association between the (+ll842)C allele and 
proliferative retinopathy patients with TlDM. Kao et a/ 1999 also examined DNA from 
164 adolescents with TlDM for the A to C substitution at the 95th nucleotide of intron 8 of 
the ALR2 gene. The authors named the alleles as 'B' where the restriction enzyme cut and 
'b' where it did not. Kao et a/ 1999 reported that this polymorphism was strongly 
associated with diabetic retinopathy in adolescent TlDM subjects of Caucasoid (Australia) 
origin. 
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tcttgg9t99 tcagg~ctg§ ,cc;:ct,cct.cca tgg~g gatgggggag 
gcctctcatc ctgtctctgg agtgtcatct gtgarr.c caccatcctc 
tcttctgagg ccagggagct gtggcgagca agccaagact gagactgaca 
cctcaccagt ggagccgtgt gccaggggca ggccttgggt ccagggccgt 
gctgtggcaa tacacctaca cctttgctca ggcccttcag cacaccgaga 
ggt 
Figure 12. Chromosome 7q35 illustrating the location of the ALR2 A(+11842)C 
polymorphism (Graham et a/1991 [a and c]). 
Previous studies by Pate! et al 1993/1996 using restriction fragment length polymorphism 
analysis had studied this BarnH1 site and found an association with microvascular 
complications. It is clearly important to understand the relationship and strength of the 
association of the A(+ 11842)C site to the 5 'ALR2 locus and relevance to the susceptibility 
to diabetic complications. 
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Author Population Diabetes Complication Polymorph Isms Association 
studied 
T1DM 
Isermann et a/2000 Caucasaid (Heidelberg, TlDM Retinopathy (CA)n -ive 
Germany) Nephropathy (CA)n -ive 
CHD (CA)n +ive 
Ng eta/2001 Caucasoid (Australian) TlDM Nephropathy (CA)n -ive 
Neuropathy (CA)n -ive 
Kao eta/1999a Caucasoid (Australian) T1DM Retinopathy (CA)n +ive 
C(-106)T +ive 
Kao etal1999b Caucasoid (Australian) TlDM Retinopathy (CA)n +ive 
A(+11842)C +ive 
Heesom eta/1997 Caucasoid (Plymouth, UK) TlDM Nephropathy (CA)n +ive 
Heesom et a/1998 Caucasoid (Plymouth, UK) TlDM Neuropathy (CA)n +ive 
Dyer eta/1999 Caucasoid (Birmingham, UK) T1DM Nephropathy (CA)n -ive 
Neamat-AIIah eta/2001 Caucasoid (Belfast, UK) TlDM Nephropathy (CA)n -ive 
C(-106)T +ive 
Caucasoid (N of E. UK) TlDM Nephropathy (CA)n -ive 
C(-106)T +ive 
Shah eta/1998 Caucasoid/Hispanic (USA) TlDM Nephropathy (CA)n +ive 
Caucasoid (Milan, Italy) TlDM Nephropathy (CA)n +ive 
Chistyakov et a/1997 Caucasoid (Moscow, Russia) TlDM Retinopathy (CA)n -ive 
Nephropathy (CA)n -ive 
Yamamoto eta/1999 Japanese (Osaka, Japan) TlDM Nephropathy (CA)n +ive 
Retinopathy (CA)n -ive 
Moczulski et a/2000 Caucasoid (Boston, USA) TlDM Nephropathy (CA)n +ive 
C(-106)T +ive 
T2DM 
Groves eta/1999 Caucasoid T2DM Retinopathy (CA)n -ive 
Neamat-AIIah eta/2001 Caucasoid (N of E, UK) T2DM Nephropathy (CA)n -ive 
C(-106)T +ive 
Pima Indian (Arizona, USA) T2DM Nephropathy (CA)n -ive 
C(-106)T -ive 
Moczulski et a/1999 Caucasoid (Boston, USA) T2DM Nephropathy (CA)n -ive 
Olmos et a/1999 Caucasoid (Madrid, Spain) T2DM Retinopathy (CA)n +ive 
Olmos et a/2000 Caucasoid (Madrid, Spain) T2DM Retinopathy (CA)n +ive 
Ko eta/1995 Chinese (Hong Kong, China) T2DM Retinopathy (CA)n +ive 
Lee et a/2001 [a] Chinese (Hong Kong, China) T2DM Retinopathy (CA)n -ive 
Li eta/2002 Chinese (Changsha, China) TlDM Retinopathy C(-106)T +ive 
C(-12)G 
Liu et a/2002 Chinese (Hong Kong, China) T2DM Nephropathy (CA)n +ive 
Qingjie etal 2002 Chinese (Xiangya, China) T2DM Retinopathy C(-106)T +ive 
C(-12)G +ive 
Fujisawa et a/1999 Japanese (Osaka, Japan) T2DM Retinopathy (CA)n +ive 
Ichikawa et a/1999 Japanese (Kurume, Japan) T2DM Retinopathy (CA)n +ive 
Nephropathy (CA)n -ive 
Neuropathy (CA)n -ive 
Ikegishi et a/1999 Japanese (Yamanashi, Japan) T2DM Retinopathy (CA)n +ive 
Maeda et a/1999 Japanese (Shiga, Japan) T2DM Nephropathy (CA)n -ive 
Park eta/2002 Korean (Seoul, South Korea) T2DM Retinopathy (CA)n -ive 
Nephropathy (CA)n -ive 
Table 5. Summary of published studies of the ALR2 polymorphisms within 
the ALR2 gene and its promoter region in TlDM and T2DM. 
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Family based studies 
Moczulslci et a/ 2000 was the first to report the investigation of the ALR2 promoter region 
polymorphisms in a family based study using the transmission disequilibrium test (TDT). 
Families used in this study had TlDM with or without persistent proteinuria or diabetic 
nephropathy, and were of Caucasoid (USA) origin. The study found that transmission of 
the Z-2 allele was 54% in case trios and 45% in control trios, which although show 
consistency with previous case control studies, did not reach statistical significance. Also 
the transmission of the T allele for the C(-106)T polymorphism was 54% in case trios and 
37% in control trios, again not reaching statistical significance. The Z-2/T haplotype was 
transmitted froJ:ll heterozygous parents 57% in the nephropathy trios and 47% in control 
trios. In should be noted however, that due to the small numbers involved in this study the 
power to detect any linkage was somewhat reduced and may have little efficacy in this 
study. 
ALR2 promoter region polymorphisms and gene expression 
Shah et a/ 1997 previously reported that aldose reductase mRNA levels in PBMC's were 
3-fold higher in TIDM patients with diabetic nephropathy than in those without 
nephropathy, and also that mRNA levels were not elevated in non-diabetics with renal 
disease. Shah et a/1998 continued this investigation by exploring the possibility of a link 
between the 5' ALR2 microsatellite polymorphism Z-2, and increased levels of ALR2 
expression in diabetic nephropathy. Their studies found that in both Caucasoid!Hispanic 
(USA) and Caucasoid (Milan, Italy) TIDM subjects, those with one or more copy of the Z-
2 allele also had higher ALR2 mRNA levels than did diabetics without the Z-2 allele. In 
contrast, among non-diabetics the ALR2 mRNA levels were similar in subjects with and 
without one or more copy of the Z-2 allele. 
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These findings are extremely exciting because firstly, the 5' ALR2 marker is associated 
with diabetic nephropathy in those patients with TlDM and is linked to this region in 
T2DM. This demonstrates that the genetic lesion is independent of the cause of diabetes. 
Secondly, it occurs across ethnic groups, which is further evidence that ALR2 plays a 
critical role in the susceptibility to, and pathogenesis of diabetic nephropathy. Thirdly, the 
Z-2 allele is associated with up-regulation of ALR2 gene expression in patients with 
diabetic nephropathy. The mechanism in which these polyrnorphisms regulate aldose 
reductase gene expression is not known. However it was suggested that because the 
5 'ALR2 microsatellite is located in the 5' region of the gene, different populations might 
be associated with differential binding of transcription factors. It may also be that the 
expression of other genes near this locus may be altered and may also modulate the risk for 
diabetic complications. Several other sequence variants have also now been reported but 
have not been so extensively investigated (Moczulski et al 2000; Kao et a/ 1999). It is 
clear from this review of the literature regarding the polyrnorphisms within the ALR2 gene 
and its promoter region that more work is now required to confirm these results in family 
based studies, and in addition to establish whether the ALR2 polyrnorphisms has a 
functional role in diabetic complications. 
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CeUular osmotic regulation and diabetic complications 
Changes in extracellular osmolality such as the effect of hyperglycaemia results in osmotic 
stress. due to unequal rates of movement of water and solutes across the cell membrane. 
The osmotic balance between intracellular and extracellular compartments is critical for 
the maintenance of cellular homeostasis. Cells respond to osmotic stress by osmoregulation 
compensatory mechanisms such as changes in cell volume, water content, and intracellular 
solute concentration. An increase in extracellular glucose levels leads to increase in the 
flux through polyol pathway, and probably an increase in activity of aldose reductase 
leading to an intracellular accumulation of sorbitol. The pathway is driven by increased 
intracellular glucose availability leading to sorbitol accumulation (Gabbay et al 1973). 
Abnormally high levels of osmolytes can be deleterious to cells, for example an 
accumulation of sorbitol has been reported to be a cause of cataract formation (Lee 1995). 
In target tissues of diabetes such as kidney, nerve, and eye, sorbitol accumulation is 
thought to exert a hyperosmotic effect that contributes to some complications of diabetes 
(Bhatnagar and Srivastava 1992). Several studies have shown that sorbitol accumulates in 
renal medulla cells and other cell types when cultured in vitro under hypertonic conditions, 
this response reaction therefore extends and increases the sorbitol accumulation and adds 
to the risk of developing complications. Osmoregulatory mechanisms occur throughout the 
human body but are known to be predominantly located in the renal medulla, this is 
because renal medullary cells are routinely exposed to a greatly hyperosmotic milieu. 
Because of the urinary concentrating mechanisms, cells in the inner mammalian renal 
medulla are constantly exposed to steep osmotic gradients by varying concentrations of salt 
and urea that may reach molar level. Similar pathways have been observed in other non-
renal cells in the body, suggesting that these are a common response to hyperosmotic 
stress. The epithelial cells lining the inner renal medulla of the kidney are protected from 
the osmotic effect of concentrated sodium ion and urea in the interstitium by several 
regulatory mechanisms described below: -
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(a) Cell volume and ionic electrolye concentration regulation 
Cells in the kidney can volume regulate in response to hypertonic challenge. Some are able 
to respond immediately by RVI, other cells require stimulation prior to exposure to 
hyperosmolarity to demonstrate RVI. An increase of intracellular osmolytes during RVI 
usually occurs by an increase ofNaCl influx either via the activation of parallel Na(+)-H+ 
and Cl(-)-HC03- exchangers, or Na(+)-K(+)-2Cl- eo-transporters. In response to 
hypotonic challenge a RVD response occurs in kidney cells. The efflux of solute during 
RVD is usually via K + loss by activation of conductance pathways. Stretch-activated K + 
channels and Ca2(+) -activated -K+ channels have been shown to be stimulated in cells 
exposed in hyposmotic solutions (Montrose-Rafizadeh et a/1990). 
(b) Regulation of urea concentration 
The deleterious effect of urea on enzymatic activities has been demonstrated in vitro on 
several enzymes including aldose reductase (Burg et a/ 1999). A high level of expression 
of the urea transporters (UT -A) is normally observed in the renal medulla and is further 
expressed by water depravation (Bagnasco et a/ 2000), similar to the genes involved in the 
osmoregulation of inner medullary cells. This suggests that the same regulatory pathways 
contribute to maintain a steady level of expression of several genes in inner medulla under 
physiological conditions (Bagnasco 2000). 
(c) Accumulation of compatible organic osmolytes 
Exposure to anisotonic media initiates a response that counteracts volume perturbations by 
complex mechanisms involving changes in the intracellular concentrations of active 
organic solutes (osmolytes). Medullary and papillary cells use these organic solutes to 
increase the intracellular concentration. These cells are protected from the osmotic effect 
of concentrated sodium ion and urea in the interstitium by accumulating compatible 
osmolytes. This process enables normal cell volume to be maintained without a deleterious 
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increase in intracellular inorganic ion (electrolyte) concentration and enables the cell 
volume and osmolality to be preserved without perturbing macromolecular protein 
structure and function over a wide range of concentrations (Yancey et a/ 1982). The 
accumulation of such osmolytes is primarily dependent on changes in gene expression of 
enzymes involved in the synthesis of osmolytes or transporters that uptake them into the 
cell. Hyperosmotic stress has been shown to induce the transcription of a number of 
proteins, which include aldose reductase and the betaine, myo-inositol, and taurine 
transporters (Garcia-Perez and Burg 1991; Burg et a/ 1995). The organic osmolytes that 
rabbit and rat kidney cortex and medulla cells accumulate include sorbitol, glycine betaine, 
inositol, taurine, and glycerophosphocholine (GPC) and were identified by proton nuclear 
magnetic resonance, mass spectrometry, and chemical assays (Bagnasco et a/ 1986). By 
accumulating these osmolytes the renal medullary cells maintain both their volume and 
their intracellular medium unperturbed under hyperosmotic stress (Somero 1986; Martin et 
al 1989; Garcia-Perez and Burg 1991). Sorbitol is produced within the cell via the 
reduction of glucose by aldose reductase, betaine, myoinositol, and taurine are transported 
into the cells by betaine/y-aminobutyric acid transporter (BGTl), Na+-dependent 
myoinositol transporter (SMIT) and taurine transporter respectively (Burg 1995). 
Signal pathways involved in the gene expression of osmolytes 
Regulation of gene expression in response to hyperosmolality has been well investigated in 
the prokaryotic organism's Escherichia coli and Salmonella typhimurium. Prokaryotes 
exhibit a variety of mechanisms responsible for osmosensory signal transduction. The 
prominent response to hyperosmotic stress is uptake of K+ and compatible osmolytes. 
These organisms have three transport systems for the uptake of K+, namely Trk, Kup, and 
Kdp, and two transporters with overlapping specificity's for proline and glycine betaine 
namely ProP and ProU (Csonka et all996). In response to hyperosmotic stress, there is an 
increase in the expression of the Pro-U operon, which encodes a high affmity betaine 
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transporter (Caimey et a! 1985), resulting in an increase in the activity of the A TP-
consuming betaine transporter and accumulation of betaine (Lucht et a! 1994). The DNA 
binding protein (H-NS) acts as a transcriptional repressor of the Pro-U operon under 
isosmotic conditions. The inhibitory effect of H-NS is relieved by extracellular 
hyperosmolality resulting in transcription of the operon (Ueguchi and Mizuno 1993 ). 
The mechanism of osmoregulation of gene expression in response to hyperosmolality is 
also better understood in yeast (Saccharomyces cerevisiae) which involves a two-
component signalling transducer system as an osmolality sensor (Maeda et a/1994, 1995; 
Posas et a/ 1996; Kultz et at 1997). The yeast responds to osmotic stress by enhanced 
production and intracellular accumulation of glycerol as a compatible solute. When 
exposed to hyperosmotic medium the stress signal is transduced through the MAP (HOG 1) 
kinase cascade to induce the synthesis of glycerol-3-phosphate dehydrogenase (GPD) 
(Albertyn et at 1994). Exposure of yeast to high extracellular osmolarity induces Sin lp-
Ypdlp-Ssklp two component osmosensorto activate the mitogen activated protein (MAP) 
kinase cascade composed of the Ssk2p and Ssk22p MAP kinase kinase kinases 
(MAPKKK's), the Pbs2p MAPKK, and the Hog1p MAPK. A second osmosensor, Sho 1p, 
also activated Pbs2p and Hog 1p, but does so through the Ste lip MAPKKK (Posas and 
Saito 1997). 
In mammals, extracellular hyperosmolality also tightly regulates the expression of several 
genes. Hypertonicity is known to induce the expression of a group of genes that are 
responsible for the intracellular accumulation of protective organic osmolytes (Burg et a! 
1997). Expression and accumulation of osmolytes within the cell is due to up-regulated 
expression of the betaine (BGT -I) gene and myo-inositol transporters (SMIT), and aldose 
reductase (ALR2) which occurs in response to extracellular NaCI and non-permeable 
osmotically active solutes (Bagnasco et a! 1987). Hyperosmolality is known to increase the 
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transcription of these genes, leading to increased mRNA abundance, enzyme levels and 
accumulation of compatible osmolytes (Burg 1997). How the initial signal of external 
hyperosmolality is relayed to the nucleus to induce the expression of genes responsible to 
increase cellular osmolytes is still not completely clear. However some degree of progress 
has been made in the venture to elucidate this and will be discussed here. Signal 
transduction pathways relate signals from the cell membrane across the cytoplasm to the 
nucleus in order to initiate an appropriate transcriptional response. The osmotic stress of 
hyperglycaemia is the extracellular stimuli, which initiates the stress response pathways. 
Osmotic shock induces marked activation of mitogen activated protein kinase (MAPK's) 
in fibroblastic cells (Matsuda et a/ 1995). Activation of transcription response to 
hyperosmolarity has been described for three MAPK pathways; (1) mitogenic extra-
cellular regulated kinase (ERK. l/2) cascade, and the less well understood pathways ERK3· 
and ERK5 cascades, (2) stress activated protein kinase (SAPK2) c-Jun N-terminal kinase 
{JNK), (3) p38 kinases. These MAPK cascade pathways function as signal transducers 
from the cell surface to the nucleus, and play an important role in transducting 
environmental stimuli to the transcriptional machinery in the nucleus. The MAP kinase 
cascade is highly conserved in all eukaryotes and is involved in numerous cellular 
responses (Wilson et a/ 199; Karin 1998). Activation of the MAPK cascade plays essential 
roles in many signal transduction pathways. Investigations by Reiser et a/ 1999 revealed 
that at least three events contribute to signal induced nuclear localisation of the MAP 
kinases; activation by phosphorylation, regulated nuclear import and export, and nuclear 
retention. Hypertonicity-induced activation and binding of transcription factors to the ORE 
are regulated by the p38 kinase and MEK-1 signalling pathways (Nadkarni et a/ 1999). 
MAPK has been demonstrated to phosphorylate and regulate numerous cellular proteins, 
including growth factor receptor, transcription factors, cytoskeletal proteins, phospholipase 
and other protein kinases. Evidence also suggests that acute activation of the MAPK 
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cascade promote G I progression/S phase entry and that chronic activation of the MAPK 
cascade inhibits this process (Tombes et a/1998). 
The growth factor signalling kinases include the ERK's. The mitogen-activated protein 
(MAP) kinases ERK-ll ERK-2 are proline directed kinases that are themselves activated 
through concomitant phosphorylation of tyrosine and threonine residues (Han et a/ 1994). 
ERK activity was not found to be essential for transcriptional regulation of betaine and 
inositol transporters (Kwon et a/ 1995). The stress activated protein kinase (SAPKI) 
pathway transmitting cellular insult to the nucleus to influence gene expression consists of 
four levels of protein kinases. Unlike the structurally related MAPK pathway, the stress-
induced kinases are not required for mitogenesis and instead induce growth arrest 
(Woodgett et a/ 1.996). JNK's respond to several forms of cellular stress including 
inflammatory cytokines such as Interleukin-1 (Il-l) and tumour necrosis factor-alpha 
(TNF-alpha), beat and chemical shock, bacterial endotoxin and ischaemia/cellular ATP 
depletion (Wilson et a/ 1997). The signal transduction pathway c-Jun N-terminal kinase 
(JNK) cascade is known to be a cellular stress response to stimulation by UV light, 
oxidative stress and inflammation, and involves phospholipase C, Raf-1 kinase, mitogen 
activated protein kinase kinase and mitogen activated protein kinase (Guan 1994; Kyriakis 
et a/ 1994). JNK has three subforms coded I, 2 and 3, and each subform has multiple 
isoforms; four for JNK1, four for JNK2 and two for JNK3 (lp and Davis 1998). P54 is the 
principle JNK that is activated by cellular stress and tumour necrosis factor (TNF)-alpba 
(Itoh et a/ 1994). P38 is tyrosine phosphorylated after extracellular changes in osmolarity 
(Han et a/1994). Four subtypes have been cloned for p38; cx,~,y,8 (Wang et a/1997). P38 
kinase mediates the activation and/or binding of the transcription factors to the ORE 
(Nadkami et a/ 1999). Nadkarni et al 1999 showed that the hypertonicity induced ALR2 
mRNA increase in HepG2 cells is attenuated by the p38 kinase and MEK1 inhibitors. 
Transfection studies also showed that the specific locus of action of the inhibitors used is 
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the activation of the ORE in response to hypertonicity. They also demonstrated the 
involvement of p38 kinase in the binding of trans-acting elements to the ORE. Their 
studies therefore indicate that the hypertonic induction of ALR2 rnRNA in HepG2 cells is 
regulated by p38 kinase and MEK1 and is mediated by the ORE. 
Gene regulation of ALR2 under osmotic stress 
Animal studies investigating the regulation of ALR2 gene expression by hypertonicity are 
numerous. Cowley et a/1990 carried out a study using Brattleboro rats and showed that an 
alteration in extra-cellular sodium, but not urea leads to a rapid change in aldose reductase 
mRNA. Russell 1990 studied a lens epithelial cell line from a transgenic mouse and 
Kaneko et al 1990 studied Chinese hamster ovary cells and both studies found similar 
results. Smardo et a/ 1992 investigated into osmotic regulation using a line of rabbit inner 
medullary cells (P AP-HT25) that accumulate large amounts of sorbitol under hyperosmotic 
conditions. They demonstrated that extracellular hyperosmolarity induces transcription of 
the ALR2 gene resulting in an increase in ALR2 mRNA followed by increased ALR2 
protein synthesis rate and subsequent rise in sorbitol levels (Garcia-Perez et al 1989; 
Uchida et a/1989). Hypertonicity in PAP-HT25 cells has been shown to increase synthesis 
of ALR2 rnRNA 15-fold in 24 hours without a detectable change in the rate of degradation 
of the ALR2 protein (Moriyama et a/ 1989). Grunewald et a/ 1998 studied the inner 
medullary collecting duct (IRMC) cells from the rat using an RT-PCR-based strategy, and 
found that increasing the extracellular osmolarity from 600 to 900 mosm/1 resulted in a 
more than 4-fold increase in mRNA for ALR2 within 24 h. Recently, important findings 
were made by Meakawa et a/2001 who investigated ALR2 mRNA levels in rat Schwann 
cells cultured under hyperglycaemic or hyperosmotic conditions. This study showed that 
the expression of ALR2 mRNA was unaltered by hyperglycaemia (30mM), but that 
osmotic stress elicited significant increases in ALR2 mRNA. 
- 155-
Chapter 2: Aldose reductase and the polyol pathway 
An osmoregulatory role of ALR2 has also been suggested by studies in cell lines derived 
from human renal inner medulla showing that increases in the osmolality of the medium is 
associated with increases in cellular sorbitol levels, ALR2 activity and ALR2 gene 
expression. Bedford et a/1987 identified aldose reductase to be an osmoregulatory protein, 
which was induced, in the renal medullary cells by high extracellular NaCI. Similarly, 
Bagnasco et al 1987 reported on a line of renal medullary cells in which aldose reductase 
activity and intracellular sorbitol was greatly increased under high NaCl conditions. 
Conversely Cowley et al 1990 reported that ALR2 mRNA and sorbitol content increase 
during dehydration or antidiuresis and that acute decreases in extracellular sodium 
increases leakage of sorbitol from the renal medulla cells into the extracellular 
environment. Several other studies carried out by several different groups also reported 
similar findings. Kaneko et al 1990 using Kidney mesangial cells, Hohman et al 1990 
using glomerular endothelial cells, Bekhor et al 1989 using lens epithelial cells and 
Ferraretto et al 1993 using human embryonic epithelial cells and Petrash et a/1992 studied 
human renal proximal tubule cells. 
Osmotic Response Element (ORE) I Tonicity Enhancer Element (TonE) 
Hyperosmolarity responsive expression of the genes involved occurs by stimulation of 
transcription requiring formation of a DNA-protein complex between a tonicity-responsive 
enhancer (TonE/ORE) and the respective binding proteins, TonE binding protein 
(TonEBP) or nuclear factor of activated T cells 5 (NFAT5). Osmotic response element 
binding protein (OREBP), the tonicity enhancer element binding protein (TonEBP) and 
nuclear factor of activated T cells 5 (NF AT5) mRNA are ubiquitously expressed and are 
detectable in the kidney, brain, liver, spleen, gonads and skeletal muscle (Lopez-Rodriguez 
et a/1999). The tonicity responsive enhancer (TonE) has the putative consensus sequence 
TGGAAANN(C/T)N(C/T) (Rim et al 1998) which has been found to regulate genes for 
SMIT (Rim et al 1998), BGTl (Miyakawa 1998), and aldose reductase (Ferraris et al 
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1996; Ko et a/1997). Miyakawa et a/1999 reported the cloning and characterisation of the 
first animal transcription factor responsible for regulating osmolyte transporter genes 
during osmotic stress. They named this transcription factor TonE binding protein 
{TonEBP) because it specifically binds to, and activates the tonicity-responsive enhancer 
element of osmoprotective genes. The TonE mediates increased transcription of genes 
involved in the accumulation of compatible osmolytes by renal cells in response to 
hypertonicity. They described a consensus sequence for TonE and the trans-activating 
factor for the TonE cis-element as well as the TonEBP. The TonE/TonEBP pathway is 
known to mediate the tonicity responsive regulation of UT-A expression (Nakayama et al 
2000; Rim et al 1998), the glycine betaine transporter (BGTI), and the myo-inositol 
transporter (SMIT). Glycine betaine (betaine) is taken up via a specialised transporter 
(BGTl), hypertonicity raises the number of transporters by increasing their transcription. 
Yamauchi et al 1992 reported the cloning of a Na(+)- and Cl(-)-dependent betaine 
transporter that is regulated by hypertonicity. The sequence of a putative osmotic response 
element of the canine betaine transporter gene (TonE) was reported by Takenaka et a/ 
1994. The 5' region of the betaine gene contains an ORE that increases its transcription in 
response to hypertonicity. The sodium/myo-inosito1 cotransporter (SMIT)1 is a plasma 
membrane protein catalysing concentrative uptake of myo-inositol (MI) using the 
electrochemical gradient of sodium across the cell membrane (Kwon et al 1992). When 
cells in the kidney and brain are exposed to hyperosmolar salt concentrations 
(hypertonicity) they survive by raising the cellular concentration of myo-inositol. 
Transcription of the Sodium/myo-inositol cotransporter gene is markedly stimulated in 
response to hypertonicity leading to an increase in the activity of the cotransporter, which 
in turn drives the osmoprotective accumulation of myo-inositol. Rim et al 1998 identified 
five tonicity responsive enhancers in a 50 kilo base region upstream of the gene, TonEA, 
TonEB2, TonEC1, TonEC2 and Ton Ep. These five TonEs are reported to provide enough 
additive enhancer activity to account for greater than tO-fold stimulation of transcription in 
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response to hypertonicity. Sorbitol is produced via the reduction of D-glucose by the 
enzyme aldose reductase. Of the organic osmolytes, sorbitol has received special attention 
since it is one of the principle organic osmolyte accumulated in kidney renal medulla cells 
in response to hyperosmotic stress (Bagnasco et a/ 1986; Gullans et a/ 1988). Sorbitol 
therefore plays a beneficial role during anti-diuresis however it also appears to be 
detrimental in diabetes through its involvement in diabetic microvascular complications 
(Lee et a! 1995; Kador et a/1985; Greene et al 1985). Aldose reductase can therefore be 
considered as an osmoregulatory protein through its involvement in sorbitol production 
under hyperosmotic stress. ALR2 is present in a variety of tissues including kidney, liver, 
ocular lens and retina and in erythrocytes. The induction of ALR2 or ALR2 mRNA by 
hyperosmolality has been demonstrated in a variety of cells, which include cell lines 
derived from animal and humans. 
Tr!lnscrlption elements involved in osmotic regulation of ALR2 
Studies investigating the molecular mechanisms involved in the osmotic regulation of the 
ALR2 gene have involved cloning of the rabbit AR gene (rAR) and the promoter region 
and characterising its structure. These studies have demonstrated that the 5' regions' 
flanking the aldose reductase gene ( -3429 to base pair -192) contains osmotic response 
elements that increase transcription in response to hypertonicity (Ferraris et a/ 1994). The 
osmotic induction ratio is reduced from 9.4 to 2.0 when the sequence is reduced from 3221 
to 11 bp, suggesting that there are other cis-elements that may potentate the osmotic 
response. Daoudal et a/ 1996 cloned the AR cDNA from mouse kidney and reported the 
isolation of the mouse AR gene promoter. They identified a sequence within the promoter 
region that is required for enhanced activity in hypertonic conditions. The sequence is 
similar to the tonicity responsive element. A later report by the same group (Daoudal et a/ 
1997) reported the isolation of the mouse AR promoter. Using chloramphenicol 
acetyl transferase reporter constructs containing various 5' flanking regions of the mouse 
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AR gene in CVl cells, they identified a sequence spanillng base pairs -1053 to -1040, 
required for an enhancer activity in hypertonic compared with isotonic cell culture 
conditions. Ferraris et al 1996 reported an 11 bp osmotic response element essential for 
osmoregulation of the rabbit AR gene located 1105bp upstream of the transcription start 
site. This element shares sequence homology with TonE of the canine betaine transporter 
gene. Aida et a/1999 isolated the rat aldose reductase gene and examined the 5' flanking 
sequence for the presence of transcription regulatory element responsive to 
hyperosmolarity. Deletion of the promoter region of the aldose reductase gene up to -
1047bp abolished the transcriptional activation in response to osmotic stimuli in transient 
transfection experiments. In this study glucose was shown to be more effective than NaCl 
in induction of aldose reductase indicating the possibility of a glucose specific response 
mechanism. Studies have found the ORE sequence to be in the regulatory region of the 
vasopressin gene and in the 5'flanking sequences of cyclooxygenase-2 gene (COX-2) 
indicating that OREBP is the key protein responsible for activating genes involved in 
protecting cells from hyperosmotic stress. 
Ko et a! 2000 reported the purification and cloning of an osmotic response element binding 
protein. The protein contains a Rel-like DNA-binding domain and a glutamine rich 
transactivation domain, suggesting that it is a transcription factor. They demonstrated that 
OREBP interacts with the ORE and mediates the hyperosmotic expression of aldose 
reductase in vivo. Two positively charged arginine residues in the DNA binding domain of 
the OREBP interacting with guanine contact points may also be involved. Possibly two 
protein species interact with ORE's. Ko et a/1997 demonstrated that when the glutamine 
rich carboxyl end was deleted the hyperosmotic induction of the aldose reductase gene is 
suppressed, indicating that this portion of the protein is involved in the hyperosmotic 
transcriptional activation of ALR2 gene. Further confirmation that OREBP is the 
hyperosmotic transcription factor came from the translocation of cloned OREBP in 
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transfected cells from the cytoplasm to the nucleus upon hyperosmotic induction. This 
translocation occurs within 1 hour indicating that the signal of hyperosmolality is quickly 
relayed to the transcription factor. However, the induction of the ALR2 gene does not 
occur until 8-12 hours (Ko et a/2000). This is a considemble lag time between the arrival 
of the transcription factor into the nucleus and gene induction. There is an increase in 
OREBP mRNA after hyperosmotic challenge therefore it is possible that an increase in the 
amount of OREBP is required through transcription and translation before hyperosmotic 
gene induction can be mediated. A signal transduction study has also shown that the p38 
and the c-Jun N-terminal kinase (SAPK/JNK) are not necessary for the transcriptional 
regulation of the ALR2 promoter through ORE (Kultz et a/ 1997). 
Identification of transcription elements within 5' ALR2 region 
Several groups have identified the osmotic response elements (OREs) of ALR2 and its 
promoter region (Daoudal et a/ 1997; Ferraris et a/ 1996; Ko et a/ 1997; Ferraris et a/ 
1994). AR transcription is regulated by a promoter that contains diverse regulatory 
elements. Recent reports describe the involvement of two ALR2 promoter cis-elements, 
the osmotic response element (ORE) (Iwata et al 1996; Ferraris et a/1996; Daoudal et a/ 
1997; Ko et a/ 1997), and the aldose reductase enhancer element (AEE) in regulating 
osmotic response (lwata et a/ 1997). The ORE and TonE share a putative consensus 
sequence NGGAAA WDHMC(N) and are responsible for mediating expression of these 
genes (Ferraris et a/ 1999). Ruepp et a/ 1996 reported the identification of a putative 
functional ORE located 3. 7kb upstream of the transcription start site of the human aldose 
reductase gene. Specifically, they reported two putative osmotic response elements, pseudo 
OREd present at position -3834 to -3819 and OREp present at position -3669 to -3654. 
However, the same group later confirmed that the results came from a cloning artefact and 
the site could not be confirmed (Ko et a/ 1997). It was also reported that an osmotic 
response region of the human ALR2 gene mediates its induction during hypertonic stress 
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(Ko et a/1997; Wang et a/1997). This was found this to be within a 132bp region located 
1325 bp upstream of the transcription start site of the human ALR2 gene. They have shown 
that hyperosmotic induction of human AR gene is mediated by three sequences 
homologous to TonE of the canine betaine transporter gene and to the ORE of the rabbit 
AR gene. These osmotic response elements located within this 132 bp region situated in 
the 5' flanking sequence of the gene were named;- OreA, OreB and OreC, (figure 13). The 
132bp region was found to contain three sequences that resemble part of TonE 
(TGGAAAAGTCCA) of the canine betaine transporter gene (Takenaka et al 1994) and 
the ORE (CGGAAAATCAC) of the rabbit AR gene (Ferraris et a/1996). ORE-A (-1230 
to -1220) and ORE-C (-1157 to -1148) are in the same orientation as TonE, ORE B (-1188 
to - 1198) is in the opposite direction. 
ORE-A ORE-B 
TTACATGGAA AAATATCTGG GCTAGTCTGT TCTGTATAAA TTTTTCCAGG 
ORE- C 
AGGGAGCACT TTTAAAGAAA GCACCAAATG GAAAATCACC GGCATGGAGT 
APl - D 
TTAGAGAGAC CTGGTGCTTG AGTCACTACC AG 
TonE 
ORE 
ORE-A (-1230 to - 1220) 
ORE- B (-1188 to - 1198) 
ORE-C (-11!57 to -1148) 
APt (-1111 to -t un 
(TGGAAAAGTCCA) 
(CGGAAAATCAC) 
(TGGAAAAAT AT) 
(TGGAAAAA TTT) 
(TGGAAAATCA) 
(TGAGTCA) 
Figure 13. Nucleotide sequence of the·l32-bp fragment containing three Ton-E like 
sequences. OreA, OreS and OreC are highlighted in red and are indicated by A, B 
and C respectively. OREA and OREC are in the same orientation as TonE, and OREB is 
in the opposite orientation. The region indicated by D is an Ap-1 consensus sequence 
(adapted from Ko et a/ 1997). 
The ALR2 ORE is most similar to TonE and to the rabbit AR ORE and it contributes most 
to the osmotic induction of transcription. The TonE element is functional in both 
orientations. These ORE's interact with a putative transcription factor under hyperosmotic 
induction and osmotic response function is reduced when any one of these three sequences 
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is mutated, suggesting that these sequences have to work in concert to provide maximum 
transcription induction. The ORE sequence differs from the NFKB binding sequence by 
one base pair. Iwata et a/1999 reported a significant induction of ALR2 by TNF-a, which 
is mediated by NFKB binding to ORE. Deletion or mutation of this element showed a 
significant effect on the response of the ALR2 promoter to TNF-a and hyperosmotic 
stress. 
Polymorphisms within AR promoter region-OREs 
To date no polyrnorphisms have been identified within the ORE gene sequences located in 
the 5'ALR2 promoter region near to the aldose reductase (CA)n microsatellite repeat 
region. A study carried out by Heesom et a/ 1997 was designed to determine whether 
polymorphisms within the ORE's may play a role in the development of diabetic 
complications. A total of 12 patients with T1DM were selected and the ORE's region was 
sequenced for each patient. No polyrnorphisms were found in any of the patients studied 
indicating that the genetic lesion lies within the coding region of the ALR2 gene. 
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Extracellular stress 
hyperosmotic/hypertonic 
Cytosol 
Transcription 
factors 
Others 
/ ~ ORE BP 
5' 
cis-
element 
MEKl __.. 
Nucleus 
toREBP 
~k" 
Transcription and 
translation 
p38 kinase 
Enhancer 
element ORE A, B. C 
tAR mRNA 
• 
tALR2 protein 
t Polyol pathway 
tsorbitol 
1235bp ~ 
ALR2 ~ 
expression 
Figure 14. Sequence of intracellular events following extracellular 
stress (hypertonicity/hyperosmotic) leading to OREBP/ORE binding in 
the 5'ALR2 promoter region and the resultant induction of ALR2 mRNA 
synthesis and polyol pathway activation. 
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Glucose-specific regulation of aldose reductase 
Pathophysiological pathways resulting from hyperglycaemia include the activation of the 
polyol pathway, non-enzymatic glycation of proteins and oxidative stress which probably 
synergise through their ability to activate the MAPK cascade leading to phosphorylation of 
transcription factors. This glucose induced transduction pathways lead to alterations of 
gene expression resulting in altered cellular phenotype, cell division, or increased 
production of extracellular material (Tomlinson 1999). Henry et al 1993 demonstrated 
human retinal pigment epithelial cells having accelerated and exaggerated production of 
sorbitol and depletion of myo-inositol upon exposure to 20mM glucose. Aida et at 1999 
suggested the presence of a glucose specific mechanism of induction in addition to that by 
NaCl. They showed that glucose was more effective than NaCl in induction of aldose 
reductase. Portois et a/1999 identified a glucose response element in the promoter region 
of the rat glucagon receptor gene, which contained two 'E-boxes' CACGTG AND 
CAGCTG. This domain exhibited threshold like activity, with low activity below 5 mM 
glucose and maximal activation as of 10 mM glucose. More recently, Henry et al 2000 
tested the hypothesis that pathophysiological levels of glucose regulate aldose reductase 
(ALR2) gene expression, protein production and activity in human retinal pigment 
epithelial (RPE) cells in vitro. They detennined that elevations in ambient glucose result in 
greater metabolism of glucose through glycolysis and polyol metabolism. Hyperosmolar 
stress itself was not a necessary determinant of ALR2 mRNA, ALR2 protein, or ALR2 
protein activity in cells that fonn the outer blood-retinal barrier. They note that increased 
facilitative glucose transport or increased glucose metabolism is required for glucose 
specific and nonosmotic regulation of ALR2 in the RPE cell in vitro. To date however, no 
such specific glucose response element has been found in the region near to the ALR2 
gene. 
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Glucose specific ALR2 gene expression in TlDM subjects 
Elevated levels of ALR2 protein have been shown to occur in neutrophils (Dent et a/ 
1994), erythrocytes (Hamada et a/l99I[a and b]; Nishimura et a/1994), and mononuclear 
cells (Ratliff et a/ 1996) isolated from patients with diabetic complications. Studies have 
shown that the mRNA levels of ALR2 in peripheral blood mononuclear cells (PBMC's) 
were increased in patients with TIDM and diabetic kidney disease than in TIDM patients 
without nephropathy, indicating that the degree of ALR2 gene expression modulates the 
risk of developing nephropathy (Shah et al I 997). Patients with diabetic microvascular 
complications have also been shown to have increased enzyrnatic activity of ALR2 as well 
as increased amounts of the protein compared with TIDM subjects with no complications 
(Hamada et a/ 1993; Maeda et a/ 1999). Hamada et a/ 1993 reported that diabetics who 
developed severe complications in less than 20 years had the highest red blood cell (RBC) 
ALR2 activity. In contrast, long standing diabetics, with no complications, had the lowest 
RBC ALR2 activity. It has also been demonstrated that ALR2 mRNA levels are induced 
under hyperglycaemia and hypertonicity. Hodgkinson et a/ 200 I reported the quantitation 
of ALR2 and SORD mRNA in cultured neutrophils from TlDM patients and normal 
controls using the ribonuclease protection assay (RP A). The study found significantly 
increased levels of ALR2 mRNA with increasing D-glucose concentrations in TlDM 
subjects with nephropathy compared to TIDM patients without nephropathy and normal 
controls. The mRNA expression of SORD was also significantly increased in TlDM 
nephropathy patients exposed to hyperglycaemic levels of D-glucose compared to 
uncomplicated TIDM patients and controls. Hamaoka et a/1999 used AR-transfected HIT 
(hamster derived B-cell line) cells, which showed enhanced metabolic activity in the 
polyol pathway. In this study when ALR2 was over-expressed these cells exhibited typical 
features of apoptosis, including a decrease in intracellular NADPH and defective activation 
ofNFkB. 
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Aims of thesis 
To investigate the genetic susceptibility to microvascular disease in subjects with DM. 
This will be achieved by studying polymorphisms (genetic variants) in candidate genes in 
discrete sporadic population of TlDM patients (n-300) with or without microvascular 
complications, as well as United Kingdom family trios (Diabetes UK- Warren 3 
collection), and a collection ofT2DM subjects of Southern Indian origin. 
• In the frrst instance, polymorphisms in the aldose reductase (ALR2) gene and the 5' 
flanking regions will be studied in these populations. This will include an intragenic 
polymorphism at Intron 8 A(+ll842)C of the ALR2 gene, a C(-106)T polymorphism 
in the promoter region of the aldose reductase gene, and the 5'ALR2 (CA)n 
microsatellite polymorphism. The Transmission disequilibrium test (TDT) will be used 
to measure the transmission of the 5' ALR2 microsatellite from parents to affected 
probands with diabetic nephropathy. 
• Genetic markers for hypertension at position D17S934 proximal to the ACE gene will 
be studied to determine any association with diabetic nephropathy, retinopathy or 
neuropathy. 
• A study of the mitochondrial polymorphism Mt5178A/C will also be carried out in the 
British Caucasoid population. 
• The study also aims to test the hypothesis that pathophysiological levels of glucose 
specifically regulate the osmotic response elements situated in the 5 'upstream region of 
the ALR2 gene in TlDM patients with microvascular complications compared to 
TlDM controls and normal healthy controls. 
This investigation aims to be the first comprehensive study of the polymorphisms in the 
ALR2 gene and its promoter region in case-control, transracial and family studies. It also 
aims to apply functional protein studies of ORE to determine any associations with 
diabetic microvascular disease. 
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Ethical Approval 
For the study of TlDM subjects of British Caucasoid ongm, local research ethics 
committee approval had been obtained from the South and West Devon Health Authority, 
Devon, U.K. Written informed consent was also obtained from all subjects at the time of 
blood collection prior to inclusion into the study. Ethical approval for research studies 
using the T2DM subjects of Southern Indian origin was carried out independently by Dr 
Vijay Viswanathan, Madras, India. The British Diabetic Association (BDA) Warren 
repository has previously obtained ethical approval from all participating centre's and was 
also reviewed by a multi-centre Research Ethics Committee .. 
Subjects 
During the course of this thesis several subject groups were investigated, the profiles of 
which are reviewed here. A large collection ofTlDM subjects of British Caucasoid origin, 
a family trio collection where the affected proband had TlDM and diabetic nephropathy, 
and a collection of T2DM subjects of Southern IndiaruDravidian origin are included. 
British Caucasoid TlDM coUection 
DNA samples were collected from over 600 unrelated British Caucasoid patients with 
grandparents born in the UK, diagnosed as having TlDM as defined by the National 
Diabetes Data Group 1979, who had attended the diabetic clinic of Consultant 
Diabetologist; Dr B. A. Millward. Venous blood samples were collected from the Diabetic 
Clinic's at Derriford Hospital in Plymouth, Kings College Hospital and Guys University 
College in London and the Renal Unit at Dulwich Hospital, London. Basic patient 
information such as date of biqh and ethnic origin was obtained from patients' medical 
notes and by patients answering a short questionnaire. The progress of patients with regard 
to their development of diabetic complications was monitored during the progression of 
their disease. Patients were monitored when they arrived to clinics by Dr Millward and 
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diabetic research nurses, Caroline Dunster and Karen Holdsworth-Cannon (see 
acknowledgements) who updated the patient proforma's accordingly. At the diabetes clinic 
both physical and biochemical parameters were stringently recorded, enabling patients to 
be classified confidently in accordance to their progression of diabetic complications. 
Fundoscopy was performed by both a diabetologist and ophthalmologist. This was carried 
out routinely and according to the criteria defmed by the National Diabetes Data Group 
1979). 
Classification criteria of TIDM subjects according to microvascular disease 
Dr Mill ward also carried out the classification of patients for this study according to their 
diabetic microvascular complications. The patients were classified at the time of blood 
sampling in accordance to their onset and progression of microvascular complications as 
follows: 
TIDM uncomplicated control subjects (n=66) 
Patients were diagnosed as having TIDM before the age ot 40 years and a sufficient 
duration of disease of at least 20 years. Patients remain free of retinopathy (fewer than 5 
dots or blots per fundus), and had normal levels of albumin excretion rate (AER) defined 
as <20j.Lg/min in an overnight sample on at least two consecutive assessments or urine 
Albustix® (Bayer, West Haven, CT) negative on three consecutive occasions over 12 
months. Patients also showed no signs of overt or autonomic neuropathy. There were 66 
uncomplicated diabetic controls included in this study and basic demographic 
characteristics of this patient group are shown in table 6. 
TIDM retinopathy subjects (n=44) 
Patients with TIDM and have retinopathy defmed as more than 5 dots or blots per fundus, 
hard or soft exudates, new vessels or flourescein angiographic evidence of maculopathy or 
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previous laser treatment for preproliferative retinopathy, and maculopathy or vitreous 
haemorrhage. Fundoscopy was performed by both a diabetologist and ophthalmologist, 
and the tests for presence of neuropathy was also performed and patients showed no signs 
of neuropathy. None of these patients had proteinuria (urine Albustix® negative on 3 
consecutive occasions over 12 months). A total of 44 subjects with diabetic retinopathy 
were included in this study for which basic demographic characteristics are shown in table 
6. 
TlDM neuropathy subjects (n= 18) 
Patients with TIDM and classified as having neuropathy ifthere was any clinical evidence 
of overt peripheral or autonomic neuropathy. Symptoms of peripheral neuropathy included 
the following features; a) symptoms of pain, numbness or parasthesia in the feet and/or 
hand, b) sensory signs such as loss of vibmtion sense (assessed using a tuning fork), light 
touch or pin-prick, and temperature (using warm and cold stimuli), c) loss of flexes in the 
legs, d) evidence of past or present neuropathic foot ulceration. Autonomic neuropathy was 
defined if there was evidence of postural hypotension, gustatory sweating, a previously 
documented Charcot joint, or loss of beat to beat variation on an electrocardiogram (ECG). 
None of these patients had other causes for neuropathy. A total of 18 subjects with diabetic 
neuropathy were included in this study for which basic demogmphic characteristics are 
shown in table 6. 
TlDM nephropathy and retinopathy subjects (n=30) 
Patients have had TIDM for at least 10 years and have persistent proteinuria (urine 
Albustix® positive on at least three consecutive occasions over 12 months or three 
successive total urinary protein excretion rates >0.5g/24hrs) in the absence of haematuria 
or infection. In all cases diabetic nephropathy was associated with diabetic retinopathy. A 
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total of 30 diabetic subjects with nephropathy and retinopathy were included in this study 
and basic demographic characteristics are shown in table 6. 
TlDM retinopathy and neuropathy subjects (n=24) 
Patients with TlDM and have retinopathy defmed as more than 5 dots or blots per fundus, 
hard or soft exudates, new vessels or flourescein angiographic evidence of maculopathy or 
previous laser treatment for preproliferative retinopathy, and maculopathy or vitreous 
haemorrhage. Patients also showed a positive result for presence of neuropathy (see under 
neuropathy subgroup). A total of 44 subjects with diabetic retinopathy and diabetic 
neuropathy were included in this study, basic demographic characteristics are shown in 
table 6. 
TlDM full house complication subjects (n=62) 
Patients with TlDM and persistent proteinuria (urine Albustix® positive on at least three 
consecutive occasions over 12 months or three successive total urinary protein excretion 
rates >0.5g/24hrs) in the absence of haematuria or infection. In association patients have 
retinopathy as defined as more than 5 dots or blots per fundus, hard or soft exudates, new 
vessels or fluorescein angiographic evidence of maculopathy or previous laser treatment 
for preproliferative retinopathy, and maculopathy or vitreous haemorrhage. Patients also 
have overt peripheral or autonomic neuropathy (see neuropathy subgroup). A total of 62 
TlDM subjects with full house complications were included in this study and basic 
demographic characteristics are shown in table 6. 
Healthy adult control subjects (n=13) 
This control group consisted of fresh venous blood taken from normal healthy adult British 
Caucasoid subjects, with no history of TlDM or T2DM or other autoimmune or renal 
diseases. This control group was used only for the protein experiments requiring fresh 
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whole blood samples. A total of 13 healthy adult subjects were included in this study and 
basic demographic characteristics are shown in table 6. 
Cord blood control subjects (n=l20) 
The normal control group for the genetic studies were taken at random from a bank of cord 
bloods collected at the time of normal healthy obstetric delivery from the labour ward, 
Derriford Hospital, Plymouth. A total of 120 cord blood controls were used, and as the 
only data available at the time was the subjects gender, limited distribution demographics 
could be established as shown in table 6. 
Subjects excluded from study 
From the large collection of over 600 TlDM subjects collected, 244 fitted the criteria for 
the study with confidence and were included in the investigation. Many subjects had to be 
excluded from the study for reasons as described here. Patients who were diagnosed as 
having TlDM but pre-insulin treatment were not included in this study, as well as patients 
who have had diabetes for less than 20 years and showed no signs of complications. This 
was because there is a possibility that some will develop complications, but as yet we do 
not know which. Patients were also excluded from the study if they did not completely 
satisfy the stringent criteria for patient groups or if insufficient data was available or 
inadequate to confidently classify them. Subjects were excluded from the study if urinary 
tract infection, cardiac failure or renal vasculitis were present. Subjects were also excluded 
from the study if they were receiving anti-hypertensive treatment. If DNA quality after 
extraction was poor, an attempt was made to re-bleed patients, however in some cases 
patients bad to be excluded as re-bleeding was not possible. 
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Clinical characteristics ofTlDM and normal control subjects 
Comparison of sex distribution using Chi-squared test showed no significant difference in 
sex distribution between cord blood controls and TIDM subject groups, or healthy adult 
controls and TIDM subject groups. The Chi-squared test was also applied to compare 
whether there is a statistically significant difference in the distribution of sex between 
study groups, there were no significant differences found. 
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Subject groups n M:F Age at time Age at Duration of 
of study diabetes onset diabetes 
(years) (years) 
T1 DM subjects 244 115:129 NA NA 
• Uncomplicated 66 26:40 46.33 ,!15.59 16.94 ± 10.03 31.35 ± 9.04 
(20-79) (1-42) (20-55) 
• Retinopathy 44 20:24 48.16 ,!14.16 20.07 .:!: 10,01 30.0.:!: 11.1 
(24-78) (1-45) (13-57) 
• Neuropathy 18 10:8 50.89 ,!13.79 25.4 ± 11.79 27.3 ± 9.96 
(24-68) (1-48) (10-44) 
• Nephropathy and 30 13:17 46.57 ,!17.38 16.5 ± 11.8 32.03 ± 
Retinopathy (19-87) (1-56) 12.92 
(13-61) 
• Retinopathy and 24 15:9 51.63 ,!13.26 22.0 ± 10.6 31.63 ± 8.84 
Neuropathy (29-79) (5-38) (19-53) 
• Full House 62 31:31 49.18 ,!13.59 18.24 ± 10.8 31.92 ± 9.91 
(19-77) (1-54) (7-52) 
Non-diabetics 
• Healthy adult 13 7:6 NA NA NA 
• Cord bloods 120 53:67 NA NA1 NA1 
Table 6. Demographic characteristics of British Caucasoid subjects with TlDM and 
normal healthy control subjects, classified in accordance to onset of diabetic 
microvascular complications. The results are expressed as mean values +/- standard 
deviation together with the range in parentheses. All diabetic subjects had TlDM as defined 
by the National Diabetes Data Group 1997 as previously described. 
1 Not applicable to controls as taken from a collection of cord blood samples. 
+1- Plus or minus standard deviation. 
M:F Male to female ratio. 
NA Not applicable. 
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British Caucasoid TlDM family trio coUection 
A United Kingdom resource of DNA was established by the British Diabetic Association 
(BDA), (now Diabetes U.K.), in order to facilitate the investigation of the genetic 
susceptibility to diabetic nephropathy in T ID M. The project involved the participation of 
seven research establishments throughout the United Kingdom. Participating 
establishments included Belfast, Edinburgh, Newcastle, Manchester, London, Plymouth 
and Birmingham. 
This study used blood collected from 172 British Caucasoids with T1DM and diabetic 
nephropathy. Blood was also collected from the parents of these individuals creating a trio 
pedigree of two parents and an affected proband. Where both parents were not available, 
blood was collected from siblings of the proband so as to facilitate the generation of 
parental haplotypes. In total 516 subjects ( 172 pro bands and 344 non-diabetic first-degree 
relatives) were included in this diabetic nephropathy family trio collection. 
The subject's included into the study were British Caucasoid with grandparents born in the 
UK, having TlDM diagnosed under the age of 31 years and requiring insulin from 
diagnosis. Subjects showed no history of recurrent urinary tract infection, cardiac failure or 
renal vasculitis. Patients in whom renal imaging (ultrasonography or intravenous 
urography) showed any abnormality were excluded from the study. The diagnosis of 
diabetic nephropathy was made at the time of venesection, on the following basis; 
• Development of persistent" proteinuria~ 10 years after diagnosis of diabetes. 
• Presence ofhypertensionc at or after the onset of persistent proteinuria. 
• Presence of diabetic retinopath/ at the time of persistent proteinuria. 
• Persistent proteinuria is defined as proteinuria present continuously for >6 months. 
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b Proteinuria can be defined in various ways including: >0.5g protein/24 hours; >300mg 
albumin I 24 hours; >200 micrograms albumin I min on timed overnight collection; urinary 
Albumin/ Creatinine Ratio >35mg/ml; dipstick positive clinic urine testing. 
c Hypertension is defmed as blood pressure >135185 (JNC VI guidelines) and/or treatment 
with antihypertensive agents. 
d Presence of diabetic retinopathy includes any degree of disease (background, pre-
proliferative & proliferative) on routine clinical examination. 
Clinical characteristics of family trio coUection 
Subject information was not available and consequently subject demographic 
characteristics cannot be calculated for the Diabetes UK-Warren repository TIDM family 
trio collection. 
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Southern Indian T2DM collection 
Blood samples were collected from a population of 62 Indian patients with T2DM (non-
insulin dependent diabetes mellitus). The blood was collected and the DNA extracted by 
Dr Vijay Viswanathan and eo-workers at the Diabetes Research Centre, Chennai, India. 
The samples were then delivered on dry ice in 1.5ml Eppendorf tubes to our laboratory 
along with comprehensive clinical data. The recorded clinical data included age, sex, 
evidence of family history of diabetes and subjects diabetic complications, which are 
summarised in table 7. 
Classification criteria of T2DM subjects according to microvascular disease 
Dr Vijay Viswanathan carried out classification of patients for this study according to their 
diabetic microvascular complications. The patients were classified according to their 
microvascular complications at the time of blood sampling as follows: 
T2DM uncomplicated controls (n= 28) 
Patients were diagnosed as having T2DM and were normoalbuminuric without 
retinopathy. Out of the 28 subjects included in this group 17 had a positive family history 
of diabetes and 10 had no family history of diabetes and I subject did not know. A total of 
28 uncomplicated diabetic subjects were included in this study and basic demographic 
characteristics are shown in table 7. 
T2DM nephropathy and retinopathy subjects (n= 32) 
Patients were diagnosed as having T2DM and subjects tested positive for proteinuria and 
fundoscopy also revealed retinopathy. Out of the 32 subjects included in this group 18 had 
a positive family history of diabetes and 16 had no family history of diabetes. A total of 32 
nephropathy and retinopathy diabetic subjects were included in this study and basic 
demographic characteristics are shown in table 7. 
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Healthy adult control subjects (n=43) 
This control group consisted of normal healthy adult Southern Indian subjects of whom 9 
had a positive family history of diabetes and 34 had no known family history of diabetes. 
A total of 43 healthy adult subjects were included in this study but no record had been 
taken of subject gender, therefore no subject demographic analysis could be made. A total 
of 43 healthy adult control subjects were included in this study. 
Clinical characteristics of T2DM and normal control subjects 
Comparison of sex distribution using chi-squared test showed no significant difference in 
sex distribution between T2DM subject groups (x.2 = 0.2, p= 0.65). As there was no record 
of control subjects gender comparisons could not be made between this group and T2DM 
subjects. 
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T2DM subjects Non-diabetics 
Uncomplicated Nephropathy and Healthy adult 
retinopathy 
n 28 32 43 
M:F 15:13 19:13 1DNA 
Age at time of 55 :!;10.11 53.8 :!;8.94 38 +6.3 
study (27-76) (37-68) (30-58) 
Age at diabetes 42.07 :!: 11.26 42.34:!: 8.46 2NA 
onset (years) (15-60) (26-57) 
Duration of 13.11:!: 7.45 11.81:!: 5.38 2NA 
diabetes (years) (2-29) (3-25) 
Table 7. Demographic characteristics of Southern Indian subjects with T2DM 
and normal healthy control subgroups classified in accordance to onset of 
diabetic microvascular complications. The results are expressed as mean values+/-
standard deviation together with the range in brackets. All patients had T2DM as 
defined by the National Diabetes Data Group 1997 as previously described. 
+1- Plus or minus standard deviation. 
M:F Male to female ratio. 
NA Not applicable. 
DNA Data not available 
1 Data regarding subjects gender was not recorded. 
2 Not applicable to controls as taken from a collection of healthy adults. 
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Blood sampling 
Trained phlebotomists and research nurses (see acknowledgements) carried out all blood 
sample collection. Venupuncture was performed using a BD-Vacutainer™ blood collection 
system (Becton Dickinson Vacutainer Systems, Oxford, U.K.). For DNA extraction 5-10 
ml of peripheral venous blood was collected into 6.0-ml BD Vacutainer Plus™ whole 
blood tubes containing potassium ethylene diarnine tetra-acetic acid (K2EDTA, spray dry, 
I 0.8mg). The blood was subsequently transferred to BD Falcon™ sterile polypropylene 50-
ml conical centrifuge tubes (Becton Dickinson, Plymouth, UK) and stored at -20°C, prior 
to subsequent DNA extraction. For cell culture 20-rnl of peripheral venous blood was 
collected into 6.0-ml BD yacutainer Plus™ Sodium Heparin whole blood tubes. These 
samples were then directly transferred to sterile 50-ml BD Falconn.4 tubes and processed 
immediately. Cord blood samples were collected into heparin syringes and transferred to 
sterile 50-ml BD Falcon ™ tubes and stored at -20°C, prior to DNA extraction. 
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Purified tap water was obtained usmg an Elix Water Purification System unit and 
Polyethylene Reservoir (Millipore Ltd, Watford, UK) and was used to make up all stock, 
general purpose and specialist solutions. Sterile water (Baxter Healthcare, Thetford, UK) 
was used to make amplimer dilutions, restriction digest reactions, and used for PCR 
applications. 
Reagents 
All general-purpose reagents used were analytical grade or equivalent and were obtained 
either directly from the manufacturers or through a local supplier listed in table 8. Super 
Taq polymerase and 10 x PCR buffer was purchased from HT Biotechnology Ltd 
(Cambridge, UK). Ultrapure dNTP set 2-Deoxynucleoside 5'-triphosphates (dNTP's), 
radioactivity (r2P ATP), and Ready-To-Go™ T4 Polynucleotide kinase were purchased 
from Amersham Pharmacia Biotech L TD (Buckinghamshire, UK). Quik-Precip™ was 
purchased from Edge BioSystems Inc. (Oxon., UK). Nucleon® BACC2 DNA extraction 
kits for whole blood were purchased from Nucleon Biosciences (Lanarkshire, Scotland, 
UK), and Wizard® PCR Preps DNA Purification System was purchased from Promega 
(Southampton, UK). Restriction endonucleases and incubation buffers were purchased 
from New England BioLabs Inc. (Herts, UK), and Roche Diagnostics LTD (East Sussex, 
UK) respectively. Perbio Science LTD (Chester, UK) supplied Coomassie® Plus Protein 
Assay Reagent Kit. Reagents used for the Electrophoretic Mobility Shift Assay which 
include T4 polynucleotide kinase lOX buffer and T4 polynucleotide kinase were supplied 
by Promega (Southampton, UK). Custom oligonucleotide synthesis was carried out by 
MWG-Biotech UK Ltd (Milton Keynes, UK). 
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Reagents/ chemical/ solution Supplier 
Redivue™ [Gamma 32P]-ATP (3000Ci/mmol), Amersham Pharmacia Biotech UK Limited, 
Stop solution, l.25ml. Buckinghamshire, UK. 
Kodak X-Omot™ Scientific Imoging Film, X-roy Anochem L TD, Beds, UK. 
developer, Rapid fixer 
Sterile water Boxter Heolthcore, Thetford, UK. 
2'¥o Bisocrylomide, 40'¥o Acrylomide Bio-Rod Laboratories, Hemel Hempstead, UK. 
Acetic acid, ethylenediamine tetra-acetic acid BDH Lob Supplies, Merck Limited, Poole, UK. 
(EDTA), Glycerol, Hydrochloric acid, 
Magnesium Chloride, Maleic acid, Orthoboric 
acid, Sodium Chloride, Sodium citrote, Sodium 
dodecyl sulphate, Sodium Hydroxide, Sucrose, 
Tris (hydroxymethyl) ominomethone 
Orange G Fisher Scientific, Loughborough, UK 
LymphoprepTM, Fetal Calf Serum (FCS), Life Technologies Ltd, Paisley, UK. 
Dulbecco's Modified Eagles Medium (DMEM), L-
glutamine, Penicillin/Streptomycin, Phosphate 
Buffered Saline (PBS), Roswell Park Memorial 
Institute 1640 (RPMI) 
Sequogel concentrate, Sequogel diluent and Notional Diagnostics, Flowgen Instruments, 
Sequogel buffer Staffordshire, UK. 
Chloroform, Ethanol, Methanol, Industrial Rothburns Limited, Walkerburn, UK. 
Methylated Spirit 
DNA molecular weight marker XIV (lOObp Roche Diagnostics Ltd. East Sussex, UK 
ladder), Agorose MP (multi purpose agarose) 
Nucleon® DNA extraction kits Scotlob, Lanarkshire, Scotland, U.K. 
Ammonium persulphote (APS),TEMED, Sigmo Chemicals, Poole, UK. 
Formamide, 3'¥o Acetic Acid stop both, Trypan 
blue, Xylene cyonol, Ethidium bromide 
Table 8. Specialist reagents listed in accordance to the manufacturer from 
which items were purchased. 
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General purpose, glass and plastic ware 
Soda-glass test tubes, Falcon TM 250-ml polystyrene tissue culture flasks, Falcon TM 
polystyrene round bottom tubes, Falcon™ 50-ml polypropylene conical tubes and 
serological pipettes were all supplied by Becton-Dickinson (Oxford, UK). Disposable 
polystyrene cuvettes were purchased from Sigma Chemical LID (Poole, UK), and filter 
paper used for polyacrylamide gel support and drying was purchased from Heto 
Laboratory Equipment (Surrey, UK). Gilson liquid handling pipettes and tips were 
purchased from Anachem (Beds. U.K). 
Specialist laboratory equipment 
This study employed the use of a range of specialist laboratory apparatus which included 
the MJ Research PTC-200 DNA Engine (MJ Research, Massachusetts, USA), Fluor-S 
multi-imaging systems and Image analysis software (Bio-Rad, UK), Ultra-Violet 
transilluminator and UVP-LabWorks™ Image acquisition and analysis software (Ultra-
Violet Products, Cambridge, UK), and y scintillation counter 5010 Cobra 10 (Packard 
Biosciences, UK). Also employed were a range of general-purpose laboratory apparatus 
which included a CK40-F Olympus Inverted Microscope (Jencons Scientific LID, 
Bedfordshire, UK), Priorclave PSILAC/EVIOO (PriorClave LID, London, UK), UVllOI 
Biotech Photometer (Cecil, UK), Cecil 5500 spectrophotometer (Cecil, UK) and a Heraeus 
Sepatech Biofuge 15/15 I 13/13 (Heraeus Instruments GmbH, Germany). For tissue culture 
work a Microflow Biological Safety Cabinet (Steriliser and Airflow Service Care, 
Hampshire, UK) and a Nuaire™ Water-Jacketed TS autoflow C02/02 incubator (Indis 
Scientific, Glasgow, UK) were used. For protein mobility shift assays the Sequigen® GT 
Nucleic Acid Electrophoresis Cell (Bio-Rad, UK), and Protean® II XI Cell (Bio-Rad, UK) 
were used with a PowerPac 3000 (Bio-Rad, UK). 
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All solutions, and all glassware and plasticware used in the techniques of DNA and protein 
analysis were autoclaved at a temperature of 121 °C, and pressure of 15 p.s.i for 30 minutes 
in a steam autoclave (PriorClave Ltd, London, UK). 
DNA extraction 
Extraction of high molecular weight genomic and mitochondrial DNA from peripheral 
blood leukocytes, was carried out employing the Nucleon® DNA extraction method and 
also a salting out method as described below. 
DNA extraction using Nucleon® BACC2 method 
The principle method utilised for DNA extraction employed the Nucleon® BACC2 (whole 
blood and cell culture) genomic DNA extraction kit (Scotlab Ltd, Lanarkshire, UK) 
according to manufacturers protocol (figure 15). The kit extracted both genomic and 
mitochondrial DNA in the same process. The kit provided 'Nucleon® Reagent B' (400mM 
Tris-HCL pH 8.0, 60mM EDT A, l50mM NaCI, 1% SDS), sodium percblorate and 
Nucleon® silica resin. In addition a 'Nucleon® Reagent A' (lOmM Tris-HCL, 320mM 
sucrose, 5mM MgCh, 1% Triton X-100,- adjusted to pH 8.0 using 40% NaOH and 
autoclaved) stock solution was used which was made up in house. 
Stored frozen peripheral venous blood samples were thawed at room temperature, and an 
aliquot of 7.5 ml was transferred to a 50-ml Falcon® tube (Becton Dickinson, Oxford, 
UK). To the sample a four-times volume of 'Nucleon® Reagent A' was added and mixed 
either by band or on a Luckbam RIOO/TW Rotatest shaker for 4 minutes. The 
blood/'Nucleon® Reagent A' solution was then centrifuged at 1300 x rpm for 4 minutes 
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using a MSE Mistral 1000 centrifuge and the supematant containing lysed red cells was 
separated from the pellet and discarded. The PBMC pellet was then re-suspended in 2ml of 
'Nucleon® Reagent B' (400mM Tris-HCL pH 8.0, 60mM EDTA 150mM NaCI, 1% SDS) 
as supplied, and incubated at 37°C for 10-15 minutes, enabling membrane disruption to 
occur. The suspension then was transferred to a 15ml Falcon® tube and 5001J.l of sodium 
perchlorate was added and mixed by gentle inversion. To extract the DNA, 2ml of ice cold 
chloroform (-20°C) was added and mixed to emulsify the two phases, which were then 
separated by centrifugation at 1300 x rpm for 3 minutes. After centrifugation, 3001J.I of 
Nucleon® silica suspension was added to the interface of the two layers by careful 
pipetting prior to a further centrifugation at 1300 x rpm for 3 minutes. The upper aqueous 
phase containing the DNA was then carefully transferred to a fresh tube, ensuring the 
interphase with silica resin and the underlying organic phase were not disturbed. 
Precipitation of DNA then carried out by inverting gently with 2-x volume of I 00% ice-
cold (-20°C) ethanol (Rathburns Ltd, U.K.). A sterilised glass pipette with a sealed tip was 
used to hook out the precipitated DNA and transfer it to a sterile Eppendorf tube. The 
DNA was then washed in 70% ethanol prior to dilution in 5001J.I ofTE buffer (lOmM Tris 
pH 7 .6, 0.1 mM EDT A pH 8.0) over 24 hours. 
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7.5ml Blood + K2 EDTA 
Add 40ml 
Reagent A 
Mix for 4 min at room 
temperature 
Centrifuge at 1300 x 
rpm for 4 min. 
Discard supernatant 
't 
~Pellet 
t 
Add 2ml Reagent B to 
pellet and vortex to re-
suspend 
t 
Incubate at 37°C for 
15 minutes. 
Transfer to 15ml falcon 
t 
Add 500J.11 Na Percforate 
and mix at room 
temperature for 15 min. 
Chapter 3: Subjects. materials and methods 
Add 2mls ice cold Chloroform 
& shake for 10 min. 
Centrifuge at 1300 x rpm for 1 min. 
Aqueous phase 
Orqanic phase 
Add 300J.ll Nucleon Silica Suspension. 
Centrifuge at 1300 x rpm for 3 min. 
DNA containing 
upper phase. 
Nucleon Silica 
Stratum 
Orqanic phase 
Remove upper layer and 
transfer to fresh tube. 
Precipitate the DNA using lOO':'o ice 
cold dhanol, wash in 70% ethanol 
and re-suspend in TE Buffer 
Figure 15. Flow Diagram of Nucleon DNA extraction using BACC2 extraction kit 
Scotlab. Adapted with modification from Scotlab Nucleon II protocol II(a) flow 
diagram (Scotlab, UK). 
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DNA extraction using 'salting out' method 
A second method employed to extract genomic DNA from peripheral blood leukocytes 
was the salting out method as described by Miller et al 1988. Frozen whole blood samples 
were taken from the freezer and thawed at room temperature, 5-l Oml was then transferred 
to a sterile 50-ml Falcon® tube. Next, 25ml of 'Red Cell Lysis Buffer' (RCLB; 0.144 M 
N&CI, 0.00 I M NaHC03) was added and incubated at room temperature for 10 minutes. 
The sample was then centrifuged for 10 minutes at 1300 x rpm and the haemolysate 
removed and discarded. This step was repeated to ensure the removal of all residual red 
blood cells. The white cell pellet was re-suspended in 3ml 'Nuclei Lysis Buffer' (NLB: 
10mM Tris-HCL pH 8.0, 400mM NaCI and 2mM Na2/EDTA), 300j.tll0% SDS and 600j.tl 
Proteinase K (2mg/rnl) (Sigma Chemicals UK). This was incubated overnight in a 37°C 
water-bath. The following day lml of saturated sodium chloride solution (6M) was added, 
shaken vigorously for 15 seconds to precipitate proteins, and centrifuged at room 
temperature for 15 minutes at 1300 x rpm. The supernatant was transferred to 2 x volume 
of 100% ice cold ( -20°C) absolute ethanol and gently inverted to precipitate the DNA. The 
DNA was hooked out using a sterile glass Pasteur pipette and dissolved in 500j.tl of TE 
buffer pH 8 at 4°C for 72 hours and then stored at -20°C. 
- 187-
Chapter 3: Subjects, materials and methods 
Quantification of DNA 
To ensure a homogeneous solution, the DNA samples were stored at 4°C for at least three 
days before taking optical density readings. Next, lJ.il of stock DNA was combined with 
99J.il ofTE buffer in a 1.5-ml micro-centrifuge tube. Optical density readings were taken at 
260nm and 280nm and compared with a TE buffer reference sample using optically 
matched quartz cuvettes employing a Cecil 5500 spectrophotometer (Cecil, UK). The 
concentration {Jlg/J.Il) of the DNA in the stock solution was determined by multiplying the 
absorbency reading at 260nm by a factor of l 00, and based upon a reading of 1-optical 
density (OD) being equivalent to 50mg/m1 of double stranded DNA. The purity of DNA 
was assessed using the ratio of A.260nm/A.280nm which should be between 1.7-2.0. 
Suitable DNA yields ranged from between 200J.ig and 250J.ig per lO ml of blood. The DNA 
samples were then stored at -20°C prior to use. Dilutions of stock DNA samples were 
made for every day use, either in sterile water (Baxter, UK) or TE buffer to give a working 
concentration of 50ng/J.il for use in PCR amplifications. These dilutions were stored at 4°C 
to minimise the number of degradative freeze-thaw processes. 
DNA clean-up process 
DNA samples which did not respond well to PCR, were 'cleaned-up' by re-precipitating 
the DNA and re-suspending in sterile water to remove any salts or inhibitors. This was 
achieved by adding 1/10 volume 5M NaCl and 2-x volume of absolute ethanol to the 
diluted DNA. This was then mixed and 'snap frozen' in liquid nitrogen for 2 minutes, and 
~entrifuged at 15110 x rpm for 15 minutes. The supernatant was removed and samples 
were allowed to air dry, then the pellet was re-suspended in double distilled water. 
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Polymorphism detection 
All assays used for the detection of polymorphisms at gene loci were PCR based. Specific 
assays for the different polymorphism's studied will be described in the following sections. 
Amplification of DNA using the Polymerase Chain Reaction (PCR) 
The technique of Polymerase Chain Reaction (PCR) was first introduced by Saiki et al 
1985; and Mullis and Faloona 1987 and has since become a fundamental tool in molecular 
biology. The principle technique of PCR involves combining a DNA sample with 
oligonucleotides (amplimers) complementary to sequences on either side of the sequence 
targeted for amplification, deoxynucleotide triphosphates and the thermostable Taq DNA 
polymerase and a suitable buffer. The mixture is then repeatedly heated and cooled to 
enable the specific amplification of the region of interest. New DNA synthesis is limited to 
the region of DNA bounded by the two amplimers. By repeating this cycle, a single copy 
of target DNA can be exponentially amplified. 
Amplimer design and production 
Pairs of amplimers were designed from sequences known to flank the specific locus of 
interest. These amplimers permit PCR amplification of the DNA region of interest, which 
may contain a known polymorphism. Design was enabled by reference to sequences 
deposited in the publicly available Internet website 'Genbank' 
(www.ncbi.nlm.nih.gov.genebank). For all sequences of interest amplimers were designed 
complementary to the 5 '-3' strand (sense) and complimentary to the 3 '-5' strand 
(antisense) either side of the sequence of interest. All amplimers were designed to be 
between 18-30 bases in length with a random base distribution, and an approximate 
guanosine and cytidine (G+C) ratio of approximately 50% or similar to that of the 
fragment being amplified. Sequences were checked on DNA Star Software (Lasergene, 
USA) to check the amplimers against each other for complementarity to prevent the 
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possibility of creating 'primer dimers' or 'hairpin loops', where the amplimers bind to each 
other and may result in the formation of anomalies or artefacts. Amplimers containing 
stretches of polypurines, polypyrimidines or other unusual sequences were avoided. All 
amplimers were commercially synthesised on an oligonucleotide synthesiser, 'Pharmacia 
Gene Assembler' (MWG Biotech, Milton Keynes, UK) at a scale of0.05-0.2 J.lmoles, and 
diluted for use to concentrations of -I Opmol J.ll"1• 
Standard reaction mixture 
The PCR conditions required achieving optimum efficacy of DNA amplification varied 
depending upon the application for which it was applied. All PCR mixtures were prepared 
on ice in 0.2ml thin walled PCR strips (Advanced Biotechnology, Epsom, UK). Most 
reaction mixtures required a 50J.ll volume containing; I 00-500ng of genomic DNA, 5J.ll of 
I 0 x PCR buffer (250mM KCL, 50 mM Tris.HCL pH 8.4 at room temperature, I% Triton 
X-100, 0.1% gelatin), 1.5-2.5 mM MgCh, 10-20 pmoles of forward and reverse primers, 
200 J.lM of each deoxynucleotide triphosphate (dATP, dCTP, dGTP, and dTTP), and 2.5 
units of Taq DNA polymerase. Sterile water was added to a total volume of 50f.ll and a few 
drops of mineral oil were added to each reaction to seal it and prevent evaporation and 
condensation. The samples were then briefly centrifuged and the PCR reaction carried out 
automatically using a PTC-200 'Thermal Cycler' {MJ Research, Essex, U.K.) or a 
'Cyclogene Thermocycler' {Techne, Cambridge, UK). 
PCR cycling strategies 
Amplification was performed by incubating the samples at three temperatures 
corresponding to the three steps in a cycle of amplification-denaturation, annealing and 
extension. Typically the double stranded DNA is denatured by briefly heating the samples 
to 90-95°C, and then cooled to 40-60°C to allow the primers to anneal to their 
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complementary sequences. This was followed by heating the reaction to 70-75°C for 
approximately !-minute per kilobase of sequence, to extend the annealed primers with the 
Taq DNA polymerase. Calculation and optimisation of the required annealing temperature 
was derived from the melting temperature (Tm) values of the primer-template pairs, where 
Tm = 4(G+C) + 2(A+T). This annealing temperature was determined by applying the 
following formula; 
Annealing temp. (0 C) = Tm Primer 1 + Tm Primer 2 - 3 
2 
Modifications to the standard PCR protocol were made for each of the PCR amplifications 
carried out in order to enhance specificity of PCR products. These strategies involved 
carrying out a MgCh titration ( 1.5-6.5mM) to determine the optimal concentration 
required, increasing or decreasing the annealing temperature, decrease in primer 
concentration and decreasing the dNTP concentration. These strategies were applied when 
PCR products showed spurious bands upon agarose gel electrophoresis alongside a 
molecular weight marker (Sambrook, Fritsch and Maniatis 1989). 
Determination of PCR efficacy by agarose gel electrophoresis 
Amplification efficacy and the product size was checked by running out an aliquot of the 
PCR product on a 1-3.5% multi-purpose agarose gel containing 0.01% ethidiurn bromide. 
A I% agarose/ethidiurn bromide gel was prepared by heating lg of ultra-pure multi-
purpose agarose (Roche Diagnostics Ltd, Sussex, U.K.) and lOOml of 0.5 Tris Borate 
EDTA (TBE) buffer. This was carried out using a 400ml-heat-proof glass bottle in a 
microwave on low power for 3 minutes or until all the agarose had dissolved. The agarose 
solution was then allowed to cool at room temperature to approximately 65°C. Next, lOJ.ll 
ofethidium bromide solution {lOmg/ml) (Sigma-Aldrich, Dorset, U.K) was added to create 
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a 0.01 w/v concentration, and gently mixed. The agarose/ethidium bromide mixture was 
carefully poured into a 20x24 cm ultraviolet light transparent Perspex casting tray (Gibco 
BRL, UK), that was sealed at both ends with masking tape. Two 28 tooth vinyl combs 
were inserted into the gel to generate the sample loading wells. The gel was allowed to set 
at room temperature and was placed at 4°C to harden. The masking tape was then removed 
from the gel tray and the gel was placed into 0.5% TBE buffer in a 'Fiowgen Submarine 
Electrophoresis Tank' (Flowgen, UK) and the combs were carefully removed. 
A 10~1 aliquot of the PCR product was mixed with 1.5~1 of xylene cyanol track dye (15% 
Ficoll-type 400, 0.25% w/v Xylene Cyanol FF, 0.25% Bromophenol Blue, in I 0 X TBE), 
or Orange G loading buffer (0.25% orange G, I 0% v/v glycerol in I 0 X TBE). The PCR 
product/loading buffer mixture was than loaded into the wells of the gel guided by a Gilson 
pipette tip. A IOObp molecular weight marker (Life Technologies, Paisley, U.K) was also 
loaded into an adjacent well, along with appropriate positive and negative controls. The 
gels were electrophoresed for 30-45 minutes at a constant voltage of 100-150V (constant 
voltage) using a BioRad 3000 power pack, (BioRad, Herts, U.K.). Gels were then viewed 
and photographed under UV illumination using an Ultra-Violet transilluminator linked to 
UVP-LabWorks™ Image acquisition and analysis software (Ultra-Violet Products, 
Cambridge, UK), and DPII + Dpsoft digital camera and software. 
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Dinucleotide repeat analysis 
Short tandem repeat polymorphisms (STRP's) otherwise termed microsatellite 
polymorphisms, are polymorphic genetic markers consisting of short nucleotide sequences 
which are sequentially repeated. Typically the repeated sequences are l-4bp in length and 
are tandemly repeated 10 to 60 times. They provide highly informative markers for human 
genetic linkage studies. Microsatellite sequences are randomly distributed in the genome, 
and occur on average every 6 kilobases (kb) (Weber and May 1989). Dinucleotide repeat 
polymorphisms were typed using the PCR (as previously described) but incorporated the 
use of Redivue [y32P] dATP radiolabelled amplimers designed to flank the region of 
interest. High-resolution acrylarnide electrophoresis was carried out to resolve the allelic 
fragments that differ in length by as little as 2 nucleotides. 
Two microsatellite markers were studied within this thesis, firstly the (CA)n dinucleotide 
repeat marker of the hypertension-linked region on chromosome 17q (D 17S934), residing 
I8cM to the ACE locus, and the second a (CA)n dinucleotide repeat marker on 
chromosome 7q35, situated 2.lkb upstream of the aldose reductase (ALR2) start site. For 
the D 17S934 locus associated to hypertension, amplimers were designed from sequences 
known to flank the (CA)n repeat region to create a 185bp fragment illustrated in figure 16. 
Each amplimer was composed of 14 (G+C) and 11 (A+T) bases, the sequences of which 
are outlined in table 9. The amplimers were chosen to share the optimum annealing 
temperature of ~68°C. Template sequences for H. sapiens D 17S934, accession number 
Z23831, were obtained from the GenBank Internet website- www.ncbi.nlm.nih.gov (Gyapay et 
a/1994). For the 5'ALR2 locus pairs ofamplimers were designed from sequences known 
to flank the (CA)n repeat sequence region to create a 138bp fragment illustrated in figure 
16 (Heesom et at 1994, Shah et at 1998). The sense amplimer was composed of 9 (G+C) 
and 13 (A+T) bases, and the antisense primer was composed of 12 (G+C) and 7 (A+T) 
bases the sequences of which are also outlined in table 9. As before amplimers were 
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chosen to share the optimum annealing temperature of o::68°C. Template sequences for H. 
sapiens, aldose reductase gene promoter region; accession number U72619 were also 
obtained from GenBank: Internet website- www.ncbi.nlm.nih.gov (K.o and Chung 1997). 
The amplification optirnisation procedure as previously described in this section was 
carried out for both rnicrosatellite regions studied in order to achieve maximum efficacy of 
the reaction. Final PCR reaction mixture and cycling conditions for both markers are 
outlined in table I 0 and table 11 respectively. All PCR products were checked against a 
molecular weight marker for size using agarose gel electrophoresis as described. 
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D17S934 (H.saplens, accession number Z23831): 
agctctgaat ggcccttggt ccatgcctct ctccctctct cctccctctt cctccacttcc 
tgacttcagg acctgttccc tcctgctccc tacaagcatg catacacaca catacacaca 
cacacacaca cacacacaca cacacacaca Qgcactcata ccccacctca gataggaaac 
gggQfttgcc ctcccaggac ctatattaag acctatgggg agtggctggg atctgggccc 
ccagtgggtc tgtgagcatg aggtggtgag tgtgcaaaag tgtgagccta tgagagtgag 
5'ALR2 (H.sapiens, accession number U72619): 
cctcatttgt cttaccttgg tcccagccca gccctatacc tagtgtgtgt gtgtgtgtgt 
gtgtgtgtgt gtgtgtgtgt gtgtgtgtg tttcctttta aattatttcc ttaggaaaaa 
ttcccatgat gggagattac tggttcagag catgttaaga ttccaattac tagagtgttt 
Figure 16. Nucleotide sequences for D17S934 and 5'ALR2 microsatellite regions 
under investigation, obtained through the GenBank Internet website-
www.ncbi.nlm.nih.gov. Dinucleotide repeat regions are italicised, and amplimer 
sequences are highlighted. 
Microsatellite Direction Sequence 
D17S934 Sense 5' -AGCTCTGAA TGGCCCTTGGTCCA TG-3' 
Anti sense 5' -G TCCTGTTTCCT A TCTGAGGTGGGG-3' 
5'ALR Sense 5'-GAATCTT AACATGCTCTGAACC-3' 
Anti sense 5'-GCCCCAGCCCT ATACCTAG-3' 
Table 9 . Amplimer pair sequences designed to amplify microsatellite polymorph isms 
at regions 5'ALR2 and D17S934. 
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Master Mix 5'ALR2 [)175934 
DNA 300ng 300ng 
10 x PCR buffer 5~1 5~1 
Sense primer 15pmol lOp mol 
Antisense primer lOp mol lOp mol 
MgCiz 1.5mM 1.5mM 
dNTP mix 0.2mM 0.2mM 
Taq DNA Polymerase 0.5 units 0.5 units 
Sterile HzO make up to 50~1 make up to 50~1 
Table 10. Optimised PCR reaction mixture for 5'ALR2 and D17S934 microsatellite 
regions. 
Cycle 
Denaturation 
then 30 cycles of: 
Denaturation 
Annealing 
Extension 
Samples were cooled at 
4°C unti l further use. 
D17S934 5'ALR 
94°C for 3 minutes 94°C for 1 minute 
94° C for 30 seconds 94°C for 30 seconds 
56°C for 2 minutes 61°C for 2 minutes 
72°C for 2 minutes 72°C for 2 minutes 
Table 11 . Optimised PCR reaction times and temperatures for 5'ALR2 and D17S934 
microsatellite regions. 
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Incorporation of radio-labelled amplimers into PCR 
Once the PCR conditions were optimised for the microsatellites studied, radiolabelling of 
the 5' flanking amplimer with Redivue [y32P] dA TP was carried out. This radio labelled 
amplimer was then incorporated into a new PCR reaction. 
S'End labelUng of amplimers using T4 polynucleotide kinase (T4-PNK) 
To facilitate detection a radioactive nucleotide precursor was incorporated into the PCR 
reaction mix. Amplirners were labelled with Redivue [y32P] dA TP (Amersham U.K) using 
Ready-to-Go™ T4-polynucleotide kinase (T4-PNK) (Pharmacia Biotech). The lyophilised 
T4-PNK was re-suspended in 25J.1l of sterile water and incubated at room temperature for 
2-5 minutes. The solution was then mixed by gently pipetting up and down using a Gilson 
pipette tip. 5-10 pmoles of sense amplimer was added along with sufficient water to bring 
the reaction volume up to 49J.1l. lJ.!I of [y32P ATP (10mCilrnl} radioactive isotope 
(Amersham U.K), was added and briefly centrifuged for 30 seconds at 1300 x rpm 
(Biofuge 13 microcentrifuge, Heraeus Sepatech, Germany). Samples were then incubated 
at 37°C in a water-bath for 30 minutes. 
Precipitation of labelled ampUmer 
A 5.5J.1l volume of 5M NaCl, and 2j.d QuickPrecip® (Edge Biosystems, Oxon, UK) was 
added along with approximately three volumes of ice-cold 100% ethanol ( -20°C} to the 
reaction tube to precipitate the DNA. After vortexing, the samples were centrifuged for 3 
minutes. Each sample was then briefly vortexed and re-centrifuged for 30 sec's. All the 
supematant fluid was decanted off and discarded and the precipitate was rinsed in both 
100% and 70% ethanol. 50J.1l of sterile water was used to resuspend the precipitated DNA. 
Incorporation of y32P was then measured using a Beckman scintillation counter (Packard 
Biosciences, UK). 
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Assessment of efficacy of amplimer labelling 
lJ . .li of the labelled amplimer was counted for radioactivity using a Beckman scintillation 
counter. This gave a count per minute (cpm) reading. Determination of the cpm for l).Ll of 
the sample allowed calculation of the volume of labelled amplimer required for each 
reaction when the desired amount of radioactivity for the PCR is 25,000cpm. 
PCR was carried out as previously described, on average 25000cpm of the labelled 
amplimer was added to the reaction mixture. All PCR products were checked by running a 
10-15).!1 aliquot of the sample and 1-1.5).!1 of loading buffer against a IOObp molecular 
weight marker on a I% agarose/ethidiurn bromide gel as previously described. The gel was 
visualised under UV light and a photograph was taken. If the PCR was successful the PCR 
products were then electrophoresed on a vertical polyacrylamide gel. 
Polyacrylamide Gel Electrophoresis (PAGE) 
For microsatellite analysis the PCR products were then size fractionated by electrophoresis 
on a vertical polyacrylamide gel. A BioRad Sequi-Gen GT electrophoresis cell (30 x 
50cm) (BioRad Laboratories, Hemel Hempstead, UK), was used with a 49 well vinyl 
sharks-tooth comb and 0.4 mm spacers. All components of the gel rig were thoroughly 
cleaned in warm water, followed by 70% Industrial Methylated Spirit (IMS) solution 
(Rathburns) and allowed to air dry. The inner surfaces of the gel plates were then 
siliconised with a thin layer of Repelcote® (BDH, UK) to prevent the gel from adhering to 
the glass plates. A small amount of petroleum jelly was run down the edges of the base 
plate to grip the vinyl 0.4-mm gel spacers that were positioned at the edges. The glass top 
plate was then positioned onto the base plate and sandwiched together using two arm 
clamps. The casting tray was then attached to the assembled plate and levelled horizontally 
using a spirit level. 
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A 5% polyacrylamide (formamide/urea) gel was prepared using a series of solutions 
(National Diagnostics U.S). 30mls Sequagel concentrate (237.5g acrylamide, 12.5g 
methylene bisacrylamide and 500g urea), 15 ml Sequagel buffer (50% 8.3M urea in IM 
Tris-Borate-20mM EDTA buffer pH 8.3), 99ml Sequagel diluent (500g 8.3M urea), 12ml 
formamide (Sigma chemicals) were mixed together in a 250 ml conical flask. 70j .. d 
TEMED and 15001J.l 10% ammonium persulphate (APS) were used to polymerise the gel 
(Sigma, UK). 
The gel solution was cast into the horizontally positioned cell using a 200 ml syringe with 
a delivery tube, according to the manufacturer instructions. The flat edge of the sharks-
tooth comb was inserted into the gel in an inverted position at the top or" the gel plates, and 
the gel was allowed to polymerise over 2 hours at room temperature. The gel rig was then 
assembled vertically into the base and equilibrated overnight in 1 x TBE buffer. The 
system was connected to a power-pack (BioRad PC3000) and pre-warmed at 1800V for 30 
minutes or until the temperature indicator read 40°C. The sharks-tooth comb was then 
removed and reinserted in the correct orientation to form the sample wells. 
PCR amplification products (61J.l) were mixed with 31J.l of 10 x formamide stop solution 
(Gibco BRL, UK) and loaded into the wells on the gel using a lOiJ.I Drummond® 
sequencing pipette (Drummond Laboratories, USA). The electrophoresis was carried out 
for 2.5 to 3 hours at 1500-2000V or maintained at a constant temperature of 50°C. The 
marker dye indicated how far the PCR products had migrated down the gel, this acted as an 
indicator to detect when the separation of bands was reached. The gel was removed from 
the plate and fixed in 10% Methanol/ Acetic acid, transferred from the cell plate to filter 
paper and dried on a vacuum/heated gel drying system (Heto, UK) at 80°C for 
approximately 1-2 hours. 
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Autoradiography of polyacrylamide gel 
The gel was then exposed to Kodak X-OMA T films between Cronex intensifying screens 
for 8 hours at -80°C. The film was developed in Kodak developing and fixing agents 
(according to manufacturer's instructions). Alternatively gels were exposed onto plates 
using a BioRad Fluor S analyser, and printed onto photographic paper (BioRad 
Phosphoimager ). 
Scoring of microsatellite alleles 
Allele scoring was carried out by two independent observers. Description of how alleles 
were assigned for each rnicrosatellite is given in the result's section. Analysis of bands was 
carried out either by eye or using BioRad analysis software. 
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Single Nucleotide Polymorphism (SNP) detection 
Three single base polymorphisms were studied by restriction site enzyme digestion, firstly 
aCto T (Bfal forming) polymorphism situated -106bp upstream of the aldose reductase 
start site, secondly an A to C polymorphism situated at nucleotide +11842 of intron 8 
within the aldose reductase gene itself, and thirdly an A to C polymorphism at nucleotide 
position 5178 within the mitochondrial genome. 
Restriction site polymorphisms 
Restriction site polymorphisms are single base polymorphic sites, which result in the 
formation or alteration of a restriction enzyme cut site. Restriction enzyme digestion of a 
PCR product containing the known polymorphic site enables the genotype to be 
determined. Amplimers can be designed to flank the known polymorphic region such that 
restriction enzyme cutting results in the production of different sized fragments, which can 
be determined by agarose gel electrophoresis. 
C(-106)T polymorphism detection by restriction enzyme digestion. 
The amplimers for the basal promoter region of the ALR2 gene were used to amplify the 
263 base pair fragment that included the novel C(-106)T polymorphic site. The amplimer 
sequences were previously ·designed by Heesom et a/ 1994 and Pate! et a/ 1996 from gene 
sequences obtained through the GenBank Internet website- www.ncbi.nlm.nih.gov (figure 
I 7). The upstream amplimer consists of 24 nucleotides spanning the -222 to -199 region, 
and the downstream amplimer consists of 21 nucleotides which extended from nucleotide 
+21 to the translation start ATG start codon (table 12). The polymorphism creates a new 
Bfa 1 restriction site and digestion produced fragments detectable by size fractionation 
(table 13). DNA was amplified by PCR as previously described using a reaction mixture 
outlined in table 14, and cycling strategy as outlined in table 15. PCR products were 
checked for efficacy on an agarose/ethidium bromide gel as previously described. It proved 
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to be very difficult to genotype all of the samples for the C-l 06T polymorphism as many 
failed to respond to the restriction enzyme digestion stage of the assay. Failure primarily 
lay with poor or incomplete restriction enzyme digestion. This probably resulted from an 
inhibiting factor preventing the enzyme from working. Despite stringent purification 
protocols being applied some samples still failed to respond. This may have been due to 
different batches of DNA used and differences in the DNA extraction protocols applied. 
Direct Purification of PCR products 
The restriction enzyme Bfa I is an isoschizomer of Mae I and Rma 1, and according to the 
manufacturers protocol Bfa I has shown minimal cleavage of unpurified PCR products. 
Therefore, PCR products required purification before Bfa I digestion. PCR products were 
purified using the Wizard® PCR PrepDNA purification system (Promega, Madison, USA) 
and a Vac-Man® laboratory vacuum manifold. PCR products were transferred to a sterile 
microcentrifuge tube and lOOJ.Ll of direct purification buffer (KCI 50mM, lOmM Tris-HCI 
(pH 8.8 at 25°C), 1.5mM MgCh and 0.1% Triton :x®-100) was added. After vortexing, 
lrnl of Wizard® PCR prep DNA purification resin was added and the mixture was briefly 
vortexed 3 times over a 1-minute period. 
For each PCR product one Wizard® mini-column was prepared by attaching a syringe 
barrel to the Luer-Lok® extension of the mini-column according to manufacturers 
instructions. This mini-column/syringe barrel assembly was inserted into the vacuum 
manifold (Promega). The resin/DNA mix was pipetted into the syringe barrel and a 
vacuum was applied to draw the mixture through the mini-column. The mini-column was 
washed with 2 m! of 80% isopropanol (Sigma chemicals). The resin was dried by 
centrifuging the mini-column at 800 x rpm in a micro-centrifuge for 2 minutes. The mini-
column was transferred to a new micro-centrifuge tube and 50J.Ll of sterile water was added 
-202-
Chapter 3: Subjects. materials and methods 
for l minute. The mini-column was re-centrifuged for 20 seconds at 800 x rpm to elute the 
DNA fragment, which was collected in a sterile l.5ml microcentrifuge tube. 
Bfal restriction endonuclease digestion 
The C( -1 06)T substitution polymorphism creates a new Bfa 1 restriction endonuclease site. 
To detect the C(-106)T polymorphism 20 ).11 of purified amplification product was 
digested using 8 units of Bfa1 (New England Biolabs, UK) and incubated in l x NE buffer 
4 (50mM potassium acetate, 20mM tris acetate, lOmM magnesium acetate, lmM 
dithiolthreitol, pH 7.9) (New England Biolabs, UK) at 37°C for 3 Y2 hours. The allelic 
variant C enabled cleavage at one site only producing two fragments 206bp and 57bp in 
size. The allelic variant T enabled Bfal cleavage at two sites, producing 147bp, 59bp and 
57bp fragments. A heterozygous CT genotype therefore produced restriction fragments 
206bp, 146bp, 59bp and 57bp (table 13). Digestion fragments were separated using 3.5% 
agarose/ethidium bromide gel electrophoresis against a lOObp molecular weight marker (as 
previously described). Timed digestion was checked by running a 3).11 aliquot with 1.5).11 of 
loading buffer and if digestion was incomplete a further 5-10 units of restriction enzyme 
was added ·in 3).11 of lO x buffer and incubated for a further hour. The enzyme 
concentration in solution was kept below 10% to minimise non-specific cleavage of DNA 
due to the presence of glycerol. Digestion fragments were viewed using a UV 
transilluminator and genotyping was carried out by eye as illustrated in figure 25. 
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5'ALR2 (H. sapiens, accession number U72619): 
-273 
tattttcgct aaagcattcg ctttcccacc agatacagca gctgaggaac tcctttctgc 
cacgcggggc gcgggcgagc gttgggggcg gaaagaatcc gctgccacta ggaccaggcg 
gaagaagcat ccccgccgac ccttggggaa ggccgccgcg gcacccccag cgcaaccaat 
cagaaggctc cttcgcgcag cggcgcgcca accgcaggcg ccctttctgc cgacctcacg 
ggctatttaa aggtacgcgc cgcggccaag gccgcaccgt tactgggcgggggtctgggga 
gcgcagcagc catggcaagc cgtctcctgc tcaacaacgg cgccaagatg cccatcctgg 
+ 
Figure 17. Nucleotide sequence for 5'ALR2 C(-106)T polymorphic region under 
investigation, obtained through the GenBank Internet website- www.ncbi.nlm.nih.gov. 
Bfa1 restriction sites are italicised and amplimer sequences are highlighted. 
Polymorphism 
C(-106)T 
Direction 
Sense 
Anti sense 
Sequence 
5' CCT TTC TGC CAC GCG GGG CGC GGG 3' 
5' CAT GGC TGC TGC GCT CCC CAG 3' 
Table 12. Amplimer pair sequences designed to amplify the 5'ALR2 C(-106)T 
polymorphic region. 
C(-106)T Restriction endonuclease Allele fragment sizes 
Bfai C: 57bp,206bp 
5' ... C• T AG ... 3' T: 57bp, 59bp, 147bp. 
3' ... G A • TC ... 5' 
Table 13. Bfa1 restriction enzyme allele fragment sizes for 5' ALR2 C( -106 )T 
polymorphism. 
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C(-106)T 
300ng 
5Jll 
lOp mol 
lOpmol 
1.5mM 
0.2mM 
1.0 units 
make up to 50Jll 
Table 14. Optimised PCR reaction mixture for 5'ALR2 C(-106)T polymorphic region. 
Cycle 
Denaturation 
then 32 cycles of: 
Denaturation 
Annealing 
Extension 
Samples were cooled at 
4°C until further use. 
C(-106)T 
96°C for 3 minutes 
94° C for 30 seconds 
70°C for 2 minutes 
72°C for 1 minutes 
Table 15. Optimised PCR reaction times for 5'ALR2 C(-106)T polymorphic region. 
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(a) Allelic variant C 
Bfa 1 cut no cut 
C(-106)T-Forward amplimer ~ ~ C(- 106)T-Reverse amplimer 
ctttctgccacgcggggc gcggg~ etag ~ ccag ~ctggggagcgcagcagccatg 
gate ggtc 
57bp fragment 206bp fragment 
(b) Allelic variant T 
Bfa 1 cut Bfa 1 cut 
~ ~ 
ctttctgccacgcggggc gcggg~ ctag ~ ctag ~ tggggagcgcagcagccatg 
gate gate 
/ 
57bp fragment 59bp fragment 
Genotype TT cc CT Control 
14 7bp fragment 
~ !57/59 bp 
:= 147 bp 
206 bp 
~ 263 bp 
Figure 18. Illustration of C( - 106)T restriction site polymorphism (RSP's). This 
figure illustrates the C(-106)T restriction site polymorphism where the 263bp PCR 
product is cut by the restriction enzyme Bfa I which detects and cuts at the 
c• TAG sequence. Alleleic variant C is cut into two restriction fragments 57 bp and 
206bp, and an allele which contains the C toT polymorphism is further cut into three 
fragments 57bp, 59bp and 147bp. Subjects heterozygous for C(-106)T polymorphism 
showed restriction fragments 57bp, 59bp, 147bp and 206bp in size. A control was 
always included where no restriction enzyme was added, producing a 263 bp uncut 
band. Alternative primer design would have resolved the 57bp and 59bp fragments. 
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ALR2 A(+11842)C polymorphism detection by restriction endonuclease digestion 
Amplimers previously designed by Kao et a! 1999 for the aldose reductase intragenic region 
containing the novel A(+ll842)C polymorphism were used to amplify the 252bp fragment of 
interest. The amplimer sequences were checked from gene sequences obtained through 
GenBank Internet website- http://www.nlm.nih.gov (figure 19). The upstream amplimer 
consists of 21 nucleotides spanning the + 11763 to + 11783 region, and the downstream 
amplimer consists of 21 nucleotides which span from + 11993 to + 12012 nucleotides upstream 
of the aldose reductase start site (table 16). The polymorphism abolishes a BamH1 restriction 
enzyme site and digestion produced fragments detectable by size fractionation (table 17). 
DNA was amplified by PCR as previously described using a reaction mixture outlined in table 
18, and cycling strategy as outlined in table 19. 
BamH1 restriction endonuclease digestion 
The A(+ 11842)C substitution polymorphism abolishes a BamH I restriction endonuclease site. 
To detect the A(+ 11842)C polymorphism 5 )ll of amplification product was then digested 
using lO units of BamH1 (New England Biolabs, UK) and incubated at 37°C for 45 minutes. 
The allelic variant C showed no cleavage by BamHI digestion and the 252bp PCR product 
remained intact. The allelic variant A enabled BamH1 cleavage at one site, producing two 
restriction fragments, 174bp and 78bp in length, detectable by agarose gel electrophoresis. A 
heterozygous AC genotype therefore produced all three fragments, 252bp, 174bp, and 78bp. 
To ensure completed restriction enzyme digestion an internal control was always incorporated 
alongside. The internal control consisted of patient DNA for which the correct genotype had 
previously been confirmed by direct sequencing methods (MWG). Digestion fragments were 
separated using 2.5% agarose/ethidium bromide gel electrophoresis alongside a 1 OObp 
molecular weight marker (as previously described). Timed digestion was checked by running 
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a 3J.1l aliquot of digestion mixture with l.5J.1l ofloading buffer and if digestion was incomplete 
a further 5-10 units of restriction enzyme was added and incubated for a further 30 minutes. 
Digestion fragments were viewed using a UV transilluminator and genotyping was carried out 
by eye. 
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ALR2 (H. sapiens, accession number AF032455): 
tcttggctgg tcaggcctgg ccctcctcca tggagtgggg gatgggggag gcctctcatc 
ctgtctctgg agtgtcatct gtgggatccc caccatcctc tcttctgagg ccagggagct 
gtggcgagca agccaagact gagactgaca cctcaccagt ggagccgtgt gccaggggca 
ggccttgggt ccagggccgt gctgtggcaa tacacctaca cctttgctca ggcccttcag 
cacaccgaga ggttacccgg ggagaatctc gctcttgagc ttcactgcct ggacctgccc 
Figure 19. Nucleotide sequence for ALR2 A(+11842)C polymorphic region within intron 8 
of the aldose reductase gene, obtained through the GenBank Internet website-
http:/ / www.ncbi.nlm.nih.gov. BamHI restriction site containing the A(+11842)C 
polymorphism is italicised and amplimer sequences are highlighted. 
Polymorphism Direction Sequence 
A(+ 11842)C Sense 
Anti sense 
5' CTG GTC AGG CCT GGC CCT CCT 3' 
5' GT A ACC TCT CGG TGT GCT GAA 3' 
Table 16. Amplimer pair sequences designed to amplify the ALR2 A(+11842)C 
polymorphic region. 
A(+ 11842)C Restriction endonuclease Allele fragment sizes 
BamH1 C: 252bp 
5' ... G ... GATC C ... 3' A: 174bp, 78bp 
3' ... C CTAG•G ... 5' 
Table 17. Restriction enzyme allele fragment s izes for ALR2 A(+11842)C polymorphism. 
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A(+11842)C 
300ng 
51ll 
lOp mol 
lOp mol 
1.5mM 
0.2mM 
1.0 units 
make up to 50J.LI 
Table 18. Optimised PCR reaction mixture for ALR2 A(+11842)C polymorphic region, 
detected using BamH1 restriction enzyme digestion. 
Cycle 
Denaturation 
then 32 cycles of: 
Denaturation 
Annealing 
Extension 
Samples were cooled at 
4°C until further use. 
A(+11842)C 
94°C for 2 minutes 
95° C for 1 minute 
66°C for 1 minute 
72°C for 1 minutes 
Table 19. Optimised PCR reaction times for ALR2 A(+11842)C polymorphic region. 
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Mitochondrial C(5178)A polymorphism detection by restriction endonuclease digestion 
Amplimers previously designed by Gong et a/ 1998 for the mitochondrial gene C(5178)A 
polymorphism were used to amplify the 417bp fragment of interest. The amplimer sequences 
were checked from gene sequences obtained through GenBank Internet website-
htto://www.nlrn.nih.gov (figure 20). The upstream amplimer consists of24 nucleotides spanning 
the Mt4949 to Mt4972 region, and the downstream amplimer consists of 24 nucleotides which 
span from Mt5342 to Mt5365 (table 20). The polymorphism abolishes a Alul restriction 
enzyme site and digestion produced fragments detectable by size fractionation (table 21 ). 
DNA was amplified by PCR as previously described using a restriction mixture outlined in 
table 22, and cycling strategy as outlined in table 23. 
Alul restriction endonuclease digestion 
The C(5178)A substitution polymorphism abolishes a BamHl restriction endonuclease site. 
To detect the C(5178)A polymorphism 1 OJ.!l of amplification product was then digested using 
10 units of Alul (New England Biolabs, UK) with NE buffer 2 (50 mM NaCl,10 mM Tris-
HCL, 10 mM MgCl, 1 mM dithiothreitol) and incubated at 37°C for 4 hours. The allelic 
variant A showed Alu1 cleavage at one site, producing two digestion fragments, 43bp and 
374bp. The allelic variant C enabled Alu1 cleavage at two sites, producing three restriction 
fragments 43bp, 188bp and 186bp in size. To ensure completed restriction enzyme digestion 
an internal control was always incorporated alongside. The internal control consisted of 
patients DNA for which the genotype had previously been confirmed by direct sequencing. 
Digestion fragments were separated using a 3% agarose/ethidium bromide gel electrophoresis 
alongside a lOObp molecular weight marker (as previously described). Timed digestion was 
checked by running a 3J.!I aliquot of digestion mixture with l.5J.!l of loading buffer and if 
digestion was incomplete a further 5-l 0 units of restriction enzyme was added and incubated 
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for a further 30 minutes. Digestion fragments were viewed using a UV tranilluminator and 
genotyping was carried out by eye. 
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(H. sapiens, accession number;NC_001807): 
tcacatgaca aaaactagcc cccatctcaa tcatatacca aatctctccc tcactaaacg 
taagccttct cctcactctc LvUC:HvLLA 
accaaaccca gctacgcaaa atcttagcat actcctcaat tacccacata ggatgaataa 
tagcagttct accgtacaac cctaacataa ccattcttaa tttaactatt tatattatcc 
taactactac cgcattccta ctactcaact taaactccag caccacgacc ctactactat 
ctcgcacctg aaacaagcta acatgactaa cacccttaat tccatccacc ctcctctccc 
taggaggcct gcccccgcta accggctttt tgcccaaatg ggccattatc gaagaattca 
La~'""'.''a•"' atccccacca tcatagccac catcaccctc cttaacctc 
aluoclltccr caatcacact actccccata tctaacaacg 
taaaaataaa atgacagttt gaacatacaa aacccacccc attcctcccc acactcatc 
Figure 20. Nucleotide sequence for Mt C(5178)A polymorphic region within the 
mitochondrial genome, obtained through the GenBank Internet website-
http:/ /www.ncbi .nlm.nih.gov. The Alu1 restriction site containing the C(5178)A 
polymorphism is italicised and amplimer sequences are highlighted. 
Polymorphism Direction Sequence 
Mt C(5178}A Sense 
Anti sense 
5' ATC CAT CAT AGC AGG CAG TIG AGG 3' 
5' GAG TAG ATI AGG CGT AGG TAG AAG 3' 
Table 20. Amplimer pair sequences designed to amplify the mitochondrial C(5178)A 
polymorphic region. 
Mt C(5178)A Restriction endonuclease Allele fragment sizes 
Alul A: 43 bp, 374bp 
5' ... AG• CT. .. 3' C: 43bp,188bp, 186bp 
3' ... TC• GA ... 5' 
Table 21. Restriction enzyme allele fragment sizes for mitochondrial C(5178)A 
polymorphism. 
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Mt C(5178)A 
300ng 
51ll 
lOp mol 
lOpmol 
1.5mM 
0.2mM 
1.0 units 
make up to 501ll 
Table 22. Optimised PCR reaction mixture for mitochondrial C(5178)A polymorphic 
region, detected using Alul restriction enzyme digestion. 
Cycle 
Denaturation 
then 32 cycles of: 
Denaturation 
Annealing 
Extension 
Samples were cooled at 
4°C until further use. 
Mt C(5178)A 
94°C for 4 minutes 
94° C for 30 seconds 
49°C for 2 minutes 
72°C for 2 minutes 
Table 23. Optimised PCR reaction times for mitochondrial C(5178)A polymorphic region, 
detected using Alul restriction enzyme digestion. 
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Electrophoretic mobility shift assay for 5' ALR2 ORE's 
The electrophoretic mobility shift assay (EMSA) was used to quantitatively detect the 
interaction between the sequence specific osmotic response element (ORE) binding proteins 
and the ORE gene sequences in the 5' promoter region of the aldose reductase gene (ALR2). 
The assay was performed by incubating a known quantity of purified nuclear protein extracts 
with a 32P end-labelled DNA fragments containing the putative protein binding sites, which in 
this study were the ORE's of 5'ALR2. The assay incorporates the use of a non-denaturing 
polyacrylamide gel to separate protein!DNA complexes from free DNA, which can then be 
analysed quantitatively. This study was carried out using a Gel Shift Assay System (Promega 
Life Sciences, Southampton, UK; http://www.promega.com). The study used the established cell 
lines Jurkat E6.1 as well as PBMC's extracted from fresh whole blood samples. 
Established cell lines 
Jurkat E6.1 Human Leukaemic T cell lymphoblast- ECACC No. 88042803 
This cell line was obtained from the European Collection of Animal Cell Cultures (ECACC, 
Porton Down, UK), and are an IL-2 producing cell line derived by incubating the cells at 41 oc 
for 48h followed by limited dilution cloning over macrophages. Morphologically these cells 
grew as a suspension. Cells were initially decanted into a centrifuge tube and centrifuged at 
70-1 OOg for 5 minutes. Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 + 
2mM Glutamine + 10% Foetal Bovine Serum (FBS) at 37°C in a 5% C02 incubator. Cells 
were grown and were sub-cultured during their log phase of growth 2-3 days following 
seeding determined by haemocytometer counting. Cells were maintained at between 3-9 x 
100,000 cells/ml. 
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Extraction of Peripheral blood mononuclear cells (PBMC's) from whole blood 
Peripheral blood mononuclear cells (PBMC's) were extracted from 20 ml fresh whole blood/ 
Heparin samples. Briefly the blood was diluted in equal volume of Dulbecco's Phosphate 
Buffered Saline (PBS) (Life Technologies, Paisley, UK) pre-warmed to 37°C in a water-bath 
(Grant, UK). 7 ml ofLymphoprep™ (Nycomed Pharma AS, Oslo, Norway) was added to each 
of 6 x 15 ml Falcon® centrifuge tubes and 7 ml of the blood/PBS solution was carefully added 
using a sterile Pasteur pipette without disturbing the LymphoprepTM surface. Lymphoprep™ 
has a density of 1.077 ± 0.001 g/ml, and osmolality of 280 + 15 mosm to facilitate the 
isolation ofPBMC's by density gradient centrifugation. The samples were centrifuged at 1600 
x rpm with no break setting for 30 min at room temperature. The lymphocytes at the interface 
layer were then removed using a sterile Pasteur pipette and transferred into a clean 15-ml 
Falcon® centrifuge tube. Cells were washed twice, using 4 x volume RPMI 1640 and 
centrifuging at 1400 x rpm for lO minutes in a bench centrifuge. Cells were then re-suspended 
at a concentration of 0.5 x 106 /ml in RPMI 1640 ( 11 mM D-glucose) supplemented with 5% 
L-Glutamine, 10% Foetal calf serum (FCS) and 5% Penicillin/Streptomycin. The cell 
suspension was divided into two 250 ml cell culture flasks (Becton-Dickinson). The cells 
were stimulated by the addition of the mitogen stimulant phytohaemagglutinin (PHA) 
(IJ.ig/ml) and incubated in a Nuaire Flow incubator (Indis Scientific, Glasgow, UK) at 37°C 
with 5% col until cell replication was achieved. 
Cryopreservation 
For future work cultured cells were stored by cryopreservation. Actively growing cells, free 
from contamination were suspended in the cryoprotectant dimethylsulphoxide (DMSO) 
complete medium 10% (v/v) and FBS to give l x 106-1 x 107 cells/ml in medium. Cell number 
was counted using trypan blue solution (Sigma Chemicals, Poole, UK) and a Neubauer 
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haemocytometer. Cells were cooled at -1 °C/min and frozen at a continuous rate to -196°C and 
transferred to gaseous phase liquid nitrogen. When required the ampoules of frozen cell lines 
were resuscitated by removing from liquid nitrogen pod, and held at room temperature for 
approximately l minute and then transferred to a 37°C water bath for 1-2 minutes until fully 
thawed. To reduce risk of contamination, ampoules were wiped with tissue soaked in 70% 
alcohol prior to opening. The contents of the ampoule were then pi petted directly into a flask 
of media pre-warmed to 37°C. 
Establishment of stress conditions 
For the purposes of studying ORE binding protein activity, cells were incubated under 
hyperosmotic and hypertonic conditions to simulate the diabetic hyperglycaemic state. 
PBMC's from TlDM patients and normal controls, as well as the cell lines were incubated at 
37°C for 24 hours before the addition of the stress factor. For the hyperglycaemia experiments 
cells were cultured in either normoglycaemic conditions (11 mmol/1 D-glucose) or 
supplemented with 17 mmol/1 D-glucose to create a 28mM/1 environment (hyperglycaemia). 
Optimal glucose dosage was obtained by carrying out the assay using 14 mmol and 28 mmol 
D-glucose. The best results were obtained from the 28 mmol assay, and this was therefore 
used for the experiments. Cells were then incubated for 5 days at 37°C in a Nuaire flow 
incubator. Cells remained viable for 5 days and this was confirmed by examination under the 
microscope and by Trypan Blue staining techniques. 
Extraction of nuclear protein from whole cells 
Nuclear protein extracts were prepared using methods previously described by Dignam et a/ 
1983 [a and b]. Non-adherent cells were re-suspended in the culture flask by gently pipetting 
the culture medium up and down using a Pasteur pipette, and transferred to a Falcon® 
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centrifuge tube. Adherent cells were detached from the cell culture flask using trypsin!EDT A 
solution and also transferred to Falcon® centrifuge tubes. Cells were then pelleted by 
centrifugation at 800 x rpm for 4 minutes. The supematant was removed and cells were 
washed twice with PBS pre-warrned to 37°C in a water-bath and centrifuged at 600 x rpm for 
30 sec's. The supernatant was discarded and the pelleted cells were re-suspended in lOOJ.!l of 
buffer A (10mM HEPES, pH 7.9, 1.5 mM MgCh, 10mM KC!, 0.5mM DTT, 0.2% NP-40, 
100mM AEBSF, 18.4mg/ml sodium orthovanadate, 42mg/ml sodium flouride and 2.2mg/ml 
aprotonin) and held on ice for 15 minutes. The resulting cell lysate was then centrifuged at 
1300 x rpm for 1 0 minutes. The supematant containing cytoplasmic proteins was removed and 
the nuclear pellet was re-suspended in 50J.1l of buffer C (20mM HEPES pH 7.9, 25% glycerol, 
0.42 M NaCl, 1.5mM MgCh, 0.5mM DTT, 0.2 EDTA, 100 mM AEBSF, 18.4 mg/rnl sodium 
orthovanadate, 42 mg/ml sodium fluoride, 2.2 mg/rnl aprotonin), and incubated on ice for 10 
minutes. After centrifugation at 1300 x rpm for I 0 minutes the supematant containing the 
nuclear protein was extracted and stored in a fresh tube at -70°C until use. 
Determination of protein concentration for nuclear fraction 
The concentration of protein in the samples was determined using a Coomassie® Plus Protein 
Assay reagent kit (Peribo Science Ltd., Chester, UK). Serial dilutions of a 2.0mg/rnl bovine 
serum albumin (BSA) protein standard were made, ranging from 0 to 2.0 mg/rnl (0, 0.2, 0.4, 
0.8, 1.6, 2.0) in clean dry glass test tubes. 1 rn1 of Coomassie® Plus Protein dye reagent was 
added to 50J.1l of each protein dilution, gently vortexed and left to stand for 5min-l hour. The 
OD595 versus reagent blank was measured using a WPA UV1101 Biotech Photometer 
(Biotech, UK), and a standard curve was plotted. Sample protein concentrations were 
established by reading from the standard curve, and accounting for appropriate dilution 
factors. 
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OUgonucleotide probe design and labelling 
Oligonucleotide sequences were designed with the aid of sequences downloaded from 
GenBank database (www.ncbi.nlm.nih.gov). Three oligonucleotides were designed, each to 
incorporate one ORE sequence within the promoter region of the ALR2 gene (figure 21, table 
24). All oligonucleotides were commercially synthesised by MWG Biotech (Milton Keynes, 
UK) at a scale of 0.2J..lmol. Oligonucleotide probes were re-suspended in sterile water to create 
a working dilution of 1.75 pmoles/ul. Phosphorylation was carried out by incubating 1.75 
pmol of oligonucleotide for 10 minutes at 37°C in a reaction mixture containing; T4 
polynucleotide kiriase 10 X buffer [100mM Tris-HCI (pH 7.6), 100 mM MgCh, 50mM DTT], 
1J..ll J.}2P-ATP, nuclease free water and 5-10 units T4 polynucleotide kinase (Promega Life 
Sciences, Southampton, UK). The reaction was stopped by adding 1J..ll of 0.5M EDTA and 
diluted in 89J..ll ofTE buffer (10mM Tris-HCI pH 8.0, 1 mM EDTA). 
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5'ALR2 (H. sapiens, accession number U72619): 
tacaaaag 
cacttt 
taaagaaagc accaaatgga aaatcaccqq catggagttt agagagacct ggtgcttgag 
Figure 21. Nucleotide sequences for 5'ALR2 promoter region containing osmotic 
response elements. Oligonucleotide sequences are highlighted in blue (OREA), green 
(ORE B), and yellow (ORE C). 
ORE 
ORE A sequence 
• ORE A probe 
ORE B sequence 
• ORE B probe 
ORE C sequence 
• ORE C probe 
Sequence 
5' TGG AAA AAT AT 3' 
5' TTA CAT GGA AAA ATA TCT GGG 
5' AAA TTT TTC CA 3' 
5' CTG TAT AAA TTT TTC CAG GAG GG 3' 
5' GAA AAT CA 3' 
5' ACC AAA TGG AAA ATC ACC GGC ATG G 3' 
Table 24. Oligonucleotide sequences designed to incorporate the osmotic response 
element of interest. 
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Preparation of non-denaturing 4% acrylamide gel 
Gel plates were wiped clean using 70% IMS solution and rinsed using warm purified water to 
remove any ionic contaminants. The glass plates were assembled using 0.75mm spacers and 
held together using clamps and a casting tray. The rig was loaded with distilled water to 
ensure a good seal and no signs of leakage. The water was poured away and well combs were 
inserted between the glass plates. The gel solution was prepared by mixing 5 ml 10 X TBE, 
2.5 ml 2% bisacrylarnide (BioRad), 10 rnl 40% acrylarnide, 3.1 ml 80% glycerol, 79.5ml 
sterile water glass wide necked conical flask. To polymerise the gel 70fll of TEMED and 
750fll of 10%APS. The gel solution was drawn up into a syringe and the gel was poured into 
the gel casting system, care being taken not to form air bubbles, and left for 30 minutes to 
polymerise. Prior to running the samples the gel was positioned in a vertical position in a 
running tank and equilibrated in a 0.5% TBE running buffer at 100V for 30 minutes. The well 
comb was removed and the wells were washed out with 0.5 TBE using a 21-gauge needle and 
synnge. 
Control and competition assay 
The specificity of the DNA binding protein for the putative binding sites was established by 
competition experiments using an AP1 consensus oligonucleotide as a probe which contains 
other unrelated DNA sequences (figure 22). 
SP-1 5' GAT CGA ACT GAC CGC CCG CGG CCC GT 3' 
AP-1 3' A TT CGA TCG GGG CGG GGC GAG C 5' 
Figure 22. Nucleotide sequence of SP-1 and APl consensus oligonucleotides used in 
competition experiments. 
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The AP 1 ( 1. 7 5 pmol) was labelled using [ y-32P] A TP using a phosphorylation reaction as 
previously described. Four reaction conditions were set up; a negative control, a positive 
control and two competition assays to demonstrate binding specificity. The reactions were set 
up in sterile microcentrifuge tubes in accordance to table 25. These were incubated for 10 
minutes at room temperature and then lJ..ll of [y_32P] ATP labelled ORE oligonucleotide was 
added to each reaction. Th.is was then incubated at room temperature for a further 20 minutes, 
following which lJ.ll of gel loading 10 x buffer (250mM Tris-HCl, 0.2% bromophenol blue, 
40% glycerol) was added to each reaction. The samples were then loaded into the wells of the 
4% acrylamide gel and electrophoresed at lOOV for 3-4 hours. The gel was then transferred to 
Wbatman 3M paper (Wbatman, Maidstone, UK) and overlaid with Saran Wrap™. The gel was 
then exposed to X-Omat photographic film (Kodak, UK) between intensifying screen for 48 
hours at -80°C. The film was then developed using developer and fixing solutions (Kodak, 
UK). The bands were analysed and quantified using a phosphoimager (BioRad) with multi 
analyst software. 
Negative control 
71-ll Nuclease free water 
21-ll Gel shift binding 5X buffer 
OJ.ll Nuclear extract 
Specific competitor 
41-ll Nuclease free water 
21-ll Gel shift binding 5X buffer 
21-ll Nuclear extract 
lJ.ll Unlabelled competitor oligo (SPl) 
Positive control 
5J..1.l Nuclease free water 
2J..ll Gel shift binding 5X buffer 
2J..1.l Nuclear extract 
Non-specific competitor 
4).11 Nuclease free water 
2).11 Gel shift binding 5X buffer 
2).11 Nuclear extract 
1).11 Unlabelled noncompetitor oligo (APl) 
Table 25. Reaction conditions for control and competition experiments for ORE A, 
B and C, using SP-1 as the competitive probe, (Promega Gel Shift Assay Systems 
Technical Bulletin No.llO. 
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Protein reaction for subject gel shift assay 
The labelled ORE probe along with a gel shift binding 5 x buffer (20% glycerol, 5mM 
MgC12, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 50mM Tris-HCl, 0.25 mg/ml poly (dl-
dc)• poly (dl-dc)) was incubated with 5-IOJ.lg of nuclear protein (determined by the protein 
assay described previously) at room temperature for 20 minutes. 5J.1l of gel loading dye (40% 
glycerol, 0.2% bromophenol blue, 250mM tris-HCl) was added and samples were loaded into 
the wells of the gel and electrophoresed as before. 
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Approaches to the detection of susceptibility loci for diabetic complications 
There are two strategies that may be applied to identify susceptibility genes for diabetic 
complications, namely linkage analysis using affected pedigrees, and population association 
case-control studies (Chowdhury et at 1999). Linkage studies involve using affected sib pairs 
or discordant sib pairs and require a large number of families with two or more affected 
offspring. It is recognised that due to the complex inheritance of TIDM and T2DM large 
affected pedigrees of this sort are rare and somewhat difficult to collect. Association studies, 
which involve comparing allele and genotype frequencies of candidate genes, in individuals 
with microvascular disease and control subjects, are therefore an alternative strategy. There 
are two main approaches to performing association based studies which include case-control 
analysis and transmission disequilibrium analysis. Since there is no superior approach to 
identifying genetic determinants of diabetic microvascular complications more than one 
approach is needed for candidate gene analysis. The candidate gene approach has the 
advantage that the availability of a polymorphism close to the gene makes it possible to report 
clear positive or negative results because recombinants between the marker and the gene are 
unlikely. However, most of the methods have limited power in assessing minor rather than 
major gene effects. The approaches that were employed in this study were as follows; 
Population based case-control association analysis 
Population association studies require the use of large numbers (at least 200/group), of similar 
age distributions obtained from the same geographical population to try to exclude ethnic 
admixture. Confirmation of a positive or negative result is also required in a separate 
population, through multi-centre collections. However, despite stringent controls to match 
cases and controls, there still remains the possibility that significant associations are due to 
bidden population stratification and are therefore spurious. A population of British Caucasoid 
diabetic subjects with microvascular disease, diabetic subjects with no evidence of 
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microvascular disease and non-diabetic controls were studied, as well as a population of 
Southern Indian Dravidian diabetic subjects and controls in the course of this thesis. 
Family based association analysis 
Family based association analysis using a collection of trios has been regarded as the gold 
standard test for genetic association studies. Trios can be used to confirm and ultimately fme 
map linkages from linkage studies, facilitate candidate gene studies and to examine genetic 
associations. The transmission/disequilibrium test {IDT) is used in the study and involves the 
analysis of the frequency of transmission of designated alleles from heterozygous parents to 
affected offspring. A large collection of British Caucasoid nephropathy trios was collected 
through a multi-centre research programme from seven locations nation-wide and used in this 
thesis. Significant variance from the expected Mendelian transmission of 50:50 would indicate 
that the allele has a role in ·the susceptibility to microvascular complications of diabetes. 
Statistical analysis of data 
All the data collected was entered into a Microsoft Excel spreadsheet (Microsoft, UK) and 
statistical analysis was performed through this program, and also by the use of Epi-Info 6, 
(Centres for Disease Control and Prevention, Atlanta, Georgia, USA) program. 
Allele and genotype frequencies 
The number of alleles detected was obtained using gene counting. Allele frequencies were 
expressed as decimals and calculated from the number of copies of an allele divided by the 
total number of chromosomes tested in the population. A homozygous genotype was counted 
as two copies of the allele. Genotype frequencies were determined as the percentage of 
subjects positive for each genotype. The frequency of the alleles and genotypes between the 
patient subgroups and normal control groups were compared using Chi-squared distribution 
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test and 2 x 2 contingency tables to test significance by degrees of freedom (df). This was 
performed on the 'Stat-Calc' program (Epi Info 6). The P values were corrected for the 
number of comparisons made (p= 0.05/n, where n is the number of independent associations 
detected), and Pc-values of <0.05 were considered to be significant (Bland 1995). Where the 
observed number in each category is <5 Fishers exact test was applied. 
Hardy-Weinberg equilibrium 
The Hardy-Weinberg principle was used in order to determine whether a hi-allelic 
polymorphism is conforming to normal distribution within a population. The underlying 
assumption is that the frequency of alleles remains constant from generation to generation. 
The expected gene frequencies are calculated by the formula; I = p2 + 2pq + q2 where p and q 
are the frequencies of the two alleles within the population under investigation. The observed 
gene frequencies were then compared with the expected frequencies using 2 x n tables and the 
Chi-squared test. Hardy-Weinberg was established if the expected frequency did not differ 
significantly(<= 0.05) from the observed (Strachan and Read 1996). 
Transmission Disequilibrium Test (TDT) 
The TDT was used in the analysis of the family data (Spielman et a/1993; Todd 1996; Schaid 
and Sommer 1994). The test evaluates the frequency with which a suspected susceptibility 
allele is transmitted from heterozygous parents to the affected offspring. TDT assesses 
deviation from 50% transmission. The association of an allele is determined by the use of the 
·i test and 2x2 contingency tables. A Pc value of <0.05 was considered to be significant. In 
order to obtain an unbiased multihaplotype TDT analysis all transmissions were counted and a 
significance level was estimated empirically (Dudbridge et a/2000). 
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Results 
Prome of TlDM Caucasoid patient groups 
Table 6 shows the clinical features of the patient sub-groups with the mean, standard 
deviation and the range for subjects of British Caucasoid origin with TlDM. The total 
number ofTlDM subjects studied was 244 consisting of 155 males and 129 females. The 
TlDM subjects were subdivided according to their diabetic complication phenotype. These 
groups include uncomplicated diabetes (n=66), diabetic retinopathy (n=44), diabetic 
neuropathy (n=18), diabetic nephropathy with diabetic retinopathy (n=30), diabetic 
retinopathy with neuropathy (n=24), and full house patients (n=62). The mean average age 
at the time of the study in all of the groups was between 46.3 (±15.6) and 51.6 (±13.3). The 
distribution of the mean average age at onset of diabetes in all groups was between 16.5 (± 
11.8) and 25.4 (± 11.8) years of age and the range was similar in all of the groups. The 
mean average duration of diabetes in all groups was between 27.3 (±9.9) and 32.0 (± 12.9). 
The range of this variable was also similar in all of the groups. There is a general elevation 
in the onset of diabetes between the ages of ll and 13, and a sharp increase in incidence in 
the early twenties. Following this the incidence drops around mid twenties with a relatively 
low incidence from the late thirties and older. 
There is no clinical data for the normal control population as they were taken from the cord 
blood. 
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Profile of T2DM Southern Indian population 
Table 7 shows the clinical features of the patient sub-groups with the mean, standard 
deviation and the range for subjects of Southern Indian/Dravidian origin diagnosed with 
T2DM. The total number of T2DM subjects was 60, consisting of 34 males and 26 
females. The T2DM subjects were sub-divided according to their diabetic complication 
phenotype. These consisted of two groups which were uncomplicated/normoalbuminuric 
diabetics (n=28), and diabetics with proteinuria (n=32). The mean average age at the time 
of the study in both groups was 55 (±10.1) and 53.8 (±8.9) respectively, and the range was 
similar in both groups. The mean average age at onset of diabetes in both groups was 42.1 
(±11.3) and 42.3 (±8.5) respectively, and the range was similar in both groups. The mean 
average duration of diabetes in both groups was between 13.1 (±7.5) and 11.8 (±5.4) and 
the range of this variable in both groups was also similar. It is important to note that the 
T2DM normoalbuminuria patient subgroup bad a duration of diabetes ranging from 2-29 
years (mean 13.11 ± 7.5). It is possible that some of these subjects will develop 
microvascular disease later during the course of their disease. The peak age at onset of 
diabetes was between 40 and 50 years of age with a relatively low incidence before and 
after this age group. 
The normal control population had a mean age of 38 ±6.3 with a range from 30 to 58, 
which was a slightly larger age range than the diabetic subjects included in the study. 
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Aldose Reductase Gene Study 
Associations of polymorphism's within the ALR2 gene and promoter region and the 
microvascular complications of TlDM and T2DM 
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Polymorphisms within the ALR2 gene and its promoter region 
Polymorphisms within the ALR2 gene and its promoter region were investigated. The 
study incorporated three subject groups of which two were case control studies and one 
was a family trio based study. The study used a population of TlDM and normal control 
subjects of British Caucasoid origin, a population of T2DM and normal control subjects of 
Southern Indian origin, and the 'Diabetes UK- Warren nephropathy family trio' collection 
of TlDM diabetic subjects of British Caucasoid origin where the proband had diabetic 
nephropathy. 
Three polymorphisms of the ALR2 gene region were studied, a (CA)n repeat microsatellite 
polymorphic marker located 2.lkb upstream of the aldose reductase gene start site, a C to 
T single base substitution polymorphism located -l 06bp upstream of the ALR2 start site, 
and an A to C polymorphism located within intron 8 (+11842) of the ALR2 gene itself 
(figure 23). The results of these studies are presented in tabular form in the following 
section. 
For the case-control studies the data was analysed for allelic and genotypic frequencies 
between subjects with diabetes and subjects without diabetes, and then with regard to 
subjects onset of diabetic microvascular disease. For the family based study the TDT was 
applied to determine transmission frequency of alleles from parents to affected offspring. 
Not all of the populations studied were investigated for all of the polymorphisms, but 
where possible the whole population of each group was analysed for the polymorphism 
studied for ease of comparability. 
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5' ALRl-(CA)n microsatellite polymorphic marker 
The (CA)n dinucleotide repeat microsatellite situated 2.lkb upstream of the aldose 
reductase transcription start sequence was investigated. Polymerase Chain Reaction was 
carried out to amplify the region upstream of the aldose reductase gene containing the 
(CA)n repeat microsatellite as described in chapter 3. Amplification products (61-11) mixed 
with stop solution (Amersham, UK) were separated on a 6% polyacrylamide gel at 1900V 
for 3 hours, and alleles were revealed by autoradiography [figure 24) and typed using the 
Fluor-s multi-imaging system (BioRad). The size of the bands was checked by running a 
[32P] ATP radiolabeled molecular weight marker alongside the subjects. The (CA)n 
microsatellite was investigated in TlDM subjects and nonnal controls of British Caucasoid 
origin, T2DM subjects and non-diabetic adult controls-of Southern Indian/Dravidian origin 
and the 'Diabetes UK- Warren family trios' collection of British Caucasoid origin, where 
the proband had diabetic nephropathy. In these studies we were able to find 12 alleles 
which differed by the number of integral repeats. Subjects were assigned their allele and 
genotype according to the number of CA repeats which were identified (table 26), where Z 
is the most common allele and consists of 24 CA repeats. Allele and genotypes were 
assigned by eye and where stutter bands were present the PCR conditions were altered by 
increasing the annealing temperature and re-running the gel. 
233 
Direction of 
migration 
Lane; 1 2 3 4 5 6 7 8 
Chapter 4. Results 
..._ Z•4 
Z•2 
._z 
..._ Z-2 
..._ Z- 4 
Figure 24. 5' ALR2 microsatellite autoradiograph. Bands were assigned by eye, and 
compared alongside alleles of known genotypes. Assignment was carried out by two 
independent observers. Where stutter peaks were observed, the PCR was a ltered 
and optimised in order to remove the shadow bands. 
5' ALR2 microsatellite autoradiograph. Seven alleles are identified in this 
autoradiograph and allocated genotypes for each of the subjects shown in lanes 1-8 
are as follows: 
Lane 1: Z/Z+2 
Lane 2: Z/Z+2 
Lane 3:Z+2/Z-2 
Lane 4: Z/Z-2 
Lane 5: Z/Z+2 
Lane 6: Z/Z +4 
Lane 7: Z+2/Z+4 
Lane 8: Z/Z 
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Allele PCR product size (bp) CA repeats 
Z+10 148 29 
Z+8 146 28 
Z+6 144 27 
Z+4 142 26 
Z+2 140 25 
z 138 24 
Z-2 136 23 
Z-4 134 22 
Z-6 132 21 
Z-8 130 20 
Z-10 128 19 
Z-16 122 16 
Table 26. Allele sizes in base pairs for the 12 different CA repeat 
polymorphisms identified. This table shows the size of the PCR amplified region 
corresponding to each allele, along with the number of dinucleotide (CA)n repeats. 
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5'ALR2- (CA)n microsatellite marker in British Caucasoid TlDM subjects and 
normal controls 
The (CA)n microsatellite marker in the 5' region of the ALR2 gene was investigated using 
244 subjects with TlDM of British Caucasoid origin as well as a collection of 120 British 
Caucasoid normal controls (clinical demographics shown in table 6). Within the TIDM 
subject population -studied, there were 66 diabetic controls, 62 full house patients, 18 with 
diabetic neuropathy, 24 with diabetic retinopathy and neuropathy, 30 with diabetic 
nephropathy and retinopathy and 44 with diabetic retinopathy alone. 
The frequency of the (CA)n alleles in both TlDM and normal control populations is shown 
in table 27. There were 9 (CA)n alleles detected at the 5'ALR2 locus in the British 
Caucasoid TlDM and control population; Z+8, Z+6, Z+4, Z+2, Z, Z-2, Z-4, Z-6 and Z-16 
where Z is the most common allele and consists of 24 CA repeats. Nine alleles gave rise to 
54 possible genotypes, of which 23 were identified here. In the analysis of allelic 
frequencies homozygotes were counted as 2 alleles, and alleles and genotypes that are not 
detected are not shown. Tables show the percentage frequency of detected alleles and 
genotypes with actual numbers detected shown in parenthesis. Possible associations were 
investigated with respect to allelic frequency and genotype and comparisons were made 
between groups using the r! test and 2x2 contingency tables. Where the observed 
frequencies were <5 a two tailed Fishers exact test was applied. 
This data set includes and extends results previously obtained and published by Angela 
Heesom (refer to acknowledgements), all of which have been re-analysed here as 
confirmation of the earlier findings. The tables include a further 76 TlDM subjects and a 
further 18 control subjects, that have been genotyped since earlier publications (Heesom et 
a/1997). 
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5' ALR2- (CA)n allelic frequencies in British Caucasoid TlDM and normal control 
subjects 
The frequency of the 5'ALR2 alleles in TIDM Caucasoid subjects is shown in tables 27 to 
33. Table 27 shows the percentage frequency of the detected 5 'ALR2 (CA)n alleles in the 
total TIDM population studied compared to the nonnal control population studied. With 
the exception of the Z+6 allele there were no significant differences found in the allelic 
frequencies between the two groups. In the case of the Z+6 allele the incidence was 
significantly higher in the nonnal controls compared to the TIDM population (2.9 vs. 
0.6%, r} = 6.3, p= 0.01 (ldf), Fishers exact correction; 0.02), this however, involved small 
numbers. 
The TIDM subjects with diabetes of more than 20 years duration of diabetes with insulin 
dependence, who had not progressed to complications, were then separated. This group of 
patients has a lower risk of developing complications after this time and therefore serve as 
an important diabetic control population. The allelic frequencies for these groups are 
shown in table 28. When comparing the TIDM subjects with one or more microvascular 
complications to the TIDM control subjects significant differences in the frequency of 
detected alleles were found. The Z-2 allele was higher in the complicated group compared 
to the uncomplicated controls (28.1 vs. 15.9%, "l = 7.7, p= 0.006 (ldf), Pc= 0.05). The 
Z+2 allele was significantly higher in the TIDM control population compared to TIDM 
subjects with one or more microvascular complication (16.9 vs. 34.9%, 'X! = 18.3, p= 
0.00002 (ldt), Pc = 0.0002). Of interest, the Z-4 allele was also increased in the TIDM 
subjects with one or more microvascular complications compared to the uncomplicated, 
and the Z+4 allele was slightly increased in the uncomplicated versus the complicated 
group. Comparison of the TIDM control allelic frequencies with the nonnal control allelic 
frequencies showed no significant difference between the frequencies of the Z-2 allele 
(15.9 vs. 21.3%, although there was a slight reduction in percentage frequency in the 
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diabetic controls. A difference was also found in the frequency of the Z+2 allele (34.9 vs. 
21.7%, ·l = 7.6, p= 0.006 (ldf), Pc= 0.05). 
Table 29 shows the allelic. frequencies for TlDM subjects according to the precise 
phenotype of the TlDM subject's microvascular complications. The frequency of the Z 
allele remains constant between all groups. All five TlDM complication subgroups show 
an increase in the percentage frequency of the Z-2 allele compared to both the 
uncomplicated and normal controls. Conversely, the Z+2 allele percentage frequency is 
decreased in all five TlDM complication subgroups compared to the uncomplicated 
diabetic controls. The groups for which these trends reach statistical significance for Z+2 
are the diabetic nephropathy and retinopathy subgroup (9.9 vs. 34.9%, x2 = 12.9, p= 
0.0003 (ldf), Pc= 0.003), and the full house patients subgroup (14.5 vs. 34.9%, x2 = 14.1, 
p= 0.0002 (ldf), Pc= 0.002). 
Table 30 shows the percentage frequency of the 5'ALR2 alleles in the amalgamated 
subgroups according to specific microvascular complications. The frequency of the Z allele 
remains consistent in all groups. All three of the complication subgroups show decreased 
frequency of the Z+2 allele compared to the uncomplicated. Firstly, the diabetic 
nephropathy subgroup (13.04 vs. 34.9%, x2 = 21.2, p= 0.0000004 (ldf), Pc= 0.000004). 
Secondly, the diabetic retinopathy subgroup (16.9 vs. 34.9%, x2 = 17.5, p= 0.00003 (ldf), 
Pc = 0.0003). Thirdly, the diabetic neuropathy subgroup (16.4 vs. 34.9%, x2 = 15.4, p= 
0.00009 (ldf), Pc = 0.0008). The Z-2 allele was increased in all three of the complicated 
sub-groups. In the case of diabetic nephropathy, (29.9 vs. 15.9%, x2 = 8.2, p= 0.004 (ldf), 
Pc= 0.04). For diabetic retinopathy, (28.4 vs. 15.9%, x2 = 7.9, p= 0.005 (1df), Pc= 0.05). 
Finally, in the case of diabetic neuropathy, (29.3 vs. 15.9%, x2 = 7.9, p= 0.005 (ldf), Pc= 
0.05). 
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Alleles TIDM subjeels Normal 
Controls 
D 488 240 
(244) (120) 
Z-16 0.2 
(I) (0) 
Z-6 1.0 1.3 
(5) (3) 
Z-4 4.9 4.2 
(24) (10) 
Z-2 24.8 21.3 
(121) (51) 
z 41.6 45.3 
(203) (110) 
Z+2 21.7 21.7 
(106) (52) 
Z+4 4.5 2.9 
(22) (7) 
Z+6 0.6 2.9 
(3) (7) 
Z+S 0.6 
(3) (0) 
Table 27. Percentage frequency of the detected 5' ALR2 (CA)n microsatellite marker 
alleles in British Caucasoid TlDM subjects compared to normal controls 
This table shows the frequency of detected alleles for TlDM subjects and normal control 
subjects. Frequencies are expressed as the percentage incidence out of the total number of 
alleles detected. Comparisons were made between the allelic frequencies for control and 
Tl DM subjects using the ·l test and 2 x 2 contingency tables. For comparisons of less than 
5 samples Fishers exact test was applied. 
n = number of alleles detected, number of subjects studied is shown in parentheses. 
TlDM vs.NC; 
Z+6; ·'l = 6.3, p= 0.01 (ldf), Fishers Exact= 0.02 
No other significant differences were found in the allelic frequencies between Tl DM 
patients and the normal control groups. 
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TIDM Nephropathy Unoompll<ated Normal Controls 
and/or Retinopathy (DC) (NC) 
and/or Neuropathy 
(DR/N/Nu) 
n 356 132 240 
(178) (66) (120) 
Z-16 0.3 
(I) (0) (0) 
Z-6 1.4 1.3 
(5) (0) (3) 
Z-4 5.9 2.3 4.2 
(21) (3) (10) 
Z-2 28.1 15.9 21.3 
(lOO) (21) (SI) 
z 42.4 39.4 45.8 
(IS I) (52) (110) 
Z+2 16.9 34.9 21.7 
(60) (46) (52) 
Z+4 4.2 5.3 2.9 
(IS) (7) (7) 
Z+6 0.3 1.5 2.9 
(I) (2) (7) 
Z+8 0.6 0.8 
(2) (I) (0) 
Table 28. Percentage frequency of the detected 5' ALR2 (CA)n microsatellite marker 
aUeles in British Caucasoid TlDM subjects with diabetic nephropathy and/or 
retinopathy and/or neuropathy (DRJN/Nu) compared to TlDM of short duration 
(SD), uncomplicated (DC) and normal controls (NC). 
This table shows the percentage frequency of detected alleles for TIDM subjects with 
microvascular disease (nephropathy, retinopathy, neuropathy) compared to the 
uncomplicated and normal controls. The percentage frequency is shown and the actual 
number of each of the alleles detected for each group is shown in parenthesis. n = number 
of alleles detected, the number of subjects is shown in parenthesis. Only significant 
differences by '"!} and correction by multiplying by the number of observed alleles, are 
shown. 
DRJN/Nu vs. Uncomplicated diabetic controls; 
;Z-2 ;x.2 = 7.7, p= 0.006 (ldf), Pc= 0.05 
;Z+2; ·/ = 18.3, p= 0.00002 (ldf), Pc= 0.0002 
NC vs. Uncomplicated diabetic controls; 
;Z+2; "/ = 7.6, p= 0.006 (ldf), Pc= 0.05 
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I 2 :J ~ ! 
Diabetic Diabetic Diabetic Diabetic Full House Uncomplicated Normal 
Retinopathy Nepbropatby Retinopathy Neuropathy Patients (DC) Controls (NC) 
and and 
Retinopathy Neuropathy 
n 88 60 48 36 124 132 240 
(44) (30) (24) (18) (62) (66) (120) 
Z-16 0.8 
(O) (0) (0) (0) (I) (O) (0) 
Z-6 2.3 1.7 1.6 1.3 
(2) (I) (0) (0) (2) (0) (3) 
Z-4 3.4 6.7 4.2 5.6 8.1 2.3 4.2 
(3) (4) (2) (2) (10) (3) (10) 
Z-2 22.7 31.7 33.3 24.9 29.0 15.9 21.3 
(20) (19) (16) (9) (36) (21) (51) 
z 38.6 46.7 35.4 47.2 44.4 39.4 45.8 
(34) (28) (17) ( 17) (55) (52) (IIO) 
Z+2 22.7 9.9 20.8 16.7 14.5 34.9 21.7 
(20) (6) (10) (6) (18) (46) (52) 
Z+4 9.1 1.7 6.3 2.8 1.6 5.3 2.9 
(8) (I) (3) (I) (2) (7) (7) 
Z+6 1.7 1.5 2.9 
(0) (I) (0) (0) (0) (2) (7) 
Z+8 1.1 2.8 0.8 
(I) (0) (0) (I) (0) (I) (0) 
Table 29. Percentage frequency of the detected 5'ALR2 (CA)n microsatellite marker 
aUeles in British Caucasoid TlDM subjects categorised in accordance to the onset of 
diabetic complications and normal control subjects. 
This table shows the percentage frequency of detected alleles for TlDM subjects with 
retinopathy (DR), nephropathy and retinopathy (DN/DR), retinopathy and neuropathy 
(DRIDNu), neuropathy (DNu), full house complications patients (FHC) and uncomplicated 
diabetics controls (DC). Also shown here is the allelic frequency of normal healthy 
controls. n = number of alleles detected, the number of subjects is shown in parenthesis. 
1 
vs. Uncomplicated-diabetic controls; Z+2; X2 = 3.7, p= ns 
1 
vs. Uncomplicated diabetic controls; Z-2; y} = 6.2, p= 0.01 (1df), Pc= ns 
Z+2; x2 = 12.9, p= 0.0003 (ldf), Pc= 0.003 
3 
vs. UncompUcated diabetic controls; Z-2; x2 = 6.5, p= 0.01 (1df), Pc= ns 
4 
vs. Uncomplicated diabetic controls; Z+2; x2 = 4.4, p= 0.04 (ldt), Pc= ns 
5 
vs. Uncomplicated diabetic controls; Z-2; X2 = 6.4, p= 0.01 (1dt), Pc= ns 
Z+2; x2 = 14.1, p= 0.0002 (ldt), Pc= 0.002 
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I 1 3 Uncomplicated Normal Diabetic Diabetic Diabetic 
Nephropathy Retinopathy Neuropathy (DC) Controls 
(DN) (DR) (DNu) (NC) 
n 184 320 208 132 240 
(92) (160) (104) (66) (120) 
Z-4 7.6 5.9 6.7 2.3 4.2 
(14) (19) (14) (3) (10) 
Z-2 29.9 28.4 29.3 15.9 21.3 
(55) (91) (61) (21) (51) 
z 45.1 41.9 42.8 39.4 45.8 
(83) (134) (89) (52) (110) 
Z+2 13.0 16.9 16.4 34.9 21.7 
(24) (54) (34) (46) (52) 
Z+4 1.6 4.4 2.9 5.3 2.9 
(3) (14) (6) (7) (7) 
Table 30. Percentage frequency of the detected 5' ALR2 (CA)n microsatelllte aUeles in 
Caucasoid TlDM subjects categorised in accordance to onset of diabetic 
nephropathy, retinopathy or neuropathy. 
This table presents the allelic frequency of the (CA)n microsatellite in TlDM subjects of 
British Caucasoid origin. Subjects are classified in accordance to onset of retinopathy, 
nephropathy or neuropathy. The nephropathy group (n=92) is an amalgamation of the 
nephropathy and retinopathy (n=30) and full house subjects (n=62) groups previously 
identified. The retinopathy group (n=l60) is an amalgamation of the retinopathy (n=44), 
nephropathy with retinopathy (n=30), retinopathy and neuropathy (n=24) and full house 
patients (n=62) groups previously identified. The neuropathy group (n=l04) consists of 
subjects diagnosed as having neuropathy in the absence of any other microvascular 
complication (n=l8), the diabetic retinopathy with neuropathy (n=24) and full house 
patients (n=62) groups. Also presented is the allelic frequency in the uncomplicated and 
normal controls. Only the Z-2, Z+2, Z, Z-4 and Z+4 alleles are shown. n = number of 
alleles detected, the number of subjects is shown in parenthesis. 
1 vs. Uncomplicated diabetic controls; 
Z-2; 12 = 8.2, p= 0.004 (ldf), Pc= 0.04 
Z+2; 12 = 21.2, p= 0.0000004 (ldf), Pc= 0.000004 
2 
vs. Uncomplicated diabetic controls; 
Z-2; 12 = 7.9, p= 0.005 (ldf), Pc= 0.05 
Z+2; 12 = 17.5, p= 0.00003 (ldf), Pc= 0.0003 
3 vs. Uncomplicated diabetic controls; 
Z-2; 12 = 7.9, p= 0.005 (ldf), Pc= 0.05 
Z+2; 12 = 15.4, p= 0.00009 (ldf), Pc= 0.0008 
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5' ALR2- (CA)n genotype frequencies in British Caucasoid TlDM and normal control 
subjects 
The frequencies of the 5'ALR2 genotypes in Caucasoid TlDM subjects and normal 
controls are shown in tables 31 to 35. Table 31 shows the detected frequency of the 
5'ALR2 genotypes in all TlDM subjects studies compared to the normal controls. No 
differences were detected between the two groups. Table 32 shows the frequency of the 
detected genotypes in the sub-groups of the TlDM population studied, diabetic 
complications, uncomplicated diabetic controls and normal controls subgroups. The low 
frequencies of many of the genotypes detected resulted in no significant differences being 
identified. However, the genotypes, which occurred more frequently in the population, 
were analysed for differences in percentage frequency. There was a significant decrease in 
the frequency of the Z/Z+2 genotype in those with complications (nephropathy, 
retinopathy, neuropathy) compared with the uncomplicated sub-group (15.7 vs. 37.9%, x} 
= 13.9, p= 0.0002 (I df), Pc = 0.009). There was an increase in the frequency of the Z/Z-2 
genotype in the diabetic complication group compared with the uncomplicated group (31.5 
vs. 12.1 %, x} = 9.3, p= 0.002 ( ldf), Pc = 0.05). The Z-2/Z-2 genotype however did not 
show a significant increase between the two groups. 
Table 33 shows the frequency of each of the genotypes detected in all of the patient 
subgroups according to the precise phenotype of the diabetic microvascular complications. 
Comparisons were made between each of the complication subgroups and the diabetic 
uncomplicated controls. With regard to the diabetic retinopathy subgroup there was an 
increase in the Z/Z-2 genotype compared to the diabetic controls, (29.6 vs. 12.1%, x} = 
5.2, p= 0.02 (ldf), Pc= ns). The Z/Z+2 genotype was decreased in the diabetic retinopathy 
group compared to the uncomplicated group, (15.9 vs. 37.9%, ·l = 6.01, p= 0.01 (ldf), Pc 
= ns). The Z/Z-2 genotype was increased in the nephropathy and retinopathy group 
compared to diabetic controls (36.7 vs. 12.1%, x.2 = 4.0, p= 0.05 (ldf), Pc= ns). The 
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ZIZ + 2 genotype was decreased in the nephropathy and retinopathy group compared to the 
diabetic controls (9.9 vs. 37.9%, "'! = 7.8, p= 0.005 (ldf), Pc = 0.1). The diabetic 
retinopathy with neuropathy, and the diabetic neuropathy only, subgroups followed a 
similar trend whereby the Z/Z-2 genotype was increased and the Z/Z+2 genotype was 
decreased in the complicated groups compared to the uncomplicated controls. The 
strongest evidence for a correlation came from the full house patient subgroup compared to 
the diabetic controls. The Z/Z-2 genotype was increased in the full house patient group 
compared to the diabetic control group (32.3 vs. 12.1 %, "'! = 7.6, p= 0.006 ( ldf), Pc = ns). 
The Z/Z+2 genotype was decreased in the full house patient groups compared to 
uncomplicated controls (14.5 vs. 37.9%, x_2 = 8.9, p= 0.003 (ldf), Pc = 0.07). No other 
differences were found in the frequency of any of the other genotypes detected. 
Table 34 shows the frequency of the detected genotypes in the TlDM patient groups 
amalgamated according to particular complication present. The diabetic nephropathy group 
showed significant correlation's whereby a reduction in the Z/Z+2 genotype and an 
increase in the Z/Z-2 genotype were both significant by the x_2 test (Z/Z-2; 33.7% vs. 
12.1%, x_2 = 9.6, p= 0.002 (tdf), Pc = 0.04, Z/Z+2; 13.04% vs. 37.9%, x2 = 13.2, p= 
0.0003 (ldf), Pc= 0.007. The diabetic retinopathy group also showed significance with the 
ZIZ+2 allele whereby there was a reduction compared to the uncomplicated group, (17.7 
vs. 37.9%, ·l = 14.4, p= 0.0002 (ldf), Pc = 0.005). The Z/Z-2 genotype was increased in 
the retinopathy group compared to the uncomplicated (31.3 vs. 12.1%, x_2 = 8.9, p= 0.003 
(ldf), Pc = 0.07). In the case of the diabetic neuropathy group the Z/Z-2 genotype was 
increased in the neuropathy group compared to the uncomplicated (30.8 vs. 12.1 %, x_2 = 
7.8, p= 0.005 (ldf), Pc = ns). In the case of Z/Z+2, there was a significant increase in the 
uncomplicated compared to the neuropaths (17.3 vs. 37.9%, x_2 = 9.04, p= 0.003 (ldf), Pc 
= 0.07). 
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Of the 92 patients with nephropathy, 45.7% had the Z-2/X genotype (where X is not Z+2), 
compared with only 24.2% in the uncomplicated diabetes group t'l = 7.6, p= 0.006 (Idf), 
Pc= 0.02). In contrast, the Z+2N genotype (where Y is not Z-2) was found in only 17.4% 
of the patients with nephropathy compared to 51.5% in the uncomplicated (X2 = 20.7, p= 
0.000005 (ldf), Pc = 0.00002) (table 35). Similarly, in the case of the 160 patients with 
retinopathy, 41.25% had the Z-2/X genotype compared with only 24.2% in the 
uncomplicated (X2 = 5.9, p= 0.02 (ldf), Pc = ns). In contrast, the Z+2N genotype was 
found in only 23.1% of patients with retinopathy, compared to 51.5% in the uncomplicated 
(X2 = 17.5, p= 0.00003 (ldf), Pc= 0.0001). Also, in the case of the 104 patients with 
neuropathy, 42.3% had the Z-2/X genotype compared with only 24.2% in the 
uncomplicated (x2 = 5.8, p= 0.02 (ldf), Pc = 0.08). In contrast, the Z+2N genotype was 
found in only 23.08% of patients with neuropathy, compared to 51.5% in the 
uncomplicated ('x.2 = 14.5, p= 0.001 (ldf), Pc= 0.0004). 
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Genotype TlDM subjects Normal Controls 
(NC) 
n 244 120 
'IJZ 12.3 20.8 
(30) (25) 
Z/Z-2 26.3 21.7 
(64) (26) 
llZ-4 4.9 2.5 
(12) (3) 
'IJZ-6 1.2 0.8 
(3) (I) 
llZ-16 0.4 
(I) (0) 
Z/Z+2 21.7 20.8 
(53) (25) 
.7JZ+4 3.3 2.5 
(8) (3) 
.7JZ+6 0.4 1.7 
(I) (2) 
.7JZ+8 0.4 
(I) (0) 
Z-2/Z-2 6.9 6.7 
(17) (8) 
Z-21Z-4 2.5 3.3 
(6) (4) 
Z-21Z+2 6.1 4.2 
(15) (5) 
Z-2/Z+4 1.2 
(3) (0) 
Z-4/Z-4 0.4 
(I) (0) 
Z-4/Z-6 0.8 1.7 
(2) (2) 
Z-41Z+2 0.4 0.8 
(I) (I) 
Z-4/Z+8 0.4 
(I) (0) 
Z+L'Z+2 4.9 8.3 
(12) (10) 
Z+2/Z+4 4.1 
(10) (0) 
Z+2/Z+6 0.8 
(0) (I) 
Z+21Z+8 0.4 
(l) (0) 
Z+4/Z+4 0.4 1.7 
(I) (2) 
Z+61Z+6 0.4 1.7 
(I) (2) 
Table 31. Percentage frequency of the detected 5'ALR2 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects compared to normal controls 
This table shows the frequency of detected genotypes for TIDM subjects and normal 
control subjects. Frequencies are expressed as the percentage incidence out of the total 
nwnber of genotypes detected. n = number of genotypes detected. Comparisons were made 
between the allelic frequencies for normal controls and TIDM subjects using the Chi-
squared test and 2 x 2 contingency tables. No significant differences were found in the 
genotype frequencies between Tl DM patients and the normal control groups. 
TlDM vs. NC; ZJZ; x2 = 5.9, p= 0.02 (ldt), Pc= ns 
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Genotypes Tl DM Nephropathy Uneompllcated Normal Controls 
and/or Retinopathy (DC) (NC) 
and/or Neuropathy 
(DRIN/Nu) 
n 178 66 120 
Z/Z 12.4 12.1 20.8 
(22) (8) (25) 
Z/Z.2 31.5 12.1 21.7 
(56) (8) (26) 
Z/Z.4 6.2 1.5 2.5 
(ll) (I) (3) 
Z/Z.6 1.7 0.8 
(3) (0) (I) 
Z/Z-16 0.6 
(I) (0) (0) 
Z/Z+2 15.7 37.9 20.8 
(28) (25) (25) 
Z/Z+4 3.9 1.5 2.5 
(7) (1) (3) 
Z/Z+6 0.6 1.7 
(I) (0) (2) 
Z/Z+8 1.5 
(0) (I) (0) 
Z.2/Z.2 7.9 4.6 6.7 
(14) (3) (8) 
Z-2/Z-4 2.3 3.03 3.3 
(4) (2) (4) 
Z.2/Z+2 6.7 4.6 4.2 
(12) (3) (5) 
Z.2/Z+4 4.6 
(0) (3) (0) 
Z-4/Z-4 0.6 
(I) (0) (0) 
Z.4/Z.6 1.1 1.7 
(2) (0) (2) 
Z-4/Z+2 0.6 0.8 
(I) (0) (I) 
Z-4/Z+S 0.6 
(I) (0) (0) 
Z+2/Z+2 2.8 10.6 8.3 
(5) (7) (10) 
Z+2/Z+4 4.5 3.03 
(8) (2) (0) 
Z+2/Z+6 0.8 
(0) (0) (I) 
Z+2/Z+8 0.6 
(I) (0) (0) 
Z+4/Z+4 1.5 1.7 
(0) (I) (2) 
Z+61Z+6 1.5 1.7 
(0) (I) (2) 
Table 32. Percentage frequency of the detected 5'ALR2 (CA)n microsatellite marker 
genotypes in British Caucasoid TIDM subjects with nephropathy and/or retinopathy and/or 
neuropathy (DRIN/Nu) compared to TlDM uncomplicated (DC) and normal controls (NC). 
This table shows the percentage freque.ncy of detected genotypes for TIDM subjects with 
microvascular disease (nephropathy, retinopathy, neuropathy) compared to the uncomplicated and 
normal controls. The percentage frequency is shown and the actual number of genotypes detected 
for each group is shown in parenthesis. n = number of genotypes detected. 
DNIR/Nu vs. uncomplicated diabetic controls; 
Z/Z-2; l = 9.3, p= 0.002 (ldf), Pc= 0.05 
Z/Z+2; y} = 13.9, p= 0.0002 (ldf), Pc= 0.005 
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Genotypes 1 2 3 4 5 Uncomplicated Normal Diabetic DlabeHc Diabetic DlabeHc Full House 
Retinopathy Nephropathy Retinopathy Neuropathy Patients (DQ Controls 
and and (Nq 
Retinopathy Neuropathy 
D 44 30 24 18 62 66 120 
ZIZ 11.4 13.3 4.2 16.7 14.5 12.1 20.8 
(5) (4) (I) (3) (9) (8) (25) 
Z/Z-2 29.6 36.7 24.9 33.3 32.3 12.1 21.7 
(13) (11) (6) (6) (20) (8) (26) 
Z/Z-4 2.3 9.9 8.3 5.6 6.5 1.5 2.5 
(I) (3) (2) (I) (4) (I) (3) 
Z/Z-6 2.3 3.3 0 1.6 0.8 
(I) (I) (0) (0) (I) (0) (I) 
Z/Z-16 1.6 
(0) (0) (0) (0) (I) (0) (0) 
Z/Z+2 15.9 9.9 20.8 22.2 14.5 37.9 20.8 
(7) (3) (5) (4) (9) (25) (25) 
ZIZ+4 4.6 3.3 8.3 3.2 1.5 2.5 
(2) (I) (2) (0) (2) (I) (3) 
Z/Z+6 3.3 1.7 
(0) (I) (0) (0) (0) (O) (2) 
ZIZ+8 1.5 
(0) (0) (0) (0) (0) (I) (0) 
Z-2/Z-2 4.6 9.9 12.5 5.6 8.1 4.6 6.7 
(2) (3) (3) (1) (5) (3) (8) 
Z-2/Z-4 3.3 5.6 3.2 3.0 3.3 
(0) (1) (0) (I) (2) (2) (4) 
Z-2/Z+2 6.8 3.3 16.7 6.5 4.6 4.2 
(3) (1) (4) (0) (4) (3) (5) 
Z-2/Z+4 4.6 
(0) (0) (0) (0) (0) (3) (0) 
Z-4/Z-4 1.6 
(0) (0) (0) (0) (I) (0) (0) 
Z-4/Z-6 2.3 1.6 1.7 
(1) (0) (0) (0) (I) (0) (2) 
Z-4/Z+2 1.6 0.8 
(0) (0) (0) (0) (1) (0) (1) 
Z-4/Z+S 2.3 
(I) (0) (0) (0) (0) (0) . (0) 
Z+2/Z+2 4.6 3.3 3.2 10.6 8.3 
(2) (I) (0) (0) (2) (7) (10) 
Z+2/Z+4 13.6 4.2 5.6 3.03 
{6) {0) {1) (I) {0) (2) (0) 
Z+2/Z+6 0.8 
(0) (0) (0) (0) (0) (0) (I) 
Z+2/Z+8 5.6 
(0) (0) (0) (I) (0) (0) (0) 
Z+4/Z+4 1.5 1.7 
(0) (0) (0) (0) (0) (I) (2) 
Z+6/Z+6 1.5 1.7 
(0) (0) (0) (0) (0) (I) (2) 
Table 33. Percentage frequency of the detected 5'ALR2 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects categorised in accordance to the onset 
of diabetic complications and uncomplicated (DC) and normal controls (NC) 
This table shows the percentage frequency of detected genotypes for TIDM subjects with 
respect to onset of microvascular complications, and normal control subjects. The 
percentage frequency is shown and the actual number of genotypes detected for each group 
is shown in parenthesis. n = number of subjects studied and genotypes detected. 
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1 
vs. uncomplicated diabetic controls; 
Z/Z-2; ·/ = 5.2, p= 0.02 (ldf), Pc= ns 
Z/Z+2; x2 = 6.01, p= 0.01 (ldf), Pc= ns 
2 
vs. uncomplicated diabetic controls; 
Z/Z-2; x2 = 4.0, p= 0.05 (ldf), Pc= ns 
Z/Z+2; X2 = 7.8, p= 0.005 (ldf), Pc= ns 
4 
vs. Uncomplicated diabetic controls; 
Z/Z-2; x2 = 4.6, p= 0.03(1df), Pc= ns 
5 
vs. Uncomplicated diabetic controls; 
Z/Z-2; x2 = 7.6, p= 0.006 (ldf), Pc= ns 
Z/Z+2; X2 = 8.9, p= 0.003 (Idf), Pc= ns 
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Chapter 4. Results 
Genotypes I z j Uncompli<aled Normal conlrols Dlnbelic Dlnbellc DlabeUo 
Nel!hrol!alhl Relinoea•hr Neuroea•hr (DC) (NC) 
n 92 160 104 66 120 
'ZJZ 16.3 11.9 12.5 12.1 20.8 
(15) (19) (13) (8) (25) 
'ZJZ-2 33.7 31.3 30.8 12.1 21.7 
(31) (50) (32) (8) (26) 
'ZJZ-4 7.6 6.3 6.7 1.5 2.5 
(7) (10) (7) (I) (3) 
'ZJZ+2 13.0 15.0 17.3 37.9 20.8 
(12) (24) (18) (25) (25) 
'ZJZ+4 3.3 4.4 3.9 1.5 2.5 
(3) (7) (4) (I) (3) 
Z-2/Z-2 8.7 8.1 8.7 4.6 6.7 
(8) (13) (9) (3) (8) 
Z-2/Z-4 3.3 1.9 2.9 3.0 3.3 
(3) (3) (3) (2) (4) 
Z-2/Z+2 5.4 7.5 7.7 4.6 4.2 
(5) (12) (8) (3) (5) 
Z-2/Z+4 4.6 
(0) (0) (0) (3) (0) 
Z-4/Z-4 1.1 0.6 0.9 
(I) (I) (I) (0) (0) 
Z-4/Z+2 1.1 0.6 0.9 0.8 
(I) (I) (I) (0) (I) 
Z+2/Z+2 3.3 3.1 1.9 10.7 8.3 
(3) (5) (2) (7) (10) 
Z+2/Z+4 4.4 1.9 3.0 
(0) (7) (2) (2) (0) 
Z+4/Z+4 1.5 1.7 
(0) (0) (0) (I) (2) 
Table 34. Percentage frequency of the detected 5' ALR2 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects categorised in accordance to onset of 
diabetic nephropathy, retinopathy or neuropathy 
This table presents the genotype frequency of the (CA)n microsatellite in TIDM subjects 
of British Caucasoid origin. Subjects are classified in accordance to onset of retinopathy, 
nephropathy or neuropathy. The nephropathy group (n=92) is an amalgamation of the 
nephropathy and retinopathy (n=30) and full house subjects (n=62) groups previously 
identified. The retinopathy group (n=I60) is an amalgamation of the retinopathy (n=44), 
nephropathy with retinopathy (n=30), retinopathy and neuropathy (n=24) and full house 
patients (n=62) groups previously identified. The neuropathy group (n=l04) consists of 
subjects diagnosed as having neuropathy in the absence of any other microvascular 
complication (n=l8), the diabetic retinopathy with neuropathy (n=24) and full house 
patients (n=62) groups. Also presented is the genotype frequency in uncomplicated and 
normal controls. Only the Z-2, Z+2, Z, Z-4 and Z+4 genotypes are shown. n = number of 
subjects analysed and genotypes detected. The percentage frequency is shown and the 
actual number of each genotype detected for each subjects group is shown in parenthesis. 
1 
vs. uncomplicated diabetic controls; 
Z/Z-2; ·l = 9.6, p= 0.002 (ldt), Pc= 0.0 
ZJZ+2; r! = 13.2, p= 0.0003 (Idt), Pc= 0.007 
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2 vs. uncomplicated diabetic controls; 
Z/Z-2; ·l = 8.9, p= 0.003 (ldf), Pc= 0.07 
Z/Z+2; ·l = 14.4, p= 0.0002 (ldf), Pc= 0.005 
Z+2/Z+2; ·l = 5.2, p= 0.02 (ldf), Pc= ns 
3 vs. uncomplicated diabetic controls; 
Z/Z-2; ·l = 7.8, p= 0.005 (ldf), Pc= ns 
Z/Z+2; ·l = 9.04, p= 0.003 (ldf), Pc= 0.07 
Z+2/Z+2; J! = 6.07, p= 0.01 (1df), Pc= ns 
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Chanter 4. Kesults 
I Diabetic 2 j U ncompllcated Normal Diabetic Diabetic 
Nephropathy Rellnoeathr Neuroealhr (DC) Controls (NC) 
D 92 160 104 66 120 
~2/X 45.7 41.3 42.3 24.2 31.7 (42) (66) (44) (16) (38) 
Z+2/Y 17.4 23.1 23.08 51.5 30.8 
(16) (37) (24) (34) (37) 
~2/Z+2 5.4 7.5 7.7 4.5 4.2 
(5) (12) (8) (3) (5) 
XIY 31.5 28.1 26.9 19.7 34.2 
(29) (45~ (28) (13) (41) 
Table 35. Frequency of the ~2 and Z+2 5'ALR2 genotypes in patients with or 
without diabetic microvascular disease. Figures in parenthesis indicate the number of 
subjects. X allele is any allele other than Z+2 and Y is any allele other than Z-2. P-values 
have been corrected by multiplying by the number of comparisons made. 
1frequency vs. Uncomplicated diabetic controls; 
Z-2/X; x.2 = 7.6, p= 0.006 (Idt), Pc= 0.02 
Z+2/Y; X2 = 20.7, p= 0.000005 (ldt), Pc= 0.00002 
2 frequency vs. Uncomplicated diabetic controls; 
Z-2/X; "C = 5.9, p= 0.02 (ldt), Pc= ns 
Z+2/Y; x.2 = 17.5, p= 0.00003 (ldt), Pc= 0.0001 
3 frequency vs. Uncomplicated diabetic controls; 
Z-2/X; x2 = 5.8, p= 0.02 (Jdt), Pc= 0.03 
Z+2/Y; x.2 = 14.5, p= 0.0001 (Idt), Pc= 0.0004 
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5'ALR2- (CA)n microsatellite marker in Southern Indian T2DM subjects and non-
diabetic controls 
The (CA)n microsatellite marker in the 5' region of the ALR2 gene was investigated using 
60 subjects with T2DM of Southern lndian/Dravidian origin as well as a collection of 43 
Southern Indian/Dravidian non-diabetic controls (clinical demographics shown in table 7). 
Within the T2DM subject population studied, there were 28 subjects that were 
normoalbuminuric without retinopathy and 32 subjects with proteinuria. The frequency of 
the (CA)n alleles in both patient and control populations is shown in table 36. There were 
10 (CA)n alleles detected at the 5'ALR2 locus in the Southern Indian T2DM and non-
diabetic control population; Z+ 10, Z+8, Z+6, Z+4, Z+2, Z, Z-2, Z-4, Z-6 and Z-10 where Z 
is the most common allele and consists of 24 CA repeats. Ten alleles gave rise to 65 
possible genotypes, of which 27 were identified here. In the analysis of allelic frequencies 
homozygotes were counted as 2 alleles, and alleles and genotypes that were not detected 
are not shown. Tables show the percentage frequency of detected alleles and genotypes, 
with actual numbers detected shown in parenthesis. Possible associations were investigated 
with respect to allelic frequency and genotype and comparisons were made between groups 
using the x2 test and 2x2 contingency tables. Where comparisons of<5 samples were made 
the Fishers exact test was applied. All of the data obtained from the 5'ALR2 study of the 
Southern Indian population is presented in the following tables. Possible associations with 
the 5'ALR2 (CA)n allelic frequencies and genotypes and the onset of proteinuria were 
investigated. 
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5' ALR2 (CA)n aUele frequencies in Southern Indian T2DM and non-diabetic subjects 
Table 36 presents the frequency of the detected alleles in the T2DM Southern Indian 
subjects investigated. All T2DM subjects are compared with the non-diabetic control 
subjects. No significant differences were found in the frequency of the alleles between the 
two groups suggesting that there is no involvement of these alleles with the onset of 
T2DM. The T2DM group was then separated into the two groups representative of their 
clinical diabetic complication phenotype, T2DM with proteinuria and T2DM with 
normoalbuminuria, which is shown in table 37. There were no significant difference in the 
frequencies of the respective alleles identified between these two groups, although upon 
observation there was a small increase in the Z-2 allele in subjects with proteinuria 
compared to those without (15.6% vs. 10.7%). Conversely, there was also a decrease in the 
frequency of the Z+2 allele in the subjects with proteinuria compared to the subjects 
without (12.5 vs. 23.2%). The lack of any significant correlation may be due to the small 
number of patients studied. It is important to note that the normoalbuminuria patients had a 
diabetes duration of between 2 and 29 years. It is possible that some of these patients may 
progress to developing proteinuria later on in the course of their disease. This may be 
masking possible associations. 
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Table 36. Percentage frequency of the detected 5' ALR2 (CA)n microsateUite marker 
alleles in Southern Indian!Dravidian T2DM subjects compared to non-diabetic 
controls. 
This table shows the frequency of detected alleles for T2DM subjects and non-diabetic 
control subjects. Frequencies are expressed as the percentage incidence out of the total 
number of alleles detected. Actual numbers of alleles detected is shown in parenthesis. 
n = number of alleles detected, number of subjects studied is shown in parentheses. Fishers 
exact test was also applied where values <5 were used. 
No significant differences were found between these groups. 
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1 TlDM with Proteinuria TlDMwlth Non-dlaheUc Controls (NDC} 
Normoalhumlnurla 
n 64 56 86 
(32) (28) (43) 
Z-10 1.2 
(0) (0) (I) 
Z-6 3.6 
(0) (2) (0) 
Z-4 3.1 3.6 2.3 
(2) (2) (2) 
Z-2 15.6 10.7 15.1 
(10) {6) (13) 
z 29.7 24.9 44.2 
(19) (14) (38) 
Z+2 12.5 23.2 19.8 
(8) (13) (17) 
Z+4 17.2 12.5 10.5 
(11) {7) (9) 
Z+6 9.4 10.7 5.8 
(6) {6) (5) 
Z+8 10.9 8.9 1.2 
(7) (5) (I) 
Z+IO 1.6 1.8 
(1) {I) (0) 
Table 37. Percentage frequency of the detected 5' ALR2 microsatellite marker alleles 
in Southern Indian/Dravidian T2DM subjects with proteinuria compared to T2DM 
subjects with normoalbuminuria and non-diabetic control subjects. 
This table shows the percentage frequency of the detected alleles for T2DM subjects with 
nonnoalbuminuria and T2DM subjects with proteinuria as well as non-diabetic controls. 
The actual number of alleles within each group is shown in parentheses. n = number of 
alleles detected, number of subjects studied is shown in parentheses. 
1 frequency compared with T2DM normoalbuminuria; 
No significant differences in the frequencies of the alleles were found. 
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5' ALR2 (CA)n genotype frequencies ln Southern Indian T2DM and non-diabetic 
control subjects 
Table 38 presents the frequency of the genotypes in the T2DM Southern Indian subjects 
against the non-diabetic controls, all genotypes detected are presented in the tables. 
Differences in frequencies of the detected genotypes were found for the Z/Z genotype. 
There was a higher incidence of the Z/Z genotype in the non-diabetic control population 
compared to the T2DM subjects (3.3 vs. 18.6%, ·l = 6.7, p= 0.01 (ldf), Fishers exact= 
0.01). Table 39 presents the genotypes detected for the T2DM subjects according to the 
onset of proteinuria or normoalbuminuria. There were no significant difference found in 
the frequencies of the detected genotypes in these groups. Through general observation, 
however, there was an increase in the Z/Z-2 genotype in the T2DM with proteinuria group 
compared to the normoalbuminuria group (15.6% vs. 7.1%). There was also a decrease in 
the frequency of the Z/Z+2 genotype in the T2DM proteinuria group compared to the 
T2DM normalbuminuria group (12.5 vs. 25.00%). Genotypes detected were then scored 
according to the presence of a Z+2 or Z-2 allele as shown in table 40. There were no other 
significant differences found. 
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Genotypes 1nnM Non-diabetic 
subjects Controls (NDC) 
n 60 43 
ZIZ 3.3 18.6 
(2) (8) 
Z/Z-2 11.7 18.6 
(7) (8) 
Z/Z-4 2.3 
(0) (I) 
Z/Z-10 2.3 
(0) (1) 
Z/Z+2 18.3 16.3 
( 11) (7) 
'ZJZ+4 8.3 9.3 
(5) (4) 
Z/Z+6 1.7 2.3 
(1) (1) 
'ZJZ+8 6.7 
(4) (0) 
Z/Z+lO 1.7 
(1) (0) 
Z-2/Z-2 2.3 
(0) (1) 
Z-2/Z-4 5.0 2.3 
(3) (I) 
Z-2/Z-6 1.7 
(1) (0) 
Z-2/Z+2 1.7 2.3 
(I) (1) 
Z-2/Z+4 3.3 2.3 
(2) (I) 
Z-2/Z+6 1.7 
(I) (0) 
Z-2/Z+S 1.7 
(1) (0) 
Z-4/Z+2 1.7 
(1) (0) 
Z+2/Z-6 1.7 
(I) (0) 
Z+2/Z+2 7.00 
(0) (3) 
Z+2/Z+4 3.3 
(2) (0) 
Z+2/Z+6 1.7 7.00 
(I) (3) 
Z+2/Z+8 6.7 
(4) (0) 
Z+4/Z+4 2.3 
(0) (I) 
Z+4/Z+6 11.7 2.3 
(7) (I) 
Z+4/Z+8 3.3 2.3 
(2) (I) 
Z+6/Z+8 1.7 
(1) (0) 
Z+6/Z+l0 1.7 
(1) (0) 
Table 38. Percentage frequency of the detected S'ALR2 (CA)n microsatellite 
genotypes in T2DM subjects compared to non-diabetic control subjects of Southern 
Indian/Dravidian origin. This table shows the percentage frequency of detected 
genotypes for T2DM subjects with respect to onset of diabetes, and non-diabetic control 
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subjects. n = number of genotypes detected. Only significant differences by ·l and 
correction are shown. Fishers exact test was also applied where values of <5 were used. 
1 vs. non-diabetic controls; 
Z/Z; r} = 6.7, p= 0.01 (1df), Fishers Exact= 0.01 
259 
ChaQter 4. Results 
Genotype 1T2DM Proteinuria T2DM Non-diabetic 
Nonnoalbuminuria Controls (NDC) 
n 32 28 43 
Z/Z 3.1 3.6 18.6 
(I) (I) (8) 
Z/Z-2 15.6 7.1 18.6 
(5) (2) (8) 
Z/Z-4 2.3 
(0) (0) (I) 
Z/Z-10 2.3 
(0) (0) {I) 
Z/Z+2 12.5 25.0 16.3 
(4) (7) (7) 
Z/Z+4 12.5 3.6 9.3 
(4) (I) (4) 
Z/Z+6 3.1 2.3 
(I) (0) (I) 
Z/Z+8 6.3 7.1 
(2) (2) (0) 
Z/Z+lO 3.1 
(I) (0) (0) 
Z-2/Z-2 2.3 
(0) (0) (I) 
Z-2/Z-4 6.3 3.6 2.3 
(2) (I) (I) 
Z-2/Z-6 3.6 
(0) (I) (0) 
Z-2/Z+2 3.6 2.3 
(0) (I) (I) 
Z-2/Z+4 6.3 2.3 
(2) (0) (I) 
Z-2/Z+6 3.6 
(0) (I) (0) 
Z-2/Z+S 3.1 
(I) (0) (0) 
Z-4/Z+2 3.6 
(0) (I) (0) 
Z+2/Z-6 3.6 
(0) (I) (0) 
Z+2/Z+2 6.98 
(0) (0) (3) 
Z+2/Z+4 3.1 3.6 
(I) (I) (0) 
Z+2/Z+6 3.1 6.98 
(I) (0) (3) 
Z+2/Z+8 6.3 7.1 
(2) (2) (0) 
Z+4/Z+4 2.3 
(0) (0) (I) 
Z+4/Z+6 9.4 14.3 2.3 
(3) (4) (I) 
Z+4/Z+8 3.1 3.6 2.3 
(I) (I) (I) 
Z+6/Z+8 3.1 
(I) (0) (0) 
Z+6/Z+10 3.6 
!Ol !I~ !02 
Table 39. Percentage frequency of the detected (CA)n 5'ALR2 microsateiUte marker 
genotypes in Southern Indian T2DM subjects classified and compared in accordance 
to presence of proteinuria or normoalbuminuria against non-diabetic controls. This 
table shows the percentage frequency of detected genotypes for T2DM subjects with 
respect to onset of proteinuria, and non-diabetic control subjects. n = number of genotypes 
detected. No significant differences by ·l and correction were found. 
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i TlDMwltb Non-diabetic Controls TlDM wltb Proteinuria Normoalbumlourla 
n 32 28 43 
Z-2/X. 34.4 17.9 25.6 (11) (5) (11) 
Z+2/Y 25.0 42.9 30.2 
(8) (12) (13) 
Z-2/Z+2 3.6 2.3 
(0) (I) (I) 
XIY 43.8 35.7 41.9 
(14) (10) (18) 
Table 40. Frequency of Z-2 and Z+2 S'ALR2 genotypes in T2DM patients with and 
without proteinuria and non-diabetic controls of Southern Indian origin. Figures in 
parenthesis indicate the number of subjects. X allele is any allele other than Z+2 and Y is 
any allele other than Z-2. No significant differences by x2 and correction were found. 
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Association of5'ALR2 and diabetic nephropathy in family based trio studies 
The 'Diabetes UK- Warren nephropathy family trio' collection was used in this study of 
the 5' ALR2 microsatellite polymorphism. The aim of which was to allow the 
determination of the transmission of alleles from parents to proband to be made, and to 
identify any alleles showing preferential transmission. There were 9 alleles identified at the 
5'ALR2 locus in the family study, which gave rise to 18 genotypes. A total of 172 family 
trios were analysed for the 5'ALR2 microsatellite polymorphism. Possible associations 
with the 5'ALR2 genotypes and alleles were investigated. Out of the 172 families 
genotyped for the 5'ALR2 microsatellite 10 showed non-paternity (5.8%), 2 trios were not 
fully genotyped due to degradation of DNA, and a further 45 trios were non-informative. 
This was due to several reasons, firstly if both of the parents within a family trio were 
heterozygous for the allele marker, transmission could not be determined, and secondly 
where parental genotype could not be accurately determined from incomplete trios where 
sibling genotypes were used. This resulted in a considerable reduction in the number of 
families that could be used to determine any significant associations. The informative 115 
family trios were analysed using the transmission disequilibrium test (TDT). The 160 
successfully genotyped nephropathy probands were also analysed (where 12 subjects were 
excluded due to non-paternity family trios and poor genotyping). In addition there were 11 
fully informative trios analysed, where there was also a sibling to the proband included and 
these were also successfully genotyped. 
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5' ALR2 microsatellite marker in British Cau~asoid families where proband has 
TlDM and diabetic nephropathy 
A total of 160 TIDM subjects with diabetic nephropathy were genotyped for the 5'ALR2 
polymorphism as part of the Diabetes UK. -Warren Nephropathy studies. The frequencies 
of alleles and genotypes are presented in tables 41 and 42 respectively. The percentage 
frequency of the Z-2 allele was 25.9% (n=83) and the percentage frequency of the Z+2 
allele was 21.3% (n=68). The percentage frequency of the Z/Z-2 genotype was 31.3% 
(n=50), and the percentage frequency of the Z/Z+2 genotype was 34.4 (n=55). 
In table 43 the frequency of transmission of the 5'ALR2 alleles from parents who were 
heterozygous for the allele to affected offspring is shown. Under the hypothesis that there 
is no linkage the expected number of transmitted versus non-transmitted alleles should be 
equal. The difference therefore between the expected number of transmissions and 
observed transmission of alleles was calculated. The 115 informative family trios 
investigated showed no significant association for the transmission of the Z+2/Z/Z-2 
alle1es from parents to proband with TIDM and nephropathy. Table 43 presents the 
frequency of transmission of the 5'ALR2 Z+2/Z/Z-2 alleles from parents to the proband 
with TIDM and nephropathy. The Z allele was transmitted 51.5% (n=88) vs. not 
transmitted 48.5% (n= 83), (X2 = 0.07, p= 0.8 (ldf), Pc = ns). The Z+2 allele was 
transmitted 45.4% (n=39) vs. not transmitted 54.7% (n=47), (x2 = 0.4, p= 0.5 (ldf), Pc = 
ns). The Z-2 allele was transmitted 56.8% (n=71) vs. not transmitted 43.2% (n=54), ("C = 
1.2, p= 0.3 (1df), Pc = ns). Therefore, there were no significant differences between the 
expected and observed number of transmissions of alleles from parents to proband. 
Although, upon observation there was a slight preference for the transmission of the Z-2 
allele and a slightly reduced preference for the transmission of the Z+2 allele from the 
expected 50:50 ratio. 
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TlDM Nephropathy 
D 320 
(160) 
z-s 0.3 (I) 
z-6 0.3 (I) 
z-4 3.8 
(12) 
z-2 25.9 
(83) 
z 41.3 
(132) 
Z+2 21.3 
(68) 
Z+4 5.6 
(18) 
Z+6 1.3 (4) 
Z+lO 0.3 (I) 
Table 41. Percentage frequency of the detected (CA)n 5'ALR2 microsatellite marker 
aUeles in British Caucasold TlDM subjects with diabetic nephropathy, taken from 
the 'DUK-Warren nephropathy coUection'. This table shows the percentage frequency 
of detected alleles for TIDM subjects with nephropathy, actual number of alleles detected 
in the population is shown in brackets. n = number of alleles detected, number of subjects 
is shown in parenthesis. 
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TIDM Nephropathy 
n 160 
(320) 
Z/Z 4.4 
(7) 
Z/Z+2 34.4 
(55) 
Z/Z+4 5.0 
(8) 
Z/Z+6 1.3 
(2) 
Z/'L-2 31.3 
(50) 
Z/'L-4 1.3 
(2) 
ZI'L-8 0.6 
(I) 
Z+2/Z+10 0.6 (I) 
Z+21Z+2 0.6 
(I) 
Z+2/Z+4 2.5 
(4) 
Z+2/Z+6 0.6 
(I) 
Z+ZI'L-2 3.1 
(5) 
Z+4/Z+6 0.6 
(I) 
'L-2/Z+4 3.1 
(5) 
'L-2/'L-2 4.4 
(7) 
'L-2/'L-4 5.0 
(8) 
'L-2/'L-6 0.6 
(I) 
'L-4/'L-4 0.6 (I) 
Table 42. Percentage frequency of the detected (CA)n 5' ALR2 microsateUite marker 
genotypes in British Caucasoid TlDM subjects with diabetic nephropathy, taken 
from the 'DUK-Warren nephropathy collection'. This table shows the percentage 
frequency of detected genotypes for TlDM subjects with nephropathy, actual number of 
genotypes detected in population is shown in brackets. n = number of genotypes detected, 
number of alleles is shown in parenthesis. 
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Transmitted Non-transmitted Total 
·i p-value Pc 
z Observed 51.5 48.5 (88) (83) (171) 0.07 ns ns 
Expected 50 50.0 
(85.5) (85.5) (171) 
Z+2 Observed 45.4 54.7 (39) (47) (86) 0.4 ns ns 
Expected 50.0 50.0 
(43) (43) (86) 
Z-2 Observed 56.8 43.2 (71) (54) (125) 1.2 ns ns 
Expected 50.0 50.0 
(62.5) (62.5) (125) 
Table 43. Frequency of transmission of the S'ALR2 Z, Z-2 and Z+2 aUeles with 
respect to TlDM and diabetic nephropathy In affected proband family trios. 
This table shows the frequency of transmission of the Z, Z-2 and Z+2 alleles from parents 
to affected offspring with respect to diabetic nephropathy. The frequency of transmission 
of the alleles from parents who were heterozygous for the 5'ALR2 allele, to affected 
offspring was determined in a total of 115 families. The number in the transmitted column 
in the observed row is the actual number of copies of the allele that was transmitted from 
parents to affected offspring. The non-transmitted value in the observed column is the 
actual number of times that the allele was not transmitted from parent to affected offspring. 
The expected number of Z, Z-2 and Z+2 alleles to be transmitted and not transmitted is 
50% of the total number of alleles. The deviation from 50% transmission or non-
transmission of the alleles from parents to affected offspring was determined using the r! 
test and 2 x 2 contingency tables. There was no significant association found for the 
transmission of the Z+2/Z/Z-2 alleles from parents to proband with TIDM and 
nephropathy in the British Caucasoid family trios studied. 
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C(-106)T polymorphism marker 
The cytosine to thymine single base polymorphism situated -I 06bp upstream of the ALR2 
gene ATG transcription start sequence was investigated. Polymerase Chain Reaction was 
carried out to amplifY the 263bp region upstream of the ALR2 gene containing the C(-
1 06)T polymorphism which creates a new Bfa 1 restriction site as described in chapter 3. 
Purified amplification products were cut using Bfa I restriction enzyme digestion, and 
separated on a 2.5% agarose/ethidium bromide gel at I OOV for I hour. The fragment sizes 
were checked by running a 1 OObp molecular weight marker alongside. Bands were 
revealed by UV (320nm) transillumination (figure 25) and subjects were assigned 
genotypes according to restriction fragments identified. A PCR control band was also 
included. After Bfal restriction enzyme digestion the homozygote genotype CC produced 
206bp and 57bp fragments, while the homozygote genotype TT produced 174bp, 59bp and 
57bp fragments. The heterozygte CT genotype produced aU three fragments (174bp, 57bp, 
59bp and 206bp). The C(-106)T polymorphism was investigated in TIDM subjects and 
normal controls of British Caucasoid origin and the 'DUK-Warren diabetic nephropathy 
family trios' of British Caucasoid origin. The assay however, failed to work using the 
T2DM Southern fudian subjects and consequently these have not been included here. A 
possible reason for the assay failing to work in the T2DM population could be that the 
DNA stock solutions contained an inhibiting factor preventing the Bfal enzyme from 
cutting the PCR product. Failure primarily lay with poor or incomplete restriction enzyme 
digestion. ·It is likely that despite the stringent purification protocols applied some 
inhibiting factors remained in the samples. 
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Chapter 4. Results 
6 
.- 57159 bp 
.- 174 bp 
.- 206bp 
Figure 25. C( -106)T polymorphism by Bfa 1 restriction digest and fragment 
separation on 2.5% agarose gel with ethidium bromide staining. Three genotypes 
were identified; homozygous Tr, homozygous CC and heterozygous CT. Allocated 
genotypes for each of the subjects shown in this figure (lanes 1-6) are as follows: 
Lane 1; CT 
Lane 2; CT 
Lane 3: TT 
Lane 4; CT 
Lane 5; CT 
Lane 6: CC 
Chapter 4 . .Kesults 
C(-106)T polymorphism in TlDM subjects and normal controls of British Caucasoid 
origin 
The C(-106)T polymorphism located in the 5' promoter region of the ALR2 gene, -106bp 
upstream of the ATG start sequence was successfully investigated using 155 TIDM 
subjects and 120 normal controls of British Caucasoid origin (clinical demographics shown 
in table 6). The remainder of the available 285 patients failed to respond to the assay and 
allele and genotypes could not be obtained with confidence. This was primarily due to poor 
or incomplete restriction enzyme digestion probably due to an inhibiting factor. Within the 
TIDM subject population studied there were 39 uncomplicated, 39 full house patients, 12 
diabetic neuropathy, 16 retinopathy and neuropathy, 26 nephropathy and retinopathy and 
23 retinopathy. The frequency of the C(-l06)T alleles in the total TIDM population versus 
the normal populations is shown in table 44. In this study we were able to find subjects 
who were homozygous CC, homozygous TT and heterozygous CT. In the analysis of 
allelic frequencies homozygotes were counted as 2 alleles, and alleles and genotypes that 
are not detected are not shown. Tables show the percentage frequency of detected alleles 
and genotypes with actual numbers detected shown in parenthesis. Possible associations 
were investigated with respect to allelic and genotype frequency and comparisons were 
made between groups using the x_2 test and 2 x 2 contingency tables. All of the data 
obtained from this study is presented in the following tables. Possible associations were 
investigated with respect to allelic and genotypic frequencies and the onset of diabetic 
complications. 
The expected frequencies for C( -1 06)T genotypes were calculated using 2 x n analysis to 
determine whether frequencies of heterozygotes and homozygotes in control groups were 
in Hardy-Weinberg equilibrium (table 45). 
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AUele and genotype frequencies of C(-106)T polymorphism in British Caucasoid 
TlDM subjects and normal control subjects 
The C(-106)T polymorphism was investigated in 155 TIDM subjects and 120 normal 
controls of British Caucasoid origin. Table 44 presents the percentage frequency of the 
detected C(-106)T alleles and genotypes for all TIDM subjects studied compared to the 
normal controls. There was a small increase in the CC (-l06)-ALR2 genotype in the 
TIDM subjects compared to the normal controls (NC), (40.0% vs. 28.3%, ·/ = 4.05, p= 
0.04 (ldf), Pc= os). There is consequently also a significant increase in the frequency of 
the C allele and a subsequent decrease in the T allele in TIDM subjects compared to the 
NC group (x2 = 6.8, p= 0.009 (ldf), Pc = 0.03). The Hardy Weinberg equilibrium 
principle was applied to the TIDM group and the NC group respectively. In both groups 
there were no significant differences between the expected and the observed frequencies 
according to the x2 test for significance, implying compliance with Hardy Weinberg 
equilibrium (table 45). 
Table 46 presents the alleles and genotypes for the Tl DM subjects according to the 
presence or absence of diabetic microvascular disease, where TIDM subjects with 
DN/DRIDNu are compared with DC and NC groups. A non-significant increase in the CC 
genotype was seen in the DRIDN/DNu group compared to the DC group (45.7 vs. 23.1%, 
r! = 6.2, p= 0.01 (ldf), Pc= ns). There was also a non-significant difference observed in 
the frequency of the TT genotype. The frequency was higher in the DC group compared to 
the DRIDN/DNu (12.8 vs. 3.5%, ·/ = 4.7, p= 0.03 (ldf), Pc= os). There was a significant 
increase in the frequency of the C ( -1 06) ALR2 allele in the DN/DRIDNu group compared 
to the uncomplicated DC group (71.1 vs. 55.1%, x2 = 6.8, p= 0.009 (ldf), Pc= 0.02). 
Table 47 presents the frequency of the ALR2 C(-106)T alleles and genotypes where the 
TIDM group has been subgrouped according to the precise diabetic complications 
observed. In the case of the FHP vs. uncomplicated DC group the frequency of the CC 
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genotype was 51.3% vs. 23.1% (x.2 = 6.6, p= 0.01 (Id f), Pc= 0.03), and the C allele was 
74.4% vs. 55.1%, x.2 = 6.3, p= 0.01 {ldt), Pc= ns), where significance was lost by 
correction. No other significant differences were found. 
Table 48 presents the C(-l06)T ALR2 alleles and genotypes detected in TIDM subjects 
according to the presence of retinopathy, or nephropathy or neuropathy. In all three groups 
the frequency of the CC genotype and the C allele was increased in the complications 
groups compared to the DC group. In the case of the DR vs. uncomplicated DC group the 
frequency of the CC genotype was 48.1% vs. 23.1% (X.2 = 7 .3, p= 0.007 (I dt), Pc = 0.02), 
and the C allele was 72.6% vs. 55.1%, x_2 = 7.9, p= 0.005 (ldt), Pc= 0.01). In the case of 
the DN vs. uncomplicated DC group the frequency of the CC genotype was 50.8% vs. 
23.1% (x.2 = 7.8, p= 0.005 {ldt), Pc= 0.02), and the C allele was 73.9% vs. 55.1%, ·l = 
7.7, p= 0.006 (ldt), Pc= 0.02). In the case of the DNu vs. DC group the frequency of the 
CC genotype was 46.3% vs. 23.1% (x.2 = 5.7, p= 0.02 (ldt), Pc= ns), and the C allele was 
71.6% vs. 55.1%, x.2 = 5.95, p= 0.01 (ldt), Pc= 0.04). Therefore, with respect to the CC 
genotype statistical significance was not attained in the DNu vs. DC group. 
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TlDM Normal Controls xz p-value Pc 
Subjects (Nq 
C(-l06)T n=l55 n=l20 
Genotype 
cc 40.0 28.3 4.05 0.04 os (62) (34) 
CT 54.2 55.8 0.07 ns ns (84) (67) 
TT 5.8 15.8 7.4 0.006 0.02 (9) (19) 
C(-l06)T n=JIO n=240 
Alleles 
c 67.1 56.3 6.8 0.009 0.03 (208) (135) 
T 32.9 43.8 6.8 0.009 0.03 (102) (105) 
Table 44. Percentage frequency of the detected C(-106)T alleles and genotypes in all 
British Caucasoid TlDM subjects studied, compared to normal control subjects. This 
table displays C(-I06)T allele and genotype frequencies in TlDM subjects and normal 
control subjects. 
Predicted Observed l p-value Pc-value 
Normal (n=l20) (n=l20} 
Controls (NC) 
cc 38 34 0.3 ns ns 
CT 59 67 1.1 ns ns 
TT 23 19 0.5 ns ns 
TIDM Patients (n=155) (n=ISS) 
cc 70 62 0.84 ns ns 
CT 68 84 3.3 ns ns 
TT 17 9 2.7 ns ns 
Table 45~ Comparison between the expected and observed frequency % of C(-106)T 
polymorphism genotypes in British Caucasoid TlDM and normal subjects. 
This table shows the expected and observed frequencies of C( -I 06)T genotypes in TlDM 
subjects and normal control subjects. This demonstrated that the distribution in the normal 
controls (NC) conforms to Hardy-Weinberg equilibrium principal (p2 +2pq+q2=1). There 
were no significant differences between the expected and observed frequencies in the 
normal controls according to the Chi-squared test for significance. There was also no 
difference between the expected and observed frequencies in the TIDM population. This 
indicates that the TIDM population is in Hardy-Weinberg equilibrium for the C-106T 
polymorphism. 
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C(-106)T 
Genotype 
cc 
CT 
TT 
C(-106)T 
Alleles 
c 
T 
TIDM Nephropathy 
and/or retinopathy 
and/or neuropathy 
116 
45.7 
(53) 
50.9 
(59) 
3.5 
·(4) 
232 
7l.l 
(165) 
28.9 
(67) 
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Uncomplicated Nonnal Controls 
(DC) (NC) 
39 120 
23.1 28.3 
(9) (34) 
64.1 55.8 
(25) (67) 
12.8 15.8 
(5) (19) 
78 240 
55.1 56.3 
(43) (135) 
44.9 43.8 
(35) (105) 
Table 46. C(-106)T aUele and genotype frequencies in normal controls and diabetic 
patients according to the presence of microvascular complications of diabetes. This 
table displays C(-106}T allele frequencies in normal controls (NC), uncomplicated (DC) 
and TIDM Nephropathy/Retinopathy/Neuropathy. For each allele the percentage 
frequency and the actual number of alleles (in parenthesis) is given. n represents the 
number of subjects in each group. Comparisons were made for each allele and genotype 
between patient and control groups using 2 x 2 contingency tables and the ·l test. P values 
were corrected for the number of comparisons made. Only significant differences by x.2 
and correction by multiplying by the number of comparisons made, are shown. 
DR/N/Nu vs. Uncomplicated diabetic controls; 
CC; x.2 = 6.2, p= 0.01 (ldf), Pc= 0.03 
TT; x.2 = 4. 7, p= 0.03 (I df), Pc= ns 
CIT; x.2 = 6.8, p= 0.009 (ldf), Pc= 0.02 
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1
oiabellc 2mabetic 1Diabetic 4 s Uncomplicated Normal Diabetic Full House 
Retinopathy Nephropathy Retinopathy Neuropathy Patients (DC) Controls (NC) 
and and 
Retinopathy Neuropathy 
C(-106)T 23 26 16 12 39 39 120 
Genotype 
cc 39.1 50.0 50.0 25.0 51.3 23.1 28.3 
(9) (13) (8) (3) (20) (9) (34) 
CT 56.5 46.2 50.0 66.7 46.2 64.1 55.8 
(13) (12) (8) (8) (18) (25) (67) 
IT 4.4 3.9 8.3 2.6 12.8 15.8 
(I) (I) (0) (I) (1) (5) (19) 
C(-106)T 46 52 32 24 78 78 240 
Alleles 
c 
T 
67.4 73.1 75.0 58.3 74.4 55.1 56.3 
(31) (38) (24) (14) (58) (43) (135) 
32.6 26.9 25.0 41.7 25.6 44.9 43.8 
(15) (14) (8) (10) (20) (35) (105) 
Table 47. C(-106)T aUele and genotype freq11encies in normal controls and diabetic 
patients according to onset of diabetic complications. This table displays C(-106)T 
allele and genotype frequencies in control and patient subjects according to their diabetic 
complication phenotype. Subjects were classified according to the onset of microvascular 
complications, diabetic retinopathy, diabetic nephropathy and retinopathy, diabetic 
retinopathy and neuropathy, diabetic neuropathy, full house patients and uncomplicated. 
For each allele the% frequency and the actual number of alleles (in parenthesis) is given. n 
represents the number of subjects in each group. Comparisons were made for each allele 
and genotype between patient and control groups using 2 x 2 contingency tables and the ·l 
test. P values were corrected for the number of comparisons made. 
1 
vs. Uncomplicated diabetic controls; 
CC; -l = 5.1, p= 0.03 (ldf), Pc= ns 
Cor T; ·l = 4.3, p= 0.04 (ldf), Pc= ns 
3 
vs. Uncomplicated diabetic controls; 
Cor T; ·l = 3.8, p= 0.05 (ldf), Pc= ns 
5 
vs. Uncomplicated diabetic controls; 
CC; ·l = 6.6, p= 0.01 (ldf), Pc= 0.03 
Cor T; ·l = 6.3, p= 0.01 (ldf), Pc= ns 
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I Dlabellc 2Diabelle 3 Dlabellc Uncomplicated Normal Controls 
Rellnopathy Nephropathy Neuropathy (Dq (Nq 
(DR) (DN) (Dnu) 
C(-106)T 104 65 67 39 120 
Genotype 
cc 48.1 50.8 46.3 23.1 28.3 
(50) (33) (31) (9) (34) 
CT 49.0 46.2 50.8 64.1 55.8 
(51) (30) (34) (25) (67) 
Tf 2.9 3.1 2.99 12.8 15.8 
(3) (2) (2) (5) (19) 
C(-106)T 208 130 134 78 240 
Alleles 
c 72.6 73.9 . 71.6 55.1 56.3 
(151) (96) (96) (43) (135) 
T 27.4 26.2 28.4 44.9 43.8 
(57) (34) (38) (35) (105) 
Table 48. C(-106)T aUele and genotype frequencies in normal controls and TlDM 
patients according to onset of diabetic complications. This table displays C( -106)T 
allele frequencies in control and patient subjects. TIDM subjects are grouped according to 
the presence of diabetic nephropathy, retinopathy or neuropathy. The retinopathy (n= I 04) 
group is an amalgamation of the retinopathy (n=23), nephropathy and retinopathy (n=26), 
retinopathy and neuropathy (n=16) and full house patients (n=39) groups previously 
identified. The nephropathy group (n=65) is an amalgamation of the nephropathy and 
retinopathy (n=26), and full house patients' (n=39) subgroups previously identified. The 
neuropathy group (n=67) is an amalgamation ofthe retinopathy and neuropathy (n=I6), the 
neuropathy (n=l2) and the full house patients' (n=39) groups also previously identified. 
For each allele the% frequency and the actual number of alleles (in parenthesis) are given. 
n represents the number of subjects in each group. Comparisons were made for each allele 
and genotype between patient and control groups using 2 x 2 contingency tables and the ·l 
test. P values were corrected for the number of comparisons made. 
1 vs. Uncomplicated diabetic controls; 
CC; x.2 = 7.3, p= 0.007 {ldf), Pc= 0.02 
IT; x.2 = 5.3, p= 0.02 ( ldt), Pc= ns 
cor T; x2 = 7.9, p= 0.005 (ldf), Pc= 0.02 
2 vs. Uncomplicated diabetic controls; 
CC; X2 = 7.8, p= 0.005 (ldf), Pc= O:o2 
Cor T; x2 = 7.7, p= 0.006 (ldt), Pc= 0.02 
3 vs. Uncomplicated diabetic controls; 
CC; x.2 = 5.7, p= 0.02 {ldt), Pc= ns 
IT; X2 = 3.9, p= 0.05 (ldf), Pc= ns 
Cor T; x2 = 5.95, p= 0.01 (ldf), Pc= 0.02 
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C(-106)T polymorphism in a TlDM Caucasoid family study 
In order to study the transmission of the C( -I 06)T alleles of the aldose reductase promoter 
region the 'Diabetes UK Warren 3 nephropathy family trios' were investigated for the 
polymmphism. A total of I 09 family trios that had been previously typed for the 5 'ALR2 
microsatellite polymorphism were genotyped for the C( -106)T polymorphism. The allele 
and genotype frequencies detected in the proband are shown in table 49, a total of 90 
probands were successfully genotyped in this study. Out of the available 172 family trios 
only 90 trios were successfully genotyped due to several reasons. Firstly, some of the DNA 
stock had been used up in the previous 5 'ALR2 assay, therefore preventing the completion 
of the family trio for the C-1 06T assay. Secondly the assay had a very high failure rate and 
reliable data was only obtained in a fraction of the subjects investigated, for reasons 
previously explained. The results of which are not included in the analysis. From the 109 
family trios genotyped for the C(-106)T polymorphism 77 trios were non-informative. 
Trios were classified as non-informative when both parents in the trio were heterozygous 
for the allele marker and transmission could not be determined, or if the parents genotype 
could not be confidently predicted from incomplete family sets. The informative 32 family 
trios were analysed using the transmission disequilibrium test. Table 49 shows the 
frequency of transmission of the C(-106)T alleles from parents who were heterozygous for 
the allele to affected offspring. If there is no linkage, the expected number of transmitted 
versus non-transmitted alleles should be equal. The difference therefore between the 
expected number of transmissions and observed transmission of alleles was calculated. 
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C(-106)T polymorphism in British Caucasoid families where proband has TIDM and 
diabetic nephropathy 
Table 49 presents the frequency of the C( -1 06)T allele and genotypes detected in the 90 
diabetic nephropathy probands of the DUK-Warren nephropathy collection. The CC 
genotype occurred in 30% of the subjects studied, the CT genotype occurred in 53.3% of 
the subjects studied and the TI genotype in 16.7% of the subjects studied. The C allele 
occurred in 56.7% of the subjects and the C allele in 43.3% of the subjects. The frequency 
of the CC, CT and TI genotypes conformed to the Hardy Weinberg equilibrium (table 50). 
Table 51 presents the frequency of the transmission of the C(-106)T alleles from parents to 
proband in the DUK-Warren Nephropathy Collection. There was no significant deviation 
from the expected 50% transmission of the alleles from parents to proband. 
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C(-106)T Genotype 
cc 
TT 
CT 
C(-106)T Alleles 
c 
T 
TIDM Nephropathy 
n=90 
30.0 
(27) 
16.7 
(15) 
53.3 
(48) 
n=l80 
56.1 
(102) 
43.3 
(78) 
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Table 49. C(-106)T allele and genotype frequencies in Diabetes UK- Warren 
nephropathy probands. This table displays C(-106)T allele and genotype frequencies in 
nephropathy proband subjects. For each allele and genotype detected the % frequency and 
the actual number of alleles and genotypes (in parenthesis) are given. n represents the 
number of subjects in each group. 
Predicted 
DUKWarren 
TIDM (n=90) 
Nephropathy 
cc 29 
CT 44 
TT 17 
Observed 
(n=90) 
27 
48 
15 
0.1 
0.4 
0.2 
p-value 
0.7 
0.6 
0.7 
Pc-value 
ns 
os 
ns 
Table 50. Comparison between the expected and observed frequency% of C(-106)T 
polymorphism genotypes in DUK- Warren British Caucasoid TIDM subjects with 
diabetic nephropathy. 
This table shows the expected and observed frequencies ofC(-!06)T genotypes in TIDM 
subjects with diabetic nephropathy obtained from the DUK Warren Nephropathy 
collection. This demonstrated that the distribution in the TIDM nephropathy subjects 
confonns· to Hardy-Weinberg equilibrium principal (P2+2pq+q2=1). There were no 
significant differences between the expected and observed frequencies according to the ·/ 
test for significance. 
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Transmitted Non-transmitted Total 2 p-value Pc X. 
c Observed 50 50 (34) (34) (68) 0.0 1.0 ns 
Expected 50 50 
(34) (34) (68) 
T Observed 50 50 (34) (34) (68) 0.0 1.0 os 
Expected 50 50 
(34) (34) (68) 
Table 51. Frequency of transmission of the C(-l06)T aUeles from parents of affected 
offspring to affected offspring in family proband study. 
This table shows the frequency of transmission of the C and T alleles from parents to 
affected offspring with respect to diabetic nephropathy. The frequency of transmission of 
the alleles from parents who were heterozygous for the C(-106)T allele, to affected 
offspring was determined in a total of 32 families. The number in the transmitted column 
in the observed row is the actual number of copies of the allele that was transmitted from 
parents to offspring. The non-transmitted value in the observed column is the actual 
number of times that the allele was not transmitted from parent to affected offspring. The 
expected number of C and T alleles to be transmitted and not-transmitted is 50% of the 
total number of alleles. The deviation from 50% transmission or non-transmission of the 
alleles from parents to affected offspring was determined using the X: test and 2x2 
contingency tables. 
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A(+l1842)C polymorphism marker 
An adenine to cytosine single base polymorphism situated + II842 base pairs downstream 
of the ALR2 gene ATG transcription start sequence was investigated. Polymerase chain 
reaction was carried out to amplify the 252bp region of intron 8 of ALR2 gene containing 
the A(+ II842)C polymorphism creating a Barn HI restriction site as described in chapter 3. 
Amplification products were cut by Barn HI restriction enzyme digestion, and separated on 
a 2.5% agarose/ethidiurn bromide gel at I OOV for I hour. The fragment sizes were checked 
by running a I OObp molecular weight marker alongside. Bands were detected by UV 
transillumination (320nm) (figure 26) and subjects were assigned a genotype according to 
restriction fragments identified. A PCR control band was also present. After Barn HI 
digestion, the homozygote genotype CC produced a 252 bp fragment, while the 
homozygote genotype AA produced 174 bp and 78 bp fragments. The heterozygote AC 
genotype produced all three fragments. The A(+II842)C polymorphism was investigated 
in the T I DM subjects and normal controls of British Caucasoid origin. 
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figure 26. A(+11842)C polymorphism by Bam HI restriction fragment separation 
on 2 . 5% agarose/ ethidium bromide gel 
Polymerase Chain Reaction was carried out to amplify a 252 bp region of the aldose 
reductase gene. The region included an intragenic polymorphic site, a single base 
substitution of A to C at 95th nucleotide of Intron 8. The polymorphism abolishes a 
Bam HI restriction site. 
Five microlitres of the PCR product was digested for 4 hours at 37°C with 10 units 
Bam HI (Promega). The genotypes were identified by 2.5io agarose gel 
electrophoresis alongside a lOObp molecular weight marker and ethidium bromide 
staining. 
After Bam HI digestion, the homozygote CC produced a 252 bp fragment, while the 
homozygote AA produced 174 bp and 78 bp fragments. The heterozygote AC 
produced all three fragments. All samples were analysed in duplicate to reduce the 
risk of erroneous resu lts. 
Three genotypes were identified, homozygous AA, homozygous CC and heterozygous 
AC. Allocated genotypes for each of the subjects shown in this figure (lanes 1-4) are 
as follows: 
Lane 1: CC 
Lane 2: AA 
Lane 3: AA 
Lane 4: CA 
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A(+l1842)C polymorphism in British Caucasoid TlDM subjects and normal controls 
The A(+ll842)C polymorphism located within the ALR2 gene itself, +11842bp 
downstream of the ATG start sequence was investigated using 244 TlDM subjects and 120 
normal controls of British Caucasoid origin (clinical demographics shown in table 6). 
Within the TlDM subject population studied there were 66 uncomplicated, 62 full house 
patients, 18 neuropathy, 24 retinopathy and neuropathy, 30 nephropathy and retinopathy, 
and 44 retinopathy patients. 
The frequency of the A(+ll842)C alleles in both TlDM and normal populations is shown 
in table 52. In this study we were able to find subjects who were homozygous CC, 
homozygous AA and heterozygous CA. In the analysis of allelic frequencies homozygotes 
were counted as 2 alleles. Tables show the percentage frequency of detected alleles and 
genotypes with actual numbers detected shown in parenthesis. Possible associations were 
investigated with respect to allelic frequency and genotype and comparisons were made 
between groups using the 1! test and 2 x 2 contingency tables. P-values were corrected for 
the number of comparisons made, and where the observed frequencies were <5 Fishers 
exact test was applied. 
All of the data obtained from this study is presented in the following tables. Possible 
associations were investigated with respect to allelic and genotypic frequencies and the 
onset of diabetic complications. The expected frequencies for A(+ 11842)C genotypes were 
calculated using 2xn analysis to determine whether frequencies of heterozygotes and 
homozygotes in control groups were in Hardy Weinberg equilibrium (table 53). 
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Allele and genotype frequencies of the A(+l1842)C polymorphism in British 
Caucasoid TlDM subjects and normal controls 
The A(+ll842)C polymorphism was investigated in 244 TIDM subjects and 120 normal 
controls of British Caucasoid origin. Table 52 presents the percentage frequency of the 
detected A(+ 11842)C alleles and genotypes for all TIDM subjects studied compared to the 
normal controls. There is a significant increase in the frequency of the AA (+11842)-
ALR2 genotype in the TIDM subjects compared to the normal controls (NC), (41.8 vs. 
6. 7%, ·l = 47 .I, p=<O.OOO I, Pc=<O.OOO I). Consequently, there is also a significant 
increase in the frequency of the A (+11842) allele in the TIDM subjects compared to the 
NC group (62.3 vs. 30.0%, x2 = 67.2, p=<O.OOOI, Pc=<O.OOOI). Both the normal and 
control groups complied with the Hardy Weinberg equilibrium (table 53). Table 54 
presents the alleles and genotypes for the Tl OM subjects according to the presence or 
absence of diabetic microvascular disease, where Tl OM subjects with DN/DR/DNu are 
compared with the uncomplicated DC and NC groups. A significant increase in the AA 
(+ 11842)-ALR2 genotype was seen in the DN/DR/DNu group compared to the 
uncomplicated DC group (52.3 vs. 13.7%, X2 = 29.5, p=<O.OOOl, Pc=<O.OOOI). There was 
a significant decrease in the frequency of the CC genotype, whereby the frequency was 
higher in the DC group compared to the TIDM DN/DR/DNu (40.9 vs. 8.4%, x2 = 35.7, 
p=<0.0001, Pc=<O.OOOI). There was alsQ a significant increase in the A (+11842)-ALR2 
allele in the TIDM DN/DR/DNU group compared to the uncomplicated DC group (71.9 
vs. 36.4%, x2 = 51.8, p=<O.OOOI, Pc=<O.OOOI). Table 55 presents the frequency of the 
ALR2 A(+li842)C alleles and genotypes where the TIDM group has been subdivided 
according to the precise diabetic complications observed. A significant increase in the AA 
(+11842) genotype was observed in all T1DM complication groups compared to the DC 
group. This was accompanied by an unequivocal increase in the A ( + 11842) allele in the 
TIDM complication subgroups compared to the DC group. Table 56 presents the 
A(+ 11842)C ALR2 alleles and genotypes detected in TIDM subjects according to the 
presence of retinopathy, or nephropathy or neuropathy. In all three groups the frequency of 
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the AA genotype and the A allele was significantly increased in the complications groups 
compared to the uncomplicated DC group. In the case of the DR vs. uncomplicated DC 
group the frequency of the AA genotype was 51.3 vs. 13.6%, x2 = 27.5, p=<O.OOOl, 
Pc=<O.OOl, and the A allele was 70.9 vs. 36.4%, x2 = 46.9, p=<O.OOOl, Pc=<O.OOI. In the 
case of the DN vs. uncomplicated DC group the frequency of the AA genotype was 45.7 
vs. 13.6%, x2 = 18.0, p=<O.OOOl, Pc=<O.OOl, and the A allele was 68.5 vs. 36.4%, x2 = 
32.0, p=<O.OOOl, Pc=<O.OOl). In the case of the DNU vs. uncomplicated DC group the 
frequency of the AA genotype was 54.8 vs. 13.6%, x2 = 28.8, p=<O.OOOl, Pc=<O.OOl, and 
the A allele was 73.6 vs. 36.4%, x2 = 46.2, p=<O.OOOI, Pc=<O.OOI. In all three groups the 
frequency of the CC genotype and the C allele was significantly decreased in the 
complications groups compared to the uncomplicated DC group. 
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TIDM Normal 
··l p-value Pc-value 
Subjects Controls 
A(+ll842)C 
Genotype n=244 n=l20 
AA 41.8 6.7 47.09 <0.0001 <0.0001 (102) (8) 
AC 41.0 46.7 1.06 ns ns (100) (56) 
cc 17.2 46.7 35.5 <0.0001 <0.0001 (42) (56) 
Allele n=488 n=240 
A 62.3 30.0 67.2 <0.0001 <0.0001 (304) (72) 
c 37.7 70.0 (184) (168) 
Table 52. Percentage frequency of the detected A(+l1842)C alleles and genotypes in 
all British Caucasoid TlDM subjects studied, compared to normal control subjects. 
This table displays A(+ll842)C allele and genotype frequencies in TIDM subjects and 
normal control subjects. 
Predicted Observed "J! p-value Pc-value 
Normal (n=l20) (n=l20) 
Controls (NC) 
AA 11 8 0.5 0.5 ns 
AC 50 56 0.6 0.4 ns 
cc 59 . 56 0.2 0.7 ns 
TIDM Patients (n=244) (n=244) 
AA 95 • 102 0.4 0.5 ns 
AC 115 100 1.9 0.2 ns 
cc 34 42 1.0 0.3 ns 
Table 53. Comparison between the expected and observed incidence of A(+lt'842)C 
polymorphism genotypes in British Caucasoid TlDM and normal subjects. 
This table shows the expected and observed frequencies of A(+ll842)C genotypes in 
TlDM subjects and normal control subjects. This demonstrates that the distribution in the 
normal controls (NC) conforms to Hardy-Weinberg equilibrium principal (P2+2pq+q2=1). 
There were no significant differences between the expected and observed frequencies in 
the normal controls and TIDM subjects according to the Chi-squared test for significance. 
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TIDI\1 Nephropathy Uncomplioated Normal Controls 
and/or retinopathy (DC) (NC) 
and/or neuropathy 
A(+l1842)C 
Genotype n=178 n=66 n=l20 
AA 52.3 13.6 6.7 
(93) (9) (8) 
AC 39.3 45.5 46.7 
(70} (30) (56) 
cc 8.4 40.9 46.7 
(15) (27) (56) 
A(+l1842)C 
Alleles n=356 n=l32 n=240 
A 71.9 36.4 30.0 
(256) (48) (72) 
c 28.1 63.6 70.0 
(lOO} (84) (168) 
Table 54. A(+11842)C aUele and genotype frequencies in normal controls and diabetic 
patients according to the presence of microvascular complications of diabetes. This 
table displays A(+ll842)C allele frequencies in nonnal controls (NC), uncomplicated 
(DC) and TIDM Nephropathy/Retinopathy/Neuropathy. For each allele the percentage 
frequency and the actual number of alleles (in parenthesis) is given. n represents the 
number of subjects in each group. Comparisons were made for each allele and genotype 
between patient and control groups using 2 x 2 contingency tables and the ·l test. P values 
were corrected for the number of comparisons made. Only significant differences by ·t! 
and correction are shown. · Where observed numbers were <5 Fishers exact test was 
applied. 
TlDM DRIN/Nu vs. Uncomplicated diabetic controls; 
AA;·/} = 29.5, p= <0.0001 (1df), Pc= <0.0001 
CC;·/ = 35.7, p= <0.000.1 (1df), Pc= <0.0001 
A or C; r! = 51.8, p= <0.0001 (ldf), Pc= <0.0001 
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I 1 3
rnabetic 
4
Diabetlc 5 Uncomplicated Normal Diabetic Diabetic Full House (DC) Controls Retinopathy Nephropathy Retinopathy Neuropathy Patients 
and and (NC) 
Retinopathy Neuropathy 
A(+ll84l)C 
n=44 n=JO n=24 n=I8 n=62 n=66 n=l20 Genotype 
AA 52.3 43.3 70.8 61.1 46.8 13.6 6.7 
(23) (13) (17) (11) (29) (9) (8) 
AC 36.4 50.0 20.8 38.9 43.6 45.5 46.7 
(16) ( 15) (5) (7) (27) (30) (56) 
cc 11.4 6.7 8.3 9.7 40.9 46.7 
(5) (2) (2) (0) (6) (27) (56) 
A(+ll84l)C 
n=88 n=60 n=48 n=36 n=l24 n=l32 n=240 Allele 
A 
c 
70.5 68.3 81.3 80.6 68.6 36.4 30.0 
(62) (41) (39) (29) (85) (48) (72) 
29.6 31.7 18.8 19.4 31.5 63.6 70.0 
(26) (19) (9) (7) (39) (84) (168) 
Table 55. A(+11842)C aUele and genotype frequencies in normal controls and diabetic 
subjects according to onset of diabetic complications. This table displays A(+II842)C 
allele and genotype frequencies in control and patient subjects according to their diabetic 
complication phenotype. Subjects were classified according to the onset of microvascular 
complications, diabetic retinopathy, diabetic nephropathy and retinopathy, diabetic 
retinopathy and neuropathy, diabetic neuropathy, full house patients and uncomplicated. 
For each allele the% frequency and the actual number of alleles (in parenthesis) is given. n 
represents the number of subjects in each group. Comparisons were made for each allele 
and genotype between patient and control groups using 2 x 2 contingency tables and the y} 
test. P values were corrected for the number of comparisons made. Only significant 
differences by x.2 and correction by multiplying by the number of comparisons made are 
shown. Where observed numbers were <5, Fishers exact test was applied. 
I vs. UDC; 
2 
vs. UDC; 
3 
vs. UDC; 
4 
vs. UDC; 
5
vs. UDC; 
AA; ·l = 19.1, p=<O.OOOI (ldf), Pc=<O.OOI 
CC; X2 = 11.17, p= 0.0008 (ldf), Pc= 0.002 
A or C; x2 = 24.0, p= <0.0001 (ldf), Pc= <0.001 
ll 
AA; X2 = I 0.3, p= 0.00 I (Id f), Pc= 0.003 
CC; X2 = 16.2, p= <0.0001 (ldf), Pc= <0.001 
A or C; l = 16.95, p= <0.000 I (I df), Pc= <0.00 I 
AA; X2 = 28.0, p= <0.0001 (ldf), Pc= <0.001 
AC; x2 = 4.5, p= 0.03 (ldf), Pc= ns 
CC; x2 = 8.6, p= 0.004 (ldf), Pc= 0.01 
A or C; ·l = 28.4, p= <0.0001 (ldf), Pc= <0.001 
AA; X2 = 17:6, p= <0.0001 (ldf), Pc= 0.001 
CC; x2 = 10.9, p= 0.0009 (ldf), Pc= 0.003 
A or C; x2 = 22.3, p= <0.0001 (ldf), Pc= <0.0001 
AA; x2 = 16.8, p= <0.0001 (ldf), Pc= <0.0001 
CC; X2 = 16.3, p= <0.0001 (ldf), Pc= 0.0001 
A or C; X2 = 26.5, p= <0.0001 (ldf), Pc= <0.0001 
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I J . Diabetic Diabetic 3Diabetic Uncomplicated Normal Controls 
Retinopathy Nephropathy Neuropathy (DC) (NC) 
(DR) (DN) (DNu) 
A(+ll842)C n=l60 n=92 n=l04 n=66 n=120 
Genotype 
AA 51.3 45.1 54.8 13.6 6.7 
(82) (42) (57) (9) (8) 
AC 39.4 45.1 37.5 45.5 46.7 
(63) (42) (39) (30) (56) 
cc 9.4 8.7 7.7 40.9 46.7 
(15) (8) (8) (27) (56) 
Allele n=320 n=184 n=208 n=132 n=240 
A 70.9 68.5 73.6 36.4 30.0 
(227) (126) (153) (48) (72) 
c 29.1 31.5 26.4 63.6 70.0 
(93) (58) (55) (84) (168) 
Table 56. A(+l1842)C aUele and genotype frequencies in normal controls and TIDM 
patients classified according to onset of diabetic complications. This table displays 
A(+ll842)T allele and genotype frequencies in control and patient subjects. TIDM 
subjects are grouped according to the presence of diabetic nephropathy, retinopathy or 
neuropathy. The retinopathy group is an amalgamation of the retinopathy, nephropathy and 
retinopathy, retinopathy and neuropathy and full house patients groups previously 
identified. The nephropathy group is an amalgamation of the nephropathy and retinopathy, 
and full house patients' subgroups previously identified. The neuropathy group is an 
amalgamation of the retinopathy and neuropathy, the neuropathy and the full house 
patients' groups also previously identified. For each allele the % frequency and the actual 
nwnber of alleles (in parenthesis) are given. n represents the number of subjects in each 
group. Comparisons were made for each allele and genotype between patient and control 
groups using 2 x 2 contingency tables and the x2 test. P values were corrected for the 
nwnber of comparisons made. Only significant differences by x2 and correction are shown . 
•• 
1 vs. Uncomplicated diabetic controls; 
AA; ·l = 27.5, p= <0.000 1 ( 1 df), Pc = <0.00 1 
CC; ·l = 30.7, p= <0.0001 (ldf), Pc= <0.001 
A or C; l = 46.9, p= <0.0001 (ldf), Pc= <0.001 
2 vs. Uncomplicated diabetic controls; 
AA; l = 18.0, p= <0.0001 (1df), Pc= <0.001 
CC; x.2 = 23.1, p= <0.0001 (ldf), Pc= <0.001 
A or C; x.2 = 32.0, p= <0.000 l (1 df), Pc = <0.00 I 
3 vs. Uncomplicated diabetic controls; 
AA; l = 28.8, p= <0.000 1 (I df), Pc= <0.00 I 
CC; l = 27.3, p= <0.0001 (ldf), Pc= <0.001 
A or C; l = 46.2, p= <0.0001 (ldf), Pc= <0.001 
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Combined genotype analysis of ALR2 polymorphisms investigated. 
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Combined genotype analysis in patients with TlDM and normal controls of British 
Caucasoid origin 
The frequency of the combined genotypes for the 5'ALR2, C(-l06)T and A(+ll842)C 
polymorphism's were investigated in the TIDM subjects of British Caucasoid origin. 
Firstly, the 5'ALR2/C(-l06)T combined genotypes were counted and analysed. Secondly, 
the 5'ALR2/A(+l1842)C and thirdly C(-l06)T/A(+ll842)C combined genotypes were 
counted and analysed. The three polymorphism's were however not investigated together 
in a combined genotype analysis (5'ALR2/C(-106)T/A(+ll842)C) as the number of 
subjects in each group with a particular genotype was very small and a significant 
difference in the percentage frequency between groups would be difficult to find. 
Comparisons were made between the frequencies of detected combined genotypes using 
the X2 test and 2x2 contingency tables. Combined genotype frequencies were investigated 
with respect to the onset of 4iabetic microvascular complications. 
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Combined genotype analysis of the 5'ALR2/C(-106)T polymorphism's in TlDM 
subjects of British Caucasoid origin 
Tables 57-60 present the combined genotype frequencies for the 5' ALR2/C(-106)T 
genotype in TIDM subjects and normal controls of British Caucasoid origin. Table 57 
presents the TIDM subjects vs. normal controls. Following the application of the Fishers 
exact test for small numbers the Z-2/X.T/T combined genotype was significantly higher in 
the normal controls vs. the TIDM subjects. Table 58 compares DRIDN/DNU and the 
uncomplicated DC group. A significant association was observed between the 
DRIDN/DNU and uncomplicated DC group with respect to the Z-2/X.C/C genotype 
whereby it was increased in the complicated group (20.7% vs. 2.6%, x.2=7.1, p=0.008, 
Pc=0.02). This however involved small numbers and more data would be required in order 
to confirm an association. Table 59 compares the 5'ALR2/C(-106)T genotype in TIDM 
subjects according to the precise onset of complications. After correction the Z-2/X.C/C 
genotype was significantly increased in the diabetic nephropathy with retinopathy and the 
full house patients groups compared to the uncomplicated diabetic controls. In the case of 
the DN/DR vs. uncomplicated DC groups (34.6% vs. 2.6%, x.2=12.3, p=0.0005, Pc=0.002, 
Fishers exact = 0.0007), and the FHP vs. uncomplicated DC groups (20.5% vs. 2.6%, 
x.2=6.2, p=O.OI, Pc=0.03, Fishers exact= 0.01). Table 60 presents the 5'ALR2/C(-106)T 
genotype in TIDM subjects according to the onset of nephropathy or retinopathy or 
11 
neuropathy. In the case of the DNu patients vs. DC patients there was a significant 
association between the Z-2/X.C/C and the X/X.C/C combined genotypes and the onset of 
diabetic neuropathy according to the Fishers exact test for small numbers. Larger numbers 
will be required to confirm this association. 
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S'ALR2/C(-106)T TIDM Subjects Nonnal Controls 
genotype (NC) 
n 155 120 
Z-2/X.Cff 10.9 10.8 
(17) (13) 
Z-2/X.C/C 16.1 7.5 
(23) (9) 
Z-2/X.Tff 6.7 
(-) (8) 
Z+21X.Cff 14.2 13.3 
(22) (16) 
Z+21X.C/C 7.1 6.7 
(11) (8) 
Z+21X.Tff 1.3 1.7 
(2) (2) 
Z-21Z+2.Cff 5.8 2.5 
(9) (3) 
Z-2/Z+2.C/C 3.2 1.7 
(5) (2) 
Z-2/Z+2.Tff 
(-) (-) 
X/X.CT 17.4 17.5 
(27) (21) 
X/X.C/C 6.5 10.0 
(10) (12) 
XIX.Trr 1.9 6.7 
(3) (8) 
Other 15.5 15.0 
(24) (18) 
Table 57. Frequency of 5'ALR2/ C(-106)T combined genotypes in patients with 
TIDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TlDM and normal control (NC) subjects. Frequencies are expressed as the percentage 
incidence out of the total number of genotypes detected. Comparisons were made between 
the genotype frequencies detected for TlDM and NC subjects using the x2 test and 2x2 
contingency tables. n= nwnber of genot~es detected, nwnber of subjects studied is shown 
in parenthesis. X= patient has neither Z-2 nor Z+2 5'ALR2 alleles. Where observed 
nwnbers were <5, Fishers exact test for small numbers was applied. 
TlDMvs.NC; 
Z-2/X.C/C; x2= 4.7, p= 0.03, Pc= ns 
Z-2/X.T/T; x2= 10.6, p= 0.001, Pc= 0.01, Fishers exact= 0.001. 
XIX.. TIT; x2= 3.9, p= 0.05, Pc= ns, Fishers exact= 0.05 
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S'ALR21C(-106)T Tl DM Nephropathy Uoromplloated Normal Control• 
genotype and/or Retinopathy (DC) (NC) 
and/or Neuropathy 
(DRIDNffiNu) 
D 116 39 120 
Z-2fX.Cff 11.2 10.3 10.8 
(13) (4) (13) 
Z-21X.C/C 20.7 2.6 7.5 
(24) (I) (9) 
Z-2/X.Trr 6.7 
(-) (-) (8) 
Z+2fXCff 11.2 23.1 13.3 
(13) (9) (16) 
Z+2tx.C/C 5.2 12.8 6.7 
(6) (5) (8) 
Z+21X.Tff 5.1 1.7 
(-) (2) (2) 
Z-2/Z+2.Cff 5.2 7.7 2.5 
(6) (3) (3) 
Z-2/Z+2.C/C 4.3 1.7 
(S) (-) (2) 
Z-2/Z+2.Tff 
(-) (-) (-) 
XIX.CT 18.1 15.4 17.5 
(21) (6) (21) 
XIX.C/C 8.6 10.0 
(10) (-) (12) 
XIX.Trr 2.6 6.7 
(3) ( -) (8) 
Other 12.9 23.1 15.0 
(IS) (9) (18) 
Table 58. Frequency of 5'ALR2/ C(-106)T combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TIDM subjects with microvascular..disease (nephropathy, retinopathy, neuropathy) 
compared to normal control (NC) subjects. Frequencies are expressed as the percentage 
incidence out of the total number of genotypes detected. Comparisons were made between 
the genotypes detected for TIDM and NC subjects using the ·l test and 2x2 contingency 
tables. n= number of genotypes detected, number of subjects studied is shown in 
parenthesis. X= patient has neither Z-2 nor Z+2 5'ALR2 alleles. Only significant 
differences by ·l and correction are shown. Where observed numbers were <5, Fishers 
exact test for small numbers was applied. 
DRIDNIDNU vs. Uncomplicated diabetic controls; 
Z-2/X.C/C; x2= 7.1, p= 0.008, Pc= 0.02 
Z+2/X.T/T; x2= 6.03, p= 0.01, Pc= ns, Fishers= 0.06 
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5'ALR2/ Diabetic Diabetic Diabetic Diabetic:: Full House Uncomplicated NormBI 
C(-106)T Retinopathy Nephropathy Retinopathy Neuropathy Patienb (DC) Controls 
genotype and and (NC) 
Retinopathy Neuropathy 
0 23 26 16 12 39 39 120 
z..2rx.crr 17.4 7.7 6.3 33.3 5.1 10.3 10.8 
(4) (2) (I) (4) (2) (4) (13) 
Z-2fX.C/C 17.4 34.6 6.3 16.7 20.5 2.6 7.5 
(4) (9) (I) (2) (8) (I) (9) 
z..2rx.Trr 6.7 
(-) (-) (-) (-) (-) (-) (8) 
Z+21X.Crf 8.7 7.7 12.5 16.7 12.8 23.1 13.3 
(2) (2) (2) (2) (5) (9) (16) 
Z+2fX.C/C 13.0 6.3 5.1 12.8 6.7 
(3) (-) (I) (-) (2) (5) (8) 
Z+2fX.Trf 5.1 1.7 
(-) (-) (-) (-) (-) (2) (2) 
Z- 8.7 3.9 6.3 5.1 7.7 2.5 
2/Z+2.Crf (2) (I) (I) (-) (2) (3) (3) 
Z- 4.4 12.5 5.1 1.7 
2/Z+2.C/C (I) (-) (2) (-) (2) (-) (2) 
Z-
2/Z+l.Trf (-) (-) (-) (-) (-) (-) (-) 
XIX.CT 17.4 19.2 25 8.3 17.95 15.4 17.5 
(4) (5) (4) (I) (7) (6) (21) 
XIX.C/C 4.4 7.7 6.3 8.3 12.8 10.0 
(I) (2) (I) (I) (5) (-) (12) 
XIX.Trr 3.9 8.3 2.6 6.7 
(-) (I) (-) (I) (I) (-) (8) 
Other 8.7 15.4 18.8 8.3 12.8 23.1 15.0 
(2) (4) (3) (I) (5) (9) (18) 
Table 59. Frequency of 5' ALR2/ C(-106)T combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined frequencies were obtained by using 
the gene counting method. This table presents the genotypes detected in the TIDM 
subjects with retinopathy (DR), nephropathy and retinopathy (DN/DR), retinopathy and 
neuropathy (DN/DNu), full house complications (FHC). Also shown are the Tl DM 
uncomplicated diabetic controls (DC) a:ld normal control (NC) subjects. Frequencies are 
expressed as the percentage incidence out of the total number of genotypes detected. 
Comparisons were made between the genotypes detected for TlDM complication groups 
and the uncomplicated DC subjects using the x.2 test and 2x2 contingency tables. n= 
number of genotypes detected, number of subjects studied is shown in parenthesis. X= 
patient has neither Z-2 nor Z+2 5' ALR2 alleles. Where observed numbers were <5, Fishers 
exact test for small numbers was applied. 
DR vs. DC; Z-2/X.C/C; x.2= 4.3, p= 0.04, Pc= ns, Fishers= 0.06. 
DNillRvs.DC; Z-2/X.C/C; x.2= I2.3, p= 0.0005, Pc= 0.002, Fishers= 0.0007. 
DRill NU vs. DC; Z-2/Z+2.C/C; x.2= 5.I, p= 0.02, Pc= ns, Fishers= 0.08. 
FHPvs.DC; Z-2/X.C/C; x.2= 6.2, p= 0.0 I, Pc= 0.03, Fishers = 0.0 I. 
XIX.CIC; x2= 5.3, p= 0.02, Pc= ns, Fishers = 0.03 
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5'ALR2/C(-106)T Diabedc Dlobellc Diabetic Un<omplicaled Normal Conlrols 
genolype Rellnopalhy Nephropalhy Neuropathy (DC) (NC) 
Q!R) (DN) (DNu) 
n 104 65 67 39 120 
L-2rx.crr 8.7 6.2 10.5 10.3 10.8 
(9) (4) (7) (4) (13) 
L-21X.CIC 21.2 26.2 16.4 2.6 7.5 
(22) ( 17) (11) (1) (9) 
L-21X.Trr 6.7 
(·) (·) (·) (·) (8) 
Z+2!X.Crf 10.6 10.8 13.4 23.1 13.3 
(11) (7) (9) (9) (16) 
Z+21X.C/C 5.8 3.1 4.5 12.8 6.7 
(6) (2) (3) (5) (8) 
Z+21X.Tff 5.1 1.7 
(·) (·) (·) (2) (2) 
L-2/Z+2.Crf 5.8 4.6 4.5 7.7 2.5 
(6) (3) (3) (3) (3) 
L-2/Z+2.C/C 4.8 3.1 5.97 1.7 
(5) (2) (4) (-) (2) 
L-2/Z+2.Trf 
(-) (·) (·) (-) (·) 
XJX.CT 19.2 18.5 17.9 15.4 17.5 
(20) (12) (12) (6) (21) 
XIX.C/C 8.7 10.8 10.5 10.0 
(9) (7) (7) (-) (12) 
XIX.Trr 1.9 3.1 2.99 6.7 
(2) (2) (2) (-) (8) 
Other 13.5 13.9 13.4 23.1 15.0 
(14) (9) (9) (9! (18) 
Table 60. Frequency of 5' ALR2/ C(-106)T combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method with those subjects who were homozygous for ·either 
the 5'ALR2 or the C(-l06)T locus or both. X= neither Z-2 nor Z+2 allele. This table 
. presents the haplotypes detected in the TlDM normal control (NC) subjects. Subjects with 
microvascular disease are classified in aw;ordance to onset of retinopathy, nephropathy or 
neuropathy. The nephropathy group (n=65) is an amalgamation of the nephropathy and 
retinopathy (n=26) and full house subjects (n=39) groups previously identified. The 
retinopathy group (n=l04) is an amalgamation of the retinopathy (n=23), nephropathy with 
retinopathy (n=26), retinopathy and neuropathy (n=l6) and full house patients (n=39) 
groups previously identified. The neuropathy group (n=67) consists of subjects diagnosed 
as having neuropathy in the absence of any other microvascular complication (n=l2), the 
diabetic retinopathy with neuropathy (n=l6) and full house patients (n=39) groups. Also 
presented is the allelic frequency in uncomplicated and normal controls. Frequencies are 
expressed as the percentage incidence out of the total number of haplotypes detected. 
Comparisons were made between the haplotypes detected for TIDM subjects with 
complications and the uncomplicated subjects using the x2 test and 2x2 contingency tables. 
n= number of genotypes detected, number of subjects studied is shown in parenthesis. 
Only significant differences by x2 and correction are shown. Where observed numbers 
were <5, Fishers exact test for small numbers was applied. 
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DR vs. Uncomplicated diabetic controls; 
Z-2/X.C/C; ·/= 7.3, p= 0.007, Pc= ns. 
Z+21X..Tff; x2= 5.4, p= 0.02, Pc= 0.07. 
DN vs. Uncomplicated diabetic controls; 
Z-2/X.C/C; x2= 9.5, p= 0.002, Pc= ns. 
DNU vs. Uncomplicated diabetic controls; 
Z-2/X.C/C; x2= 4. 7, p= 0.03, Pc= ns, Fishers = 0.03. 
XIX..C/C; x2= 4.4, p= 0.04, Pc= ns, Fishers = 0.04. 
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Chapter 4. Results 
Combined genotype analysis of the 5'ALR2/A(+ll842)C polymorphisms in TlDM 
subjects of British Caucasoid origin 
Tables 61-64 present the frequencies of the 5 'ALR2/ A( +ll842)C genotypes in TIDM 
subjects and normal controls of British Caucasoid origin. Table 61 presents the frequencies 
in the T I DM vs. the normal controls, and no significant correlation's were found between 
the two groups by the y} test, or Fishers exact test for small numbers. Table 62 presents the 
5'ALR2/A(+I 1842)C genotypes in TIDM subjects with DN/DR/DNU vs. uncomplicated 
DC group. The Z+2/X.C/A genotype was found to be significantly increased in the TIDM 
control group (6.7% vs. 22.7%, x.2=12.5, p=0.0004, Pc= 0.005). Table 63 presents the 
5'ALR2/A(+l1842)C genotypes in TIDM subjects according to the precise onset of 
diabetic complications. No significant differences were found by the Chi squared test , 
however, Fishers exact test found an increased frequency of the Z+2/X.C/A and Z-
2/Z+2.A/A combined genotypes in DC vs. DRIDNu. Table 64 presents the 
5'ALR2/A{+II842)C genotypes in TIDM subjects according to the onset of nephropathy 
or retinopathy or neuropathy. In the case of the DR vs. uncomplicated DC groups the 
Z+2/X.C/A genotype was lower in the DR group (5.6% vs. 22.7%, x.2=14.4, p= 0.0002, 
Pc= 0.003). In the case of the DN vs. uncomplicated DC groups the Z+2/X.C/A genotype 
was lower in the DN group (4.4% vs. 22.7%, x.2=12.3, p=0.0005, Pc=0.007). In the case of 
the DNU vs. uncomplicated DC groups the Z+2/X.C/A genotype was lower in the DNU 
ft 
group (6.7% vs. 22.7%, x.2=9.2, p=0.003, Pc=0.04). 
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S'ALRliA(+II842)C TIDM Subjects Normal Controls 
genotype <N9 
n 244 120 
Z-2/X.C/A 13.5 10.0 
(33) (12) 
Z-2/X.C/C 4.5 1.7 
(11) (2) 
Z-2fX..A/A 11.5 13.3 
(28) (16) 
Z+2fX..C/A 11.1 13.3 
(27) (16) 
Z+2fX..C/C 2.1 0.8 
(5) (I) 
Z+2fX..A/A 13.5 8.3 
(33) (10) 
Z-2/Z+2.C/A 1.6 3.3 
(4) (4) 
Z-2/Z+2.C/C 0.4 
(l) (-) 
Z-2/Z+2.A/A 4.1 0.8 
(10) (!) 
XIX.. CA 10.2 14.2 
(25) (17) 
XIX.C/C 2.9 3.3 
(7) (4) 
XIX.A/A 12.3 15.8 
(30) (19) 
Other 12.3 15.0 
(30) (18) 
Table 61. Frequency of 5'ALR2/A(+11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TlDM and normal control (NC) subjects. Frequencies are expressed as the percentage 
incidence out of the total number of genotypes detected. Comparisons were made between 
the genotype frequencies detected for TlDM and NC subjects using the x2 test and 2x2 
contingency tables. n= number of genotypes detected, number of subjects studied is shown 
in parenthesis. 
No significant differences were detected between the TlDM and the normal control 
populations with respect to the 5 'ALR2/ A(+ 11842)C combined genotype. 
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S'ALR2/A(+II84l)C, TIDM Nephropathy Uncomplirated Normal Controls 
genotype and/or Retinopathy (DC) (NC) 
ond/or Neuropathy 
~DRIDNIDNu) 
n 178 66 120 
Z-2/X.C/A 15.2 9.1 10.0 
(27) (6) (12) 
Z-2/X.C/C 5.1 3.0 1.7 
(9) (2) (2) 
Z-2/X.A/A 13.5 6.1 13.3 
(24) (4) (16) 
Z+2/X.C/A 6.7 22.7 13.3 
(12) (15) (16) 
Z+21X.C/C 1.1 4.6 0.83 
(2) (3) (I) 
Z+21X.A/A 13.5 13.6 8.3 
(24) (9) (10) 
Z-2/Z+2.C/A 1.7 1.5 3.3 
(3) (I) (4) 
Z-2/Z+l.C/C 0.6 
(I) (-) 
Z-2/Z+2.A/A 4.5 3.0 0.8 
(8) (2) (I) 
XIX. CA 11.8 6.1 14.2 
(21) (4) (17) 
XIX.C/C 1.7 6.1 3.3 
(3) (4) (4) 
XIX.A/A 14.0 7.6 15.8 
(25) (5) (19) 
Other 10.7 16.7 15.0 
(19) (11) (18) 
Table 62. Frequency of 5' ALR2/ A(+ 11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TlDM subjects with microvascul~ disease (nephropathy, retinopathy, neuropathy) 
compared to uncomplicated and normal control (NC) subjects. Frequencies are expressed 
as the percentage incidence out of the total number of genotypes detected. Comparisons 
were made between the genotypes detected for TlDM and DC subjects using the x.2 test 
and 2x2 contingency tables. n= number of genotypes detected, number of subjects studied 
is shown in parenthesis. Only significant differences by x.2 and correction are shown. 
Where observed numbers were <5, Fishers exact test for small numbers was applied. 
DRIDNffiNU vs. Uncomplicated diabetic controls; 
Z+2/X.C/A; x.2= 12.5, p= 0.0004, Pc= 0.005*. 
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S'ALR2/ 
A(+li842)C 
genotype 
n 
~2/X.C/A 
~2/X.C/C 
~2/X.A/A 
Z+2/X.C/A 
Z+2/X.C/C 
Z+21X.A/A 
~ 
2/Z+2.C/A 
~ 
2/Z+2.C/C 
~ 
2/Z+2.A/A 
XIX. CA 
XIX.C/C 
XIX.A/A 
Other 
iDiobetlc 1Diabetlc 
Retinopathy Nephropathy 
and 
Retinopathy 
44 30 
13.6 23.3 
(6) (7) 
2.3 6.7 
(I) (2) 
13.6 10.0 
(6) (3) 
9.1 3.3 
(4) (I) 
2.3 
(I) (-) 
18.2 6.7 
(8) (2) 
3.3 
(-) (I) 
2.3 
(I) (-) 
4.6 
(2) (-) 
11.4 16.7 
(5) (5) 
4.6 
(2) (-) 
9.1 16.7 
(4) (5) 
9.1 13.3 
(4) (4) 
'mobetlc 
Retinopathy 
and 
Neuropathy 
24 
4.2 
(I) 
8.3 
(2) 
12.5 
(3) 
4.2 
(I) 
(-) 
20.8 
(5) 
(-) 
(-) 
16.7 
(4) 
8.3 
(2) 
(-) 
12.5 
(3) 
12.5 
(3) 
'Diabetic 
Neuropathy 
18 
16.7 
(3) 
(-) 
22.2 
(4) 
16.7 
(3) 
(-) 
16.7 
(3) 
(-) 
(-) 
(-) 
5.6 
(I) 
(-) 
16.7 
(3) 
5.6 
(I) 
1Full House Uncomplicated 
Patients (DC) 
62 66 
16.1 9.1 
(10) (6) 
6.5 3.0 
(4) (2) 
12.9 6.1 
(8) (4) 
4.8 22.7 
(3) (15) 
1.6 4.6 
(I) (3) 
9.7 13.6 
(6) (9) 
3.2 1.5 
(2) (1) 
(-) (-) 
3.2 3.0 
(2) (2) 
12.9 6.1 
(8) (4) 
1.6 6.1 
(I) (4) 
16.1 7.6 
(10) (5) 
11.3 16.7 
(7) (11) 
Normal 
Controls 
(NC) 
120 
10.0 
(12) 
1.7 
(2) 
13.3 
(16) 
13.3 
(16) 
0.8 
(I) 
8.3 
(10) 
3.3 
(4) 
(-) 
0.83 
(I) 
14.2 
(17) 
3.3 
(4) 
15.8 
(19) 
15.0 
(18) 
Table 63. Frequency of 5' ALR2/ A(+ 11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined frequencies were obtained by using 
the gene counting method. This table presents the genotypes detected in the TIDM 
subjects with retinopathy (DR), nephronr-thy and retinopathy (DN/DR), retinopathy and 
neuropathy (DN/DNu), full house complications (FHC). Also shown are the TIDM 
diabetic controls (DC) and normal control (NC) subjects. Frequencies are expressed as the 
percentage incidence out of the total number of genotypes detected. Comparisons were 
made between the genotypes detected for TIDM complication groups and the 
uncomplicated DC subjects using the ·l test and 2x2 contingency tables. n= number of 
genotypes detected, number of subjects studied is shown in parenthesis. Only significant 
differences by x2 and correction are shown. Where observed numbers were <5, Fishers 
exact test for small numbers was applied. 
2 
vs. Uncomplicated diabetic controls; 
Z+2/X.C/A; x2=5.59, p=0.02, Pc=ns. 
3 
vs. Uncomplicated diabetic controls; 
Z+2/X.C/A; x2=4.15, p=0.04, Pc=ns, Fishers=0.03. 
Z-2/Z+l.A/A; x2=5.26, p=0.02, Pc=ns, Fishers= 0.04. 
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4 
vs. Uncomplicated diabetic controls; 
Z-2/X.A/A; x2=4.29, p=0.04, Pc=ns, 0.06. 
5 
vs. Uncomplicated diabetic controls; 
Z+2/X.C/A; x2=8.47, p=0.004, Pc=ns. 
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S'ALR2/A(+Il842)C Diabetic DiabeHc Diabetic Unrompflcaled Normal Coolrols 
genolype Relinopalhy Nephropalhy Neuropalhy (DC) (NC) 
(DR! . (DN) ~Nu~ 
n 160 92 104 66 120 
Z-2fX.CIA 15.0 18.5 13.5 9.1 10.0 
(24) (17) (14) (6) (12) 
Z-2fX.CIC 5.6 6.5 5.8 3.0 1.7 
(9) (6) (6) (2) (2) 
Z-21X.A/A 12.5 11.96 14.4 6.1 13.3 
(20) (11) (15) (4) (16) 
Z+2fX.CIA 5.6 4.4 6.7 22.7. 13.3 
(9) (4) (7) (15) (16) 
Z+21X.CIC 1.3 1.1 0.96 4.6 0.8 
(2) (I) (I) (3) (I) 
Z+21X.AIA 13.1 8.7 13.5 13.6 8.3 
(21) (8) (14) (9) (10) 
Z-21Z+2.CIA 1.9 3.3 1.9 1.5 3.3 
(3) (3) (2) (I) (4) 
Z-21Z+2.CIC 0.6 
(I) (-) (-) (-) (·) 
Z-21Z+2.AJA 5.0 2.2 5.8 3.0 0.8 
(8) (2) (6) (2) (I) 
X/X.CA 12.5 14.1 10.6 6.1 14.2 
(20) (13) (11) (4) (17) 
XIX.CIC 1.9 1.1 0.96 6.1 3.3 
(3) (I) (I) (4) (4) 
XIX.AIA 13.8 16.3 15.4 7.6 15.8 
(22) (15) (16) (5) (19) 
Other 11.3 11.96 10.6 16.7 15.0 
(18) ( 11) (11) (11) (18) 
Table 64. Frequency of 5'ALR2/ A(+11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. X= neither Z-2 nor Z+2 allele. Subjects with 
microvascular disease are classified in accordance to onset of retinopathy, nephropathy or 
neuropathy. The nephropathy group (n=92) is an amalgamation of the nephropathy and 
retinopathy (n=30) and full house subjects (n=62) groups previously identified. The 
retinopathy group (n=l60) is ail amalgamation of the retinopathy (n=44), nephropathy with 
retinopathy (n=30), retinopathy and neuropathy (n=24) and full house patients (n=62) 
groups previously identified. The neuropathy group (n= I 04) consists of subjects diagnosed 
as having neuropathy in the absence of any other microvascular complication (n= 18), the 
diabetic retinopathy with neuropathy (n=24) and full house patients (n=62) groups. Also 
presented is the allelic frequency in uncomplicated and normal controls. Frequencies are 
expressed as the percentage incidence out of the total number of genotypes detected. 
Comparisons were made between the genotypes detected for TIDM subjects with 
complications and uncomplicated subjects using the x2 test and 2x2 contingency tables. n= 
number of alleles detected, number of subjects studied is shown in parenthesis. Only 
significant differences by x2 and correction are shown. Where observed numbers were <5, 
Fishers exact test for small numbers was applied. 
DR vs. DC; Z+21X..C/A; x2= 14.4, p= 0.0002, Pc= 0.003. 
DN vs. DC; Z+21X..C/A; x2= 12.3, p= 0.0005, Pc= 0.007. 
DNU vs. DC; Z+2/X.C/A; x2= 9.2, p= 0.003, Pc= 0.04. 
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Combined genotype analysis of the C(-106)T/A(+l1842)C polymorphism's in TlDM 
subjects of British Caucasoid origin 
Tables 65-68 present the C(-l06)T/A(+ll842)C combined genotypes observed in the 
TlDM subjects and normal controls of British Caucasoid origin. Table 65 compares the 
TIDM subjects with the normal control subjects frequencies. There was a significant 
increase in the T/T.A/C combined genotype in the normal controls compared to the TIDM 
subjects (7.5% vs. 0.6%, x.2=9.07, p=0.003, Pc=0.03). Table 66 compares the TIDM 
DRIDN/DNU subjects and the diabetic controls. Following correction no significant 
associations were found. Table 67 compares the uncomplicated DC group with the TIDM 
subjects according to the precise onset of complications. Following correction no 
significant associations were found. Table 68 compares the TIDM subjects with the 
uncomplicated DC subjects according to the onset on nephropathy or retinopathy or 
neuropathy. Following correction no significant differences were found, however in all 
groups the C/C.A/ A was borderline of significance where there was a higher frequency in 
the complication groups compared to the uncomplicated DC group. 
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C(-106)T/A(+II842)C TIDIII Subjects Nonnal Controls 
genollj!< {NC) 
n 155 120 
C/C-A/C 21.3 10.8 
(33) (13) 
CIC-AlA 16.1 11.7 
(25) (14) 
C/C-C/C 2.6 5.0 
(4) (6) 
Tff-A/C 0.6 7.5 
(I) (9) 
Tff-A/A "4.5 7.5 
(7) (9) 
Tff-C/C 
(-) (-) 
Cff-AIC 25.2 27.5 
(39) (33) 
Cff-A/A 26.5 28.3 
(41) (34) 
Cff-C/C 3.2 1.7 
(5) (2) 
C(·l06)T 
C aUele present(%) 75.5 85.0 
(117) (102) 
T allele present (%) 60.0 72.5 
(93) (87) 
A(+ll842)C 
C aUele present(%) 52.9 52.5 
(82) (63) 
A allele present (%) 94.2 93.3 
(146) (112) 
Table 65. Frequency of C(-106)T/ A(+ll842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TIDM and normal control (NC) subjects. Frequencies are expressed as the percentage 
incidence out of the total number of genotypes detected. Comparisons were made between 
the genotype frequencies detected for TlDM and NC subjects using the·/ test and 2x2 
contingency tables. n= number of genotypes detected, number of subjects studied is shown 
in parenthesis. Only significant differences by x2 and correction are shown. Where 
observed numbers were <5, Fishers exact test for small numbers was applied. 
TlDMvs. NC; 
2 C/C.A/C; X = 5.3, p= 0.02, Pc= ns. 
2 TIT.A/C; X = 9.07, p= 0.003, Pc= 0.03. 
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C(·I06)T/A(+li842)C genotype TIDM Nephropathy Uncomplicated Normal Controls 
and/or Retinopathy (DC) (NC) 
and/or Neuropathy 
(DRIDN/DNu) 
n 116 39 120 
C/C-A/C 23.3 15.4 10.8 
(27) (6) (13) 
CIC-AlA 19.8 5.1 11.7 
(23) (2) (14) 
C/C-C/C 2.6 2.6 5.0 
(3) (I) (6) 
Tff-AJC 2.6 7.5 
(-) (I) (9) 
Tff-AJA 3.5 7.7 7.5 
(4) (3) (9) 
Tff-C/C 
(-) (-) (-) 
Cff-A/C 21.6 35.9 27.5 
(25) (14) (33) 
Cff-A/A 26.7 25.6 28.3 
(31) (10) (34) 
Cff-C/C 2.6 5.1 1.7 
(3) (2) (2) 
C(·106)T 
C allele present(%) 96.6 89.7 85.0 
(112) (35) (102) 
T aUele present{%) 54.3 76.9 72.5 
(63) (30) (87) 
A(+11842)C 
C allele present(%) 50.0 61.5 52.5 
(58) (24) (63) 
A aUele present{%) 94.8 92.3 93.3 
(110) (36) (I 12) 
Table 66. Frequency of C(-106)T/ A(+l1842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method. This table presents the combined genotypes detected in 
the TIDM subjects with microvascular disease (nephropathy, retinopathy, neuropathy) 
compared to TIDM uncomplicated and normal control (NC) subjects. Frequencies are 
expressed as the percentage incidence out of the total number of genotypes detected. 
Comparisons were made between the genotypes detected for TIDM and NC subjects using 
the r} test and 2x2· contingency tables. n= number of genotypes detected, number of 
subjects studied is shown in parenthesis. Only significant differences by x2 and correction 
are shown. 
DRIDN/DNU vs. Uncomplicated diabetic controls; 
· C/C.A/A; x2= 4.7, p= 0.03, Pc= ns. 
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C(-106)T/ Diabetic Diabetic Diabetic Diabetic Full House Uncomplicated Normal 
A(+II842)C Retinopathy Nephropathy Retinopathy Neuropathy PaUents (DC} Controls (NC) 
genotype and and 
Rellno~ath;r Neurol!ath;r 
n 23 26 16 12 39 39 120 
C/C-AIC 21.7 26.9 18.8 8.3 28.2 15.4 10.8 
(5) (7) (3) (I) ( 11) (6} (13) 
CIC-AlA 17.4 19.2 25.0 16.7 20.5 5.1 11.7 
(4) (5) (4) (2) (8) (2) (14) 
C/C-C/C 3.9 6.3 2.6 2.6 5.0 
(-) (I) (I) (-) (I) (I) (6) 
TIT-AIC 2.6 7.5 
(-) (-) (-) (-) (-) (I) (9) 
TIT-A/A 4.4 3.9 8.3 2.6 7.7 7.5 
(I) (I) (-) (I) (I) (3) (9) 
TIT-C/C 
(-) (-) (-) (-) (-) (-) (-) 
CIT-AIC 17.4 23.1 12.5 41.7 20.5 35.9 27.5 
(4) (6) (2) (5) (8) (14) (33) 
C/T-A/A 30.4 19.2 37.5 25.0 25.6 25.6 28.3 
(7) (5) (6) (3) (10) ( 10) (34) 
CIT-CIC 8.7 3.9 5.1 1.7 
(2) (I) (-) (-) (-) (2) (2) 
C(-106)T 
C aUele . 95.7 96.2 100.0 91.7 97.4 89.7 85.0 
present(%) (22) (25) (16) (11) (38) (35) (102) 
T allele 60.9 50.0 50.0 75.0 48.7 76.9 72.5 
present(%) (14) (13) (8) (9) (19) (30) (87) 
A(+ll84l)C 
C aUele 47.8 57.7 37.5 50.0 51.3 61.5 52.5 
present(%) (11) (IS) (6) (6) (20) (24) (63) 
A aUele 91.3 92.3 93.8 100.0 97.4 92.3 93.3 
present(%) (21) (24) (15) (12) (38) (36) (112) 
Table 67. Frequency of C(-106)T/ A(+11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined frequencies were obtained by using 
the gene counting method. This table 'f,resents the genotypes detected in the TIDM 
subjects with retinopathy (DR), nephropathy and retinopathy (DN/DR), retinopathy and 
neuropathy (DN/DNu), full house complications (FHC). Also shown are the TIDM 
uncomplicated diabetic controls (DC) and normal control (NC) subjects. Frequencies are 
expressed as the percentage incidence out of the total number of genotypes detected. 
Comparisons were made between the genotypes detected for TIDM complication groups 
and the DC subjects using the x2 test and 2x2 contingency tables. n= number of genotypes 
detected, number of subjects studied is shown in parenthesis. Only significant differences 
by "/ and correction are shown. Where observed numbers were <5, Fishers exact test for 
small numbers was applied. 
DNIDR vs. Uncomplicated diabetic controls; 
C/C.A/A; x2= 4.6, p= 0.03, Pc= ns. 
No other significant differences were detected. 
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C(-106)T/A(+I184Z)C Diabetic Dlabellc Diabetic Uncomplicated Normal Controls 
genotype Retinopathy Nephropathy Neuropathy (DC) (NC) 
(DR) (DN) (DNu) 
n 104 77 67 39 120 
C/C-A/C 25.0 24.7 22.4 15.4 10.8 
(26) (19) (15) (6) (13) 
C/C-A/A 20.2 19.5 20.9 5.1 11.7 
(21) (15) (14) (2) ( 14) 
C/C-C/C 2.9 2.6 2.9 2.6 5.0 
(3) (2) (2) (I) (6) 
Tff-A/C 2.6 7.5 
(-) (-) (-) (I) (9) 
Tff-A/A 2.9 3.9 2.9 7.7 7.5 
(3) (3) (2) (3) (9) 
Tff-C/C 
(-) (-) (-) (-) (-) 
Cff-A/C 19.2 24.7 22.4 35.9 27.5 
(20) (19) (15) (14) (33) 
Cff-AIA 26.9 23.4 28.4 25.6 28.3 
(28) (18) (19) (10) (34) 
C/T-C/C 2.9 1.3 5.1 1.7 
(3) (I) (-) (2) {2) 
C(-106)T 
C allele present 97.1 96.1 97.0 89.7 85.0 
(%) (101) {74) {65) (35) (102) 
T allele present 51.9 53.3 53.7 76.9 72.5 
(%) (54) (41) (36) (30) (87) 
A(+11842)C 
C allele present 50.0 53.3 47.8 61.5 52.5 
(%) (52) {41) {32) (24) (63) 
A allele present 50.0 96.1 97.0 92.3 93.3 
(%) {52) {74) {65) (36) (112) 
Table 68. Frequency of C(-106)T/ A(+11842)C combined genotypes in patients with 
TlDM of British Caucasoid origin. The combined genotype frequencies were obtained 
by using the gene counting method X= neither Z-2 nor Z+2 allele. Subjects with 
microvascular disease are classified in a~cordance to onset of retinopathy, nephropathy or 
neuropathy. The nephropathy group (n=77) is an amalgamation of the nephropathy and 
retinopathy (n=26) and full house subjects (n=39) groups previously identified. The 
retinopathy group (n= l 04) is an amalgamation of the retinopathy (n=23), nephropathy with 
retinopathy (n=26), retinopathy and neuropathy (n=l6) and full house patients (n=39) 
groups previously identified. The neuropathy group (n=67) consists of subjects diagnosed 
as having neuropathy in the absence of any other microvascular complication (n=I2), the 
diabetic retinopathy with neuropathy (n=l6) and full house patients (n=39) groups. Also 
presented is the allelic frequency in uncomplicated and normal controls. Frequencies are 
expressed as the percentage incidence out of the total number of genotypes detected. 
Comparisons were made between the genotypes detected for TIDM and NC subjects using 
the x2 test and 2x2 contingency tables. n= number of alleles detected, number of subjects 
studied is shown in parenthesis. Only significant differences by x2 and correction are 
shown. Where observed numbers were <5, Fishers exact test for small numbers was 
applied. 
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DR vs. Uncomplicated diabetic controls; 
C/C.AJA; x2= 4.8, p= 0.03, Pc= ns. 
C/T.AJC; x2= 4.4, p= 0.04, Pc= ns. 
DN vs. Uncomplicated diabetic controls; 
C/C.AJA; x2= 4.3, p= 0.04, Pc= ns. 
DNU vs. Uncomplicated diabetic controls; 
CIC.AJA; x2= 4.8, p= 0.03, Pc= ns . 
• 
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Chapter 4. KesuJts 
Aldose Reductase Gene Study 
Binding activity of OREBP to ALR2 promoter osmotic response elements by 
electrophoretic mobility shift assay in TlDM subjects and healthy adult controls. 
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Binding activity of OREBP to OREA,B and C ofthe ALR2 promoter region 
Analysis of the binding activity of OREBP to the ORE sites within the aldose reductase 
gene promoter was performed by Electrophoretic Mobility Shift Assay (EMSA). Nuclear 
extracts were prepared from peripheral blood mononuclear cells from whole blood donated 
from TIDM subjects and normal control subjects cultured under normoglycemic 
(llmMIL) and hyperglycemic (28mMIL) conditions. Within the TIDM subject group 
studied 6 were diagnosed as having diabetic nephropathy and retinopathy, 6 were full 
· house patients and 3 were uncomplicated diabetic controls. Results were also obtained 
from 13 normal control subjects. 
Nuclear extracts containing 5J.1g protein (determined by Coomassie protein assay) were 
incubated with a radio-labelled probe for 20 minutes at room temperature in appropriate 
buffer. Samples were then loaded onto a 4% bis-acrylamide urea gel and electrophoresed at 
lOOV for 3-4 hours (refer to materials and methods). The gel was exposed to X-Omat 
photographic paper and bands were analysed and quantified using a phosphoimager 
(BioRad) with multi-analyst software (figure 27). The activation of OREBP binding was 
determined as a fold increase between the llmM and 28mM glucose exposed samples, 
therefore above the level obtained under normal conditions. 
Results are expressed a means ± SE. Statistical significance of comparisons were made 
between groups using the ANOV A test to detect variance and a P-value of the F-test, 
greater or equal to 0.05 was considered significant. The Student t test was also applied 
between groups. 
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Figure 27. Electrophoretic Mobility Shift Assay analysis of binding activity to 
ORE of ALR2 promoter. 
A. Competition experiments to demonstrate the specificity of the ORE band in 
Jurkat cells, the OREB and OREC competition experiments are shown here. 
B This autoradiograph shows the expression of OREBPC in 4 patients with diabetic 
nephropathy. The level of ORE BP binding was increased in samples stimulated with 
28mM D-glucose and the increase is expressed as fold increases. 
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Binding activity of OREBP to OREA, B and C in TlDM subjects and normal controls 
of British Caucasoid origin 
Figure 27 shows the EMSA analysis of the binding activity to Osmotic Response Elements 
of the aldose reductase promoter region. The fold increases of the ORE binding protein 
activity for OREA, B and C with respect to the onset of diabetic complications are shown 
in tables 69 and 70. No data was available for the diabetic control subjects for the OREA 
region. The results are expressed as fold increases in ORE/OREBP above the level 
obtained under normal conditions. In the TIDM subjects with microvascular complications 
the mean fold increase for OREA is 1.38 (± 0.43), for OREB is 2.23 (±1.98), and for 
OREC is 2.23 (±3.12). In contrast to this, the uncomplicated diabetic controls show a slight 
reduction in ORE/OREBP compared to the level obtained under normal conditions, for 
OREB 0. 78 (±0.22), and for OREC 0.89 (±0.22). The normal control subjects also show an 
increase in the ORE/OREBP above the level obtained under normal conditions for OREA 
and OREB. With respect to OREA the mean increase was 1.4 (±0.47), OREB the mean 
increase was 1.10 (±0.41), and for OREC the level was decreased 0.93 (±0.93). The 
differences in response of ORE/OREBP between TIDM with complications and the 
diabetic controls showed statistical significance following the ANOV A test and the P value 
of the F-test. With respect to the OREB the mean averages were 2.2 vs. 0.8 (P=0.02), and 
OREC the mean averages were 2.2 vs. 0.9 (P=0.01). The differences in response of 
ORE/OREBP between TIDM with complications and normal controls were also 
determined. With respect to OREA no significant difference was detected (1.4 vs. 1.4, 
P=0.9). With respect to OREB and OREC however there were significant differences 
detected, OREB 2.2 vs. 1.1, P=<0.001, OREC 2.2 vs. 0.9, P=<O.OOL 
Table 70 presents the fold increases in the· ORE/OREBP levels above the level achieved 
under normal conditions with respect to the exact complications of diabetes. Two groups 
were studied, firstly, those with diabetic nephropathy and retinopathy, and secondly those 
with full house complications. In the case of the DN/DR group vs. uncomplicated DC 
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group the OREC showed a significant fold increase (1.4 vs. 0.9, P=<0.0001). For the full 
house patients the OREB fold increase was higher in the FHP group than the diabetic 
controls (3.0 vs. 0.8, P=O.Ol5), and the normal controls (3.08 vs. 1.1, P= <0.0001). For the 
Full house patients the OREC fold increase is also higher in the FHP group than the 
uncomplicated DC (2.9 vs. 0.9, P=0.006), and the normal controls (2.9 vs. 0.9, 
P=<O.OOOI). 
The data is also presented in box and whisker plots in figures 28 and 29. It is apparent from 
the box and whisker plots, however, that there is a large standard error with respect to the 
variation in binding activities between subjects within each of the groups studied. 
Although the mean averages are significantly different, there is significant overlap between 
the subject groups. It is therefore difficult to draw confident conclusions from this data, 
and a larger group now needs to be analysed in order to reduce the standard errors found 
here. 
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Tl DM with microvascular Uncomplicated Diabetic Normal controls 
complications Controls 
Glucose OREA ORES OREC OREA ORES OREC OREA ORES OREC 
concentration n=9 n=12 n=ll n=O n=3 n=3 n=13 n=13 n=12 
Q b c 
Hyperglycae 1.38 2.23 2.23 0.78 0.89 1.40 1.10 0.93 
m la !,0.43 !,1.98 !. 3.12 !. 0.22 !,0.22 !,0.47 !. '0.41 !. 0.19 28mM 
Table 69. Overall mean levels of OREBP binding activity to ALR2 OREA, OREB and OREC in TlDM subjects according to o~set of microvascular 
disease, and normal adult controls. The results are expressed as a fold increases in ORE/OREBP activity above the level obtained under normal conditions 
(IlmM). The results are expressed as mean values± standard error. 
a vs. uncomplicated, P = no data available, and vs. normal controls, P = 0.85 
b vs. uncomplicated, P = 0.02*, and vs. normal controls, P = 0.000004* 
c vs. uncomplicated, p = 0.01 *, and vs. normal controls, p = <0.00001 * 
Jurkats Diabetic nephropathy Diabetic Full House Uncomplicated Normal controls 
and retinoeath~ Patients Diabetic Controls 
Glucose OREA ORES OREC OREA ORES OREC OREA OREB OREC OREA ORES OREC OREA ORES OREC 
concentration n=4 n=4 n=4 n=5 n=6 n=5 n=4 n=6 n=6 n=O n=3 n=3 n=13 n=13 n=12 
Q b c d e f 
Hyper- 0.61 1.62 1.21 1.48 1.38 1.43 1.26 3.08 2.99 0.78 0.89 1.40 1.10 0.93 
glycaemia :!:,0.28 :!:,0.98 :!:,0.56 :!:,0.52 :!:,0.77 :!:,0.89 :!:. 0.33 :!:. 2.52 :!:. 4.19 :!:. 0.22 :!:,0.22 :!:,0.47 :!:. 0.41 :!:. 0.19 
28mM 
Table 70. Overall mean levels of OREBP binding activity to ALR2 OREA, OREB and OREC in Jurkat cells and TlDM subjects according to onset 
of microvascular disease, and normal adult controls. The results are expressed as a fold increases in ORE/OREBP activity above the level obtained under 
normal conditions ( llmM). The results are expressed as mean values± standard error. 
a vs. uncomplicated, P =no data available, and vs. normal controls, P = 0.7 
b vs. uncomplicated, P = 0.17, and vs. normal controls, P = 0.096 
c vs. uncomplicated, P = 0.12, and vs. normal controls, P = 0.00009* 
d vs. uncomplicated, P = no data available, and vs. normal controls, P = 0.62 
e vs. uncomplicated, P = 0.015*, and vs. normal controls, P = 0.000001 * 
f vs. uncomplicated, P = 0.006*, and vs. normal controls, P = < 0.00001 * 
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Figure 28.Box and whisker plots comparing the activation (fold) in the ORE A,B 
and C regions investigated according to onset of diabetic microvascular disease. 
a) normal controls 
b) uncomplicated diabetic controls 
c) diabetic nephropathy with retinopathy 
d) full house patients 
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Figure 29. Box and whisker plots comparing the OREBP/ORE binding activity 
detected between groups according to ORE binding site investigated. 
(a) Activation (fold) at ORE A 
(b) Activation (fold) at ORE B 
(c) Activation (fold) at ORE C 
0 
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D17S934 Hypertension-Linked Gene Study 
Associations of a polymorphism at D17S934 locus situated 18cM proximal to the ACE 
gene and the microvascular complications ofTtDM and T2DM 
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Polymorphism at the Dl7S934 region 
A microsatellite polymorphism located l8cM proximal to the ACE gene on chromosome 
I 7q was investigated. The study incorporated two subject groups for which the case control 
study utilised a population of TIDM and normal control subjects of British Caucasoid 
origin, and a population of T2DM and normal control subjects of Southern 
Indian/Dravidian origin. A single microsatellite polymorphism was studied, a (CA)n repeat 
microsatellite polymorphic marker located l8cM proximal to the ACE gene. The results of 
this study are presented in tabular form in the following section. For the case-control 
studies the data was initially analysed for allelic and genotypic frequencies between 
subjects with diabetes and subjects without diabetes, and then with regard to subjects onset 
of diabetic microvascular disease. The data was then amalgamated and subject haplotype 
· analysis was carried out with respect to diabetic complications. All subjects previously 
genotyped for the 5 'ALR2 polymorphism were genotyped for the D 178934 polymorphism 
for ease of comparability. 
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Chromosome 17q EC 3.4.15.1 
Angiotensin Converting Ezyme loci 
17q23 
D17S934/~Z56VB9/AFMZ56~9 
Essential hypertension susceptibility 
loci 
I· 
18 cM 
17q21-22 
Figure 30. Diagrammatic representation of the polymorphic region studied within the region proximal to the ACE 
gene located on chromosome 17 q 
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DI7S934 (CA)n microsatellite polymorphic marker 
The (CA)n dinucleotide repeat microsatellite situated l8cM proximal to the ACE gene was 
investigated. Polymerase chain reaction was carried out to amplify the region upstream of 
the ACE gene containing the (CA)n repeat microsatellite as described in chapter 3. 
Amplification products (6Jll) mixed with stop solution (Amersham, UK) were separated on 
a 6% polyacrylamide gel at 1900V for 3 hours, and alleles were revealed by 
autoradiography (figure 31 ), and typed using the Fluor-s multi-imaging system (BioRad}. 
The size of the bands was checked by running a [32P] A TP radio-labelled molecular 
weight marker alongside the subjects. The (CA)n microsatellite was investigated in TIDM 
subjects and nonnal controls of British Caucasoid origin and T2DM subjects and non-
diabetic controls of Southern Indian/Dravidian origin. In these studies we were able to find 
11 alleles which differed by the number of integral repeats. Subjects were assigned their 
allele and genotype according to the number of CA repeats which were identified (table 
71). 
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(a) 
.._ 9 
.._ 8 
.._ 7 
Direction of .._ 6 
migration .._ 5 
.._ 4 
.._ 3 
.._ 2 
.._ 
1 
Lane; 1 2 3 4 5 6 7 8 
(b) 
Allele 6 
Allele 1 
'"" 
Figure 31. D17S934 microsatellite autoradiograpn, and (b) quantification of 
bands using Fluor-s multi-imaging software. 
(a) D17S934 microsatellite autoradiograpn. Nine alleles are identified in this 
autoradiograph and allocated genotypes for each of the subjects shown in lanes 1-8 
are as follows: 
Lane 1: 5.5 
Lane 2: 1.6 
Lane 3: 2.2 
Lane 4: 3 .6 
Lane 5: 2.8 
Lane 6: 1.8 
Lane 7: 2.7 
Lane 8: 2.2 
(b) Image analysis quantification output for sample 2 in autoradiograph 
shown above. The bands appear as peaks in the graph which correspond to 
D17S934 al le les, shadow bands were a lso detected. 
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Allele PCR product size CA repeats 
(b) 
1 181 16 
2 183 17 
3 185 18 
4 187 19 
5 189 20 
6 191 21 
7 193 22 
8 195 23 
9 197 24 
10 199 25 
12 201 26 
Table 71. Allele sizes In base pairs for the 11 different CA repeat 
polymorphisms identified. This table shows the size of the PCR amplified region 
corresponding to each allele, along with the number of dinucleotide (CA)n repeats. 
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Dl7S934 (CA)n microsatellite marker in British Caucasoid TlDM subjects and 
normal controls 
The (CA)n microsatellite marker in the proximal region of the ACE gene was investigated 
using 244 subjects with TlDM of British Caucasoid origin as well as a collection of 120 
British Caucasoid normal controls (clinical demographics shown in table 6). Within the 
TlDM population studies there were 66 uncomplicated diabetic controls, 62 full house 
patients, 18 with diabetic neuropathy, 24 with diabetic retinopathy and neuropathy, 30 with 
diabetic nephropathy and retinopathy and 44 with diabetic retinopathy. 
The frequency of the (CA)n alleles in both TIDM and normal control populations is shown 
in table 72. There were 11 (CA)n alleles detected at the 5' ALR2 locus in the British 
Caucasoid TIDM and control population; 1,2,3,4,5,6,7,8,9,10 and 12. Eleven alleles gave 
rise to 66 possible genotypes of which 38 were detected in this study population. In the 
analysis of allelic frequencies homozygotes were counted as two alleles, and alleles and 
genotypes that were not detected are not shown. Tables show the percentage frequency of 
detected alleles and genotypes with actual numbers detected shown in parenthesis. Possible 
associations were investigated with respect to allelic frequency and genotype and 
comparisons were made between groups using the r! test and 2x2 contingency tables. 
324 
Chapter 4. Results 
D17S934 (CA)n aUelic frequencies in British Caucasoid TlDM and normal control 
subjects 
The frequency of the DI7S934 alleles in TIDM British Caucasoid subjects is shown in 
tables 72 to 75. Table 72 shows the percentage frequency of the detected D 17S934 (CA)n 
alleles in the total TIDM population studied compared to the normal control population 
studied. No significant differences were found in the frequencies of alleles between these 
two groups. In the case of allele I there was a higher frequency in the TIDM subjects 
compared to the normal controls (12.5% vs. 7.5%, ·l = 4.2, p= 0.04, Pc= ns). In the case of 
allele 2 there was also a higher frequency in the TIDM subjects compared to the NC 
(28.7% vs. 19.9%, x2 = 6.34, p= 0.01, Pc= ns). In the case of allele 6 there was a lower 
frequency in the TIDM subjects compared to the NC (7.90/o vs. 13.3%, l = 5.2, p= 0.02, 
Pc= ns). In the case of allele 8 there was a lower incidence in the TIDM group compared 
to the NC ( 1.6% vs. 4.6%, x2 = 6.3, p= 0.02, Pc= ns). 
Table 73 compares the percentage frequencies of alleles detected in the TIDM subjects 
with DN/DRJDNU and the uncomplicated DC group. No significant differences were 
found. Table 74. presents the frequency of the detected D 17S934 microsatellite marker 
alleles according to the precise complications detected. Upon application of the Chi-
squared test for significance and Fishers ~xact test for numbers <5, no associations were 
found with respect to the onset of microvascular complications of TIDM. Table 75 
presents the frequency of the detected D 17S934 (CA)n microsatellite alleles in subjects 
according to the onset of diabetic nephropathy, retinopathy or neuropathy. There were no 
significant associations detected with respect to the onset of the microvascular 
complications ofTIDM. 
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Alleles TIDM subjects Normal Controls 
(NC) 
n 488 240 
I 12.5 7.5 
(61) (18) 
2 28.7 19.9 
(140) (48) 
3 17.8 23.3 
(87) (56) 
4 15.9 18.8 
(78) (45) 
5 12.5 8.8 
(61) (21) 
6 7.9 13.3 
(39) (32) 
7 2.5 2.9 
(12) (7) 
8 1.6 4.6 
(8) (I I) 
9 0.008 
(0) (2) 
10 0.2 
(I) (-) 
12 0.2 
(I) (-) 
Table 72. Percentage frequency of the detected 0178934 (CA)n marker aUeles in 
British Caucasoid TlDM subjects compared to normal controls. 
This table shows the frequency of detected alleles for TlDM subjects and normal control 
subjects. Frequencies are expressed as the percentage incidence out of the total number of 
alleles detected. Comparisons were made between the allelic frequencies for control and 
TIDM subjects using the x} test and 2x2 contingency tables. n = number of alleles 
detected, number of subjects studied is shown in parenthesis. Only significant differences 
by ·l and correction are shown. Where observed numbers were <5, Fishers exact test for 
small numbers was applied. 
TlDMvs.NC; 
• 
1; r} = 4.16, p= 0.04 (ldf), Pc= ns 
2; r! = 6.34, p= 0.01 (ldf), Pc= ns 
6;-/ = 5.22, p= 0.02 (ldf), Pc= ns 
8; ·l = 5.49, p= 0.02 (ldf), Pc= ns 
The remaining allele frequencies were not analysed as only a small number were detected and 
significant correlation's would be difficult to determine. 
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TIDM Nephropathy Uncompll<ated Normal Controls (Nq 
and/or Retinopathy (Dq 
and/or Neuropathy 
(DRIN/Nu) 
D 356 132 240 
{178) (66) {120) 
1 12.9 11.4 7.5 
(46) (15) (18) 
2 29.8 25.8 19.9 
(106) (34) (48) 
3 16.9 20.5 23.3 
(60) (27) (56) 
4 16.3 15.2 18.8 
(58) (20) (45) 
5 12.9 11.4 8.8 
(46) (15) (21) 
6 7.9 8.3 13.3 
(28) (11) (32) 
7 1.4 5.3 2.9 
(S) (7) (7) 
8 1.4 2.3 4.6 
(S) (3) (11) 
9 0.008 
(-) (-) (2) 
10 0.3 
{I) (-) (-) 
12 0.3 
{I (-) (-) 
Table 73. Percentage frequency of the detected D17S934 (CA)n microsateUite marker aUeles 
in British Caucasoid TlDM subjects with diabetic nephropathy and/or retinopathy and/or 
neuropathy (DRIN/Nu) compared to uncompllcated (DC) and normal controls (NC). 
This table shows the percentage frequency of detected DI7S934 aUeles for TIDM subjects with 
microvascular disease (nephropathy, retinopathy, neuropathy) compared to uncomplicated and 
normal controls. The percentage frequency is shown and the actual number of each of the aUeles 
detected for each group is shown in parenthesis. n = number of alleles detected, the number of 
subjects is shown in parenthesis. Only significant differences by ·i and correction are shown. 
DRIDN/DNU vs. Uncompllcated diabetic controls; 
7; ·i = 6.1, p= 0.01 (ld.f), Pc= ns 
The remaining allele frequencies were not analysed as only a small number were detected and 
significant correlation's would be difficult to determine. 
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I 2 3 4 5 Uooomplloated Normal Diabetic Diabetic Diabetic Diabetic Full House (Dq Controls Retinopathy Nephropathy Retln~pathy Neuropathy Patients (Nq 
and and 
Retinopathy Neuropathy 
0 88 60 48 36 124 132 240 
(44) (30) (24) (18) (62) (76) (120) 
I 7.95 11.7 22.9 16.7 12.1 11.4 7.5 
(7) (7) (11) (6) (15) (15) (18) 
2 34.1 28.3 33.3 30.6 25.8 25.8 19.9 
(30) (17) (16) (I I) (32) (34) (48) 
3 18.2 14.99 12.5 11.1 20.2 20.5 23.3 
(16) (9) (6) (4) (25) (27) (56) 
4 17.1 19.99 12.5 19.4 14.5 15.2 18.8 
(15) (12) (6) (7) (18) (20) (45) 
5 10.2 9.99 8.3 13.9 17.7 11.4 8.8 
(9) (6) (4) (5) (22) (15) (21) 
6 6.8 4.99 10.4 8.3 8.9 8.3 13.3 . 
(6) (3) (5) (3) (11) (11) (32) 
7 3.4 1.7 0.81 5.3 2.9 
(3) (I) (-) (-) (I) (7) (7) 
8 2.3 4.99 2.3 4.6 
(2) (3) (-) ( -) (-) (3) (I I) 
9 1.7 0.008 
(-) (-) (-) (-) (-) (-) (2) 
10 1.7 
(-) (I) (-) (-) (-) (-) (-) 
12 1.7 
(-) (I) (-) (-) (-) (-) (-) 
Table 74. Percentage frequency of the detected Dl7S934 (CA)n microsatellite marker 
aUeles in British Caucasoid TlDM subjects categorised in accordance to the onset of 
diabetic complications and normal control subjects. 
This table shows the percentage frequency of detected alleles for TIDM subjects with 
retinopathy (DR), nephropathy and retinopathy (DN/DR), retinopathy and neuropathy 
(DRIDNu), neuropathy (DNu), full house complications patients (FHC) and uncomplicated 
diabetics controls (DC). Also shown here is the allelic frequency of normal healthy 
controls. 
n = number of alleles detected, the number of subjects is shown in parenthesis. 
Upon application of the Chi squared test for significance and Fishers exact test for numbers 
<5, no associations were found between the frequencies of each of the alleles detected and 
onset of microvascular complications ofTlDM. 
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I z j UnrompUcated Normal Diabetic Diabetic Diabetic (DC) Controls Nephropathy Retinopathy Neuropathy (NC) (DN) (DR) (DNu) 
n 184 320 208 132 240 
(92) (160) (104) (76) (120) 
I 11.96 12.5 15.4 11.4 7.5 
(22) (40) (32) "(15) (18) 
2 26.6 29.7 28.4 25.8 19.9 
(49) (95) (59) {34) (48) 
3 18.0 17.5 16.8 20.5 23.3 
(34) (56) (35) {27) {56) 
4 16.3 15.9 14.9 15.2 18.8 
(30) {51) {31) {20) (45) 
5 15.2 12.8 14.9 11.4 8.8 
(28) (41) (31) (15) (21) 
6 7.6 7.8 9.1 8.3 13.3 
(14) {25) {19) (11) {32) 
7 1.09 1.6 0.5 5.3 2.9 
(2) {5) {1) {7) (7) 
8 1.6 1.6 2.3 4.6 
(3) (5) (-) (3) (11) 
9 0.008 
(-) (-) (-) (-) (2) 
10 0.5 0.3 
(I) (I) (-) (-) (-) 
12 0.5 0.3 
{-) (-) (-) (-) {-) 
Table 75. Percentage frequency of ~e detected D17S934 (CA)n microsatellite aUeles 
in Caucasoid TlDM subjects categorised in accordance to onset of diabetic 
nephropathy, retinopathy or neuropathy. 
This table presents the allelic frequency of the D 17S934 (CA)n microsatellite in TIDM 
subjects of British Caucasoid origin. Subjects are classified in accordance to onset of 
retinopathy, nephropathy or neuropathy. The nephropathy group (n=92) is an 
amalgamation of the nephropathy and retinopathy (n=30) and full house subjects (n=62) 
groups previously identified. The retinopathy group (n=l60) is an amalgamation of the 
retinopathy (n=44), nephropathy with retinopathy (n=30), retinopathy and neuropathy 
(n=24) and full house patients (n=62) groups previously identified. The neuropathy group 
(n=I04) consists of subjects diagnosed as having neuropathy in the absence of any other 
microvascular complication (n=l8), the diabetic retinopathy with neuropathy (n=24) and 
full house patients (n=62) groups. Also presented is the allelic frequency in uncomplicated 
and normal controls. n = number of alleles detected, the number of subjects is shown in 
parenthesis. 
Upon application of the Chi squared test for significance and Fishers exact test where 
numbers were <5, no associations were found between the frequencies of each of the 
alleles detected and onset of microvascular complications ofTIDM. 
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D17S934- (CA)n genotype frequencies in British Caucasoid TlDM and normal 
control subjects 
The frequencies of the D 178934 genotype frequencies· in British Caucasoid Tl DM and 
normal controls are shown in tables 76-79. Table 76 shows the detected frequency of the 
DI7S934 genotypes in all TIDM subjects studied compared to the normal controls. There 
were no significant differences in the frequencies of the detected genotypes between the 
two groups. Table 77 shows the frequency of the detected genotypes in the subgroups of 
the subjects studied; T1 DM diabetic microvascular disease, uncomplicated diabetic 
controls and normal controls. There were no significant differences found when the Chi-
squared test was applied. Table 78 shows the frequency of each of the genotypes detected 
in all of the patient subgroups according to the precise phenotype of diabetic microvascular 
complications. Comparisons were made between each of the complication subgroups and 
the TIDM uncomplicated controls. There were no significant differences detected between 
the frequencies of any of the genotypes detected between these groups. Equally, in table 
79, whereby the patient subgroups were amalgamated according to the presence of 
nephropathy or retinopathy or neuropathy no significant differences were found indicating 
that this polymorphism is not associated with the onset of microvascular complications of 
diabetes in the population studied here. 
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Genotype TIDM subjects Nonnal Controls (NC) 
n 244 120 
1.1 2.0 1.7 
(5) (2) 
1.2 6.6 1.7 
(16) (2) 
1.3 4.5 3.3 
(11) (4) 
1.4 4.1 3.3 
(10) (4) 
1.5 2.9 2.5 
(7) (3) 
1.6 2.0 
(5) (-) 
1.7 0.4 0.8 
(I) (I) 
1.8 0.4 
(I) (-) 
2.2 10.2 8.3 
(25) (10) 
2.3 9.0 4.99 
(22) (6) 
2.4 9.0 7.5 
(22) (9) 
2.5 6.9 2.5 
(I7) (3) 
2.6 3.3 4.2 
(8) (5) 
2.7 1.2 0.8 
(3) (I) 
2.8 0.8 0.8 
(2) (I) 
2.9 0.8 
(-) (I) 
3.3 2.9 7.5 
(7) (9) 
3.4 6.I I2.5 
(I5) (15) 
3.5 5.3 4.2 
(I3) (5) 
3.6 3.3 5.8 
(8) (7) 
3.7 1.2 
(3) (-) 
3.8 0.4 0.8 
(I) (I) 
4.4 1.6 3.3 
(4) (4) 
4.5 5.7 2.5 
(I4) (3) 
4.6 2.5 4.2 
(6) (5) 
4.7 0.4 0.8 
(I) (I) 
4.8 0.8 
(2) (-) 
5.5 0.4 2.5 
(I) (3) 
5.6 2.5 
(6) (-) 
5.7 0.8 
(2) (-) 
5.8 0.8 
(-) (I) 
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6.6 0.8 4.99 
(2) (6) 
6.7 1.7 
(-) (2) 
6.8 0.8 0.8 
(2) (1) 
7.7 0.4 0.8 
(I) (I) 
8.8 2.5 
(-) (3) 
8.9 0.8 
(0) (!) 
10.12 0.4 
(I) -) 
Table 76. Percentage frequency of the detected D17S934 (CA}n microsatellite marker 
genotypes in British Caucasoid TlDM subjects compared to normal controls. 
This table shows the frequency of detected genotypes for TIDM subjects and normal 
control subjects. Frequencies are expressed as the percentage incidence out of the total 
number of genotypes detected. n = number of genotypes detected. Comparisons were made 
between the genotype frequencies for normal controls and Tl DM subjects using the x2 test 
and 2 x 2 contingency tables. P-values were corrected for the number of comparisons 
made. Where observed values were <5 Fishers exact test was used. No significant 
differences were found. 
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Genotype TI DM Nephropathy and/or Uncomplicated Normal Controls 
Rellnopathy and/or (DC) (NC) 
Neuropathy 
RIN/Nu 
n 178 66 120 
1.1 2.3 1.52 1.7 
(4) (1) (2) 
1.2 7.3 4.6 1.7 
(l3) (3) (2) 
1.3 5.6 1.5 3.3 
(10) (I) (4) 
1.4 3.9 4.6 3.3 
(7) (3) (4) 
1.5 2.8 3.0 2.5 
(5) (2) (3) 
1.6 l.l 4.6 
(2) (3) (-) 
1.7 1.5 0.8 
(-) (1) (I) 
1.8 0.6 
(l) (-) (-) 
2.2 10.7 9.1 8.3 
(19) (6) (10) 
2.3 8.99 9.1 4.99 
(16) (6) (6) 
2.4 10.1 6.1 7.5 
(18) (4) (9) 
2.5 6.2 9.1 2.5 
(ll) (6) (3) 
2.6 3.4 3.0 4.2 
(6) (2) (5) 
2.7 l.l 1.5 0.8 
(2) (I) (I) 
2.8 l.l 0.8 
(2) (-) (I) 
2.9 0.8 
(-) (-) (I) 
3.3 1.7 6.1 7.5 
(3) (4) (9) 
3.4 6.2 6.1 12.5 
(11) (4) (15) 
3.5 6.2 3.0 4.2 
(11) (2) (5) 
3.6 3.4 3.0 5.8 
(6) (2) (7) 
3.7 4.6 
(-) (3) (-) 
3.8 1.5 0.8 
(-) (I) (I) 
4.4 1.7 1.5 3.3 
(3) (I) (4) 
4.5 6.7 3.0 2.5 
(12) (2) (3) 
4.6 2.3 3.0 4.2 
(4) (2) (5) 
4.7 1.5 0.8 
(-) (I) (I) 
4.8 3.0 
(-) (2) (-) 
5.5 0.6 2.5 
(1) (-) (3) 
5.6 2.3 3.0 
(4) (2) (-) 
5.7 0.6 1.5 
(I) (I) (-) 
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5.8 0.8 
(-) (-) (1) 
6.6 J.l 4.99 
(2) (-) (6) 
6.7 1.7 
(-) (-) (2) 
6.8 J.l 0.8 
(2) (-) (l) 
7.7 0.6 0.8 
(1) (-) (l) 
7.9 
(-) (-) (-) 
8.8 2.5 
(-) (-) (3) 
8.9 0.8 
(-) (-) (l) 
10.12 0.6 
(l) (-) (-) 
Table 77. Percentage frequency of the detected Dl7S934 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects with nephropathy and/or retinopathy 
and/or neuropathy (DR/N/Nu) compared to uncomplicated (DC) and normal controls 
(NC). This table shows the percentage frequency of detected genotypes for TIDM subjects 
with microvascular disease (nephropathy, retinopathy, neuropathy) compared to 
uncomplicated and normal controls. The percentage frequency is shown and the actual 
number of genotypes detected for each group is shown in parenthesis. n = number of 
genotypes detected. 
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1Diabetic 5oiabedc 1Diabetic 4DJabetic 5Full House Uncomplicated Normal 
Genolyp Retinopathy Nephropathy Retinopathy Neuropathy Patients (DC) Controls 
e and and (NC) 
Retinopathy Neuropathy 
n 44 30 24 18 62 66 120 
1.1 12.5 1.6 1.5 1.7 
(-) (-) (3) (-) (I) (I) (2) 
1.2 4.6 6.7 16.7 5.6 6.5 4.6 1.7 
(2) (2) (4) (I) (4) (3) (2) 
1.3 4.6 9.99 4.2 5.6 4.8 1.5 3.3 
(2) (3) (I) (I) (3) (I) (4) 
1.4 22.2 4.8 4.6 3.3 
(-) (-) (-) (4) (3) (3) (4) 
1.5 6.8 3.3 1.6 3.0 2.5 
(3) (I) (-) (-) (I) (2) (3) 
1.6 3.2 4.6 
(-) (-) (-) (-) (2) (3) (-) 
1.7 1.5 0.8 
(-) (-) (-) (-) (-) (I) (I) 
1.8 3.3 
(-) (I) (-) (-) (-) (-) (-) 
2.2 15.9 6.7 12.5 16.7 6.5 9.1 8.3 
(7) (2) (3) (3) (4) (6) (10) 
2.3 4.6 6.7 4.2 5.6 16.1 9.1 4.99 
(2) (2) (I) (I) (10) (6) (6) 
2.4 13.6 16.7 12.5 6.5 6.1 7.5 
(6) (5) (3) (-) (4) (4) (9) 
2.5 9.1 6.7 4.2 11.1 3.2 9.1 2.5 
.(4) (2) (I) (2) (2) (6) (3) 
2.6 2.3 4.2 5.6 4.8 3.0 4.2 
(I) (-) (I) (1) (3) (2) (5) 
2.7 3.3 1.6 1.5 0.8 
(-) (I) (-) (-) (I) (I) (I) 
2.8 2.3 3.3 0.8 
(I) (1) (-) (-) (-) (-) (I) 
2.9 0.8 
(-) (-) (-) (-) (-) (-) (I) 
3.3 4.6 1.6 6.1 7.5 
(2) (-) (-) (-) (I) (4) (9) 
3.4 11.4 6.7 4.2 4.8 6.1 12.5 
(5) (2) (I) (-) (3) (4) (15) 
3.5 3.3 8.3 5.6 11.3 3.0 4.2 
(-) (I) (2) (1) (7) (2) (5) 
3.6 6.8 3.3 4.2 5.6 3.0 5.8 
(3) (I) (I) (I) (-) (2) (7) 
3.7 4.6 
(-) (-) (-) (-) (-) (3) (-) 
3.8 1.5 0.8 
(-) (-) (-) (-) (-) (I) (I) 
4.4 2.3 3.3 1.6 1.5 3.3 
(I) (I) (-) (-) (1) (I) (4) 
4.5 2.3 6.7 4.2 11.1 9.7 3.0 2.5 
(I) (2) (I) (2) (6) (2) (3) 
4.6 2.3 3.3 4.2 5.6 3.0 4.2 
(I) (I) (I) (I) (-) (2) (5) 
4.7 1.5 0.8 
(-) (-) (-) (-) (-) (I) (I) 
4.8 3.0 
(-) (-) (-) (-) (-) (2) (-) 
5.5 1.6 2.5 
(-) (-) (-) (-) (I) (-) (3) 
5.6 6.5 3.0 
(-) (-) (-) (-) (4) (2) (-) 
5.7 2.3 1.5 
(I) (-) (-) (-) (-) (I) (-) 
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5.8 0.8 
(-) (-) (-) (-) (-) (-) (I) 
6.6 4.2 1.6 4.99 
(-) (-) (I) (-) (I) (-) (6) 
6.7 1.1 
(-) (-) (-) (-) (-) (-) (2) 
6.8 2.3 3.3 0.8 
(I) (I) (-) (-) (-) (-) (I) 
7.7 2.3 0.8 
(I) (-) (-) (-) (-) (-) (I) 
7.9 
(-) (-) (-) (-) (-) (-) (-) 
8.8 2.5 
(-) (-) (-) (-) (-) (-) (3) 
8.9 0.8 
(-) (-) (-) (-) (-) (-) (I) 
1Q.12 3.3 
(-) (I) (-) (-) (-) (-) (-) 
Table 78. Percentage frequency of the detected D17S934 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects categorised in accordance to the onset 
of diabetic complications and uncomplicated (DC) and normal controls (NC). 
This table shows the percentage frequency of detected genotypes for TIDM subjects with 
respect to onset of microvascular complications, and normal control subjects. The 
percentage frequency is shown and the actual number of genotypes detected for each group 
is shown in parenthesis. n = number of subjects studied and genotypes detected. 
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I 2 j Unrompllcated Normal Diabetic Diabetic Diabetic 
Genotype Nephropathy Retinopathy Neuropothy (DC) Controls 
(D~ (DR! (DNu! (NC) 
n 92 160 104 66 120 
1.1 l.l 2.5 3.9 1.5 1.7 
(I) (4) (4) (I) (2) 
1.2 6.5 7.5 8.7 4.6 1.7 
(6) (12) (9) (3) (2) 
1.3 6.5 5.6 4.8 1.5 3.3 
(6) (9) (5) (I) (4) 
1.4 3.3 1.9 6.7 4.6 3.3 
(3) (3) (7) (3) (4) 
1.5 2.2 3.1 0.9 3.0 2.5 
(2) (5) (I) (2) (3)' 
1.6 2.2 1.3 1.9 4.6 
(2) (2) (2) (3) (-) 
1.7 1.5 0.8 
(-) (-) (-) (I) (I) 
1.8 l.l 0.6 
(I) (I) (-) (-) (-) 
2.2 6.5 10.0 9.6 9.1 8.3 
(6) (I6) (10) (6) (10) 
2.3 13.0 9.4 Il.5 9.I 4.99 
(I2) (I5) (12) (6) (6) 
2.4 9.8 11.3 6.7 6.1 7.5 
(9) (I8) (7) (4) (9) 
2.5 4.4 5.6 4.8 9.1 2.5 
(4) (9) (5) (6) (3) 
2.6 3.3 3.1 4.8 3.0 4.2 
(3) (5) (5) (2) (5) 
2.7 2.2 1.3 0.96 1.5 0.8 
(2) (2) (I) . (I) (I) 
2.8 1.1 1.3 0.8 
(I) (2) (-) (-) (I) 
2.9 0.8 
(-) (-) (-) (-) (I) 
3.3 1.1 1.9 0.96 6.1 7.5 
(I) (3) (I) (4) (9) 
3.4 5.4 6.9 3.8 6.1 I2.5 
(5) (IJ) (4) (4) (15) 
3.5 8.7 6.3 9.6 3.0 4.2 
(8) (IO) (10) (2) (5) 
3.6 1.1· 3.1 1.9 3.0 5.8 
(I) (5) (2) (2) (7) 
3.7 4.6 
(-) (-) (-) . (3) (-) 
3.8 1.5 0.8 
(-) (-) (-) (I) (I) 
4.4 2.2 1.9 0.96 1.5 3.3 
(2) (3) (I) (I) (4) 
4.5 8.7 6.3 8.7 3.0 2.5 
(8) (10) (9) (2) (3) 
4.6 1.1 1.9 1.9 3.0 4.2 
(I) (3) (2) (2) (5) 
4.7 1.5 0.8 
(-) (-) (-) (I) (I) 
4.8 3.0 
(-) (-) (-) (2) (-) 
5.5 l.l 0.6 0.96 2.5 
(I) (I) (I) (-) (3) 
5.6 4.4 2.5 3.9 3.0 
(4) (4) (4) (2) (-) 
5.7 0.6 1.5 
(-) (I) (-) (I) (-) 
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5.8 0.8 
(-) (-) (-) (-) (I) 
6.6 1.1 1.3 1.9 4.99 
(I) (2) (2) (-) (6) 
6.7 1.7 
(-) (-) (-) (-) (2) 
6.8 1.1 1.3 0.8 
(I) (2) (-) (-) (I) 
7.7 0.6 0.8 
(-) (1) (-) (-) (I) 
8.8 2.5 
(-) (-) (-) (-) (3) 
8.9 0.8 
(-) (-) (-) (-) (1) 
IO.IZ 1.1 0.6 
(I) (1) (-) (-) (-) 
Table 79. Percentage frequency of the detected D17S934 (CA)n microsatellite marker 
genotypes in British Caucasoid TlDM subjects categorised in accordance to onset of 
diabetic nephropathy, retinopathy or neuropathy. 
This table presents the genotype frequency of the 0178934 (CA)n microsatellite in TIDM 
subjects of British Caucasoid origin. Subjects are classified in accordance to onset of 
retinopathy, nephropathy or neuropathy. The nephropathy group (n=92) is an 
amalgamation of the nephropathy and retinopathy (n=30) and full house subjects (n=62) 
groups previously identified. The retinopathy group (n=I60) is an amalgamation of the 
retinopathy (n=44), nephropathy with retinopathy (n=30), retinopathy and neuropathy 
(n=24) and full house patients (n=62) groups previously identified. The neuropathy group 
(n=I04) consists of subjects diagnosed as having neuropathy in the absence of any other 
microvascular complication (n= 18), the diabetic retinopathy with neuropathy (n=24) and 
full house patients (n=62) groups. Also presented is the genotype frequency in 
uncomplicated and normal controls. n = number of subjects analysed and genotypes 
detected. The percentage frequency is shown and the actual number of each genotype 
detected for each subjects group is shown in parenthesis. 
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DI7S934- (CA)n microsatellite marker in Southern Indian T2DM subjects and non-
diabetic controls 
The (CA)n microsatellite marker at D 17S934 in the proximal region of the ACE gene was 
investigated using 60 subjects with T2DM of Southern Indian origin as well as a collection 
of 42 Southern lndian/Dravidian non-diabetic controls (clinical demographics shown in 
table 7). Within the T2DM subject population studied, there. were 28 subjects that were 
. 
normoalbuminuric without retinopathy and 32 subjects with proteinuria. The frequency of 
the (CA)n alleles in both patient and control populations is shown in tables 80 to 81. There 
were 9 (CA)n alleles detected at the Dl7S934 locus in the Southern Indian T2DM and 
non-diabetic control population; 1,2,3,4,5,6,7,8 from which 29 genotypes were also 
identified. Tables show the percentage frequency of detected alleles and genotypes, with 
actual numbers detected shown in parenthesis. Possible associations were investigated with 
respect to allelic frequency and genotype and comparisons were made between groups 
using the Chi-squared test and 2x2 contingency tables. All of the data obtained from the 
D 178934 study of the Southern Indian population is presented in the following tables. 
Possible associations with the D 178934 (CA)n allelic frequencies and genotypes and the 
onset of proteinuria were investigated. 
339 
Chapter 4. I<.esults 
Dl7S934 (CA)n allelic frequencies in Southern Indian T2DM and non-diabetic 
control subjects 
The frequency of the D l7S934 alleles in T2DM Southern Indian/Dravidian subjects is 
shown in tables 80 to 81. Table 80 shows the percentage frequency of the Dl7S934 (CA)n 
alleles in the total T2DM population studied compared to the non-diabetic control 
population studied. Several significant differences were found in the frequencies of the 
detected alleles between the two groups. Significant differences were found between the 
two groups with respect to alleles 3,6 and 7. Table 81 compares the percentage frequencies 
of alleles detected in the T2DM population with proteinuria and with normoalbuminuria 
There were no significant differences found in the frequencies of the detected alleles 
between the two groups. 
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AUel .. T2DM subjects Noo-dlabetlc Controls 
n 120 84 
(60) . (42) 
1 9.2 1.2 
(ll) (I) 
2 4.99 15.5 
(6) (13) 
3 4.2 20.2 
(5) (17) 
4 21.7 30.95 
(26) (26) 
s 17.5 27.4 
(21) (23) 
6 18.3 3.6 
(22) (3) 
7 13.3 
(16) (-) 
8 6.7 1.2 
(8) (I) 
9 4.2 
(5) (-
Table 80. Percentage frequency of the detected Dl7S934 (CA)n microsatellite marker 
alleles in Southern Indian/Dravid.ian T2DM subjects compared to non-diabetic 
controls. 
This table shows the frequency of detected Dl7S934 alleles for T2DM subjects and non-
diabetic control subjects. Frequencies are expressed as the percentage incidence out of the 
total number of alleles detected. Actual numbers of alleles detected is shown in 
parenthesis. 
n = total number of alleles detected, number of subjects studied is shown in parentheses. 
Only significant differences by ·l and correction are shown. 
T2DM vs. NDC; I;x2 =5.7,p=0.02(1df),Pc=ns 
2; ·l = 6.4, p= 0.01 (1df), Pc= ns 
3; x2 = 13.3, p= 0.0003 (1df), Pc= 0.003 * 
6; x2 = 10.01, p= 0.002 (ldf), Pc= 0.02 * 
7; x2 = 12.2, p= 0.0005 (ldf), Pc= 0.005 * 
8; x2 = 3.98, p= 0.05 (ldf), Pc= ns 
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TlDM wltb Proteinuria TlDMwlth Non..<flabetlc Controls (NDC) 
Normoalbumlnurla 
n 56 64 84 
(28) (32) (42) 
1 7.1 10.9 1.2 
(4) (7) (I) 
2 1.8 7.8 15.5 
(1) (5) (13) 
3 3.6 4.7 20.2 
(2) (3) (17) 
4 19.6 23.4 30.95 
(11) (15) (26) 
5 14.3 20.3 27.4 
(8) (13) (23) 
6 17.9 18.8 3.6 
(10) (12) (3) 
7 19.6 7.8 
(11) (5) (-) 
8 7.1 6.3 1.2 
(4) (4) (I) 
9 8.9 
(5) (-) (-) 
Table 81. Percentage frequency of the detected D17S934 microsatellite marker alleles 
in Southern Indian/Dravidian T2DM subjects with proteinuria compared to T2DM 
subjects with normoalbuminuria and non-diabetic control subjects. This table shows 
the percentage frequency of the detected alleles for T2DM subjects with nonnoalbuminuria 
and T2DM subjects with proteinuria as well as non-diabetic controls. The actual number of 
alleles within each group is shown in parentheses. 
n = number of alleles detected, number of subjects studied is shown in parentheses. 
No significant correlations were found. 
342 
Chapter 4. Kesutts 
D17S934 (CA)n genotype frequencies in Southern Indian T2DM and non-diabetic 
control subjects 
Table 82 presents the frequency of the detected genotn'es in the T2DM Southern Indian 
subjects compared with the non-diabetic controls, all genotypes detected are presented in 
the tables. Due to the low frequencies of each of the genotypes detected, no significant 
correlations could be n:tade between the T2DM and non-diabetic control groups. Table 83. 
presents the genotypes detected for the T2DM subjects according to the onset of 
proteinuria and normoalbuminuria. There were no significant differences found in the 
frequencies of the detected genotypes in these groups. There. was a low frequency of each 
of the genotypes detected and consequently no significant correlations could be made 
between the T2DM normoalbuminuria and proteinuria groups and the non-diabetic 
controls. 
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Genotype TlDM subject& Non-diabetic 
Controls (ND9 
D 60 42 
1.1 1.7 
(I) (-) 
1.2 1.7 
(I) (-) 
1.3 3.3 
(2) (-) 
1.4 3.3 
(2) (-) 
l.S 4.99 2.4 
(3) (I) 
1.6 1.7 
(I) (-) 
2.2 2.4 
(-) (I) 
2.4 3.3 19.1 
(2) (8) 
2.5 7.1 
(-) (3) 
2.6 3.3 
(2) (-) 
2.9 1.7 
(I) (-) 
3.3 4.8 
(-) (2) 
3.4 14.3 
(-) (6) 
3.S 14.3 
(-) (6) 
3.6 3.3 
(2) (-) 
3.8 1.7 2.4 
(I) (I) 
4.4 6.7 9.5 
(4) (4) 
4.S 9.99 4.8 
(6) (2) 
4.6 4.99 4.8 
(3) (2) 
4.7 6.7 
(4) (-) 
4.9 1.7 
(I) (-) 
s.s 3.3 11.9 
(2) (5) 
S.6 9.99 2.4 
(6) (I) 
S.8 3.3 
(2) (-) 
6.6 1.7 
(I) (-) 
6.7 9.99 
(6) (-) 
7.8 6.7 
(4) (-) 
7.9 3.3 
(2) (-) 
8.9 1.7 
(I (-) 
Table 82. Percentage frequency of the detected D17S934 (CA)n microsatellite 
genotypes in T2DM subjects compared to non-diabetic control subjects of Southern 
lndian!Dravidian origin. This table shows the percentage frequency of detected 
genotypes for T2DM subjects with respect to onset of diabetes, and non-diabetic control 
subjects. n = number of genotypes detected. Due to the low frequencies of each of the 
genotypes detected no significant correlation's could be made between the T2DM group 
and the non-diabetic controls. 
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Genotype T2DM Proteinuria T2DM Non-dlabetlr Controls 
Normoalbuminuria (NDC) 
D 28 32 42 
1.1 3.6 
{I) (·) (-) 
1.2 3.1 
{·) (I) (·) 
1.3 3.6 3.1 
(I) (I) (-) 
1.4 3.6 3.1 
(I) (I) (-) 
1.5 9.4 2.4 
(-) (3) (I) 
1.6 3.1 
(·) (I) (-) 
2.2 2.4 
(·) (·) (I) 
2.4 6.3 19.1 
(·) (2) (8) 
2.5 7.1 
(-) (·) (3) 
2.6 6.3 
(-) (2) (-) 
2.9 3.6 
(I) (·) (-) 
3.3 4.8 
(-) (·) (2) 
3.4 14.3 
(-) (·) (6) 
3.5. 14.3 
(-) (·) (6) 
3.6 3.6 3.1 
(I) (I) (·) 
3.8 3.1 2.4 
(-) (I) (I) 
4.4 7.1 6.3 9.5 
(2) (2) (4) 
4.5 10.7 9.4 4.8 
(3) (3) (2) 
4.6 9.4 4.8 
(·) (3) (2) 
4.7 7.1 6.3 
(2) (2) (·) 
4.9 3.6 
(I) (-) (·) 
5.5 6.3 11.9 
(-) (2) (5) 
5.6 17.9 3.1 2.4 
(5) (I) (I) 
5.8 6.3 
(·) (2) (·) 
6.6 3.1 
(-) (I) (-) 
6.7 14.3 6.3 
(4) (2) (·) 
7.8 10.7 3.1 
(3) (I) (·) 
7.9 7.1 
(2) (-) (·) 
8.9 3.6 
(I (· (-) 
Table 83. Percentage frequency of the detected (CA)n DI7S934 microsatelllte marker 
genotypes in Southern Indian TlDM subjects classified and compared in accordance to 
presence of proteinuria or normoalbuminuria against non-diabetic controls. 
This table shows the percentage frequency of detected genotypes for T2DM subjects with respect 
to onset of proteinuria, and non-diabetic control subjects. n =number of genotypes detected. Due to 
the low frequencies of each of the genotypes detected no significant.correlation's could be made 
between the T2DM normoalbuminuria and proteinuria groups and the non-diabetic controls. 
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Mitochondrial genome study 
Associations of polymorphism's within the mitochondrial genome and the 
microvascular complications of TlDM 
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Polymorphism at the C(Mt5178)A region 
The Mt5178A/C polymorphism situated at position 5178 of the mitochondrial genome was 
investigated. Polymerase Chain Reaction (PCR) was carried out to amplify the region 
within the NADH dehydrogenase (ND2) region containing the polymorphism as described 
in chapter 3 (figure 32). Amplification products were digested overnight at 37°C with Alul 
restriction enzyme, and separated on a 2.5% agarose/ethidium gel at 1 OOV for 1 hour. The 
fragment sizes were checked by running a 1 OObp molecular weight marker alongside. 
Bands were revealed by UV transillumination (320nm) (figure 33) and subjects were 
assigned a genotype according to the restriction fragments identified. A PCR control band 
was also present. 
The Mt5178A/C polymorphism located within NADH dehydrogenase (ND2) region of the 
mitochondrial genome was investigated using 126 TlDM subjects and 91 normal controls 
of British Caucasoid origin (clinical demographics shown in table 6). Within the TlDM 
subject population studied there were 32 uncomplicated, 30 full house patients, 0 
neuropathy patients, 19 retinopathy and neuropathy patients, 13 nephropathy and 
retinopathy and 29 retinopathy. In this study we were only able to identify subject who 
were homozygous CC. The A polymorphism was not detected in any of the subjects 
investigated. It was not felt necessary to analyse further patients or controls for this 
polymorphism because the A polymorphism had not been detected in a single subject. 
Therefore felt to be unlikely to be a significant polymorphism in the subjects investigated. 
No association could therefore be made with respect to the mitochondrial gene region and 
diabetic microvascular complications. 
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Figure 33. C(Mt5178)A polymorphism by restriction enzyme digestion and 
fragment separation on 2. 5% agarose gel with ethidium bromide staining. Only 
one genotype was identified; homozygous CC. All subjects analysed in this figure have 
the CC genotype. 
PCR was carried out to amptify the 417bp region of the mitochondrial genome. The 
region included a polymorphic site, a single base substitution of C to A and resultant 
amino acid exchange from Leu to Met. Five microlitres of the PCR product was 
digested overnight at 37°C with 10 units of Alul restriction enzyme (Promega, UK). 
The genotypes were identified by 2.5'Yo agarose gel electrophoresis alongside a lOObp 
molecular weight marker and ethidium bromide staining. After Alul digestion the 
homozygous CC produced 43bp, 188bp and 186bp fragments. All samples were 
analysed in duplicated to reduce the risk of error. 
Chapter 4 . .Kesults 
C(Mt5178)A polymorphic marker in British Caucasoid TlDM subjects and normal 
controls 
The polymorphism was not detected in the British Caucasoid TlDM or nonnal control 
populations studied here. No analysis could therefore be made with regard to the onset of 
diabetic microvascular disease with respect to this polymorphism. 
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